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This thesis describes the potential use of silver(I) complexes of 9-
anthracenecarboxylic (9-acaH) and imidazoles as new antimicrobial and 
anticancer drugs. The detailed synthesis of silver(I)-containing carboxylates, 
such as polymeric [Ag2(9-aca)2]n and [Ag2(9-aca)2(DMSO)2]n, and the ammonia-
containing complex, [Ag4(9-aca)4(NH3)2], are provided along with imidazole 
derivatives, such as [Ag2(9-aca)2(DMSO)2]n and [Ag6(imidH)4(9-aca)6(MeOH)2]. 
Silver(I) carboxylates containing substituted imidazole ligands were also 
prepared and include the complex salts, [Ag(1-Me-imid)2]2[Ag4(9-aca)6] and 
[Ag(1-Bu-imid)2]2[Ag4(9-aca)6], along with [Ag2(1-Me-imid)2(9-aca)2], [Ag(2-
Me-imidH)2(9-aca)], [Ag2(1-Bu-imid)2(9-aca)2], [Ag(apim)](9-aca)·H2O, [Ag(4-
Ph-imidH)2(9-aca)] and [Ag2(2-Mebenz-imidH)4](9-aca)2. Polymeric silver(I) 
imidazolate complexes were made from 2-phenylimidazole, 4,5-
dicyanoimidazole, benzimidazole and 2-methylbenzimidazole. All complexes 
were characterised by IR and NMR spectroscopy, microanalysis and, in many 
instances, by X-ray crystallography. The fluorescence properties of a selection 
of the complexes were also recorded. 
 
Complexes were screened, in vitro, for their antifungal (Candida albicans) and 
antibacterial activity (Escherichia coli and methicillin-resistant Staphylococcus 
aureus (MRSA)). Many of the new silver(I) complexes were more active than the 
prescription drugs currently used to treat microbial infections and cancerous 
tumours. For example, [Ag4(9-aca)4(NH3)2] was ca. 32 times more active than 
the prescription antifungal drug, Ketoconazole. This complex also exhibited 
high cytotoxicity towards bacterial cells, being ca. 9 times more active against 
both E. coli and MRSA than the known antibacterial agent, silver sulfadiazine. 
The hexanuclear imidazole complex, [Ag6(imidH)4(9-aca)6(MeOH)2], was the 
most active at inhibiting bacterial growth, being ca. 39 times better than silver 
sulfadiazine against E. coli.  
 
The in vivo cytotoxicity and antifungal characteristics of the silver(I) complexes 
was also examined using the insect model, Galleria mellonella. Healthy G. 
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mellonella larvae appeared to be unaffected when treated with the silver(I) 
complexes at concentrations up to 100 µg cm-3. The silver(I) complexes also 
increased the survival rate of larvae administered with a lethal dose of C. 
albicans. Again, the ammonia-containing complex, [Ag4(9-aca)4(NH3)2], was the 
most effective at increasing the survival rate, greatly surpassing the efficacy of 
Ketoconazole. 
 
The silver(I) complexes were screened, in vitro, against a number of mammalian 
tumour cell lines (MCF-7, HT-29, Hep-G2 and A-498) and they all decreased cell 
proliferation. While most of the complexes were more active towards MCF-7 
cells (breast cancer cells), [Ag(4-Ph-imidH)2(9-aca)] was equally cytotoxic 
against HT-29 cells (colon cancer cells). [Ag6(imidH)4(9-aca)6(MeOH)2], [Ag(1-
Bu-imid)2]2[Ag4(9-aca)6], [Ag(1-Me-imid)2]2[Ag4(9-aca)6] and [Ag4(9-
aca)4(NH3)2] were all ca. 7 times more active against breast cancer cells than the 








1-Bu-imid   1-butylimidazole 
1-Me-imid   1-methylimidazole 
2-Me-imidH   2-methylimidazole 
2-Me-imid¯   2-methylimidazolate anion 
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1.1 Structure of Introduction 
 
The Introduction is structured to give the reader an understanding of the scope 
of this research and the terms used throughout this thesis. An introduction to 
fungal and bacterial infections concentrating on Candida albicans, Escherichia 
coli and methicillin resistant Staphylococcus aureus is provided, along with a 
brief review of current antimicrobial drugs. An insight into the history and 
methodology of in vivo antifungal screening is also given. An introduction to 
cancer is included along with a review of metal-based anticancer agents. Finally, 
the chemistry and biological activity of silver is discussed along with details of 
the ligands used in the synthetic processes. 
 
 
1.2 Fungal Infections 
 
Fungi are eukaryotic organisms, distinct from both plants and animals. Most are 
multicellular and differ from other eukaryotes in nutritional mode, structural 
organisation, growth and reproduction. Many fungi are parasites on plants and 
animals, causing conditions that can range from mild to life-threatening while 
others can form symbiotic relationships with their hosts. Fungi are also used as 
major sources of pharmacologically active drug compounds (e.g. penicillins) 
and are widely used in the food and brewing industry.   
 
1.2.1 Candida albicans 
The genus Candida is comprised of approximately 200 yeast species and, of 
these, about 12 are associated with human commensalism or disease1. Candida 
albicans is an opportunistic fungal pathogen that usually resides harmlessly as 
commensals in human and animal hosts. It is the species that is most frequently 
associated with human infection2 and is carried innocuously by a large 
proportion of people on the epithelial surfaces of the mouth, gastro-intestinal 
tract, vagina and skin, where it is generally kept in check by host defences and 
the normal microbial flora of the body3.  
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C. albicans exhibits structural dimorphism and, as such, can exist in two 
different morphologies. It can exist as ovoid blastospores (simple yeast cells) 
and as true hyphae, known as germ tubes (Figure 1). Both morphologies have 
been shown to cause disease in human and animal hosts. 
 
 
                                (a)                                                                           (b) 
Figure 1. C. albicans cells: (a) ovoid blastospores and (b) germ tubes. 
 
Candida infections of virtually every tissue of the human body have been 
reported, with the most common manifestations being superficial lesions of the 
mouth or vagina (Figure 2). It is capable of causing a wide range of infections 
and can be particularly problematic for immuno-compromised individuals such 
as AIDS patients, transplant recipients, cancer patients, burn patients and 
premature infants. The improper use of broad spectrum antibiotics can also 
lead to a Candida infection due to the lack of friendly bacteria to keep it under 
control. It can also cause more serious and potentially life-threatening systemic 
infections of organs, including the kidney, liver and brain. It is the fourth most 
common cause of nosocomially acquired bloodstream infections and candidal 
pathogeneisis occurs in the following steps1: 
 
• Candida cells adhere to the epithelial surface via specific interactions 
between candidal adhesions and host ligands. 
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• Once they have bound to the tissue the fungal cells begin to proliferate 
and produce hyphae. 
• Growth continues by budding and production of hyphae (often 
associated with the formation of a biofilm). 
• Fungal hyphae and cells eventually penetrate through the epithelial layer 
to the tissues below, reaching the bloodstream and spreading through 
the body causing disseminated candidosis.  
 
 
                                (a)                                                                       (b) 
Figure 2. C. albicans infection of (a) the mouth and (b) the toes. 
 
1.2.2 Current Antifungal Drugs 
The development of drugs specific to fungal cells is a challenging task due to the 
close similarities of fungal and mammalian cells. The number of agents available 
to treat fungal infections has increased by 30% since the year 2000, yet still 
only 15 agents are approved for clinical use4. At present, fungal infections are 
generally treated by the use of echinocandins, polyene and azole drugs, but 
none of the existing systemic antifungals satisfies the medical need completely. 
There are weaknesses in the spectrum, potency, safety and pharmacokinetic 
properties of these drugs and new alternatives are urgently being sought.  
 
1.2.2.1 Polyene Antifungal Drugs 
Polyenes are a family of antifungal compounds isolated from Streptomyces 
species that contain alternating double bonds as part of their macrolide ring 
structure. Although many polyenes have been isolated from Streptomyces, only 
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amphotericin B and nystatin are in current widespread use (Figure 3). These 
two polyenes have the broadest activity spectrum of any antifungal agent in  
 
 
Figure 3. Structures of amphotericin B and nystatin. 
 
clinical use and they inhibit fungal growth by interacting with ergosterol in the 
fungal cell membrane and compromising its barrier function5. The biological 
activity of polyenes is attributed to their polar hydroxyl groups, which are 
located opposite to the double bonds on the macrocyclic ring, giving the 
compounds an amphipathic nature6. The polyenes bind to ergosterol in the 
fungal cell membrane forming pores through which vital cytoplasmic 
components, such as potassium ions, ammonium ions, small neutral sugars, 
phosphate esters and nucleotides, can leak from the cell, leading to cell death. 
 
Due to the similarity between sterols in fungal and mammalian cell membranes 
(cholesterol in mammals and ergosterol in fungi), polyenes can affect both the 
pathogen and the host. Amphotericin B and nystatin have a higher affinity for 
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properties7. They are not absorbed readily from the gastrointestinal tract and 
so must be administered intravenously.  
 
 
Figure 4. Interaction of amphotericin B (AmB) with cholesterol and ergosterol 
forming different sized pores in the membranes through which vital 
cytoplasmic components leak (sterol molecules in yellow)8. 
 
A major problem with polyenes is their side effects and toxicity, particularly 
nephrotoxicity. Side effects, such as depression, headaches, cramps, anorexia, 
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nausea and muscle pain are not uncommon. Approximately 30% of individuals 
who undergo treatment with amphotericin B suffer from acute renal failure6. To 
overcome this toxicity, they can be incorporated into liposomes which are less 
toxic. This combination maintains the beneficial therapeutic properties and can 
be administered in larger doses. 
 
1.2.2.2 Azole Derivatives 
The azole drugs are totally synthetic and are the most rapidly expanding group 
of antifungal agents. They can be classified as imidazoles (2 nitrogens in a 5-
membered ring) or triazoles (3 nitrogens in a 5-membered ring)9. They inhibit 
the action of the cytochrome P450-dependent enzyme lanosterol demethylase, 
which is a major component of the fungal plasma membrane and a key 
ingredient in the biosynthesis of ergosterol. This enzyme is also present in 
mammalian cells but, at the required therapeutic concentrations, the azoles 
have a greater affinity for the fungal demethylase. In this way, the azoles cause a 
depletion of ergosterol and an accumulation of 14α-methylated sterol. This 
disrupts both the structure of the membrane and its functions in nutrient 
transport and chitin synthesis6.  
 
Imidazole-based compounds, including ketoconazole, miconazole and 
clotrimazole (Figure 5) were discovered in the 1960s but only ketoconazole 
was available for treatment of systemic infections due to its superior aqueous 
solubility. The nitrogen of the azole binds to the iron of the lanosterol 
demethylase enzyme and this prevents the activation of oxygen which is 
necessary for the demethylation of lanosterol10. A second nitrogen also 
interacts with the apoprotein of lanosterol demethylase and this may be the 
determining factor of the specificity of different azoles for the enzyme11. The 
toxicity of azoles is relatively low but they can induce side effects such as a 
decrease in testosterone and glucocorticoids due to their interaction with 
mammalian cytochrome P-4505. 
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Figure 5. Azole structures: (a) ketoconazole, (b) miconazole and (c) 
clotrimazole. 
 
Triazoles, such as fluconazole, itraconazole, voriconazole, posaconazole and 
ravuconazole (Figure 6), were developed at a later stage and these tend to be 
more specific in their mode of action. They can be used to treat both superficial 
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Figure 6. Triazole structures: (a) posaconazole, (b) itraconazole, (c) fluconazole 
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1.2.2.3 Echinocandins 
The echinocandins are the first new class of antifungal drug to be introduced on 
the market in more than 15 years. They are synthetically modified lipopeptides 
originally derived from fermentation broths of various fungi12. Echinocandins 
are large cyclic peptides linked to a long-chain fatty acid. Naturally occurring 
echinocandins have also been isolated and examples include aculeacin A (from 
Aspergillus aculeatus), echinocandin B (from Aspergillus rugulovalvus) (Figure 
7), pneumocandin B (from Zalerion arboricola) and papulacandins (from 
Papularia sphaerosperma). While the toxicity of these natural echinocandins can 
be quite high, semi-synthetic analogues with reduced toxicity have been 
synthesised and licensed for clinical use. Examples include caspofungin 
(Merck), micafungin (Fujisawa) and anidulafungin (Versicor). 
 
 
Figure 7. Structure of echinocandin B. 
 
Echinocandins have a distinct target which is different from azoles and 
polyenes. These compounds inhibit the synthesis of β-D-glucan in fungal cell 
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favourable kinetics which allows once a day dosing. However, echinocandins 
have poor oral absorption (ca. 3%) and therefore are administered 
intravenously. The drugs are concentrated in the liver, spleen and gut with 
equal concentrations distributed in the blood plasma and in the lungs, along 
with lower concentrations in other tissues.  
 
1.2.2.4 Other Antifungal Agents 
There are many other antifungal agents which do not fall into the three classes 
already discussed. These include the allylamines, terbinafine and butenafine, 
and flucytosine (Figure 8). The allylamines are synthetic, reversible, 
noncompetitive inhibitors of squalene epoxidase. This enzyme, together with 
squalene cyclase, converts squalene to lanosterol, which ultimately forms 
ergosterol in the fungal cells13. Terbinafine is an oral systemic agent whereas 
butenafine is used for the treatment of topical infections.  
 
The fluoropyrimidine, flucytosine (5-fluorocytosine), is the only antimetabolite 
type antifungal drug available. It is converted into 5-fluorouracil within the 
fungal cells, which gets incorporated into the RNA and causes premature chain 
termination and inhibition of DNA synthesis. It is selectively toxic to fungal cells 
as mammalian cells lack cytosine permease which converts the flucytosine into 
the active 5-fluorouracil6. Due to its very limited activity spectrum it is mainly 
used in combination with amphotericin B5. 
 
1.2.3 Fungal Resistance 
Over many years, some strains of fungi have developed resistance to 
commercial antifungal agents14. Resistance usually arises either after long 
periods of exposure to the drug or in conditions that may support the gradual 
stepwise development of the fungus11. It is very unlikely that any single 
mutation will transform a susceptible strain into a highly resistant one, but a 
combination of mutations and alterations can lead to the occurrence of resistant 
strains. The fungal cells have developed a number of mechanisms which give 
rise to this resistance, including alterations in sterol synthesis, targets sites,  




Figure 8. Structures of (a) terbinafine, (b) butenafine and (c) flucytosine. 
 
along with the uptake and efflux of drugs10. To date, polyene resistance has not 
been a major clinical problem with very few polyene-resistant isolates being 
reported and characterised11. However, resistance to azoles is much more 
common and widespread, being a major concern for immuno-compromised 
AIDS patients who regularly suffer from oropharyngeal Candida infections15. 
Resistance to allylamines has not been reported for medically important fungi, 
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1.2.4 In vivo Antifungal Screening Using Galleria mellonella 
In vivo screening of compounds allows scientists to see how they may react 
when contained within a living organism. This is imperative in the development 
of candidate drug compounds for clinical use as it allows observations of any 
detrimental effects which could limit or even disqualify them for use. By using 
animal and insect models, the cytotoxic and antimicrobial properties of 
potential new drugs can be determined.  
 
1.2.4.1 Immunity 
The immune system of vertebrates comprises the innate immune system and 
the adaptive immune system.  These two systems interact with each other via 
dendritric cells, macrophages and some T cells to yield an excellent defence 
mechanism against the invasion of harmful pathogens16 (Figure 9).  
 
 
Figure 9. Interaction of the innate and adaptive immune systems. 
 
The innate, or non-specific, immune system is the first line of defence against 
infection and constitutes a set of disease-resistant mechanisms that are not 
pathogen specific. Recent studies have shown that the initial cell responses of 
the innate immune system are critical in the initiation and maintenance of an 
Acute infection
Innate immune response
Cytokine release Antimicrobial activity
Adaptive immune response
Fever
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immune response to C. albicans17. The innate immune system has both cellular 
and molecular components that recognise classes of molecules common to 
frequently encountered pathogens. Whereas the innate immune system has 
defences that are already present at the time of infection, the adaptive or 
specific immune system requires days or even weeks to develop maximum 
efficiency against invading organisms. This latter system is antigen specific and 
reacts only with the organism that induced the response. Specificity such as this 
comes with the major advantage of immunological memory. Exposure to the 
same antigen in the future will result in a memory response which occurs faster 
and stronger than the initial response. The innate response does not 
demonstrate any immunological memory but it reacts equally well to a variety 
of organisms. 
 
While the existence of an invertebrate adaptive immune system similar to that 
of vertebrates is still a matter of fierce debate18,19, the innate immune system of 
insects and mammals has been shown to exhibit a high degree of structural and 
functional homology19,20. This homology has led to further research into the 
response of insects to infection as this could provide valuable information into 
the functioning of the mammalian innate system21-24. Many insects have been 
involved in the pathogenic study of microorganisms, including Drosophila 
melanogaster25,26, Galleria mellonella23,27-29 and, more recently, Locusta 
migratoria30. Insects are renowned for being the most successful groups of 
animals on Earth, accounting for nearly one million species and 1018 
individuals31. They can be found in a vast array of differing habitats, with the 
oceans being one of the few places they have failed to colonise.  
 
The key to insect survival is the methods they have developed methods to 
combat the large variety of pathogens which they encounter. The ability to 
detect an invading pathogen and activate an instantaneous defence is crucial for 
the survival of any species. The innate immune system provides this response 
and it has both cellular and humoral elements which consist of four parts: 
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(i) anatomic barriers (the skin and mucous membranes); 
(ii) physiologic barriers (temperature, pH and chemical mediators);  
(iii) phagocytic/endocytic barriers (phagocytes/haemocytes); 
(iv) inflammatory barriers. 
 
The cuticle and haemolymph of insects are analogous to the skin and blood of 
mammals. The haemolymph transports nutrients, waste products and signal 
molecules throughout the haemocoel or body cavity but, unlike blood, it plays 
no role in respiration. It is the main site of the immune response of insects to 
microorganisms. The haemolymph contains cells called haemocytes which are 
similar to phagocytes in mammals. Haemocytes can be subdivided into 
prohaemocytes, plasmatocytes, granulocytes, coagulocytes, spherulocytes and 
oenocytoids32.  
 
The phagocytic/endocytic barriers of insects and mammals show many 
similarities28. Plasmatocytes and granulocytes are the predominant phagocytic 
cells in insects, participating also in nodule formation and encapsulation33. In 
mammals, the two main phagocytic cells are the 
neutrophiles/polymorphonuclear cells and the monocytes/macrophages34 
(Figure 10). Phagocytic cells respond to signals generated at the site of an 
infection, which are usually peptides released by the invading microorganism or 
by tissues that have come into contact with the foreign pathogen. This leads to 
an increase in the glucose and oxygen consumption and is referred to as the 
respiratory burst35. The burst produces a number of oxygen-containing 
compounds (reactive oxygen intermediates) which have been shown to kill 
invading microorganisms within the confines of the phagocytic vacuole in both 
mammals and insects36,37.  
 
The humoral immune response is mediated by antibodies, proteins and the 
processes that accompany the production of them. In mammals and other 
vertebrates this is usually more concerned with the adaptive immune system 
and the production of antibodies which bind to specific antigens on the surface 
of microorganisms identifying them as foreign bodies for destruction.  
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Figure 10. Steps in phagocytosis and an SEM image of macrophage attacking E. 
coli during phagocytosis. 
 
Insects have a non-specific humoral immune response that involves the 
production of a range of antimicrobial peptides and proteins20. This is the last 
line of defence in the case of a large infection by microorganisms and the 
antimicrobial peptides and proteins are released into the haemolymph where 
they attack the cell walls of the pathogens38. The humoral immune response 
parallels the mammalian acute phase response and covers the processes of 
melanisation, haemolymph clotting and wound healing in response to injury31.  
 
1.2.4.2 Galleria mellonella as an In vivo Model 
The greater wax moth, Galleria mellonella, is approximately 12-18 mm long and 
has a wing span of 20-25 mm. The larvae can grow up to 25 mm in length and 
are pale yellow in colour (Figure 11). The life cycle usually takes from 3-6 
months but under favourable conditions it can occur in as few as 6 weeks. The 
natural habitat of G. mellonella is in beehives containing older, dark 
honeycombs. The eggs are deposited in the cracks and crevices of the hives and 
the larvae which emerge feed on the wax within the hive. They bore holes and 
leave silk-lined tunnels (known as galleries) in the wax.  
 
At present, most research into human pathogens involves the use of mammalian 
models, including rodent, simian and feline hosts. There are many concerns 
with the utilisation of these models, both from an ethical and a practical view-
point. These studies are often very time consuming, incur considerable costs 
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Figure 11. The different developmental stages of Galleria mellonella: (a) egg, 
(b) young larvae, (c) fully grown larvae wrapped in silken webbing, (d) cocoon 
and (e) adult moth. 
 
and undoubtedly cause some amount of animal suffering. In vivo studies 
involving G. mellonella date back as far as 198227 and so far it has been used to 
study the pathogenicity of many different bacteria and fungi. Larvae of G. 
mellonella are inexpensive to purchase, easily cultured and inoculated, allowing 
a large number of test subjects to be screened in a relatively short period of 
time.  
 
G. mellonella have been utilised to examine the properties of the bacteria 
Psuedomonas aeruginosa39 and it is suggested that the underlying mechanisms 
of infection are similar to that in the mouse model40. It has also been effective in 
the study of Proteus mirabilus41, Aspergillus fumigatus42, Escherichia coli, 
Bacillus cereus27 and the pathogenic insect bacteria, Xenorhabdus 
nematophilus29. 
 
The use of G. mellonella larvae in the study of pathogenic fungi is also well 
documented. They have been proven to have the ability to distinguish between 
pathogenic and non-pathogenic yeast isolates, as well as heat-killed and viable 
cells21. Cryptococcus neoformans, a non-specific fungal pathogen, contains genes 
shown to be involved in mammalian virulence and which also play a role in the 
killing of G. mellonella23. In the study of C. albicans, a correlation has been 
demonstrated in the fungal virulence and reduction of the fungal hyphal 
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formation in both G. mellonella and the mouse model43. Studies into the 
response mechanism of G. mellonella have shown that, upon infection with C. 
albicans, the number of haemocytes in the body cavity of the larvae increases, 
along with the level of expression of the genes coding for antimicrobial 
peptides44. It has also been shown that insect haemocytes phagocytose and kill 
microorganisms by a mechanism similar to that used by human neutrophils via 
the production of superoxide45. The production of haemocytes in G. mellonella is 
also related to the physical surroundings and stresses experienced by the 
larvae. Exposure of the larvae to either mild thermal shock conditions (4 °C or 
37 °C) or to non-lethal physical stress prior to infection induces the protective 
immune response of increased haemocyte production and elevated expression 
of antimicrobial peptides as previously mentioned46,47. 
 
Due to the high level of immunological homology shown by insects and 
mammals, insects are now being used to evaluate the therapeutic effects and in 
vivo activity of known and novel antimicrobial drugs. Previously, the 
assessment of these drugs relied heavily on immunocompetent and 
immunosuppressed animal models, but they are now also being screened using 
the fruit fly Drosophila melanpogaster48, the silkworm Bombyx mori49 and, more 
recently, the larvae of the greater wax moth G. mellonella50.  
 
Amphotericin B, flucytosine and fluconazole all prolonged the survival of C. 
neoformans infected G. mellonella, with the combinational therapy of 
amphotericin B plus flucytosine being the most effective23. These results were 
in agreement with the findings of other model systems, including mammalian 
models23. The antifungal efficacy of the silver(I) compounds, AgNO3 and 
[Ag2(mal)(phen)3] (malH2 = malonic acid, phen = 1,10-phenanthroline) in C. 
albicans-infected G. mellonella has been determined50. It was shown that 
administration of the silver(I) compounds 1 h prior to, or 1 h and 4 h 
subsequent to infection by a lethal dose of C. albicans can significantly increase 
the survival time of the larvae. It was suggested that the increase in 
concentration of haemocytes and the expression of genes for antimicrobial 
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1.3 Bacterial Infections 
 
Bacteria are prokaryotic cells that are essential for life on Earth. They inhabit 
nearly all niches on the planet, from soil to hot springs and even deep within the 
Earth’s crust51. Bacteria have a diverse roll in both the environment and in our 
bodies. They decompose matter from dead organism and return vital nutrients 
to the earth. Bacteria can live symbiotically with hosts, keeping other 
pathogenic organisms in check. Most bacteria are very beneficial to our 
environment but there are some which cause disease in animals and plants. 
 
1.3.1 Escherichia coli 
Escherichia coli is a Gram-negative bacterium (Figure 12) that is commonly 
found in the lower intestine of humans and warm-blooded animals52. They are 
part of the normal flora of the gastrointestinal tract and are the dominant 
species in the aerobic faecal flora of humans. They are actively mobile due to the 
presence of flagella. These bacteria benefit the host through the production of 
vitamin K and by preventing the unwanted growth of other bacteria.  
 
Although most E. coli strains are harmless there are some which can cause 
serious illnesses (e.g. E. coli O157:H7) and distinguishing between commensal 
and pathogenic strains can be difficult53. Transmission of E. coli is by faecal-oral 
contact (usually by ingestion of food and water) and the presence of E. coli in 
water or soil is an indicator of faecal contamination. The bacterium produces 
toxins, known as Shiga toxins, which damage the lining of the intestines and 
other target organs such as the kidneys. They can cause diarrhoea, urinary tract 
infections, meningitis, wound infections and pneumonia. E. coli O157:H7 is 
responsible for 73,500 cases of infection, 2,150 hospitalisations and 61 deaths 
in the USA every year54. Strains of E. coli resistant to many broad spectrum 
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antibiotics (including cephalosporins) have emerged over the last number of 
years, mainly in hospital environments52. 
 
  
Figure 12. SEM of E. coli rods. 
 
1.3.2 Methicillin-resistant Staphylococcus aureus (MRSA) 
Staphylococcus aureus is a Gram-positive spherical bacterium that is commonly 
found in the nasopharynx or on our skin52 (Figure 13). It can cause infections 
ranging from minor skin abscesses to serious diseases such as meningitis, 
endocarditis and septicaemia. MRSA is a strain of S. aureus that is resistant to 
the β-lactam class of antibiotics, including the penicillins and cephalosporins. It 
is one of the most commonly acquired nosocomial infections and is known as 
the hospital superbug53. It can be transmitted by touch alone, and due to this, 
hospitals and nursing homes, containing patients which are more susceptible to 
infection, are ideal breeding grounds for it. MRSA becomes particularly 
problematic if it enters the body and treatment is generally by administration of 
glycopeptide antibiotics like vancomycin and teicoplanin. These antibiotics 
inhibit the growth of bacterial cells by binding to the amino acids in the cell 
walls and preventing peptidoglycan synthesis.  
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(a)                                                                       (b) 
Figure 13. (a) SEM of S. aureus cells and (b) S. aureus infection of the leg. 
 
1.3.3 Antibiotics and Antibacterial Agents 
An antibiotic is any substance that kills or inhibits the growth of bacteria. There 
are many classes of antibiotics, with the classical ones being sulfonamides, 
penicillins, cephalosporins and aminoglycosides (Figure 14)55,56. Many 
antibiotics are produced naturally by microorganisms (e.g. penicillin), while 
some of these natural compounds provide a building block for the manufacture 
of synthetic derivatives. Most antibiotics from microorganisms have fewer side-
effects than synthetic chemical compounds and this can be largely accredited to 
their increased target specificity.  
 
Sulfonamides are synthetic antibiotics that target bacterial enzymes by binding 
to them and inhibiting the production of essential compounds within the cell 
(e.g. co-factor tetrahydrofolate)55. Penicillins and cephalosporins are β-lactam 
antibiotics which act on the cell wall of bacteria56. They share the structural 
feature of a β-lactam ring and inhibit the formation of peptidoglycan cross-links 
within the cell wall, which weakens the wall osmotically and causes cell death. 
Aminoglycosides consist of a linked ring system composed of aminosugars and 
an aminosubstituted cyclic polyalcohol. They bind to proteins in the ribosome 
of the bacterial cell and prevent DNA replication. Aminoglycosides are poorly 
absorbed when given orally and so are administered intravenously. They also 
exhibit high toxicity, affecting the ear and kidney56. 
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1.3.4 Bacterial Resistance 
Bacterial resistance to antibiotics and antibacterial agents has emerged in much 
the same manner as fungal resistance. This is not a new phenomenon, with 
resistance to penicillin documented in the 1940s. Resistance can arise through 
either a modification of the target site or enzyme, prevention of access for the 
antibiotics or production of enzymes that destroy or inactivate the antibiotic55. 
Resistance to bacteria usually begins in hospital environments, where patients 
suffering from severe illnesses are treated with the most recent and 
sophisticated antibiotics. Bacterial resistance in communities is a growing cause 
for concern and the indiscriminate use of broad spectrum antibiotics is thought 
to be one of the primary causes for the recent rise in its occurrence.  
 
β-Lactam antibiotics all contain the β-lactam ring structure and it is this 
characteristic that has led to their downfall. All bacteria contain enzymes (β-
lactamases) capable of hydrolysing the β-lactam ring and forming an inactive 
product56. In general, these enzymes are only produced in small amounts, but in 
certain strains of bacteria an overproduction of the enzymes has been 
associated with treatment failure (e.g. MRSA, Pseudomonas aureginosa). 
Resistance to aminoglycosides results largely from interference with the drug 
transport mechanism following modification of the antibiotic by one or more of 





Cancer is a set of diseases characterised by unregulated cell growth leading to 
invasion of surrounding tissues and spread (metastasis) to other parts of the 
body57. It is represented by a population of cells within the body which escapes 
from normal control and continues to increase until, unless treated, leads to the 
death of the host. It can affect almost any tissue of the body, with the skin, 
digestive organs, lungs and breasts being the most prone to infection. Cancer 
has been known for thousands of years, as far back as the early Egyptians57. It is 
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one of the leading causes of death worldwide, accounting for 7.4 million deaths 
(~13% of total deaths) in 200458. Deaths from cancer are projected to continue 
rising, with an estimated 12 million deaths in 2030. The most frequent types of 
cancer differ between men and women, but tobacco smoking is the single most 
important risk factor. More than 30% of cancer could be prevented by 
modifying or avoiding key risk factors, including: 
 
• tobacco use 
• obesity 
• low fruit and vegetable intake 
• physical activity 
• alcohol use 
• pollution from fossil fuels. 
 
1.4.1 Tumour Growth 
Cancer can arise from a change in one single cell. This change may be initiated 
by external agents (carcinogens) or by inherited genetic factors. When 
cancerous cells begin to grow uncontrollably they form a swelling known as a 
tumour59. This growth can invade and destroy surrounding normal tissues as 
well as travel through the lymphatic vessels or circulatory system to other sites 
forming secondary growths called metastases (process known as metastasis). 
Metastasis is the major cause of death from cancer58. 
 
Mitosis is the processes of cell division used by nearly all cells in the body (the 
exception being reproductive cells)59. It is regulated by certain growth factors 
and environmental stimuli (e.g. contact with other cells) to limit the number of 
cells being produced. In general, normal, non-malignant cells divide to replace a 
cell which has been lost, thus maintaining a constant cell population. Cancer 
cells do not respond to these factors and so their proliferation goes 
unregulated57. There can also be a decrease in the number of cells undergoing 
apoptosis (programmed cell death) and this, when combined with unrestricted 
proliferation, leads to a massive increase in cell populations.  
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1.4.2 Cancer Treatment 
The treatment of cancer is very complicated due to the biological similarity of 
normal and malignant cells. Treatments include surgery, chemotherapy, 
radiotherapy, immunotherapy, hormonal therapy, angiogenesis or a 
combination of these. There is significant research into anticancer agents in the 
hope to find a cure, but it is very likely that a single cure will never be found. 
This is due to the vast number of ways in which cancer can affect different parts 
of the body.  
 
1.4.2.1 Chemotherapy 
Chemotherapy is the main form of drug treatment at all stages of cancer 
illnesses. The chemicals involved are aimed at interrupting the cell cycle, in 
particular by inhibiting cell division59. Chemotherapy drugs can have very high 
toxicity levels and are generally not very specific. This can lead to many side 
effects, particularly in bodily systems that have a rapid turnover of cells similar 
to a malignant growth, such as the skin, hair, gastrointestinal and bone marrow. 
To increase their efficacy, combinational chemotherapy is often used. 
Chemoptherapy agents can be divided into three main categories by their 
mechanism of action60: 
 
• stopping the synthesis of pre-DNA molecule building blocks (e.g. 
methotrexate, fluorouracil) 
• directly damaging the DNA in the nucleus of the cell (e.g. cisplatin, 
doxorubicin) 
• effect the synthesis or breakdown of the mitotic spindles (e.g. 
vinblastine, pacitaxel) 
 
1.4.2.2 Metal-based Chemotherapy 
The field of metal-based anticancer drugs was initiated by cisplatin (cis-
diaminedichloroplatinum(II)) in the 1960s (Figure 15). It was approved for 
clinical use in 1978 and it revolutionised the treatment of many cancer forms, 
including testicular cancer for which, if tumours are discovered early, a highly 
impressive cure rate of nearly 100% is now achieved61. Since its discovery, 
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three other structurally related platinum drugs have also been approved for 
clinical use. These are, carboplatin, nedaplatin and oxaliplatin (Figure 15). 
Together, these drugs have sales in excess of US$2 billion per year62. Their 
efficacy and importance is shown by the fact that there are very few cancer 
treatment regimens today that do not contain a platinum drug.  
 
 
Figure 15. Structures of (a) cisplatin, (b) carboplatin, (c) nedaplatin and (d) 
oxaliplatin. 
 
Cisplatin contains a square planar platinum(II) centre with two ammonia and 
two chloride ligands coordinated in a cis conformation. The complex inhibits 
cell growth through interaction with DNA. It is administered by injection and 
remains intact until it crosses the cell membrane, at which point one or both of 
the chloride ligands gets replaced by water. The cationic platinum complex then 
interacts with bases on DNA (most commonly guanine), disrupting it and 
inhibiting replication. The cell then gets flagged as damaged and apoptosis 
occurs62. Unfortunately, cisplatin is highly toxic and can only be administered in 
small doses. Side effects include nephrotoxicity, nausea, vomiting and loss of 
sensation in the extremities. These arise from the non-specificity of the drug 
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The success of cisplatin led to a huge increase in the synthesis and screening of 
platinum compounds for their anticancer potential. Cisplatin was used as a 
benchmark, with the targeted structure being a square planar platinum(II) 
centre with two cis-amines and two leaving groups. The analogues of cisplatin 
were shown to have similar efficacy but with no real benefits over cisplatin63. 
Carboplatin was shown to be less toxic than cisplatin but it also has reduced 
activity against testicular, head and neck cancers. In 2004, Sanofi-Aventis 
released oxaliplatin, a new platinum(II) drug with a different activity spectrum 
than cisplatin. It was effective against colorectal cancer, a disease not treatable 
by either cisplatin or carboplatin, and was also effective against some cisplatin-
resistant cancers62.  
 
Although the cis-isomer has been proven to provide anticancer activity, the 
trans-isomer has not been completely ignored. Transplatin has been shown to 
be biologically inactive64, but trans compounds containing pyridine, alkylamine, 
isopropylamine and iminoether ligands have similar potency to cisplatin and, 
more importantly, are active against cisplatin-resistant strains65-68. There are 
many more platinum drugs currently in clinical trials but, for now, cisplatin 
remains the platinum-based drug of choice for many cancers. 
 
Metal-based chemotherapy does not solely involve platinum, and complexes 
containing ruthenium, iron, titanium, gallium, arsenic, gold and silver are under 
investigation62,69-72. The ligand exchange kinetics of ruthenium(II) are similar to 
that of platinum(II) and many research groups have based their work around 
this fact62. Ruthenium drugs have a similar mode of action to platinum drugs by 
interacting with DNA to inhibit replication. The first ruthenium drug to enter 
clinical trials was NAMI-A (imadozolium trans-
[tetrachloro(dimethylsulfoxide(imidazole)ruthenate(III)]) (Figure 16). 
Unusually, it was inactive against primary tumours but very potent against 
metastasis tumours. This particular quality could be very beneficial in 
combinational chemotherapy. The structurally similar complex, KP1019 
(indazolium trans-[tetrachloro-bis(1H-indazole)ruthenate(III)]) (Figure 16), is 
active against primary tumours and is currently being investigated for use in 
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the treatment of colorectal cancers. A family of ruthenium(II)-arene complexes 
have also been designed which exhibit high in vitro and in vivo anticancer 
activity73.  
 
A number of iron-containing anticancer drugs based on substituted ferrocenes 
have shown good potential as anticancer agents69. These include ferrcenium 
picrate and ferrocifen, the ferrocene derivative of tamoxifen (Figure 16). These 
compounds do not interact with DNA directly but form reactive oxygen species 
which leads to oxidative DNA damage. 
 
 
Figure 16. Structures of some anticancer agents: (a) NAMI-A, (b) KP1019, (c) 
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Some titanium(IV) complexes have shown promising results and titanocene 
dichloride (Figure 16) was the first of these compounds to enter clinical trials. 
The downfall to these compounds is their poor aqueous solubility and 
substituted titanocenes are currently being developed to combat this (e.g. 
Titanocene Y)74. The mechanism of action of titanocenes is not fully understood 
but they are thought to covalently bind to DNA and induce apoptosis75. 
 
Although arsenic can cause severe health problems in high concentrations, 
arsenic compounds (e.g. arsenic trioxide) have been shown to have many 
anticancer properties70,76. Arsenic trioxide and its methylated species are 
known carcinogens,77 yet As2O3 has been proven to be very effective against 
certain haematological malignancies, such as acute promyelocytic leukemia78. 
Arsenic compounds target the mitochondrial proteins involved in regulating the 
production of reactive oxygen species. The inhibition of these proteins leads to 
an increase in reactive oxygen species and induces apoptotic signalling 
pathways70. 
 
The use of silver(I) in anticancer therapies has been very limited to date. There 
are now many research groups investigating the anticancer activity of silver(I) 
and the results appear promising. The silver(I) complex [Ag2(phen)3(mal)]·H2O 
(phen = 1,10-phenanthroline, malH2 = malonic acid) has been shown to be 3.5 
times more active than cisplatin at inhibiting human renal and hepatocellular 
cancer cells in vitro79, while silver(I)-coumarin complexes were found to be 
between 2.5 and 5.5 times more cytotoxic than cisplatin72,80. There was also a 
tendency for the coumarin complexes to be selectively cytotoxic to the 
carcinoma-derived cell lines relative to normal renal and hepatic cells. Activity 
towards breast and ovarian cancer has also been reported, with preliminary in 
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1.5 Introduction to Silver 
 
1.5.1 A Brief History of Silver 
The chemical symbol for silver, Ag, is derived from the Latin argentum, meaning 
shiny or glistening. It is commonly found throughout nature as the metal and as 
sulfide ores, usually accompanied by sulfides of Fe, Cu and Ni83. Its abundance 
in the Earth’s crust is 0.07 ppm and it is isolated as a by-product in the 
processing of certain metal ores, such as galena (PbS) and copper pyrite 
(CuFeS2), as well as cyanide leaching from silver ores84. The final purification of 
silver is generally carried out by electrolysis. It has been widely used 
throughout history, in jewellery, ornaments and coinage material, and also has 
medicinal, photographic and catalytic applications.  
 
1.5.2 The Chemistry of Silver 
Silver exists in two isotopic forms, 107Ag and 109Ag, found in similar proportions. 
The metal has the highest known electrical and thermal conductivities of all 
metals and its outer electronic configuration is 5s1 4d10. Due to this 
configuration, silver metal is borderline between main group metals and 
transition metals. While Ag0 is relatively inert, the oxidised species, Ag+ and 
Ag2+, can undergo many reactions. The interconversion of Ag0 and Ag+ can be 
understood by studying the reduction potential of this couple in water83:  
 
Ag+  +  e-                 Ag0      E0 = +0.799 V 
 
The reduction potential of +0.799 V indicates a relatively strong 
thermodynamic driving force for the reduction of free, uncomplexed Ag+ ions to 
the Ag0 state. However, the presence of complexing ligands can greatly affect 
this potential83. For example, when the Ag+ ion is ligated with two ammonia 
ligands reduction to Ag0 becomes more difficult, while with cyanide ligands 
reduction becomes even less likely: 
 
Chapter 1.                                                                                                               Introduction 
30 
[Ag(NH3)2]+  +  e-                 Ag(s)  +  2NH3      E0 = +0.37 V 
[Ag(CN)2]-  +  e-                  Ag0  +  2CN-       E0 = -0.31 V 
 
Phototropic glass utilises this reversible property of silver. It contains an Ag+ 
halide salt, which darkens on exposure to sunlight. Under these conditions, the 
electrons in the halide ions acquire enough energy to move and reduce the Ag+ 
ions to metallic Ag0. The resulting silver atoms then aggregate into tiny 
particles, scattering light and turning the glass dark. The reaction reverses upon 
the removal of the light source. 
 
The Ag+ ion, with its d10 electron configuration, has zero ligand field 
stabilisation energy (LFSE) and will form labile complexes in which there will 
be rapid exchange of the original ligand set for new ligands available from the 
surrounding system. The low charge density on Ag+ allows it to act as a ‘soft’ 
Lewis acid and, as such, will tend to have a relatively small affinity for ‘hard’ O-
donors, a large affinity for ‘soft’ S-, Se- and P-donors,  and a moderate affinity 
towards N-donor atoms. Studies on ligand-exchange reactions have suggested 
the relative order of Ag+ bond strengths to be85:  
 
Ag-P > Ag-S >> Ag-Cl > Ag-N >> Ag-O 
 
Transition metals have been used widely in organic synthesis for many 
decades86-88. Silver is used in heterogeneous oxidation processes and 
homogeneous silver-mediated and catalysed reactions. Silver(I) is considered a 
mild oxidising agent and, as such, is suitable for the efficient oxidation of 
primary and secondary alcohols to aldehydes and ketones89. Silver(I) oxide 
(Ag2O) in aqueous ammonia is known as Tollens’ reagent and is used to oxidise 
aldehydes to carboxylic acids, producing metallic silver in the process90. In 
many cases, the application of silver in organic synthesis is driven by its Lewis 
acidity and the solubility of its salts, in particular its halogen salt formations91. 
The silver salts activate the reactions towards nucleophilic substitutions and 
eliminations by interacting with the halogen atom forming insoluble silver 
halides.  
Chapter 1.                                                                                                               Introduction 
31 
Research into the catalytic properties of silver(I) was inspired by the use of 
gold(I) as a catalyst in organic synthesis92-94 and these have been utilised 
extensively since then89. The advantages of using a silver catalyst include 
shorter reaction times, increased stability towards exposure to air and 
moisture, and ease of preparation and storage. Some examples of silver(I) 
catalysts include the BINAP-Ag(I) catalyst (BINAP = 2,2'-
bis(diphenylphosphino)-1,1'-binaphthyl) for enantioselective allylation of 
aldehydes with allylic stannanes,95 and an amino acid derived phosphine-Ag(I) 
catalyst that efficiently promotes enantioselective Mannich reactions of silyl 
ethers and aryl imines regardless of the quality of the solvent or exposure of the 
reaction mixture to air96. 
 
1.5.3 Coordination Chemistry of Silver 
Silver has four oxidation states, with Ag(I) being the most common. The 
spherically symmetric configuration of the Ag(I) ion allows the coordination 
number to vary from 2-6. The dz2 and s orbitals of silver are close in energy 
allowing for extensive hybridisation to occur97,98. Electrons within these hybrid 
orbitals (Ψ1 and Ψ2) form a high electron density circular region repelling 
ligands, and also a relatively low electron density region above and below this 
ring in which ligands are attracted. The further mixing of the Ψ2 and pz orbitals 
leads to two hybrid orbitals suitable for forming linear covalent bonds (Figure 
17).  
 
Silver(I) is stable in aqueous solution as [Ag(H2O)2]+ but the Ag+ ion has a low 
affinity for the hard aqua ligand giving a tendency for its crystalline inorganic 
salts to be anhydrous. Silver halides (AgX) can easily be prepared by direct 
addition of X- to Ag+ solutions and their solubility in water increases in the 
order Cl > Br > I. The solubility of silver(I) halides is increased in an alkaline 
solution of ammonia due to the formation of [Ag(NH3)2]+[X]- salts. Silver(I) 
halides can react with further halide ions to yield anionic complexes which can 
occur in polymeric form84, while cationic species, such as [Ag2X]+ and [Ag3X2]+, 
can be formed when silver halides are reacted with either AgNO3 or AgClO4. 
Chapter 1.                                                                                                               Introduction 
32 
Silver halides are highly light-sensitive and it is this property that makes them 
useful in photography. 
 
Figure 17. Hybrid orbitals from (a) a dz2 and s orbital (Ψ1 and Ψ2) and (b) the 
hybrids that can be formed from Ψ2 and the pz orbital. 
 
Silver complexes containing N-donor ligands readily form in aqueous solutions 
with large formation constants observed for complexes of the type [AgL]+ and 
[AgL2]+ due to their preference for linear coordination99. Tetrahedral silver(I) 
complexes can be formed when nonaqueous conditions are employed83 and 
complexes with a square planar geometry are also known100. There has been 
extensive research into silver(I) complexes with N-donor ligands, including 
those of aromatic ligands such as azoles101-103. The most important classes of O-
donor ligands for complexation with silver(I) include carboxylates, crown 
ethers and calixarenes. Silver(I) carboxylates are light-sensitive and generally 
very insoluble, which leads to difficulty in their characterisation. Silver(I) also 
forms numerous complexes with the donor atoms S, Se, P and As, and also binds 
to peptides and proteins, with a preference for the thioether sulfur atoms and 
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Argentophilicity is the tendency of Ag(I) ions to aggregate at distances below 
the van der Waals diameter of 3.44 Å104. This tendency is also observed with the 
d10 gold(I) ion (called aurophilicity)105. The covalent radius of a 2-coordinate 
Ag(I) ion (1.33 Å) is larger than that of both Cu(I) (1.13 Å) and Au(I) (1.25 Å)106. 
The ionic radius of Ag+ is 1.29 Å83. Whilst the interaction between the gold(I) 
ions is comparable in strength to hydrogen bonds, the Ag(I)···Ag(I) interactions 
appear to be much weaker. The strength of these interactions can be 
responsible for the structural arrangement of crystals. Whilst aurophilicity in 
gold(I) complexes can be a determining factor in the complex structure, the 
argentophilicity of silver(I) complexes is weaker and the structure may be 
governed by the strength of the hydrogen bonds. 
 
The other oxidation states of silver include Ag(II), Ag(III) and Ag(IV). The Ag2+ 
ion is an orange, transient species ([Ag(H2O)6]2+) produced by the oxidation of 
Ag(I) salts with ozone in strongly acidic solution84. Silver is known to have a 
catalytic effect on the reactions of many gases with fluorine. This is due to the 
formation of the dark brown Ag(II) species, AgF2, as an intermediate. Fluoride 
ions and AgF2 can interact to form the complexes [AgF3]-, [AgF4]2- and [AgF6]4-. 
Ag(II) also forms stable complexes with a variety of nitrogen donor ligands, 
such as pyridine, substituted bipyridines, phenanthroline and porphyrins. They 
are usually formed by reaction of a silver(I) salt with peroxodisulfate in the 
presence of the ligand. Ag(III) and Ag(IV) are not as commonly found. The 
commercially available oxide, AgO, has been shown not to contain Ag(II) but to 
be a mixed-valence compound containing Ag(I) and Ag(III)83. The Ag(III) ion has 
square coordination while the Ag(I) ion has linear coordination. Trisilver 
tetroxide, Ag3O4, contains both divalent and trivalent silver and can be written 
as AgIIAgIII2O4. Fluorination of a mixture of CsCl and AgCl under pressure yields 
the complex salt of tetravalent silver Cs2[AgF6], which contains Ag(IV)84. 
 
1.5.4 Biological Activity of Silver 
Silver is present in the human body at very low concentrations (<2.3 µg l-1) and 
is absorbed through the lungs, gastrointestinal tract, mucus membranes and the 
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skin107. It is absorbed mainly in the form of silver protein complexes but has no 
physiological or biochemical role within the body108. It can be tolerated at high 
concentrations within the body, does not appear to be a cumulative poison and 
is eliminated from the body through the urine and faeces107.  
 
1.5.4.1 Argyria 
Argyria is a condition associated with the accumulation of silver in the blood 
and soft tissues, particularly the skin. It occurs in individuals who are exposed 
to high levels of silver occupationally or through the consumption or inhalation 
of silver hygiene products for long periods. The condition presents itself by the 
darkening of the skin (from blue-grey to black depending on the severity) due 
to the deposition of silver sulfide, silver selenide or colloidal silver, particularly 
in the regions of the sweat glands and hair follicles (Figure 18). Argyria cases 
are quite rare and, although cosmetically undesirable, it is not thought to be life-
threatening109. 
 
      
                                       (a)                                                                  (b) 
Figure 18. (a) Rosemary Jacobs, presented with argyria after using nasal drops 
containing colloidal silver for four years and (b) Paul Karason, an argyria 
sufferer. 
 
1.5.4.2 Silver in Health Care 
The antimicrobial properties of silver have been known for centuries. It was 
used in ancient Greece and Rome as a disinfectant, while the Macedonians used 
it to encourage the healing of wounds110. With the advent of modern antibiotics 
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in the 20th century, silver became less favoured. However, in more recent times 
silver has been incorporated into many medicinal and commercial products due 
to its high antimicrobial potency. Such products include plasters, dressings, 
clothing, mobile phones, washing machines, paints and even antiperspirant 
sprays (Figure 19). 
 
                   
                                   (a)                                                                     (b) 
Figure 19. (a) Curad plasters which contain a fine mesh of silver(0) and (b) 
Aquacel Ag Hydrofibre dressing on a leg wound. 
 
It is thought that the antimicrobial properties of silver complexes is dependent 
on the release of biologically active silver(I) ions108,111. The exact mode of action 
of the Ag+ ions is still a matter for debate, but silver-related degenerative 
changes in bacterial RNA and DNA, mitochondrial respiration and cytosolic 
protein have been shown to lead to cell death112. In C. albicans, silver(I) inhibits 
the enzyme phosphomannose isomerase by binding to thiol groups on cytesine 
residues113,114. This enzyme is essential in the synthesis of the cell wall and 
defects lead to the release of vital nutrients, such as phosphates and glutamine. 
 
Silver is being incorporated into many materials to give increased antimicrobial 
protection115. Clinical catheters for central vascular insertion or for urethral 
drainage are notoriously prone to infection with nosocomial organisms,  leading 
to biofilm formation, infection and blockages116. New technologies have 
incorporated silver as a component of catheter polymers or as a hydrophilic 
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coating to inhibit the growth of bacteria and fungi117,118. Occasionally, other 
antibiotics (e.g. gentamycin) are included to compliment the activity of the 
silver. Infection associated with the insertion of surgical pins, screws and 
prostheses is also a common problem. Research is ongoing into the use of silver 
within these devices, or in the form of coatings, to prevent infection. 
Polymethacrylate bone cements containing silver have been proven to inhibit 
the growth of P. aeruginosa, S. aureus and E. coli in vitro but have yet to be 
proven in clinical trials116. Although infection associated with prosthetic valves 
in cardiovascular surgery leads to an 80% fatality rate, silver devices have had 
very limited success in lowering this figure116. 
 
In the past number of years, a new generation of silver-containing wound 
dressings have become available for use, such as Arglaes (Medline), Aquacel Ag 
(Conva Tec) and Calgitrol (Magnus Bio-Medical Technologies). They have 
proven to be very effective at inhibiting the growth of S. aureus, E. coli and C. 
albicans with the form, location and release rate of the silver being a major 
influence on their efficacy119-121. In clinical use, these dressings have promoted 
wound cleansing, controlled inflammation and bacterial load, and improved the 
healing time of chronic wounds122. In each case, wound fluids and exudates 
trigger the release of free silver ions for antimicrobial action and absorption 
into tissues of the wound bed. 
 
Silver sulfadiazine is the most important and widely used medicinal silver-
containing product. It is marketed under the names of Silvadene and Flamazine 
and contains silver(I) sulfadiazine in a 1% concentration. It is used in the 
treatment of burns (Figure 20) where it releases silver ions into the wound site. 
It has been shown that approximately 10% of the silver released is absorbed 
into the wounds, with a higher percentage uptake in more vascularised 
wounds109.  
 
Research into the antimicrobial properties of silver has continued growing over 
the last number of years and there are now many different silver complexes 
exhibiting a broad spectrum of antimicrobial action. The present research work 
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aims to provide alternatives to some of the products on the market, to widen 
the spectrum of microbial pathogens susceptible to silver and also to target 





Figure 20. Silver sulfadiazine, the active ingredient in the antimicrobial burn 
cream Flamazine. 
 
Previous research within our group in NUI Maynooth has shown the 
antimicrobial effect of various silver(I) complexes incorporating ligands such as, 
1,10-phenanthroline,  1,10-phenanthroline-5,6-dione, imidazoles and 



























Figure 21. X-ray crystal structures of the antimicrobial silver(I) complexes (a) 
[Ag2(salH)2(NH3)2] (salH2 = salicylic acid) and (b) [Ag(phendione)2]ClO4 
(phendione = 1,10-phenanthroline-5,6-dione). 
 
A number of antimicrobically active silver(I)-coumarin complexes have also 
been prepared128,129. These complexes possess an ability to disrupt microbial 
respiration and also block the synthesis of cytochromes130. Some silver(I) 
carboxylate complexes have been shown to be highly cytotoxic to cancer cells 
but, unfortunately, they also damaged normal cells131,132. 
 
1.5.4.3 Resistance to Silver  
Microbial resistance to heavy metals is well known133. Unfortunately, silver is 
not exempt from this trend, although presently, silver-resistant microorganisms 
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are not a serious clinical problem121. Definitive evidence that an organism is 
resistant to silver or another metallic agent is provided by molecular biology 
and gene sequencing, which identifies the presence of a mutagenic change 
within its genome. True resistance must be stable within a population and not a 
once-off mutation. The basis of most resistance systems is either the energy-
dependent efflux of toxic ions or the plasmid-mediated binding of toxins134. 
Both mechanisms stop the accumulation of unwanted molecules/ions within 
the cell. 
 
Resistance to silver has been known for many years and is most likely to be 
found in environments where there are high levels of silver present or a high 
usage of silver-containing products. In 1984, Pseudomonas stutzeri AG259 was 
isolated from a silver mine in Utah, USA135. It was found that it carried a plasmid 
encoding for silver resistance, but the actual mechanism of action was not 
determined until recently136. Resistance mechanisms specific to silver ions were 
discovered by analysis of a silver-resistant strain of Salmonella typhimurium 
isolated from a burn patient in Massachusetts General Hospital. This strain was 
transmitted between patients in adjacent rooms and caused severe septicaemia 
fatalities and the closure of the burns unit. The bacterium contained a plasmid 
determinant that encodes a periplasmic silver-specific binding protein (SilE) 
which binds silver at the cell surface, thus protecting the cell. Further genes 
were found (SilA, SilB, SilC, SilP, SilR, and SilS) that encode for two parallel 
efflux pumps which remove any silver ions that had slipped past the binding 
protein136,137 (Figure 22). 
 
At present, there are a number of other bacterial species which have exhibited 
resistance to silver. These include strains of E. coli, Enterobacter cloacae, 
Klebsiella pneumonia and Acinetobacter buamannii134,138,139. These strains have 
only emerged in rare, isolated instances, so it is thought that the risk of transfer 
of the silver resistance genes is low. 
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Figure 22. The proposed function of genes encoding for silver resistance140. 
 
 
1.6 Metal Carboxylate Chemistry 
 
Carboxylates are a very important class of ligand in bioinorganic chemistry. 
This can be accredited to the versatility of the RCOO- ligand and the wide range 
of coordination modes that it can adopt. A large number of carboxylate 
complexes have been characterised and the coordination chemistry of 
carboxylic acids is well documented141. In metal carboxylate complexes the 
cationic metal centres (Mn+) combine with the anionic carboxylate groups 
(RCOO-). The bonding can range from ionic to polar covalent with the physical 
and chemical properties being dependant on the nature of the R group141. 
 
1.6.1 Coordination Modes of Carboxylates 
The carboxylate functional group has four lone pairs of electrons on the two 
oxygen atoms which are available for metal binding (Figure 23). These lone 
pairs can be divided into syn- and anti-lone pairs and are separated by ca. 120°. 
It has been suggested that the syn-lone pairs are more basic than those in the 
anti position142.  
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Figure 23. The carboxylate functional group showing syn- and anti-lone pairs 
of electrons on the oxygen atoms. 
 
There are five different coordination modes for carboxylate groups141: 
 
(i) Ionic. The carboxylate salts of Na+, K+, Rb+ and Cs+ have been shown 
to be ionic and there are only coulombic interactions between the 
metal and the carboxylic anions (Figure 24(a)). 
 
(ii) Monodentate. The metal is coordinated to only one of the carboxylate 
oxygens (Figure 24(b)). 
 
(iii) Bidentate chelating. Carboxylates may coordinate to the metal 
through both oxygen atoms forming a chelate ring. They can do this 
in a symmetrical mode (Figure 24(c)) with the metal-oxygen bonds 
of the same length or in an asymmetrical mode (Figure 24(d)) with 
metal-oxygen bonds of different lengths. The ‘bite angle’ (O-M-O 
angle) for a chelating carboxylate is ca. 60°. 
 
(iv) Bidentate bridging. Carboxylates can form complexes which bridge 
two metal atoms (Figure 24(e)-(g)). Depending on the lone pair of 
electrons used in coordination, the complexes can be syn-syn, syn-
anti or anti-anti. The syn-syn coordination mode allows for the 
possibility of short metal-metal bonds occurring in the complexes. 
 
(v) Monodentate terminal bridging. This is the rarest of the coordination 
modes and is thought to act as an intermediate between other 
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Figure 24. Coordination modes of carboxylate groups. 
 
1.6.2 Synthesis of Metal Carboxylates 
The main synthetic routes to metal carboxylates are:141 
 
(i) Precipitation reactions. The metal salt is reacted with a stoichiometric 
amount of the carboxylic acid in aqueous or alcoholic media. Reactions are 
generally planned so that one of the products will remain in solution and the 
other will precipitate out. 
 
MXn + nM’O2CR  →  M(O2CR)n + nM’X 








































(h) monodentate terminal bridging
M
M
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(ii) Acid/base reactions. Carboxylic acids can be reacted directly with 
electropositive metals or with basic metal salts. 
 
Mg + 2RCO2H  →  Mg(O2CR)2 + H2 
MCO3 + 2RCO2H  →  M(O2CR)2 + CO2 + H2O 
M(OH2) + 2RCO2H  →  M(O2CR)2 + 2H2O 
(M = Ca, Ba, Cu, Zn, etc.) 
 
(iii) Carbon dioxide insertion reactions. Carbon dioxide is inserted into the 
metal-alkyl/aryl or metal-hydride carbon bonds to form the alkyl/aryl 
carboxylate or formate. 
 
PhMgBr + CO2  →  BrMgO2CPh (Grignard reagent) 
[Ru(H)2(PPh3)4] + CO2  →  [RuH(O2CH)(PPh3)3] 
 
(iv) Metathesis reactions. These are carboxylate ligand exchange reactions in 
which a metal carboxylate complex is treated with a large excess of new 
carboxylic acid or carboxylate salt and ligand exchange occurs to generate the 
new metal carboxylate. The reactions proceed by stepwise substitution with 
acetates being the most common starting material. 
 
M(O2CCH3)2 + 2RCO2H  →  M(O2CR)2 + 2CH3CO2H 
(M = Mn, Co, Rh, Ni, Cu, Mo, Ru, etc.; R = C2H5, C6H5, CF3, etc.) 
 
1.6.3 Infra-red Spectra of Carboxylate Complexes143 
The position of the strong C=O absorption band in the carboxylic acid group of 
the free carboxylic acid occurs at ca. 1760-1680 cm-1. Upon complexation to a 
metal centre, this ν(C=O) band disappears and two new bands relating to the 
asymmetric (ν(OCO)asym) and symmetric (ν(OCO)sym) stretches appear in the 
regions 1650-1550 and 1440-1335 cm-1, respectively144. The magnitude of the 
separation between these two bands (Δ(OCO) cm-1) has been used, tentatively, as 
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a diagnostic aid in the determination of the nature of the carboxylate 
coordination143. 
Δ(OCO)  =  (ν(OCO)asym – ν(OCO)sym) cm-1 
 
Guidelines for diagnosing the type of carboxylate coordination based on the IR 
spectrum of the metal complex were compiled by Deacon and Philips143, based 
on eighty four complexed acetates and halogenoacetates143. Their findings 
were: 
 
(i) Ionic acetates (e.g. those of alkali metals) have Δ(OCO) values of ca. 165 
cm-1. For ionic trifluoroacetates the Δ(OCO) value was ca. 235 cm-1. 
 
(ii) Δ(OCO) values <105 cm-1 indicated symmetric chelating carboxylate 
coordination. Complexes in which the carboxylates bridge short 
metal-metal bonds may also exhibit values in this region. 
 
(iii) Δ(OCO) values substantially less than the ionic values (<150 cm-1) 
indicate the presence of chelating or bridging carboxylates. 
Monodentate carboxylates containing hydrogen bonds (pseudo-
bridging) may also fall into this category. 
 
(iv) Δ(OCO) values of transition metal complexes similar to that of ionic 
acetates (ca. 165 cm-1) were found to be untrustworthy as many 
examples of each type of coordination mode were found in this 
category. 
 
(v) Δ(OCO) values of >200 cm-1 indicates monodentate coordination. This 
large difference in energy is thought to arise from the bonding of one 
oxygen atom to the metal with the other oxygen free, increasing the 
energy of the asymmetric stretching mode. 
 
There have been many contradictions to the Δ(OCO) assignments143, primarily 
concerned with locating the exact position of the Δ(OCO)sym absorption band, and 
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as such, great care is required when using these guidelines. Tentative 
assignments for the coordination modes of carboxylate ligands, based on Δ(OCO) 
values, are listed in Table 1. 
 




<105 Symmetric chelating or short bridging 
<150 Chelating or bridging 
ca. 165 Untrustworthy assignments 
>200 Monodentate 
 
1.6.4 Silver Carboxylates 
There are many known silver carboxylate complexes with varying modes of 
coordination. The silver-oxygen bonds have a strong influence on the 
morphology of the complexes but there are also π-π and argentophilic 
interactions to take into consideration.  
 
Zhu et al. have shown coordination polymers containing Ag-Ag bonds with 
mono and bidentate chelation of the carboxylate groups (Figure 25)131.  The Ag-
Ag bonds in these complexes are shorter than that of metallic silver yet the Ag-O 
bonds are slightly longer than those of common Ag-O bonds in aromatic 
carboxylic acids. Yu et al. synthesised a silver(I) complex containing an anion of 
acridine-9-carboxylic acid and in which there is coordination to silver by the 
carboxylate oxygen atoms and the nitrogen of the acridine, forming a 1D 
polymeric chain (Figure 26)145. Other silver(I) carboxylate complexes include 
adducts of AgCF3COO and CH3COO with 2,2’-bipyridyl146, silver-1,2-


















Figure 26. Polymeric structure of [Ag(ac-9-ca)]n (ac-9-caH = acridine-9-
carboxylic acid)145. 
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Figure 27. X-ray crystal structure of silver-acetyl-benzoate147. 
 
1.6.5 9-Anthracenecarboxylic Acid (9-acaH) 
9-Anthracenecarboxylic acid (also known as 9-anthroic acid) is a polycyclic 
aromatic complex consisting of three fused benzene rings with a –COOH group 
substituted at the 9-position (Figure 28). The large conjugated π-system of the 
anthracene ring is currently of interest in the development of fluorescent 
materials. The acid is used as a model compound for electroluminescence148, 
chemosensors149 and photoinduced electron-transfer sensors150-152.  
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It has been shown that the photophysics of 9-acaH is quite different to that of its 
parent molecule, anthracene153. In alcoholic solvents, 9-acaH forms a hydrogen-
bonded dimer in its ground state154 (Figure 29). This then associates with 
another dimer to form an excited tetramer which exhibits a distinctive broad 
fluorescence band at 470 nm155. The dimer is thought to have a linear-type 
configuration in which the two anthracene rings lie on the same plane with the 
carboxylate bridge almost perpendicular to it. More recently, 9-acaH has been 




Figure 29. Hydrogen bonded dimer of 9-anthracenecarboxylic acid. 
 
 
Figure 30. Photodimerisation of 9-anthracenecarboxylic acid. 
 
1.6.6 Metal Complexes of 9-Anthracenecarboxylic Acid 
Many metal complexes contain the 9-anthracenecarboxylate anion (9-aca-) as 
an O-donor ligand and it exhibits a number of different coordination modes. 
Recently, Amini et al. have made di- and triorganotin(IV) complexes with 9-
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carboxylate oxygen atom (Figure 31 and 32) or via the bidentate chelating 
mode. Liu et al. have synthesised Cu(II), Co(II) and Ni(II) complexes containing 
9-acaH158. The dinuclear Cu(II) complex exhibits syn-syn bidentate chelating 
coordination and is linked into chains via intermolecular hydrogen bonds 
(Figure 33). Zinc(II) complexes involving 9-acaH have also been synthesised in 
which the 9-aca- can have either mono- or bidentate coordination modes159. 
 
 
Figure 31. X-ray crystal structures of [Me3Sn(9-aca)]157. 
 
 
Figure 32. X-ray crystal structures of [Me2Sn(9-aca)2·MeOH]157. 
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Figure 33. X-ray crystal structure of (a) [Cu2(9-aca)4(MeOH)2](MeOH) and (b) 





Imidazoles contain a 5-membered aromatic heterocyclic ring with nitrogen 
atoms at the 1- and 3- positions (Figure 34). The carbons are sp2 hybridised and 
each donates one electron into the π-system. The imine nitrogen (3-position) 
donates one electron and the amine nitrogen (1-position) donates its lone pair 
of electrons into the π-system. The lone pair of electrons on the imine nitrogen 
gives imidazole both basic and nucleophilic properties, and it is through this 
lone pair of electrons that imidazole can bond to transition metals, such as 
silver(I). Free energy data obtained from potentiometric studies indicate that 
imidazole forms some of the most stable complexes of all the heterocyclic-N 
ligands102. 
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Figure 34. Imidazole and its resonance structures. 
 
The imidazole ring is incorporated into many important biological molecules, 
such as the amino acid histidine. Imidazole has become an important 
constituent group in many active drug compounds, as already seen with the 
azole antifungal agents. Substitution may occur at each of the five atoms in 
imidazole, yielding a vast array of different ligand molecules for complexation 




1.8 Aims of Research 
 
The purpose of this research was to synthesise new silver(I)-containing 
complexes that would have novel structural features and would be effective 
antimicrobial and anticancer agents. The complexes would contain 9-
anthracenecarboxylate and imidazole ligands and be screened, in vitro, against 
fungal and bacterial pathogens, as well as against selected human cancer cell 
lines. In vivo cytotoxicity and antifungal studies would also be conducted using 
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Figure 35. Imidazole derivitives used as ligands in the current work. (a) 1-
Methylimidazole, (b) 2-methylimidazole, (c) 1-butylimidazole, (d) 2-
phenylimidazole, (e) 4-phenylimidazole, (f) benzimidazole, (g) 2-













































Infrared (IR) spectra were recorded in the region 4,000–370 cm-1 on a Perkin 
Elmer System 2000 FT spectrometer. Solid samples were ground with an excess 
of anhydrous potassium bromide (KBr) and compacted into a disc. Oil samples 
were placed between two sodium chloride windows. 
 
NMR spectra were recorded on a Bruker Avance spectrometer at a probe 
temperature of 25 °C, unless otherwise stated, operating at 300 MHz for the 
1
H 
nucleus and 75.5 MHz for the 
13
C nucleus. Spectra were recorded in deuterated 
dimethylsulfoxide ((CD3)2SO) unless otherwise stated. Chemical shifts are given in 
ppm downfield from the internal standard and coupling constants are given in Hz. 
Data were reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t 
= triplet, q = quartet, quin = quintet, sex = sextet, m = multiplet, and dd = doublet of 
doublets), integration. 
 
Microanalytical data were provided by the Microanalytical Laboratory, National 
University of Ireland Cork, Cork, Ireland and the Microanalytical Laboratory, 
University College Dublin, Belfield, Dublin 4, Ireland. Samples were analysed an 
Exeter Analytical CE-440 elemental analyser in oxygen with a helium carrier gas at 
975 °C in a combustion tube. 
 
X-ray crystallography work was carried out by Prof. Vickie McKee, Chemistry 
Department, Loughborough University, Loughborough, Leics., LE11 3TU, UK. 
The data were collected at 150(2)K on a Bruker APEX II diffractometer. The 
structures were solved by direct methods and refined on F2 using all the 
reflections. All the non-hydrogen atoms were refined using anisotropic atomic 
displacement parameters and hydrogen atoms were inserted at calculated 
positions using a riding model. Parameters for data collection and refinement 
are summarised in the Appendix with a full list available in the Electronic 
Appendix. 
Fluorescence studies were performed by Dr. Patrick Lynch and Dr. Mary 
McNamara, School of Chemical and Pharmaceutical Sciences, Dublin Institute of 
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Technology, Kevin Street, Dublin 2, Ireland. UV-Vis spectra were recorded using 
a Perkin Elmer Lambda 900 UV/VIS/NIR spectrometer using the 
preprogrammed “Sphere” instrumental method. This spectrometer has a 
double-beam, double monochromator ratio recording system with tungsten-
halogen and deuterium lamps as sources. The spectrometer has a range of 175 
to 3300 nm with an accuracy of 0.08 nm in the UV-Vis region. It has a 
photometric range of ± 6 in absorbance. Fluorescence spectra were measured 
using a Perkin Elmer LS55B Luminescence spectrometer and were recorded 
using an attenuated scan method which has a 1% attenuation setting. The 
sample was excited at the λmax of absorption determined using the UV-Vis 
absorption spectra. Excitation was provided by a pulsed xenon discharge lamp, 
of pulse width at half peak height of <10 micro seconds and pulse power of 20 
kW. The source was monochromated using a Monk-Gillieson type 
monochromator with a range of 200-800 nm. The excitation and emission slits 
were set to allow maximum intensity in a complex ligand set. These settings 
were maintained for all measurements within the same complex ligand set to 
allow for comparison of emission intensity between complexes and ligands. 
 
Atomic absorption spectroscopy was performed using a Perkin Elmer AAnalyst 
200 atomic absorption spectrometer and calibration plots were made using 
AgNO3. Samples were ashed in a ceramic crucible over a Bunsen burner and 
dissolved in 50% (v/v) nitric acid. 
 
Sterilisation of microbiological equipment and media was carried out in a 
Dixons ST2228 autoclave at 121 °C and 124 kPa for 20 min. Solutions that were 
susceptible to decomposition during autoclaving were sterilised by membrane 
filtration using 0.45 µm Millipore membrane filters. All worktops and benches 
were sterilised by washing with 70% (v/v) ethanol/water prior to use. 
 
Round-bottomed microtitre plates were read using a Labsystems iEMS Reader 
MF at 540 nm (Candida strains). Flat-bottomed microtitre plates were read 
using a Bio-Tek Synergy HT plate reader at 600 nm (E. coli and MRSA strains). 
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Fungal cell density was measured using a Neubauer hemocytometer under a 
light microscope at a magnification of x400. Bacterial cell density was recorded 
at an optical density of 600 nm using an Eppendorf Biophotometer. 
 
Significance of the survival rates of G. mellonella larvae was analysed at 24, 48 
and 72 h intervals using the log rank (Mantel-Cox) method utilising GraphPad 
Prism software (version 5). Three categories of significance were used (* = 
p<0.05, ** = p<0.01 and *** = p<0.001). 
 
Anticancer studies were carried out by Dr. Denise Egan, Centre for 
Pharmaceutical Research & Development (CPRD), Institute of Technology, 
Tallaght, Dublin 24, Ireland (Hep-G2 and A-498 cell lines) and Dr. Siobhan 
McClean, Centre of Microbial Host Interactions, Institute of Technology Tallaght, 
Dublin 24, Ireland (MCF7 and HT29 cell lines).  
 
 
2.2 Chemicals, Materials and Biological Species 
 
Chemicals were purchased from commercial sources and, unless specified, were 
used without further purification. Solvents were dried and purified in 
accordance with established procedures. 
 
Candida albicans ATCC 10231 was obtained from the American Type Culture 
Collection, Manassas, VA, USA. Escherichia coli was obtained as a clinical isolate 
from the Clinical Microbiology Laboratory, St. James’s Hospital, Dublin, Ireland, 
and was originally isolated from a wound infection. Methicillin Resistant 
Staphylococcus aureus (MRSA) was obtained as a clinical isolate from 
Microbiologics, North St. Cloud Mn, USA, and was originally isolated from a 
wound infection. 
 
Cancer cell lines Hep-G2, A-498, MCF7 and HT29 were purchased from the 
American Tissue Culture Collection (ATCC). 
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Galleria mellonella larvae in the sixth developmental stage were obtained from 
Livefoods Direct Ltd., Sheffield, S25 4JJ, UK. They were stored at 15 °C in wood 
shavings and used within 3 weeks of delivery. 
 
 
2.3 Synthesis of Silver(I) Complexes 
 
The syntheses of all silver complexes were conducted in the absence of light and 
the products were also stored in the dark at all times. 
 
2.3.1 [Ag2(9-aca)2]n  
Method 1: 
Silver(I) oxide (0.695 g, 3.00 mmoles) was suspended in ethanol (20 cm3) and 
added to a refluxing solution of 9-anthracenecarboxylic acid (9-acaH) (1.332 g, 
6.00 mmoles) in ethanol (170 cm3). The resulting green suspension was 
refluxed for 1 h. The solid was filtered off and placed in refluxing ethanol 
(350cm3) for 1 h.  A brown precipitate was filtered off and the filtrate reduced 
to low volume to yield a yellow solid. The yellow solid was filtered, washed with 
cold ethanol and allowed to air-dry. Crystals suitable for X-ray structural 
analysis were obtained by recrystallisation from hot ethanol.  
 
Yield: 0.41 g (21%). 
Molecular formuala (weight): C30H18O4Ag2 (658.18 g mol-1). 
Solubility: soluble in hot EtOH, hot MeOH, DMSO, CHCl3 and MeCN. 
Anal. Calc.: C, 54.74; H, 2.76%.  
Anal. Found: C, 54.36; H, 2.66%. 
IR (cm-1, KBr): 3384, 3047, 1566, 1537, 1429, 1391, 1319, 1275, 1012. 
1H NMR (δ, DMSO): 8.44 (s, 2H); 8.18 (m, 4H); 8.03 (m, 4H); 7.47 (m, 8H). 
 
Method 2: 
Silver(I) oxide (0.695 g, 3.00 mmoles) was suspended in ethanol (15 cm3) and 
added to a solution of 9-anthracenecarboxylic acid (9-acaH) (1.332 g, 6.00 
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mmoles) in ethanol (120 cm3). The mixture was stirred at room temperature for 
24 h. The resulting green precipitate which was filtered, washed with cold 
ethanol and allowed to air dry. This green solid was then taken up in hot 
acetonitrile (160 cm3) and the solution filtered to remove any undissolved 
material. The filtrate was reduced to a low volume on a rotary evaporator to 
yield a yellow solid. This yellow solid was filtered off, washed with cold ethanol 
and allowed to air-dry. 
 
Yield: 1.373 g (70%). 
 
Method 3: 
9-anthracenecarboxylic acid (9-acaH) (1.117 g, 5.03 mmoles) was added slowly 
to a solution of potassium hydroxide (0.282 g, 5.03 mmoles) in water (30 cm3). 
The pH was checked to ensure the solution was neutral and then it was filtered 
to remove any undissolved material. Silver nitrate (0.849 g, 5.03 mmoles) was 
dissolved in  water (10 cm3) and added dropwise to the K+(9-aca)- solution. A 
yellow precipitate immediately formed. The mixture was stirred for 0.5 h, 
filtered and the solid washed with ethanol. The solid was recrystallised from 
hot ethanol to yield crystals suitable for X-ray structural analysis.   
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1H NMR (DMSO): [Ag2(9-aca)2]n 
 
 
2.3.2 [Ag2(9-aca)2(DMSO)2]n  
[Ag2(9-aca)2]n (0.100g, 0.15 mmoles) was dissolved in dimethylsulfoxide (4 
cm3). The mixture was heated to 80 °C for 20 min. Ethanol (15 cm3) was added 
and the solution was brought to reflux and then filtered. The filtrate was left to 
stand and after 3 days yellow needle-like crystals were collected by filtration, 
washed with ethanol and allowed to air-dry. 
 
Yield: 0.062 g (50%). 
Molecular formula (weight): C34H30O6S2Ag2 (814.44 g mol-1). 
Solubility: soluble in MeCN and DMSO. 
Anal. Calc.: C, 50.14; H, 3.71%. 
Anal. Found: C, 50.22; H, 3.70%. 
IR (cm-1, KBr): 3411, 3050, 1620, 1587, 1565, 1538, 1427, 1389, 1320, 1276, 
1018. 












1H NMR (DMSO): [Ag2(9-aca)2(DMSO)2] 
 
 
2.3.3 [Ag(imidH)2.3(CH3CN)0.7](9-aca)  
[Ag2(9-aca)2]n (0.329 g, 0.5 mmoles) was dissolved in hot acetonitrile (70 cm3) 
and the solution was filtered to remove any undissolved material. Imidazole 
(imidH) (0.207 g, 3 mmoles) was dissolved in acetonitrile (10 cm3) and added 
slowly to the [Ag2(9-aca)2]n solution with constant stirring. A white cloudy 
precipitate formed which was removed by filtration. The clear filtrate was 
allowed to stand overnight and white crystals formed. The crystals were 
washed with acetonitrile and air-dried.  
 
Yield: 0.09 g (18%). 
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Molecular formula (weight): C23.30H20.30N5.30O2Ag (514.42 g mol-1). 
Solubility: soluble in MeOH, hot EtOH and DMSO. 
Anal. Calc.: C, 54.40; H, 3.98; N, 14.43%.  
Anal. Found: C, 54.15; H, 3.91; N, 14.61%. 
IR (cm-1, KBr): 3436, 3128, 3030, 2923, 2837, 2700, 2624, 2250, 1625, 1562, 
1448, 1426, 1390, 1320, 1275, 1261, 1072. 
1H NMR (δ, DMSO): 8.41 (s, 1H); 8.15 (m, 2H); 8.03 (m, 2H); 7.90 (s, 2.5H); 7.46 





1H NMR (DMSO): [Ag(imidH)2.3(CH3CN)0.7](9-aca) 
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2.3.4 [Ag6(imidH)4(9-aca)6(MeOH)2]  
[Ag2(9-aca)2]n (0.109 g, 0.16 mmoles) was suspended in methanol (10 cm3) and 
to this was added a methanolic solution of imidazole (1 cm3, 0.16 M, 0.16 
mmoles). The mixture was stirred for 1 h and then filtered. Diethyl ether was 
added to the filtrate to precipitate the pale yellow product. The solid was 
filtered off, washed with diethyl ether and air-dried.  
 
Yield: 0.04g (44%). 
Molecular formula (weight): C104H78N8O14Ag6 (2310.96 g mol-1). 
Solubility: soluble in MeOH and DMSO. 
Anal. Calc.: C, 54.05; H, 3.40; N, 4.85%. 
Anal. Found: C, 53.75; H, 3.39; N, 4.73%. 
IR (cm-1, KBr): 3448, 3045, 1625, 1538, 1484, 1433, 1393, 1320, 1273, 1238, 
1178, 1090. 
1H NMR (δ, DMSO):  8.46 (s, 6H); 8.16 (m, 12H); 8.06 (m, 12H); 7.49 (m, 24H); 
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1H NMR (DMSO): [Ag6(imidH)4(9-aca)6(MeOH)2] 
 
 
2.3.5 [Ag(1-Me-imidH)2]2[Ag4(9-aca)6]  
[Ag2(9-aca)2]n (0.165 g, 0.25 mmoles) was suspended in ethanol (30 cm3) and 
heated gently. 1-Methylimidazole (0.82 g, 1 mmole) was added directly to the 
hot suspension of [Ag2(9-aca)2]n and the mixture immediately turned clear. It 
was filtered to remove any insoluble particles and the filtrate was reduced to a 
low volume on a rotary evaporator. Diethyl ether was added to precipitate the 
beige solid, which was filtered off, washed with diethyl ether and allowed to air-
dry. The solid was dissolved in DMSO and the solution reduced on a rotary 
evaporator to yield the beige product. 
 
Yield: 0.075 g (37%). 
Molecular formula (weight): C106H78N8O12Ag6 (2303.01 g mol-1). 
Solubility: soluble in hot MeOH, EtOH and DMSO. 
Anal. Calc.: C, 55.27; H, 3.42; N, 4.87%. 
Anal. Found: C, 54.98; H, 3.42; N, 4.63%. 
IR (cm-1, KBr): 3468, 3116, 1621, 1565, 1536, 1428, 1392, 1321, 1275, 1235, 
1180, 1112, 1087, 1017. 
1H NMR (δ, DMSO): 8.40 (s, 6H); 8.16 (m, 12H); 8.05 (m, 12H); 7.84 (s, 4H); 7.46 
(m, 24H); 7.28 (s, 4H); 7.03 (s, 4H); 3.72 (s, 12H). 
 
 





1H NMR (DMSO): [Ag(1-Me-imidH)2]2[Ag4(9-aca)6] 
 
 
2.3.6 [Ag2(1-Me-imid)2(9-aca)2]  
[Ag2(9-aca)2]n (0.165 g, 0.25 mmoles) was suspended in ethanol (30 cm3) and 
heated gently. 1-Methylimidazole (0.82 g, 1 mmole) was added directly to the 
hot suspension of [Ag2(9-aca)2]n and the mixture immediately turned clear. It 
was filtered to remove any insoluble particles and the filtrate was reduced to a 
low volume on a rotary evaporator. Diethyl ether was added to precipitate the 
beige product, which was filtered off, washed with diethyl ether and allowed to 
air-dry.  
 
Yield: 0.093 g (45%). 
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Molecular formula (weight): C38H30N4O4Ag2 (822.46 g mol-1). 
Solubility: soluble in hot MeOH, EtOH and DMSO. 
Anal. Calc.: C, 55.49; H, 3.68; N, 6.81%. 
Anal. Found: C, 55.31; H, 3.72, N, 6.70%. 
IR (cm-1, KBr): 3411, 3116, 1612, 1566, 1536, 1428, 1391, 1320, 1275, 1235, 
1180, 1111, 1086, 1017. 
1H NMR (δ, CDCl3):  8.36 (m, 3H); 7.95 (m, 2H); 7.55 (s, 1H); 7.45 (m, 4H); 7.00 





1H NMR (CDCl3): [Ag2(1-Me-imidH)2](9-aca)2 
 
 


























Chapter 2.                                                                                                              Experimental 
65 
2.3.7 [Ag(2-Me-imidH)2(9-aca)]  
[Ag2(9-aca)2]n (0.068 g, 0.10 mmoles) was dissolved in acetonitrile (10 cm3) and 
a solution of 2-Methylimidazole (0.035 g, 0.40 mmoles) in acetonitrile (2 cm3) 
was added dropwise with stirring. A white precipitate immediately formed 
which quickly redissolved. The solution was stirred for 1 h at room temperature 
and a yellow precipitate formed. The yellow solid was collected by filtration, 
washed with a small portion of ethanol and diethyl ether. The yellow solid was 
recrystallised from acetonitrile to yield light yellow crystals suitable for X-ray 
crystal analysis. 
 
Yield: 0.050 g (51%). 
Molecular formula (weight): C23H21N4O2Ag (493.31 g mol-1). 
Solubility: soluble in MeOH, EtOH, MeCN and DMSO. 
Anal. Calc.: C, 56.00; H, 4.29; N, 11.36%. 
Anal. Found: C, 55.70; H, 4.29; N, 11.08%. 
IR (cm-1, KBr): 3047, 2909, 2855, 2685, 1590, 1554, 1484, 1422, 1386, 1358, 
1318, 1275, 1166, 1130, 1113, 1013. 
1H NMR (δ, DMSO):  8.43 (s, 1H); 8.20 (m, 2H); 8.08 (m, 2H); 7.50 (m, 4H); 7.08 
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1H NMR (DMSO): [Ag(2-Me-imidH)2(9-aca)] 
 
 
2.3.8 [Ag(1-Bu-imid)2]2[Ag4(9-aca)6]  
[Ag2(9-aca)2]n (0.750 g, 1.14 mmoles) was dissolved in hot acetonitrile (80 cm3) 
and the solution filtered and cooled to room temperature. 1-Butylimidazole 
(0.567 g, 4.56 mmoles) was added and the resulting solution was stirred at 
room temperature for 20 h. After gravity filtration the filtrate was reduced to a 
low volume on a rotary evaporator and diethyl ether added to yield a beige 
precipitate. The solid was filtered off, washed with diethyl ether and allowed to 
air-dry. The solid was recrystallised from hot to yield yellow crystals, which 
were filtered, washed with cold ethanol (1 cm3) and allowed to air-dry. 
 
Yield: 0.301 g (51%). 
Molecular formula (weight): C118H102N8O12Ag6 (2471.30 g mol-1). 
Solubility: soluble in MeOH, hot EtOH, CHCl3 and DMSO. 
Anal. Calc.: C, 57.35; H, 4.16; N, 4.53%. 
Anal. Found: C, 57.23; H, 4.23; N, 4.47%. 
IR (cm-1, KBr): 3468, 2958, 1622, 1565, 1536, 1427, 1391, 1321, 1274, 1232, 
1179, 1112, 1085, 1018. 
1H NMR (δ, DMSO):  8.44 (s, 6H); 8.20 (m, 12H); 8.06 (m, 16H); 7.47 (m, 28H); 
7.13 (s, 4H); 4.06 (t, 8H); 1.73 (quin, 8H); 1.23 (sex, 8H); 0.90 (t, 12H). 
 
 





1H NMR (DMSO): [Ag(1-Bu-imid)2]2[Ag4(9-aca)6] 
 
 
2.3.9 [Ag2(1-Bu-imid)2(9-aca)2]  
[Ag2(9-aca)2]n (0.750 g, 1.14 mmoles) was dissolved in hot acetonitrile (80 cm3) 
and the resulting solution was filtered and cooled to room temperature. 1-
Butylimidazole (0.567 g, 4.56 mmoles) was added to the [Ag2(9-aca)2]n solution 
and the mixture stirred at room temperature for 20 h. The solution was gravity 
filtered and the filtrate reduced on a rotary evaporator to a low volume and 
diethyl ether was added to yield a beige precipitate. The product was filtered, 
washed with cold ethanol and allowed to air-dry. 
 
Yield: 0.734g (71%). 
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Molecular formula (weight): C44H42N4O4Ag2 (906.56 g mol-1). 
Solubility: soluble in MeOH, hot EtOH, CHCl3 and DMSO. 
Anal. Calc.: C, 58.29; H, 4.67; N, 6.18; Ag, 23.80%.  
Anal. Found: C, 58.33; H, 4.67; N, 6.16; Ag, 23.42%. 
IR (cm-1, KBr): 3652, 3393, 2958, 2872, 1611, 1567, 1429, 1392, 1320, 1275, 
1232, 1172, 1156, 1112, 1086, 1016. 
1H NMR (δ, DMSO): 8.43 (s, 2H); 8.17 (m, 4H); 8.04 (m, 4H); 8.00 (s, 2H); 7.47 
(m, 8H); 7.40 (s, 2H); 7.10 (s, 2H); 4.05 (t, 4H); 1.72 (quin, 4H); 1.25 (sex, 4H); 





1H NMR (DMSO): [Ag2(1-Bu-imid)2(9-aca)2] 
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2.3.10 [Ag(apim)](9-aca)·H2O  
[Ag2(9-aca)2]n (0.500 g, 0.76 mmoles) was dissolved in hot acetonitrile (70 cm3) 
and the solution filtered to remove any undissolved particles. 1-(3-
Aminoproply)imidazole (0.190 g, 1.52 mmoles) was dissolved in acetonitrile (5 
cm3) and added to the [Ag2(9-aca)2]n solution with stirring. The suspension was 
stirred for 0.5 h at room temperature and the beige solid was filtered off, 
washed with acetonitrile and air-dried. The product was recrystallised from a 
9:1 mixture of ethanol:methanol to yield colourless crystals suitable for X-ray 
analysis.  
 
Yield: 0.589g (82%). 
Molecular formula (weight): C21H22N3O3Ag (472.29 g mol-1). 
Solubility: soluble in MeOH, hot EtOH and DMSO. 
Anal. Calc.: C, 53.40; H, 4.70%; N, 8.90%.  
Anal. Found: C, 53.31; H, 4.58%; N, 8.89%. 
IR (cm-1, KBr): 3427, 3236, 3129, 3046, 2932, 1568, 1518, 1425, 1389, 1319, 
1277, 1231, 1112, 1089, 1055. 
1H NMR (δ, DMSO): 8.39 (s, 1H); 8.15 (m, 2H); 8.01 (m, 2H); 7.87 (s, 1H); 7.44 
(m, 4H); 7.33 (s, 1H); 7.01 (s, 1H); 4.11 (t, 2H); 2.61 (t, 2H); 1.93 (quin, 2H).  
COSY NMR (DMSO): shows coupling between protons on the imidazole ring that 
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1H NMR (DMSO): [Ag(apim)](9-aca)•H2O 
 
 
2.3.11 [Ag(2-Ph-imid)]  
[Ag2(9-aca)2]n (0.500 g, 0.76 mmoles) was dissolved in hot acetonitrile (40 cm3) 
and the solution was filtered to remove any undissolved material. 2-
Phenylimidazole (0.219 g, 1.52 mmoles) was dissolved in hot acetonitrile (20 
cm3) and this was added to the hot [Ag2(9-aca)2]n solution. The resulting 
suspension was stirred at room temperature for 0.25 h. The beige precipitate 
was filtered, washed with ethanol and air-dried. 
 
Yield: 0.246 g (64%). 
Molecular formula (weight): C9H7N2Ag (251.05 g mol-1). 
Solubility: The complex was only slightly soluble in DMSO. 
Anal. Calc.: C, 43.06; H, 2.82; N, 11.16%. 
Anal. Found: C, 43.62; H, 2.81; N, 10.58%. 
IR (cm-1, KBr): 3445, 3040, 1601, 1578, 1482, 1458, 1413, 1318, 1298, 1280, 
1147, 1074, 1023. 















[Ag2(9-aca)2]n (0.658 g, 1.00 mmoles) was dissolved in hot acetonitrile (100 
cm3) and the solution was filtered to remove any undissolved material. 4-
Phenylimidazole (0.438 g, 3.04 mmoles) was dissolved in hot acetonitrile and 
added to the hot solution of [Ag2(9-aca)2]n. The mixture was stirred at room 
temperature for 0.5 h. The suspension was filtered and the beige precipitate 
was washed with a small portion of cold ethanol and air-dried.  
 
Yield: 0.887 g (81%). 
Molecular formula (weight): C33H25N4O2Ag (617.44 g mol-1). 
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Solubility: soluble in DMSO. 
Anal. Calc.: C, 64.19; H, 4.08; N, 9.07; Ag, 17.47%. 
Anal. Found: C, 63.74; H, 4.14; N, 8.88; Ag, 17.78%. 
IR (cm-1, KBr): 3430, 3280, 3129, 3057, 2977, 2821, 2709, 2633, 1614, 1579, 
1553, 1495, 1442, 1424, 1387, 1355, 1318, 1273, 1180, 1136, 1073, 1029, 1012. 
1H NMR (δ, DMSO):  8.47 (s, 1H); 8.14 (m, 2H); 8.06 (m, 2H); 7.88 (s, 2H); 7.83 





1H NMR (DMSO): [Ag(4-Ph-imid)2(9-aca)] 
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2.3.13 [Ag(4,5-dicyanoimid)]  
[Ag2(9-aca)2]n (0.500 g, 0.76 mmoles) was dissolved in hot acetonitrile (50 cm3) 
and the solution filtered to remove any undissolved material. 4,5-
Dicyanoimidazole (0.359 g, 3.04 mmoles) was dissolved in acetonitrile (5 cm3) 
and added to the hot [Ag2(9-aca)2]n solution. A beige precipitate immediately 
formed and the suspension was stirred at room temperature for 1 h. The beige 
solid was filtered, washed with a small portion of cold ethanol and air-dried. 
 
Yield: 0.240 g (70%). 
Molecular formula (weight): C5HN4Ag (224.97 g mol-1). 
Solubility: insoluble in water and all common solvents. 
Anal. Calc.: C, 26.69; H, 0.49; N, 24.91%. 
Anal. Found: C, 26.62; H, 0.41; N, 24.59%. 
IR (cm-1, KBr): 3534, 2227, 2176, 1748, 1720, 1583, 1492, 1471, 1457, 1438, 
1321, 1303, 1283, 1250, 1115, 1105, 958, 878, 861. 





2.3.14 [Ag(Benz-imid)]  
[Ag2(9-aca)2]n (0.200 g, 0.30 mmoles) was suspended in methanol (40 cm3) at 
room temperature and a solution of benzimidazole (0.072 g, 0.60 mmoles) in 
methanol (5 cm3) was added to the suspension. A beige precipitate formed and 
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the suspension was stirred at room temperature for 0.5 h. The beige solid was 
filtered, washed with cold methanol and air-dried. 
 
Yield: 0.093 g (68%). 
Molecular formula (weight): C7H5N2Ag (225.01 g mol-1). 
Solubility: insoluble in water and all common solvents. 
Anal. Calc.: C, 37.36; H, 2.24; N, 12.45%. 
Anal. Found: C, 37.65; H, 2.29; N, 11.97%. 
IR (cm-1, KBr): 3443, 3073, 1759, 1609, 1584, 1463, 1453, 1365, 1300, 1281, 
1239, 1185, 1145, 1113, 1015, 999. 






[Ag2(9-aca)2]n (1.000 g, 1.52 mmoles) was dissolved in hot acetonitrile (100 
cm3) and the solution was filtered to remove any undissolved material. The 
filtrate was brought to reflux and a solution of 2-methylbenzimidazole (0.804 g, 
6.08 mmoles) in hot acetonitrile (30 cm3) was added. A white precipitate 
immediately formed. The suspension was removed from the heat source and 
was stirred at room temperature for 1 h. The beige solid was filtered off, 
washed with a small portion of cold ethanol and air-dried.  
 
Yield: 1.562 g (87%). 
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Molecular formula (weight): C62H50N8O4Ag2 (1186.88 g mol-1). 
Solubility: soluble in hot MeOH and DMSO. 
Anal. Calc.: C, 62.74; H, 4,25; N, 9.44%. 
Anal. Found: C, 62.40; H, 4.17; N, 9.44%. 
IR (cm-1, KBr): 3446, 3047, 2524, 1888, 1625, 1599, 1558, 1532, 1456, 1427, 
1388, 1318, 1282, 1223, 1041, 1005. 
1H NMR (δ, DMSO): 8.63 (s, 1H); 8.09 (m, 4H); 8.03 (s, 2H); 7.56 (m, 4H); 7.49 





1H NMR (DMSO): [Ag2(2-Mebenz-imidH)4](9-aca)2 
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2.3.16 [Ag(2-Mebenz-imid)]  
[Ag2(9-aca)2]n (0.500 g, 0.76 mmoles) was suspended in methanol (50 cm3) at 
room temperature. 2-Methylbenzimidazole (0.201 g, 1.52 mmoles) was 
dissolved in methanol (10 cm3) and added to the stirring suspension of [Ag2(9-
aca)2]n. The mixture was heated and a beige precipitate formed. The solid was 
filtered while hot, washed with methanol and allowed to air-dry. 
 
Yield: 0.288 g (79%). 
Molecular formula (weight): C8H7N2Ag (239.04 g mol-1). 
Solubility: insoluble in water and all common solvents. 
Anal. Calc.: C, 40.19; H, 2.96; N, 11.72%. 
Anal. Found: C, 40.27; H, 2.97; N, 11.24%. 
IR (cm-1, KBr): 3434, 3056, 3025, 2915, 1868, 1751, 1608, 1579, 1473, 1448, 
1397, 1285, 1226, 1148, 1110, 1076, 1002. 





2.3.17 [Ag4(9-aca)4(NH3)2]  
Silver nitrate (0.510 g, 3.00 mmoles) was dissolved in water (5 cm3) and conc. 
Ammonia (density = 0.88 g cm-3) (ca. 1 cm3) was added until all of the 
precipitate redissolved. This solution was added to a solution of 9-
anthracenecarboxylic acid (9-acaH) (0.666 g, 3.00 mmoles) in 4:1 ethanol:water 
(100 cm3). Conc. ammonia (10 cm3) was added slowly with constant stirring 
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and after the addition was complete the solution was stirred for 0.5 h. The 
solution was reduced to near dryness using a rotary evaporator yielding a light 
yellow precipitate, which was washed with cold ethanol and allowed to air-dry. 
To obtain crystals suitable for X-ray structural analysis the original filtrate was 
allowed to slowly evaporate to a low volume over a period of days.  
 
Yield: 0.457 g (45%). 
Molecular formula (weight): C60H42N2O8Ag4 (1350.44 g mol-1). 
Solubility: soluble in hot EtOH, MeCN and DMSO. 
Anal. Calc.: C, 53.36; H, 3.14; N, 2.07%.  
Anal. Found: C, 53.20; H, 3.03; N, 2.12%. 
IR (cm-1, KBr): 3370, 3050, 1620, 1551, 1443, 1424, 1390, 1319, 1277, 1220, 
1155, 1011. 
1H NMR (δ, DMSO): 8.41 (s, 4H); 8.15 (m, 8H); 8.03 (m, 8H); 7.47 (m, 16H); 3.01 
(s, 6H). 
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2.4 Fluorescence Studies 
 
Spectra of the silver(I) complexes were recorded as 1×10-4 M solutions 
prepared in DMSO. Spectra of the metal-free ligands were recorded at the same 
concentration as the ligands that were present in the silver complex solutions. 
 
 
2.5 In vitro Antimicrobial Screening 
 
2.5.1 Microbial Growth Media 
Deionised (Millipore) water was used to make all media. 
 
Minimal Growth Media (MM) was composed of 2% (w/v) glucose, 0.5% (w/v) 
ammonium sulphate and 0.17% (w/v) yeast nigtogen base (without amino 
acids or ammonium sulphate). To solidify the media 2% (w/v) bacteriological 
agar was added when required. 
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Yeast Extract Peptone Dextrose (YEPD) media was composed of 2% (w/v) 
glucose, 2% (w/v) bacteriological peptone, and 1% (w/v) yeast extract. To 
solidify the media 2% (w/v) bacteriological agar was added when required. 
 
Nutrient Broth was obtained from Scharlau Microbiology and made up 
according to the manufacturer’s instructions (13 g in 1 litre deionised water). 
 
Phosphate Buffered Saline (PBS) was obtained from Aldrich and made up 
according to the manufacturer’s instructions (1 tablet in 200 cm3 deionised 
water). 
 
2.5.2 In vitro Fungal Susceptibility Testing 
Candida albicans (ATCC 10231) was grown on Yeast Extract Peptone Dextrose 
(YEPD) agar plates at 37 °C and maintained at 4 °C for short-term storage. 
Cultures were routinely sub-cultured every 4-6 weeks. All assays were run in 
triplicate and on 3 independent occasions. 
 
Fresh solutions of complexes were prepared immediately prior to testing. 
Complexes (0.020 g) were dissolved in DMSO (1 cm3) and added to water (9 
cm3) to give a stock solution (concentration 2000 µg cm-3). Complexes with low 
solubility were tested as fine suspensions. This stock solution (0.5 cm3) was 
added to water (9.5 cm3) to give a solution with a concentration of 100 µg cm-3.  
 
Minimal Media (100 µl) was added to each well of a 96-well, round-bottomed 
microtitre plate. Water (100 µl) was added to column 1 of the plate (negative 
control, media with no fungal cells). Column 2 was the positive control (media 
and fungal cells only). 100 µl of the above complex solution (100 µg cm-3) was 
added to every well in column 3. Serial dilutions (1:1) were made from columns 
3-12 to produce a test concentration range of 50–0.1 µg cm-3.  
 
C. albicans was grown to the stationary phase overnight at 37 °C on YEPD 
media. The cells were washed with PBS solution and resuspended in minimal 
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media at a density of 5×105 cells cm-3. The cell suspension (100 µl) was added to 
every well in columns 2–12. The completed plate was then covered with acetate 
foil (Sarstedt) to prevent dehydration. The plate was incubated at 37 °C with 
continuous shaking for 24 h. The optical density (at 540 nm) of each well was 
recorded at 1 h intervals. Minimum Inhibitory Concentration (MIC100) values 
(minimum concentration required to inhibit 100% of cell growth) were then 
determined. 
 
2.5.3 In vitro Bacterial Susceptibility Testing 
Escherichia coli and Methicillin Resistant Staphylococcus aureus (MRSA) were 
grown on nutrient broth agar plates at 37 °C and maintained at 4 °C for short-
term storage. Cultures were routinely sub-cultured every 4-6 weeks. All assays 
were run in triplicate and on 3 independent occasions. 
 
Fresh solutions of complexes were prepared immediately prior to testing. 
Complexes (0.020 g) were dissolved in DMSO (1 cm3) and added to water (9 
cm3) to give a stock solution (concentration 2000 µg cm-3). Complexes with low 
solubility were tested as fine suspensions. This stock solution (1 cm3) was 
added to water (9 cm3) to yield a solution with a concentration of 200 µg cm-3.  
 
Nutrient broth (100 µl) was added to each well of a 96-well flat-bottomed 
microtitre plate. Water (100 µl) was added to column 1 of the plate (negative 
control). Column 2 was the positive control. 100 µl of the above complex 
solution (200 µg cm-3) was added to every well in column 3. Serial dilutions 
(1:1) were made from column 3-12 to produce a test concentration range of 
100–0.2 µg cm-3.  
 
E. coli and MRSA were grown overnight to the stationary phase in nutrient 
broth at 37 °C and 200 rpm. The cells were diluted to give an OD600 = 0.1. The 
cell suspension (100 µl) was added to every well in columns 2–12. The 
completed plates were incubated at 37 °C in a static incubator and the final 
optical density (600 nm) recorded. Minimum Inhibitory Concentration (MIC50) 
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2.6 In vivo Galleria mellonella Studies 
 
2.6.1 Cytotoxicity Studies 
Galleria mellonella larvae in the 6th developmental stage were used to 
determine the in vivo cytotoxicity of the silver(I) complexes. Ten healthy larvae 
between 0.200-0.400 g in weight with no cuticle discolouration were used for 
each experiment. Fresh solutions of the test complexes were prepared 
immediately prior to testing. Complexes (0.020 g) were dissolved in DMSO (1 
cm3) and added to water (9 cm3) to give a stock solution (concentration 2000 
µg cm-3). Test solutions were made from this stock solution. Each compound 
was tested at three concentrations; twice their MIC100 value, 10 µg cm-3 and 100 
µg cm-3. The test solution (20 µl) was administered to the larvae by injection 
directly into the haemocoel through the last pro-leg. The base of the pro-leg can 
be opened by applying gentle pressure to the sides of the larvae and this 
aperture will re-seal after removal of the syringe without leaving a scar. Larvae 
were placed in sterile petri dishes and incubated at 30 °C for 72 h. The survival 
of the larvae was monitored every 24 h. Death was assessed by the lack of 
movement in response to stimulus together with discolouration of the cuticle. 
 
Three controls were employed in all assays. The first consisted of untouched 
larvae maintained at the same temperature as the test larvae. The second was 
larvae with the pro-leg pierced with an inoculation needle but no substance 
injected into them. The third control was larvae that were inoculated with 20 µl 
of the same sterile water used to make the test solutions. 
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2.6.2 Antifungal Screening 
G. mellonella larvae in the 6th developmental stage were used to determine the 
in vivo antimicrobial activity of the silver(I) complexes. Ten healthy larvae 
between 0.200-0.400 g in weight with no cuticle discolouration were used for 
each experiment. Fresh solutions of complexes were prepared immediately 
prior to testing. Complexes (0.020 g) were dissolved in DMSO (1 cm3) and 
added to water (9 cm3) to give a stock solution (concentration 2000 µg cm-3). 
Test solutions were made from this stock solution. Each compound was tested 
at three concentrations; twice their MIC100 value (µg cm-3), 10 µg cm-3 and 100 
µg cm-3.  
 
C. albicans was grown to the stationary phase in YEPD media at 37 °C for 24 h. 
The cell concentration was assessed using a haemocytometer following a 
dilution of the culture in PBS. The cells were washed three times with PBS and 
resuspended in sterile PBS following harvesting by centrifugation at 4000 rpm 
for 10 min to yield a concentration of 1×108 cell cm-3.  
 
Two treatments were employed in the screening of the test solutions. In each 
case, four controls were employed in all assays along with a reference. The first 
control consisted of untouched larvae maintained at the same temperature as 
the test larvae (negative control). The second was larvae with the pro-leg 
pierced with an inoculation needle but no substance injected into them. The 
third control was larvae that were inoculated with 20 µl of the same sterile 
water used to make the test solutions, and the fourth is larvae inoculated with 
the same sterile PBS solution that was used to wash and make the C. albicans 
suspension. The positive control was larvae inoculated with C. albicans but no 
test solution was administered to them.  
 
2.6.2.1 Prophylactic Treatment 
The test solution (20 µl) was administered to the larvae by injection directly 
into the haemocoel through the last pro-leg. Larvae were then placed in sterile 
petri dishes and incubated at 30 °C for 1 h, after which time they were 
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inoculated with 20 µl of the C. albicans suspension (2×106 cells). The larvae 
were incubated at 30 °C for 72 h and larvae survival was monitored every 24 h.  
 
2.6.2.2 Treatment of Infection 
Larvae were inoculated with 20 µl of the C. albicans suspension (2×106 cells) by 
injection directly into the haemocoel through the last pro-leg. Larvae were then 
placed in sterile petri dishes and incubated at 30 °C for 1 h, after which time the 
test solution (20 µl) was administered by injection. The larvae were incubated 
at 30 °C for 72 h and larvae survival was monitored every 24 h. 
  
 
2.7 In vitro Anticancer Screening 
 
2.7.1 Hep-G2 and A-498 cell lines: 
Human hepatocellular liver carcinoma (Hep-G2) and human renal carcinoma (A-
498) cells were grown as a monolayer in Eagle’s minimum essential medium, 
supplemented with 2.00 mM L-glutamine and Earle’s balanced salt solution, 
containing 1.500 g dm-3 sodium bicarbonate, 0.10 mM non-essential amino 
acids, 1.00 mM sodium pyruvate, 100 µg cm-3 penicillin and 100 µg cm-3 
streptomycin supplemented to contain 10% (v/v) foetal bovine serum. Cells 
were grown at 37 °C in a humidified atmosphere in the presence of 5% CO2 and 
were in the exponential phase of growth at the time of assay. A 100 μl aliquot of 
Hep-G2 and A-498 cells were seeded at a density of 5x104 and 2.5x104 cells cm-3, 
respectively, into sterile 96-well, flat-bottomed plates and grown in 5% CO2 at 
37 °C. Test complexes were dissolved in DMSO and diluted with culture media. 
The maximum percentage of DMSO present in all wells was 0.2 % (v/v). Each 
drug solution (100 μl) was added to replicate wells (5 replicates) in the 
concentration range of 0.1-500 µM and incubated for 96 h. A miniaturised 
viability assay, using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide (MTT), was carried out. This method is based on the reduction of the 
tetrazolium salt, methylthiazolyldiphenyl-tetrazolium bromide (MTT) into a 
crystalline blue formazan product by the cellular oxidoreductases of viable cells. 
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The resultant formazan crystal formation is proportional to the number of 
viable cells. 
 
Following drug incubation, cells were assayed by the addition of 20 µl of 5 mg 
cm-3 MTT in 0.1 M PBS (pH 7.2) and incubated for 4 h at 37 °C. The overlying 
medium was aspirated with a syringe and DMSO (100 µl) was then added to 
dissolve the formazan crystals. Plates were agitated at high speed in order to 
ensure complete dissolution of the crystals. The optical density was measured 
at 550 nm, and cell viability was expressed as a percentage of solvent-treated 
control cells. The complete assay was repeated 3 times giving a total of 15 
readings for each concentration. The IC50 value was calculated and is defined as 
the concentration of test compound required to reduce the absorbance of the 
MTT-formazan crystals by 50%, indicating 50% cell deactivation. The 
significance of any reduction in cellular viability was determined using one-way 
ANOVA (analysis of variance). A probability of 0.05 or less was deemed 
statistically significant. 
 
2.6.2 MCF7 and HT29 cell lines: 
Human colon cancer cells,  HT29 (passage 15 to 30, ATCC, USA), were grown in 
McCoys’s 5a Medium supplemented with 2mM L-glutamine, 10% fetal bovine 
serum (FBS), penicillin-streptomycin solution with 100 µg cm-3 penicillin and 
100 µg cm-3 streptomycin at 37 °C in a humidified atmosphere with 5% CO2. 
Human breast cancer cells, MCF-7 (passage 6 to 21, ATCC, USA), were grown in 
Eagle’s Minimum Essential Medium containing 2.00 mM L-glutamine, penicillin-
streptomycin solution with 100 µg cm-3 penicillin and 100 µg cm-3 
streptomycin,  FBS (10%), 100 mM sodium pyruvate solution (1%) and 1% 
(v/v) MEM non-essential amino acid solution at 37 °C in a humidified 
atmosphere with 5% CO2. 
 
The cytotoxic potential of each test compound was determined following 
incubation of exponentially growing cells using the MTT assay. Cells were 
seeded at 4×105 cells cm-3 in 96-well plates and incubated at 37 °C in 5% CO2 
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for 24 h.  Cells were treated (in triplicate) with a four log range of 
concentrations of the test compounds (0.10-100 µM) or with a solvent control 
(0.5% DMSO) in complete medium. 
 
Following 24 h incubation, cells were treated with 20 µl of MTT (5 mg cm-3) in 
0.10 M PBS, pH 7.4 at 37 °C in a humid atmosphere with 5% CO2 for 4 h. Media 
was then gently aspirated from the test cultures and 100 µl of DMSO was added 
to all wells. The plates were shaken for 2 min in a microtiter plate reader and 
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3.1 Synthesis and Structures of Ag(I) Complexes 
 
In discussing the 1H NMR spectra of all compounds in this section the 
numbering system for the hydrogen atoms on 9-anthracenecarboxylic acid is 
illustrated in Figure 35. 
 
 




[Ag2(9-aca)2]n was first synthesised from Ag2O and 9-acaH in ethanol at 80 °C 
for 1 h (Scheme 1(a)). A low product yield (21%) was accredited to the 
deposition of elemental silver on the reaction flask when the reaction mixture 
was refluxed for extended periods of time. This metal deposition problem was 
solved by either maintaining the reaction mixture at room temperature for an 
extended time period (Scheme 1(b), (70%)) or by synthesising the potassium–
anthracene salt and using it as a precursor to [Ag2(9-aca)2]n (Scheme 1(c), 
(73%)). In this way the product yield was increased from 21% to 73%. 
 
The X-ray crystal structure of [Ag2(9-aca)2]n is shown in Figures 36-38 and 
selected bond lengths and angles are given in Table 2. The structure consists of 
polymeric ribbons of linked disilver(I) dicarboxylate units. There are two 
independent [Ag2(9-aca)2] units in the asymmetric unit (Figure 36), generating 
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Scheme 1. Synthesis of [Ag2(9-aca)2]n. 
 
 
Figure 36. Structures of the two polymeric strands in [Ag2(9-aca)2]n. 
Ag2O  +  9-acaH
[Ag2(9-aca)2]n
EtOH
78 oC, 1 h
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Bond Bond Angle 
(°) 
Ag(1)-O(1) 2.170 O(1)-Ag(1)-O(2A) 162.20 
Ag(1)-O(2A) 2.190 O(1)-Ag(1)-O(2AA) 116.66 
Ag(1)-O(2AA) 2.473 O(2A)-Ag(1)-O(2AA) 76.88 
Ag(1)-Ag(1A) 2.851 C(1)-O(1)-Ag(1) 120.30 





The carboxylate ligands are syn-syn bridging to the bimetallic core (Ag-O 
average bond length of 2.183 Å) and this unit is further linked to neighbouring 
cores by weaker, equatorial Ag-O interactions (Ag-O average bond length of 
2.393 Å). A similar coordination mode for the carboxylates was observed in the 
structure of the binuclear copper(II) complex, [Cu2(9-aca)4(MeOH)2](MeOH)158. 
In this copper(II) complex the metals have square pyramidal geometry and the 
bimetallic units are linked into chains by hydrogen bonds (H-bonds). 
 
Each silver is 4-coordinate and the Ag(1)-Ag(1A) distance in [Ag2(9-aca)2]n is 
2.851 Å, similar to that in [Ag(fbc)]n (fbc = 4-fluorobenzoic acid), where the 
metal is also bonded to three different carboxylate groups (Figure 25)131. The 
Ag-Ag bond distance in [Ag2(9-aca)2]n is also shorter than that in metallic silver 
(2.89 Å)106. Besides the short Ag(1)-Ag(1A) bond there are also weaker Ag-Ag 
interactions (e.g. Ag(1)-Ag(1B) or Ag(2)-Ag(2D)), with Ag-Ag distances of 3.657 
and 3.615 Å for the Ag(1) and Ag(2) chains, respectively.  
 
The IR spectrum of [Ag2(9-aca)2]n shows a small, characteristic band at 1621 
cm-1 for the ring system of the anthracene group144 and a strong band at 1535 
cm-1 for the C=C stretching vibrations of the aromatic rings. Two more bands for 
the anthracene ring vibrations are present at 736 and 768 cm-1 144,160. The 
ν(OCO)asym and ν(OCO)sym vibrations for the carboxylate function occur at 1566 and 
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1429 cm-1, respectively, giving a Δ(OCO) value of 137 cm-1. This value indicates a 
chelating or bridging coordination mode for the carboxylate ligand143. 
 
The 1H NMR spectrum of [Ag2(9-aca)2]n exhibits peaks for the aromatic protons 
at 8.44 (H10), 8.18 (H1,8), 8.03 (H4,5) and 7.47 ppm (H2,3,6,7). The attachment of 
the silver has caused a shielding of the anthracene protons and a shift upfield 
relative to uncoordinated 9-anthracenecarboxylic acid. This can be accredited 
to the changes in electron density and in π-electron circulation about the 
anthracene ring system caused by the coordination to the silver(I) ion103. 
 
3.1.2 [Ag2(9-aca)2(DMSO)2]n 
The DMSO adduct of [Ag2(9-aca)2]n was readily prepared in 50% yield from 
[Ag2(9-aca)2]n by heating in DMSO and ethanol (Scheme 2).  
 
 
Scheme 2. Synthesis of [Ag2(9-aca)2(DMSO)2]n. 
 
The X-ray crystal structure of [Ag2(9-aca)2(DMSO)2]n was determined (Figures 
39-42) and selected bond lengths and angles are given in Table 3. The complex 
is polymeric with the chains lying parallel to the a-axis. The complex may also 
be viewed as being tetranuclear (Figures 39 and 41) with units being linked by 
DMSO. 
 
The Ag(1)-Ag(2) bond length in [Ag2(9-aca)2(DMSO)2]n (2.914 Å) is longer than 
that in [Ag2(9-aca)2]n (2.851 Å) and the distance between Ag(1) and Ag(1A) is 
3.147 Å. This latter bond length is shorter than the corresponding silver-silver 
distances observed in [Ag2(9-aca)2]n (3.657 Å). The Ag-O bonds of the 
carboxylate and bridging DMSO ligands in [Ag2(9-aca)2(DMSO)2]n are of similar 
length (average bond length of 2.440 and 2.465 Å, respectively), but are longer 
than those in [Ag2(9-aca)2]n (2.183 Å). The longer metal-oxygen bond lengths in 
[Ag2(9-aca)2]n
1) DMSO, 80 oC, 20 min
2) EtOH, 80 oC, 2 min
[Ag2(9-aca)2(DMSO)2]n
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[Ag2(9-aca)2(DMSO)2]n may be a consequence of the increased number of donor 





Figure 39. Structure of two tetrameric units of [Ag2(9-aca)2(DMSO)2]n 
(anthracene rings omitted for clarity in (b)). 
 
Figure 40. X-ray crystal structure of one asymmetric unit of [Ag2(9-
aca)2(DMSO)2]n showing some disorder in the anthracene rings (60:40). 
Chapter 3.                                                                            Drug Structures and Properties 
92 
 
Figure 41. Structure of the tetrameric core of [Ag2(9-aca)2(DMSO)2]n with 
anthracene rings omitted for clarity. 
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Bond Bond Angle 
(°) 
Ag(1)-Ag(2) 2.914 O(11)-Ag(1)-O(11A) 97.65 
Ag(1)-Ag(1A) 3.147 O(11)-Ag(1)-O(31) 110.86 
Ag(1)-O(11) 2.358 O(11)-Ag(1)-O(1) 90.51 
Ag(1)-O(11A) 2.421 O(31)-Ag(1)-O(1) 99.46 
Ag(1)-O(1) 2.428 O(31)-Ag(1)-O(11A) 151.23 
Ag(1)-O(32) 2.598 O(31)-Ag(1)-O(32) 52.25 
 
In Ag2(9-aca)2(DMSO)2]n the two carboxylate oxygen atoms (O(31), O(32)) 
bridge Ag(1) and Ag(2) in a similar syn-syn fashion as seen in [Ag2(9-aca)2]n 
(Figure 40). The same oxygen atoms (O(31), O(32)) can also be viewed as 
chelating to Ag(1). This unusual bonding arrangement has not, to our 
knowledge, been previously reported for silver(I) carboxylates. This additional 
Ag-O bond (Ag(1)-O(32)) is longer than the syn-syn Ag-O bonds (2.598, 2.384 
and 2.421 Å, respectively). 
 
The IR spectrum of [Ag2(9-aca)2(DMSO)2]n is very similar to that of [Ag2(9-
aca)2]n apart from the inclusion of the bands associated with the DMSO ligands. 
A band is observed at 708 cm-1 for the symmetric stretching vibration of the 
S=O moiety along with a strong band at 955 cm-1 corresponding to the S-CH3 
rocking vibration of the methyl groups144. The ν(OCO)asym and ν(OCO)sym stretching 
vibrations occur at 1587 and 1427 cm-1, respectively, giving a Δ(OCO) value of 
160 cm-1. Using this value it is not possible to identify the carboxylate 
coordination mode as predictions with Δ(OCO) values of ca. 165 cm-1 have been 
shown to be untrustworthy143. 
 
The 1H NMR spectrum of [Ag2(9-aca)2(DMSO)2]n is very similar to that of 
[Ag2(9-aca)2]n, the only difference being the presence of a singlet at 2.56 ppm 
for the methyl groups of the DMSO ligands. It is believed that the DMSO ligands 
dissociate in solution as the position of this singlet is unchanged when 
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compared to uncoordinated DMSO161. Coordination to the silver ion is expected 




The imidazole complex, [Ag2(9-aca)2(DMSO)2]n, was synthesised in 18% yield 
from [Ag2(9-aca)2]n and imidazole in the presence of acetonitrile (Scheme 3). In 
this process, polymeric [Ag2(9-aca)2]n disintegrates and re-assembles as a 
mononuclear complex where the silver(I) is ligated by imidazole and 
acetonitrile. The 9-aca- ligand has now become an uncoordinated counterion.  
 
 
Scheme 3. Synthesis of [Ag(imid)2.3(CH3CN)0.7](9-aca). 
 
The X-ray crystal structure of [Ag(imidH)2.3(CH3CN)0.7](9-aca) was determined 
(Figures 43-47) and selected bond lengths and angles are given in Table 4.  
 
 
Figure 43. X-ray crystal structure of [Ag(imidH)2.3(CH3CN)0.7](9-aca). 
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Figure 44. One of the asymmetric units of [Ag(imidH)2.3(CH3CN)0.7](9-aca) 




Figure 45. Weak interactions of the silver(I) centre with the carboxylate oxygen 
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Figure 46. Chains of [Ag(imidH)2.3(CH3CN)0.7](9-aca) units showing the H-
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Bond Bond Angle 
(°) 
Ag(1)-N(21) 2.126 N(21)-Ag(1)-N(31) 168.51 
Ag(1)-N(31) 2.126 N(21)-Ag(1)-N(41) 96.10 
Ag(1)-N(41) 2.588 N(31)-Ag(1)-N(41) 94.70 
Ag(1)-N(51) 2.713 N(21)-Ag(1)-N(51) 93.70 
Ag(1)-O(2B) 3.009 N(31)-Ag(1)-N(51) 96.00 
 
The Ag+ forms short bonds to the imine nitrogen of each of the two imidazole 
groups (2.126 Å) with a third ligand coordinated to the silver disordered 70:30 
between acetonitrile and imidazole, respectively. These Ag-N bonds are similar 
in length to those found in the trisilver(I) complex, [Ag3(imid)6](ClO4)3 (2.075 
Å)162. There is also a longer interaction (3.009 Å) with the carboxylate oxygen 
atom of a neighbouring 9-aca unit (Figure 45). In [Ag(imidH)2.3(CH3CN)0.7](9-
aca) the silver is coordinated approximately linearly with the first two 
imidazole groups, with a N(21)-Ag(1)-N(31) bond angle of 169°. The third 
ligand is approximately perpendicular to this linear arrangement, with a N(21)-
Ag(1)-N(51) angle of 94°. The structure is linked into chains by H-bonding 
between the carboxylate and imidazole groups. This assembly is further 
supported by π-π stacking of the imidazole groups, with a centroid-centroid 
distance of 3.638 Å (Figure 46). 
 
The IR spectrum of [Ag(imid)2.3(CH3CN)0.7](9-aca) exhibits a weak band at 2250 
cm-1 for the CN bond stretching vibration. Bands are also observed at 3436 
and 1072 cm-1 corresponding to the N-H and C-N stretching vibrations of 
imidazole, respectively. Bands for the anthracene ring system occur at 1625, 
760 and 739 cm-1 144,160. The ν(OCO)asym and ν(OCO)sym vibrations occur at 1562 and 
1426 cm-1, respectively, giving a Δ(OCO) value of 136 cm-1. This value indicates a 
bridging carboxylate which, in this case, corresponds to the “pseudo-bridging” 
of the H-bonds143. 
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In the 1H NMR spectrum of [Ag(imid)2.3(CH3CN)0.7](9-aca), peaks corresponding 
to the aromatic protons of the anthracene ring appear at 8.41(H10), 8.15 (H1,8), 
8.03 (H4,5) and 7.46 ppm (H2,3,6,7). The aromatic protons of the imidazole ligand 
occur at 7.90 (H in the 4- and 5-positions) and 7.16 (H in the 2-position) ppm. 
The aromatic protons on the imidazole rings are slightly deshielded in 
comparison to the free ligand (7.64 and 7.02 ppm) and the peak for the 
hydrogen on the amine nitrogen is absent. Such shifts in peak positions and the 
absence of the amine proton has previously been reported for Cu2+ and Ag+ 
azole complexes103,163. A peak is also present at 2.08 ppm for the methyl protons 
of the acetonitrile ligand. 
 
3.1.4 [Ag6(imidH)4(9-aca)6(MeOH)2] 
[Ag6(imidH)4(9-aca)6(MeOH)2] was synthesised from [Ag2(9-aca)2]n  and 
imidazole in MeOH, with a yield of 44% (Scheme 4). Thus, a minor change in the 
reaction conditions (methanol as solvent as opposed to acetonitrile) causes a 
dramatic change in the product formulation. 
 
 
Scheme 4. Synthesis of [Ag6(imidH)4(9-aca)6(MeOH)2]. 
 
[Ag6(imidH)4(9-aca)6(MeOH)2] was recrystallised from methanol and the X-ray 
crystal structure of the complex was obtained (Figures 48-51). A list of selected 
bond lengths and angles is presented in Table 5. The hexanuclear complex has a 
two-fold axis through the molecule and contains both three- and five-coordinate 
silver(I) ions (Figure 49). 
 
[Ag2(9-aca)2]n  +  imidH
MeOH, RT, 1 h
[Ag6(imidH)4(9-aca)6(MeOH)2]
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Figure 49. Simplified structure of [Ag6(imidH)4(9-aca)6(MeOH)2] with the 
imidazole and anthracene rings omitted for clarity.  
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Figure 50. Intermolecular H-bonding in [Ag6(imidH)4(9-aca)6(MeOH)2]. 
 
 
Figure 51. Packing diagram for [Ag6(imidH)4(9-aca)6(MeOH)2]. 
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Bond Bond Angle 
(°) 
Ag(1)-Ag(2) 3.065 N(21)-Ag(1)-N(31) 174.33 
Ag(3)-Ag(3A) 2.882 N(21)-Ag(1)-Ag(2) 111.93 
Ag(1)-N(21) 2.088 N(31)-Ag(1)-Ag(2) 73.35 
Ag(3)-O(41) 2.467 O(1A)-Ag(2)-O(2A) 54.34 
Ag(3)-O(1C) 2.168 O(1D)-Ag(3)-Ag(3A) 81.52 
Ag(2)-O(1B) 2.218 O(1D)-Ag(3)-O(1C) 162.45 
 
The Ag(1)-Ag(2) bond length is 3.065 Å while the Ag(3)-Ag(3A) bond is 
significantly shorter at 2.882 Å. Ag(1) is coordinated approximately linearly by 
two imidazole groups (N(21)-Ag(1)-N(31) bond angle of 174°) with an Ag-N 
bond length of 2.088 Å. This latter bond is slightly shorter than the 
corresponding Ag-N bond of the ordered imidazole in 
[Ag(imidH)2.3(CH3CN)0.7](9-aca) (2.126 Å). 
 
In [Ag6(imidH)4(9-aca)6(MeOH)2], Ag(2) is coordinated to three different 
carboxylate groups as well as being bonded to Ag(1). Ag(3) is also coordinated 
to three different carboxylate groups, plus the oxygen of a methanol and 
another silver ion (Ag(3A)). Two of the carboxylate ligands are in the syn-syn 
configuration (O1C and O1Ca, O1D and O1DA), two are syn-anti (O1B and O2B, 
O1BA and O2BA) and two are coordinated in a symmetrical, bidentate, 
chelation mode (O1A and O2A, O1AA and O2AA).  
 
[Ag6(imidH)4(9-aca)6(MeOH)2] also displays intramolecular H-bonding between 
the OH of the alcohol group and a neighbouring carboxylate oxygen atom 
(Figure 48), as well as intermolecular H-bonding between the amine hydrogen 
of the imidazole and a carboxylate oxygen of a neighbouring 9-aca molecule 
(Figures 50 and 51). A very weak π-interaction between Ag(1) and the 
anthracene ring of a neighbouring molecule is also observed. 
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The IR spectrum of [Ag6(imidH)4(9-aca)6(MeOH)2] exhibits peaks at 3448 and 
1091 cm-1 for the N-H and C-N stretching vibrations of imidazole, respectively. 
Distinctive bands for the vibrations of the ring system of anthracene occur at 
1625, 760 and 736 cm-1 144,160. The ν(OCO)asym and ν(OCO)sym vibrations occur at 
1538 and 1433 cm-1, respectively, giving a Δ(OCO) value of 105 cm-1. This value 
indicates the presence of bridging carboxylates143. 
 
The 1H NMR spectrum of [Ag6(imidH)4(9-aca)6(MeOH)2] contains peaks for the 
aromatic protons of the anthracene ring at 8.46 (H10), 8.16 (H1,8), 8.06 (H4,5) and 
7.49 ppm (H2,3,6,7). As expected, this spectral region is very similar to that seen 
for [Ag2(9-aca)2]n. The aromatic C-H protons of the four imidazole ligands 
appear to be equivalent as there is only one singlet at 7.33 ppm integrating for 
12 hydrogens. This equivalence was reported for [AgCl(imidH)(PPh3)2]103 and 
was accredited to the fluxional behaviour of the complex in solution. A peak is 
also observed at 3.17 ppm corresponding to the methyl protons of the methanol 
ligands in [Ag6(imidH)4(9-aca)6(MeOH)2]. 
 
3.1.5 [Ag(1-Me-imid)2]2[Ag4(9-aca)6] 
[Ag(1-Me-imid)2]2[Ag4(9-aca)6] was made from [Ag2(9-aca)2]n and 1-
methylimidazole (1-Me-imidH) in ethanol with a yield of 37% (Scheme 5).  
 
 
Scheme 5. Synthesis of [Ag(1-Me-imid)2]2[Ag4(9-aca)6]. 
 
[Ag(1-Me-imid)2]2[Ag4(9-aca)6] was recrystallised from DMSO and the X-ray 
crystal structure was determined (Figures 52-56). Selected bond lengths and 
angles are listed in Table 6. The complex consists of two independent 
centrosymmetric molecules which differ in the angle between the planes of the 
anthracene ligands (Figure 53). 
[Ag2(9-aca)2]n  +  1-Me-imid [Ag(1-Me-imid)2]2[Ag4(9-aca)6]
1) EtOH
2) DMSO
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Figure 52. X-ray crystal structure of [Ag(1-Me-imid)2]2[Ag4(9-aca)6]. 
 
 
Figure 53. The two independent molecules of [Ag(1-Me-imid)2]2[Ag4(9-aca)6] 
illustrating the difference in arrangement of the anthracene ligands. 






Figure 54. Simplified structures of [Ag(1-Me-imid)2]2[Ag4(9-aca)6] showing (a) 
Ag-Ag and Ag-O bonding and (b) Ag-Ag bond lengths and distances. 
 
 
Figure 55. Ball and stick representation of [Ag(1-Me-imid)2]2[Ag4(9-aca)6]. 
3.7952.786
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Figure 56. Packing diagram for [Ag(1-Me-imid)2]2[Ag4(9-aca)6]. 
 
Both of the [Ag(1-Me-imid)2]2[Ag4(9-aca)6] molecules contain a dianionic 
complex central core, [Ag4(9-aca)6]2-, with the two complex cations, [Ag(1-Me-
imidH)2]+, on the periphery of the molecule. The central tetrasilver cluster 
contains Ag-Ag bond lengths ranging from 2.786-3.009 Å. The average distance 
from a core Ag+ to a peripheral Ag+ is 5.821 Å (Figure 54). Two 9-aca- ligands 
(O(11C), O(12C) and O(11I), O(12I)) are coordinated in a sys-syn fashion to 
central silver(I) ions (Ag(1), Ag(1A)). The four remaining 9-aca- ligands are 
coordinated to two central silver(I) ions and one peripheral silver(I) ion. The 
average core Ag-O bond length is 2.304 Å (eg. Ag(1)-O(11)) and the average 
peripheral Ag-O bond length is 2.671 Å (eg. (Ag(5)-O(11A)). 
 
The 1-Me-imid ligands are coordinated to the metals through the imine nitrogen 
and lie in an approximately linear arrangement (N(1A)-Ag(5)-N(1B) bond angle 
of 171.10°). The methyl groups on each of the two imidazole ligands are cis to 
each other and are orientated towards the centre of the molecule.  
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Bond Bond Angle 
(°) 
Ag(1)-Ag(1A) 2.786 Ag(2)-Ag(1)-Ag(2A) 124.37 
Ag(1)-Ag(2) 3.009 Ag(2)-Ag(1)-O(11C) 107.63 
Ag(1)-Ag(2A) 2.962 O(11A)-Ag(1)-Ag(2) 74.06 
Ag(1)-O(11C) 2.270 Ag(2)-Ag(1)-O(11B) 158.49 
Ag(1A)-O(12C) 2.248 O(11A)-Ag(1)-O(11B) 88.22 
Ag(1)-O(11A) 2.314 O(11A)-Ag(1)-Ag(1A) 134.03 
Ag(1)-O(11B) 2.383 Ag(1)-Ag(2)-Ag(1A) 55.62 
Ag(5)-O(11A) 2.713 Ag(2)-Ag(1)-Ag(1A) 61.34 
Ag(5)-O(11B) 2.629 Ag(1)-O(11A)-Ag(5) 97.72 
Ag(5)-N(1A) 2.141 O(11A)-Ag(5)-O(11B) 75.46 
Ag(5)-N(1B) 2.125 N(1A)-Ag(5)-N(1B) 171.10 
 
The IR spectrum of [Ag(1-Me-imid)2]2[Ag4(9-aca)6] contains bands at 1621, 772 
and 736 cm-1 for the ring system of anthracene144,160. There are also bands at 
3468 and 1087 cm-1 for the N-H and C-N stretching vibrations of imidazole, 
respectively. The ν(OCO)asym and ν(OCO)sym vibrations occur at 1565 and 1428 cm-1, 
respectively, giving a Δ(OCO) value of 137 cm-1. This value indicates the presence 
of carboxylates with a chelating and/or bridging mode of coordination143. 
 
The 1H NMR spectrum of [Ag(1-Me-imid)2]2[Ag4(9-aca)6] shows peaks for the 
aromatic anthracene hydrogen atoms at 8.40 (H10), 8.16 (H1,8), 8.05 (H4,5) and 
7.46 (H2,3,6,7) ppm. Peaks for the aromatic hydrogen atoms of the 1-
methylimidazole ligand occur at 7.84 (H in the 2-position), 7.28 (H in the 4-
position) and 7.03 ppm (H in the 5-position). The protons of the methyl group 
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on the imidazole are present as a singlet at 3.72 ppm. Peak integration 
confirmed the ratio of 9-aca:1-Me-imidH to be 3:2.  
 
3.1.6 [Ag2(1-Me-imid)2(9-aca)2] 
[Ag2(1-Me-imid)2(9-aca)2] was synthesised from [Ag2(9-aca)2]n and 1-
methylimidazole (1-Me-imidH) with a yield of 45% (Scheme 6). Unlike [Ag(1-
Me-imid)2]2[Ag4(9-aca)6], [Ag2(1-Me-imid)2(9-aca)2] was not recrystallised 
from DMSO and this would appear to cause the formation of a different product. 
 
 
Scheme 6. Synthesis of [Ag2(1-Me-imid)2(9-aca)2]. 
 
Unfortunately, repeated attempts to obtain crystals suitable for X-ray analysis 
by recrystallisation from alternative solvents proved unsuccessful. The IR 
spectrum of [Ag2(1-Me-imid)2(9-aca)2] displays bands for the vibration of the 
anthracene ring system at 1612, 772 and 737 cm-1 144,160. A broad band is 
present at 3411 cm-1 for the N-H stretching vibration and a band at 1086 cm-1 
represents the C-N stretching vibration of imidazole. The ν(OCO)asym and ν(OCO)sym 
vibrations occur at 1566 and 1428 cm-1, respectively, giving a Δ(OCO) value of 
138 cm-1. This value indicates that the carboxylate ligands are coordinated in 
either a chelating or a bridging mode143. 
 
The 1H NMR spectrum of [Ag2(1-Me-imid)2(9-aca)2] shows peaks for the 
aromatic anthracene protons at 8.36 (H4,5,10), 7.95 (H1,8) and 7.45 ppm (H2,3,6,7). 
The aromatic protons of the imidazoles occur at 7.55 (H2a), 7.00 (H4a) and 6.90 
(H5a) ppm and the methyl protons appear at 3.59 ppm (H6a) (Figure 3.1.6a). 
Peak integration indicates that the ratio of 9-aca:1-Me-imid is 1:1 and the 
microanalytical data confirms the ratio of Ag:9-aca:1-Me-imid as 1:1:1. 
 
A tentative structure for [Ag2(1-Me-imid)2(9-aca)2] is given in Figure 57. The 
Δ(OCO) value (138 cm-1) was similar to that found for [Ag(1-Me-imid)2]2[Ag4(9-
aca)6] (137 cm-1) and corresponds to a bridging mode of coordination for the 
[Ag2(9-aca)2]n  +  1-Me-imidH [Ag2(1-Me-imid)2(9-aca)2]
EtOH
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carboxylate ligand. The proton peaks in the 1H NMR spectra of [Ag2(1-Me-
imid)2(9-aca)2] and [Ag(1-Me-imid)2]2[Ag4(9-aca)6] are slightly shifted relative 
to each other due to the use of different deuterated solvents (d6 DMSO for 
[Ag(1-Me-imid)2]2[Ag4(9-aca)6] and d4 MeOD for [Ag2(1-Me-imid)2(9-aca)2]). It 
is proposed that [Ag2(1-Me-imid)2(9-aca)2] exists as a dimer, with the 
carboxylate ligands coordinating in a syn-syn bridging mode to the silver ions. 
The imidazole ligands are coordinated through the imine nitrogen making each 
silver(I) ion essentially four-coordinate. 
 
 
Figure 57. Tentative structure for [Ag2(1-Me-imid)2(9-aca)2]. 
 
It is evident from the formulations of [Ag(imidH)2.3(CH3CN)0.7](9-aca), 
[Ag6(imidH)4(9-aca)6(MeOH)2], [Ag(1-Me-imid)2]2[Ag4(9-aca)6] and [Ag2(1-Me-
imid)2(9-aca)2] that a slight change in either the reaction solvent or the 
imidazole employed (1-methylimidazole as opposed to imidazole) causes quite 
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3.1.7 [Ag(2-Me-imidH)2(9-aca)] 
[Ag(2-Me-imidH)2(9-aca)] was synthesised from [Ag2(9-aca)2] and 2-
methylimidazole (2-Me-imidH) in 51% yield using acetonitrile as the reaction 
solvent (Scheme 7). 
 
 
Scheme 7. Synthesis of [Ag(2-Me-imidH)2(9-aca)]. 
 
[Ag(2-Me-imidH)2(9-aca)] was  recrystallised from acetonitrile and the X-ray 
crystal structure solved (Figures 58-62). Selected bond lengths and angles are 
listed in Table 7.  
 
In [Ag(2-Me-imid)2(9-aca)], the silver(I) ion is coordinated to the imine 
nitrogen atoms of the two imidazole rings and also to one carboxylate oxygen 
atom of the anthracene ligand. This monodentate Ag-O bond length (2.494 Å) is 
significantly longer than that in [Ag2(9-aca)2]n where the carboxylates are 
bridging bidentate (Ag-O bond length of 2.183 Å). The average Ag-N bond 
length in [Ag(2-Me-imid)2(9-aca)] (2.113 Å) is similar to that found for the 
ordered imidazole in [Ag(imid)2.3(CH3CN)0.7](9-aca) (2.126 Å) and also to the 
Ag-N bonds in [Ag6(imidH)4(9-aca)6(MeOH)2] (2.088 Å). The imidazole ligands 
in [Ag(2-Me-imid)2(9-aca)] are coordinated approximately linearly to each 
other (N(21)-Ag(1)-N(31) bond angle of 162°) with the 9-aca- ligand almost 
perpendicular (N(31)-Ag(1)-O(1) bond angle of 97°). The methyl groups at the 
2-position on the imidazole ring are in a cis-conformation to each other and lie 
approximately perpendicular to the plane of the anthracene ring (Figure 59). 
 
[Ag2(9-aca)2]n  +  2-Me-imidH [Ag(2-Me-imidH)2(9-aca)]
MeCN, RT, 1 h
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Figure 59. Intermolecular H-bonding in [Ag(2-Me-imidH)2(9-aca)]. 
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Figure 61. Stacking of the anthracene rings in [Ag(2-Me-imidH)2(9-aca)]. 
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Figure 62. Packing diagram for [Ag(2-Me-imidH)2(9-aca)]. 
 





Bond Bond Angle 
(°) 
Ag(1)-N(21) 2.115 N(21)-Ag(1)-N(31) 162.07 
Ag(1)-N(31) 2.111 N(21)-Ag(1)-O(1) 101.00 
Ag(1)-O(1) 2.494 N(31)-Ag(1)-O(1) 96.93 
Ag(1)-Ag(1A) 4.193 N(21)-Ag(1)-Ag(1A) 95.26 
 
Three distinct intermolecular forces link the molecules of [Ag(2-Me-imid)2(9-
aca)] together. There is H-bonding between the amine and the carboxylate 
group (Figure 59), π-π stacking interactions of the imidazole groups (Figure 60) 
and π-π stacking interactions of the anthracene groups (Figure 61). The Ag-Ag 
distance (4.193 Å) is considered to be too long to allow significant interaction 
between the metal centres. 
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The IR spectrum of [Ag(2-Me-imidH)2(9-aca)] has bands at 3047 and 1113 cm-1 
representing the N-H and C-N stretching vibrations of the imidazole ligand, 
respectively. Bands are also evident at 1622, 762 and 734 cm-1 for the 
vibrations of the anthracene ring system144,160. The ν(OCO)asym and ν(OCO)sym 
vibrations occur at 1590 and 1421 cm-1, respectively, giving a Δ(OCO) value of 
169 cm-1. Unfortunately, this value does not allow an accurate assignment of the 
coordination mode of the carboxylate ligand143. 
 
The 1H NMR spectrum of [Ag(2-Me-imidH)2(9-aca)] exhibits peaks for the 
aromatic anthracene protons at 8.43 (H10), 8.20 (H1,8), 8.08 (H4,5) and 7.50 ppm 
(H2,3,6,7), and these peaks are in similar positions to those of complexes 
previously discussed. The aromatic protons on the imidazole ring occur as a 




[Ag(1-Bu-imid)2]2[Ag4(9-aca)6] was synthesised from [Ag2(9-aca)2] and 1-
butylimidazole (1-bu-imid) in acetonitrile and ethanol and formed in a yield of 
51% (Scheme 8).  
 
 
Scheme 8. Synthesis of [Ag(1-Bu-imid)2]2[Ag4(9-aca)6]. 
 
The X-ray crystal structure of [Ag(1-Bu-imid)2]2[Ag4(9-aca)6] is shown in 
Figures 63-65 and selected bond lengths and angles are listed in Table 8. There 
are two very similar independent assemblies within one asymmetric unit of 
[Ag(1-Bu-imid)2]2[Ag4(9-aca)6], which are orientated at 90° to each other 
(Figure 63). There is also some disorder within the butyl chains of the imidazole 
ligands. 
 
[Ag2(9-aca)2]n  +  1-Bu-imid [Ag(1-Bu-imid)2]2[Ag4(9-aca)6]
1) MeCN, RT, 20 h
2) EtOH, 80 oC, 5 min
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Figure 63. X-ray crystal structure of [Ag(1-Bu-imid)2]2[Ag4(9-aca)6] showing 
the two independent assemblies. 
 
 
Figure 64. Structure of [Ag(1-Bu-imid)2]2[Ag4(9-aca)6] with the anthracene 
rings and alkyl chains removed for clarity. 
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Figure 65. Packing diagram for [Ag(1-Bu-imid)2]2[Ag4(9-aca)6]. 
 






Bond Bond Angle 
(°) 
Ag(1)-Ag(2) 2.903 Ag(1)-Ag(2)-Ag(3) 
Ag(3)-Ag(4)-Ag(1) 
120.83 
Ag(2)-Ag(3) 2.877 Ag(2)-Ag(3)-Ag(4) 
Ag(4)-Ag(1)-Ag(2) 
58.87 
Ag(3)-Ag(4) 2.895 O(2A)-Ag(2)-O(1B) 93.86 
Ag(4)-Ag(1) 2.875 O(1D)-Ag(4)-O(2C) 89.46 
Ag(2)-Ag(4) 2.837 O(1A)-Ag(1)-Ag(2) 83.96 
Ag(5)-N(1A/1B) 2.116 N(1A)-Ag(5)-N(1B) 176.98 
Ag(6)-N(1C/1D) 2.131 N(1C)-Ag(6)-N(1D) 175.10 
Ag(5)-O(2A/1B) 2.696/2.809 O(2C)-Ag(4)-O(2E) 102.37 
Ag(6)-O(1D/2C) 2.603/2.756 O(2C)-Ag(4)-O(2F) 93.00 
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[Ag(1-Bu-imid)2]2[Ag4(9-aca)6] contains two-, four- and six-coordinate silver(I) 
ions (Figure 64). Two of the metals are coordinated approximately linearly to 
the imine nitrogen atoms of two 1-Bu-imid ligands (bond angles of 175° and 
177°), with an average Ag-N bond length of 2.124 Å. There are also longer 
interactions of these silver ions with carboxylate oxygen atoms at the central 
core of the molecule (Ag(6)-O(2C) and Ag(6)-O(1D) bond lengths of 2.756 and 
2.603 Å, respectively). 
 
Within the central [Ag4(9-aca)6]2- core there are five Ag-Ag bonds, with lengths 
ranging from 2.837 to 2.903 Å. All of the anthracene ligands use both of their 
carboxylate oxygen atoms to coordinate to two different silver ions in a syn-syn 
binding mode. There are no intramolecular or intermolecular π-π interactions 
between either the anthracene or the imidazole rings. The structure of [Ag(1-
Bu-imid)2]2[Ag4(9-aca)6] is very similar to that of [Ag(1-Me-imid)2]2[Ag4(9-
aca)6] which was discussed previously. In this instance, the change in the length 
of the alkyl chain (from methyl to butyl) on the imidazole ring does not appear 
to affect the core structure of the product. 
 
The IR spectrum of [Ag(1-Bu-imid)2]2[Ag4(9-aca)6] contains bands for the 
anthracene ring system at 1622, 759 and 732 cm-1 144,160. The band representing 
the C-N stretching vibration of the 1-Bu-imid ligands occur at 1085 cm-1. The 
ν(OCO)asym and ν(OCO)sym vibrations appear at 1565 and 1427 cm-1, respectively, 
giving a Δ(OCO) value of 138 cm-1. This indicates that the carboxylate ligands are 
coordinated in either a chelating or a bridging mode143. 
  
The 1H NMR spectrum of [Ag(1-Bu-imid)2]2[Ag4(9-aca)6] shows that the 
aromatic protons  of the 1-Bu-imid have become deshielded compared to that of 
uncoordinated 1-Bu-imid. These peaks now appear further downfield (8.06 (H 
in the 2-position) and 7.47 (H in the 4-position) and 7.13 ppm (H in the 5-
position)). The peaks for the aromatic anthracene protons are present at 8.44 
(H10), 8.20 (H1,8), 8.06 (H4,5) and 7.47 ppm (H2,3,6,7) whilst peaks for the protons 
of the butyl chain remain unchanged compared to the free ligand and occur at 
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4.06 (CH2, triplet), 1.73 (CH2, quintet), 1.23 (CH2, sextet) and 0.90 ppm (CH3, 
triplet). Peak integration gives a ligand ratio of 3:2 (9-aca:1-Bu-imid). 
 
3.1.9 [Ag2(1-Bu-imid)2(9-aca)2] 
[Ag2(1-Bu-imid)2(9-aca)2] was synthesised from [Ag2(9-aca)2] and 1-
butylimidazole in good yield (71%) (Scheme 9). Unlike [Ag(1-Bu-
imid)2]2[Ag4(9-aca)6], [Ag2(1-Bu-imid)2(9-aca)2] was not recrystalised from 
ethanol and it is this somewhat minor variation in reaction conditions that has 
prompted a major change in the product formulation. 
 
 
Scheme 9. Synthesis of [Ag2(1-Bu-imid)2(9-aca)2]. 
 
The IR spectrum of [Ag2(1-Bu-imid)2(9-aca)2] displays bands at 1611, 758 and 
737 cm-1 for the stretching vibrations of the anthracene ring system144,160. A 
band is present at 1086 cm-1 for the C-N stretching vibration of the imidazole 
ring. The ν(OCO)asym and ν(OCO)sym vibrations occur at 1567 and 1429 cm-1, 
respectively, giving a Δ(OCO) value of 138 cm-1. This value suggests that the 
carboxylate ligands are coordinated to the metal centre in either a bridging or a 
chelating mode143. 
 
The 1H NMR spectrum of [Ag2(1-Bu-imid)2(9-aca)2] shows the aromatic 
anthracene protons at 8.43 (H10), 8.17 (H1,8), 8.04 (H4,5), and 7.47 ppm (H2,3,6,7). 
The aromatic protons of the imidazole ring appear at 8.00 (H2a), 7.40 (H4a) and 
7.10 ppm (H5a) (Figure 66), and are more shielded in comparison to those 
observed for [Ag(1-Bu-imid)2]2[Ag4(9-aca)6]. The proton peaks associated with 
the butyl chain are present in the same positions as those seen in the spectra of 
[Ag(1-Bu-imid)2]2[Ag4(9-aca)6] and the free ligand (4.05 (H6a, triplet), 1.72 (H7a, 
quintet), 1.25 (H8a, sextet) and 0.90 ppm (H9a, triplet)). Peak integration gives a 
9-aca:1-Bu-imid ratio of 1:1 and the microanalytical data confirms the ratio of 
Ag:9-aca:1-butyl-imid as 1:1:1. 
 
[Ag2(9-aca)2]n  +  1-Bu-imid [Ag2(1-Bu-imid)2(9-aca)2]
MeCN, RT
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A tentative structure for [Ag2(1-Me-imid)2(9-aca)2] is given in Figure 66. This 
structure is very similar to that proposed for [Ag2(1-Me-imidH)2(9-aca)2], with 
the carboxylate ligands bridging two silver(I) ions. The 1-Bu-imid ligands are 
coordinated through the imine nitrogen atom and there is a possibility of some 
Ag-Ag interactions.  
 
 
Figure 66. Tentative structure for [Ag2(1-Bu-imid)2(9-aca)2]. 
 
3.1.10 [Ag(apim)](9-aca)·H2O 
[Ag(apim)](9-aca)·H2O was synthesised from [Ag2(9-aca)2]n and 1-(3-
aminopropyl)-imidazole (apim) in acetonitrile giving a product yield of 82% 
(Scheme 15). The complex was recrystallised from a mixture of ethanol and 
methanol (9:1) and the X-ray crystal structure was obtained (Figures 67-72). 
Selected bond lengths and angle are listed in Table 9. 
 
 















[Ag2(9-aca)2]n  +  apim [Ag(apim)](9-aca).H2O
MeCN, RT, 0.5 h
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Figure 67. Structure of one asymmetric unit of [Ag(apim)](9-aca)·H2O. 
 
 
Figure 68. Polymeric cationic chains of [Ag(apim)]nn+. 
 
 
Figure 69. π-π stacking interactions of the imidazole rings in [Ag(apim)](9-
aca)·H2O.. 
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Figure 71. Packing of the polymeric cationic and anionic chains in 
[Ag(apim)](9-aca)·H2O. 
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Figure 72. Packing diagram for [Ag(apim)](9-aca)·H2O. 
 





Bond Bond Angle 
(°) 
Ag(1)-N(1) 2.084 N(1)-Ag(1)-N(3A) 177.76 
Ag(1)-N(3A) 2.107 Ag(1)-N(1)-C(22) 129.35 
 
In [Ag(apim)](9-aca)·H2O, the metal is bonded to the imine nitrogen of the 
imidazole ring with an Ag(1)-N(1) bond length of 2.084 Å. The silver and 
imidazole form 1-D zig-zag polymeric chains with the silver being coordinated 
approximately linearly to the imine nitrogen of one imidazole and the amine 
(NH2) nitrogen of another imidazole (N(1)-Ag(1)-N(3A) bond angle of 178°) 
(Figure 68). π-π Stacking interactions are also observed between the imidazole 
rings creating 2-D sheets with a centroid distance of 3.558 Å (Figure 69). 
 
The water molecules in [Ag(apim)](9-aca)·H2O link up with the anionic 9-aca- 
units through H-bonds (Figure 70) forming polymeric chains which zig-zag in-
and-out through the spaces in the [Ag(apim)]nn+ sheets (Figure 71). The H-
bonds in this chain are relatively strong and there are also longer, weaker 
interactions linking the carboxylate oxygen to the hydrogen of the pendant 
amine group.  
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Due to the relatively long distance between the sheets, there are no π-π 
interactions involving the anthracene rings. The structurally similar complex, 
[Ag(apim)]ClO4126, also shows the same type of zig-zag arrangement of 
polymeric [Ag(apim)]nn+ chains but this complex has weak metal-anion 
interactions which are not present in [Ag(apim)](9-aca)·H2O. 
 
The IR spectrum of [Ag(apim)](9-aca)·H2O contains a band at 3427 cm-1 
corresponding to the apim NH2 stretching vibration and a band at 1089 cm-1 for 
the C-N stretching vibration of the imidazole ring. Two bands are present at 761 
and 735 cm-1 for the stretching vibrations of the anthracene ring system144,160, 
but the third band, which is usually located at approximately 1625 cm-1, is 
masked by the strong ν(OCO)asym stretching band centred at 1568 cm-1. The 
ν(OCO)sym stretching vibration occurs at 1426 cm-1, thus giving a Δ(OCO) value of 
142 cm-1. Although this value implies that the carboxylate is either chelating or 
bridging143, it is evident from the X-ray crystal structure of the complex that this 
is not the case. Thus, it must be stressed that coordination mode assignments 
based on Δ(OCO) values can indeed be quite tentative. 
 
The 1H NMR spectrum of [Ag(apim)](9-aca)·H2O shows peaks for the aromatic 
anthracene protons at 8.39 (H10), 8.15 (H1,8), 8.01 (H4,5) and 7.44 ppm (H2,3,6,7). 
The aromatic imidazole protons appear as singlets at 7.87, 7.33 and 7.01 ppm. 
Although the 1H NMR spectrum does not show any coupling between the 
protons on the imidazole ring, a COSY NMR spectrum provided evidence that 
coupling does occur. The protons in the propyl chain appear at 4.11 (triplet), 
2.61 (triplet) and 1.93 (quintet) ppm with the amine protons being masked by 
the residual peak for the DMSO solvent at 2.55 ppm.  
 
3.1.11 [Ag(2-Ph-imid)] 
[Ag(2-Ph-imid)] was made in a 79% yield from [Ag2(9-aca)2]n and 2-
phenylimidazole (2-Ph-imidH) in acetonitrile (Scheme 11). 
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Scheme 11. Synthesis of [Ag(2-Ph-imid)]. 
 
The IR spectrum of [Ag(2-Ph-imid)] shows bands for the C=C and C=N 
stretching vibrations of the imidazole ring at 1601 and 1578 cm-1, respectively. 
These bands are masked in previous complexes by the ν(OCO)asym band of the 
carboxylate moiety. The strong band for the C=O stretching of the carboxylate 
group is absent. The aromatic C=C stretching band of the 2-Ph-imidH occurs as 
a strong band at 1458 cm-1 and there is also a band at 1074 cm-1 for the C-N 
stretching vibration of the imidazole ring. The distinctive band for the 
stretching vibration of the anthracene ring system, at ca. 1625 cm-1, is also 
absent. 
 
The 1H NMR spectrum of [Ag(2-Ph-imid)] shows only peaks associated with the 
protons for the 2-Ph-imid ligand at 7.92 (H6,10), 7.41 (H7,9), 7.33 (H8), 7.24 (H4) 
and 7.02 ppm (H5) (Figure 73). The microanalytical data indicates a ratio of 
silver:2-Ph-imid of 1:1. Thus, in this reaction the 9-aca- ligands in the [Ag2(9-
aca)2]n starting complex have been replaced by the anionic 2-Ph-imid- ligands. 
Deprotonation of the 2-Ph-imidH is thought to be assisted by the ability of the 
phenyl substituent to delocalise electron density from the resulting N- atom on 
the imidazole ring. 
 
It is believed that [Ag(2-Ph-imid)] will form polymeric chains in which the silver 
is coordinated to the deprotonated amine N of one 2-Ph-imid ligand and the 
imine nitrogen of a neighbouring 2-Ph-imid ligand (Figure 73(b)). Similar 
polymeric chains have been reported for the silver(I)-4-nitroimidazole complex, 
[Ag(4-NO2-imid)]164, and also for metal-imidazolate complexes of Ni(II), Cu(II), 
Zn(II) and Ag(I)102. 
[Ag2(9-aca)2]n  +  2-Ph-imidH [Ag(2-Ph-imid)]
MeCN, RT, 0.25 h
Chapter 3.                                                                            Drug Structures and Properties 
124 
 




[Ag(4-Ph-imidH)2(9-aca)] was synthesised from [Ag2(9-aca)2]n and 4-
phenylimidazole (4-Ph-imidH) in good yield (81%) (Scheme 12). Although the 
synthesis conditions are very similar to those used in reactions involving 2-Ph-
imidH, the products obtained are very different. The 9-aca- anion was absent in 
the product involving 2-Ph-imidH whereas the carboxylate was retained in the 
product where the 4-Ph-imidH was employed as a reactant. 
 
 
Scheme 12. Synthesis of [Ag(4-Ph-imidH)2(9-aca)]. 
 
The IR spectrum of [Ag(4-Ph-imidH)2(9-aca)] contains bands at 1614, 755 and 




















[Ag2(9-aca)2]n  +  4-Ph-imidH [Ag(4-Ph-imidH)2(9-aca)]
MeCN, RT, 0.5 h
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present at 3129 and 1073 cm-1 for the N-H and C-N stretching vibrations of the 
imidazole ring, respectively. The ν(OCO)asym and ν(OCO)sym vibrations occur at 1553 
and 1424 cm-1, respectively, giving a Δ(OCO) value of 129 cm-1. This value 
suggests that the carboxylate is coordinated in either a chelating or a bridging 
mode143. 
 
The 1H NMR spectrum of [Ag(4-Ph-imidH)2(9-aca)] indicates that the ratio of 9-
aca:4-Ph-imid is 1:2. The aromatic anthracene protons give rise to peaks at 8.47 
(H10), 8.14 (H1,8), 8.06 (H4,5) and 7.48 ppm (H2,3,6,7). Peaks for the 4-Ph-imid 
protons occur at 7.88 (H2a), 7.83 (H7a,11a), 7.59 (H9a), 7.39 (H8a,10a) and 7.25 ppm 
(H5a) (Figure 74). The anthracene peaks are not shifted significantly when 
compared to those in the spectrum of the starting material [Ag2(9-aca)2]n, while 
the 4-Ph-imid peaks are shifted downfield in comparison to those observed in 
the spectrum of the free ligand.  
 
It is thought that [Ag(4-Ph-imidH)2(9-aca)] may have a similar structure to 
[Ag(2-Me-imidH)2(9-aca)], with the silver coordinated to the imine nitrogen of 
the imidazole ring (Figure 74). This approximately linear alignment of the 
imidazole ligands is a common arrangement in silver(I) imidazole complexes as 
observed in complexes previously discussed. The IR spectrum of [Ag(4-Ph-
imidH)2(9-aca)] indicates that the carboxylate may be in either a bridging or a 
chelating mode of coordination which may indicate either the presence of H-
bonding or an interaction of the carboxylate oxygen with the silver(I) ion. 
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3.1.13 [Ag(4,5-dicyanoimid)] 
[Ag(4,5-dicyanoimid)] was synthesised from [Ag2(9-aca)2]n and 4,5-
dicyanoimidazole in acetonitrile with a yield of 70% (Scheme 13).  
 
 
Scheme 13. Synthesis of [Ag(4,5-dicyanoimid)]. 
 
The IR spectrum of [Ag(4,5-dicyanoimid)] contains a strong band at 2227 cm-1 
for the CN stretching vibration of the cyanoimidazole ligand. The 
characteristic bands for the anthracene ring system at approximately 1620 and 
750 cm-1, along with the νOCO stretching vibrations of the carboxylate ligand are 
absent. Also, the N-H stretching vibration at 3100 cm-1 is not present, indicating 
that the 4,5-dicyanoimidazole has been deprotonated forming an anion. It is 
expected that the electron-withdrawing cyano substituents on the imidazole 
ring helps stabilise the negatively charged imidazolate ion. 
 
As a consequence of insolubility, it was not possible to obtain a solution 1H NMR 
spectrum of [Ag(4,5-dicyanoimid)]. The microanalytical data for [Ag(4,5-
dicyanoimid)] indicates a ratio of Ag:4,5-dicyanoimid of 1:1 and a tentative 
structure of the complex is shown in Figure 75. The imidazole is deprotonated 
at the amine nitrogen and it is likely that the lone pair of electrons on the imine 
nitrogen will also interact with the silver of another molecule forming a 
polymeric chain similar to that postulated for [Ag(2-Ph-imid)] (Figure 75(b)). 
 
[Ag2(9-aca)2]n  +  4,5-dicyanoimidH [Ag(4,5-dicyanoimid)]
MeCN, RT, 1 h
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Figure 75. Proposed structure of [Ag(4,5-dicyanoimid)]: (a) an isolated unit 
and (b) a polymeric chain. 
 
3.1.14 [Ag(Benz-imid)] 
[Ag(Benz-imid)] was synthesised from [Ag2(9-aca)2]n and benzimidazole (Benz-
imidH) in methanol with a yield of 68% (Scheme 14). 
 
 
Scheme 14. Synthesis of [Ag(Benz-imid)]. 
 
The IR spectrum of [Ag(Benz-imid)] contains bands for the C=C and C=N 
stretching vibrations of the imidazole ring at 1609 and 1584 cm-1, respectively, 
along with a strong band at 1463 cm-1 for the C=C stretching vibration of the 
aromatic benzene ring system. The band for the stretching vibration of the 
carboxylate group is absent, as well as the band at ca. 1625 cm-1 for the 
stretching of the anthracene ring system. 
 
As a result of insolubility, it was not possible to obtain a 1H NMR spectrum of 
























[Ag2(9-aca)2]n  +  Benz-imidH [Ag(Benz-imid)]
MeOH, RT, 0.5 h
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that the ratio of Ag:Benzimid is 1:1 and a tentative structure for the complex is 
given in Figure 76. The silver is coordinated to the amine nitrogen of the 
deprotonated imidazole ring. As indicated previously for [Ag(2-Ph-imid)] and 
[Ag(4,5-dicyanoimid)], there is a possibility that [Ag(Benz-imid)] may form 
polymeric chains by the coordination of the silver(I) ion to the imine nitrogen of 
a neighbouring molecule (Figure 76(b)). 
 
 
Figure 76. Tentative structure of [Ag(Benz-imid)]: (a) and isolated unit and (b) 
a polymeric chain. 
 
3.1.15 [Ag2(2-Mebenz-imidH)4](9-aca)2 
[Ag2(2-Mebenz-imidH)4](9-aca)2 was synthesised from [Ag2(9-aca)2]n and 2-
methylbenzimidazole (2-Mebenz-imidH) in acetonitrile and the product formed 
in excellent yield (87%) (Scheme 15). 
 
 













[Ag2(9-aca)2]n  +  2-Mebenz-imidH
[Ag2(2-Mebenz-imidH)4](9-aca)2]
MeCN, RT, 1 h
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The IR spectrum of [Ag2(2-Mebenz-imidH)4](9-aca)2 shows the N-H stretching 
vibrations at 3446 cm-1 along with the C=C ring vibration of the benzimidazole 
at 1599 cm-1. The bands at 1625, 764 and 728 cm-1 correspond to the stretching 
vibrations of the anthracene ring system144,160. There is a broad band centred at 
2524 cm-1 which indicates the presence of H-bonding144, possibly between the 
carboxylate oxygen atoms and the amine hydrogen of the imidazole ring.  The 
ν(OCO)asym and ν(OCO)sym vibrations occur at 1558 and 1427 cm-1, respectively, 
giving a Δ(OCO) value of 131 cm-1. This value suggests that the carboxylate group 
may have a chelating or a bridging mode of coordination143. 
 
Peak integrations in the 1H NMR spectrum of [Ag2(2-Mebenz-imidH)4](9-aca)2 
indicates a ratio of 9-aca:2-Mebenz-imidH of 2:3. However, this is not consistent 
with the microanalytical data (discussed below). [Ag2(2-Mebenz-imidH)4](9-
aca)2 is very insoluble in common solvents and a good quality 1H NMR spectrum 
could not be obtained (even in hot DMSO). There is a possibility that, due to the 
large amount of heat required to dissolve some of the sample prior to running 
the 1H NMR spectrum, the complex undergoes changes and is not 
representative of the formula of the solid form. Such changes were observed 
previously for [Ag2(1-Me-imidH)2(9-aca)2] which were ultimately overcome by 
using an alternate NMR solvent. Unfortunately, a change of solvent was not an 
option in this case due to insolubility. The poor quality spectrum shows the 
aromatic protons of the anthracene ring at 8.63 (H10), 8.09 (H1,8), 8.03 (H4,5) and 
7.49 ppm (H2,3,6,7). The protons of the benzene ring appear as multiplets at 7.56 
and 7.15 ppm, while the peak for the protons of the methyl group is masked by 
the DMSO residual peak at 2.50 ppm. 
 
Microanalytical data for the complex indicate a ratio of Ag:9-aca:2-Mebenz-
imidH of 1:1:2 and a tentative structure for [Ag2(2-Mebenz-imidH)4](9-aca)2 is 
given in Figure 77. This proposed structure is similar to that of the known 
complex, [Ag2(imidH)4](salH)2126, with the silver being coordinated to the imine 
nitrogen of the imidazole ring and the carboxylate acting as a counterion. 
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Figure 77. Proposed structure of [Ag2(2-Mebenz-imidH)4](9-aca)2. 
 
In an attempt to recrystallise [Ag2(2-Mebenz-imidH)4](9-aca)2 from ethanol the 
silver-free, monohydrate salt, (2-Mebenz-imidH2)(9-aca)·H2O, crystallised and 
was subsequently characterised using X-ray crystallography (Figures 78-80). 
Bond lengths and angles are listed in Tables 29 and 30 in the Appendix. 
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Figure 79. Chains of (2-Mebenz-imidH2)(9-aca)·H2O linked by H-bonds. 
 
 
Figure 80. Packing diagram for (2-Mebenz-imidH2)(9-aca)·H2O showing 
hydrogen bonds between chains. 
 
H-bonding links the 9-aca- anions and the 2-Mebenz-imidH2+ cations via the 
water molecule and this allows the structure to form chains (Figure 79). Inter-
chain H-bonding is also observed in the structure of (2-Mebenz-imidH2)(9-
aca)·H2O (Figure 80). Some π-π stacking interactions occur between the 
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cationic imidazolate and the anionic anthracene ring (centroid distance 3.480-
3.592 Å) (Figure 3.1.14d).  
 
3.1.16 [Ag(2-Mebenz-imid)] 
[Ag(2-Mebenz-imid)] was synthesised from [Ag2(9-aca)2]n and 2-
methylbenzimidazole in methanol and the product formed in good yield (79%) 
(Scheme 16). The small changes in the reaction conditions, compared to the 
synthesis of [Ag2(2-Mebenz-imidH)4](9-aca)2 (methanol as opposed to 
acetonitrile and an increase in temperature), has led to a product that is 
structurally quite different with no 9-acaH present. 
 
 
Scheme 16. Synthesis of [Ag(2-Mebenz-imid)]. 
 
In the IR spectrum of [Ag(2-Mebenz-imid)] bands are observed for the C=C and 
the C=N stretching vibrations of the imidazole ring at 1608 and 1579 cm-1, 
respectively. These bands are masked in previous complexes (e.g. 
[Ag6(imidH)4(9-aca)6(MeOH)2] and [Ag(1-Me-imid)2]2[Ag4(9-aca)6]) by the 
ν(OCO)asym band of the carboxylate group. The strong aromatic C=C stretching 
band occurs at 1448 cm-1 and a band is also present at 1076 cm-1 for the C-N 
stretching vibration of the imidazole ring. The absence of the distinctive bands 
for the anthracene ring stretching vibrations at approximately 1625 and 750 
cm-1 confirms the omission of the 9-acaH in the complex. 
 
As a consequence of its insolubility, it was not possible to obtain a solution 1H 
NMR spectrum of [Ag(2-Mebenz-imid)]. However, the microanalytical data 
indicates the ratio of silver:2-Mebenz-imid to be 1:1. It is thought that the silver 
[Ag2(9-aca)2]n  +  2-Mebenz-imidH
[Ag(2-Mebenz-imid)]
MeOH, 60 oC, 0.5 h
Chapter 3.                                                                            Drug Structures and Properties 
133 
bonds to the amine nitrogen of the deprotonated imidazole ring (Figure 81(a)). 
This complex, as suggested for [Ag(2-Ph-imid)] and [Ag(4,5-dicyanoimid)], may 
possibly form a polymeric chain through interaction of the silver(I) with the 
lone pair of electrons on the imine nitrogen of another molecule of  [Ag(2-
Mebenz-imid)] (Figure 81(b)).  
 
 




[Ag4(9-aca)4(NH3)2] was synthesised from 9-anthracenecarboxylic acid and 
silver nitrate in an ethanol/water mixture (4:1) to give the product with a yield  
of 45% (Scheme 17). The aqueous ammonia was used to prevent the 
precipitation of insoluble silver(I) oxide. 
 
 














9-acaH  +  AgNO3 [Ag4(9-aca)4(NH3)2]
NH3 (aq)
EtOH/H2O, RT, 0.5 h
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Crystals suitable for X-ray crystallographic analysis were grown from the 
reaction filtrate and the structure of [Ag4(9-aca)4(NH3)2] is shown in Figures 
82-85. Selected bond lengths and angles are listed in Table 10. 
 
 





Figure 83. Space-filled structural diagram for [Ag4(9-aca)4(NH3)2] (Ag = purple, 
O = red, N = blue, C = grey, H = white). 
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Figure 85. Packing diagram for [Ag4(9-aca)4(NH3)2]. 
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Bond Bond Angle 
(°) 
Ag(1)-Ag(1A) 2.939 O(1)-Ag(1)-Ag(1A) 164.17 
Ag(1)-O(1) 2.329 O(3)-Ag(1)-O(4A) 155.63 
Ag(1)-O(3) 2.192 O(3)-Ag(1)-Ag(1A) 85.15 
Ag(1)-O(4A) 2.261 N(1)-Ag(2)-O(2) 170.60 
Ag(2)-O(2) 2.135 O(3)-Ag(1)-O(1) 100.39 
Ag(2)-N(1) 2.148 O(4A)-Ag(1)-Ag(1A) 75.23 
 
[Ag4(9-aca)4(NH3)2] is dimeric and centrosymmetric, containing two four-
coordinate silver(I) ions and two two-coordinate silver(I) ions. The Ag(1)-
Ag(1A) distance is 2.939 Å. The two carboxylates that are linked to the metal-
metal bimetallic core are syn-syn bridging. The two carboxylates in the 
equatorial plane are in the syn-anti configuration, being coordinated to one 
silver of the bimetallic core and a second, non-core silver (Ag2). A space-filled 
structural diagram for [Ag4(9-aca)4(NH3)2] shows it to resemble a sandwich 
complex with the bimetallic core at the centre encased by the carboxylate 
ligands (Figure 83). 
 
In [Ag4(9-aca)4(NH3)2], Ag(2) is coordinated approximately linearly by 
ammonia and carboxylate ligands, and this metal also interacts with the 
anthracene π-systems of a neighbouring molecule (Figure 84). This interaction 
is supported by two long H-bonds from the hydrogens of the ammonia ligand to 
the carboxylate oxygen atoms of the same neighbouring molecule. These 
interactions lead to the packing arrangement illustrated in Figure 85. 
 
The IR spectrum of [Ag4(9-aca)4(NH3)2] contains a band at 3370 cm-1 for the N-
H stretching vibration of the ammonia ligand. Bands are also present at 1620, 
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764 and 736 cm-1 for the stretching vibrations of the anthracene ring 
system144,160. The ν(OCO)asym and ν(OCO)sym vibrations occur at 1551 and 1424 cm-1, 
respectively, giving a Δ(OCO) value of 127 cm-1. This value is consistent with the 
carboxylate ligands being in a bridging coordination mode143. 
 
The 1H NMR spectrum of [Ag4(9-aca)4(NH3)2] is very similar to that of [Ag2(9-
aca)2]n, with the anthracene aromatic proton peaks occurring at 8.41 (H10), 8.15 
(H1,8),  8.03 (H4,5) and 7.47 ppm (H2,3,6,7). There is also a singlet at 3.01 ppm for 
the protons of the NH3 ligands. The presence of the silver(I) ions and amine 
groups have caused a shielding of anthracene protons, shifting them slightly 




3.2 Fluorescence of Silver(I) Complexes 
 
The fluorescence properties of uncomplexed 9-anthracenecarboxylic acid have 
been of interest to research groups for over thirty years154. Some preliminary 
fluorescence studies were carried out on a selection of the current silver(I) 
anthracene complexes in order to investigate the effect that coordination to 
silver(I) metal centres has on the fluorescence of the free ligands. The UV-Vis 
absorption spectrum was recorded to identify the maximum absorption 
wavelength of each complex and 9-acaH (Figures 86, 88, 90, 92, 94, 96, 98, 100, 
and 102). The four peaks at ca. 365 nm in the absorption spectrum are assigned 
to vibrational levels of the 1La state while the peak at ca. 260 nm are assigned to 
the 1Bb state153,165. These absorptions arise from the excitation of electrons into 
the π* orbital of the anthracene moiety from various levels within the ground 
state. Fluorescence spectra were then recorded and compared to that of metal-
free 9-acaH (Figures 87, 89, 91, 93, 95, 97, 99, 101 and 103). The broad 
fluorescence band of 9-acaH centred at ca. 450 nm is thought to arise the 
presence of H-bonded dimers in the solutions154,155. UV-Vis and fluorescence 
data are listed in Tables 33-35 in the Appendix. 
 




Figure 86. UV-Vis absorption spectra of [Ag2(9-aca)2]n (red) and 9-acaH (blue). 
 
 
Figure 87. Fluorescence spectra of [Ag2(9-aca)2]n (red) and 9-acaH (blue). 
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Figure 88. UV-Vis absorption spectra of [Ag(imidH)2.3(CH3CN)0.7](9-aca) 
(green), 9-acaH (red) and imidH (blue). 
 
 
Figure 89. Fluorescence spectra of [Ag(imidH)2.3(CH3CN)0.7](9-aca) (green), 9-
acaH (red) and imidH (blue). 
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Figure 90. UV-Vis absorption spectra of [Ag(apim)](9-aca)·H2O (green), 9-acaH 
(red) and apim (blue). 
 
 
Figure 91. Fluorescence spectra of [Ag(apim)](9-aca)·H2O (red), 9-acaH 
(green) and apim (blue). 
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Figure 93. Fluorescence spectra of [Ag(2-Ph-imid)] (blue) and 2-Ph-imidH 
(red). 
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Figure 94. UV-Vis absorption spectra of [Ag(4-Ph-imidH)2(9-aca)] (green), 9-
acaH (red) and 4-Ph-imidH (blue). 
 
 
Figure 95. Fluorescence spectra of [Ag(4-Ph-imidH)2(9-aca)] (green), 9-acaH 
(red) and 4-Ph-imidH (blue). 
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Figure 97. Fluorescence spectra of [Ag(4,5-dicyanoimid)] (red) and 4,5-
dicyanoimidH (blue). 
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Figure 98. UV-Vis absorption spectra of [Ag2(2-Mebenz-imidH)4](9-aca)2 
(green), 9-acaH (red) and 2-MebenzimidH (blue). 
 
Figure 99. Fluorescence spectra of [Ag2(2-Mebenz-imidH)4](9-aca)2 (red, 
excited at 283 nm), [Ag2(2-Mebenz-imidH)4](9-aca)2 (pink, excited at 366 nm), 
2-Mebenz-imidH (blue) and 9-acaH (light blue). 
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Figure 101. Fluorescence spectra of [Ag4(9-aca)4(NH3)2] (blue) and 9-acaH 
(green). 
 













































Chapter 3.                                                                            Drug Structures and Properties 
146 
 
Figure 102. UV-Vis absorption spectra of [Na(9-aca)] (blue) and 9-acaH (red). 
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For all of the silver(I) complexes containing the 9-aca- anion and also the simple 
sodium salt, Na+9-aca-, fluorescence decreases dramatically with respect to that 
for free 9-acaH. [Ag(imidH)2.3(CH3CN)0.7](9-aca) caused the biggest reduction in 
fluorescence, quenching the fluorescence of 9-acaH by a factor of ca. 63. With 
the exception of [Ag(4,5-dicyanoimid)], all of the silver(I) imidazolate 
complexes (9-aca- absent) fluoresce with a higher intensity than that of the 
corresponding free imidazole ligand. In the case of [Ag(4,5-dicyanoimid)], 
coordination to the silver(I) ion and deprotonation of the imidazole causes a 
reduction in fluorescence intensity when compared to that of the free 4,5-
dicyanoimidH. 
 
The ability of the silver(I) complexes to reduce the fluorescence of 9-acaH may 
be useful in identifying the manner in which the silver(I) carboxylate complexes 
interact with microbial or cancer cells. An increase in the fluorescence of the 
compounds within the cells could possibly indicate dissociation of the complex 
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4.1 Antimicrobial Growth 
 
The growth of  fungal and bacterial cells can be divided into four phases: 
 
(i) Lag Phase. Growth is slow at first while the cells acclimatise to the 
new environmental conditions to which they have been introduced 
(pH, temperature, nutrients, etc.). There is no significant increase in 
cell numbers with time. 
(ii) Exponential phase. Once the cells are accustomed to their 
surroundings they begin to multiply exponentially, doubling every 
few minutes. 
(iii) Stationary phase. The rapid growth ceases due to limited supply of 
food, nutrients and space. There is no significant increase or decrease 
in cell numbers with time. 
(iv) Death phase. Toxic waste products build up, nutrient supplies are 
depleted and cells begin to die. 
 
Typical growth curves for healthy microbial (control cells) and drug-treated 
cells are illustrated in Figure 104. 
 
 
Figure 104. Growth curve for non-drug treated (control) and drug-treated 
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4.2 In vitro Antifungal Screening 
 
The silver(I) complexes, simple silver(I) compounds (silver nitrate, silver 
perchlorate and silver oxide) and the prescription antifungal drug, 
Ketoconazole, were screened in vitro for their ability to inhibit the growth of C. 
albicans. MIC100 values for these compounds are given in Table 11 and Figure 
105. All of the test solutions were made by dissolving the complex in DMSO (1 
cm3) and diluting with water to yield the required concentration. The maximum 
DMSO concentration in any sample was 0.5% v/v, and at this level the DMSO 
does not inhibit the growth of C. albicans cells. The metal-free ligands were also 
screened for their biological activity and all proved to be inactive at a 
concentration of 100 µg cm-3. The activity of the complexes, relative to the 
quantity (µM) of Ag+ ion present, is also given in Table 11. 
 
Of the silver-containing samples tested in this work, all but three were more 
active than Ketoconazole. The simple silver(I) compounds (silver nitrate, silver 
perchlorate and silver oxide) were all more cytotoxic than Ketoconazole (MIC100 
values of 1.83, 1.50, 0.67 and 4.70, respectively). Interestingly, the water-
insoluble Ag2O was more active than water-soluble AgNO3 and AgClO4, 
suggesting that lipophilicity might be a desirable property. 
 
The most effective silver(I) complex at inhibiting the growth of C. albicans cells 
was [Ag4(9-aca)4(NH3)2]. The MIC100 value for the complex (0.14 µM) showed 
that it was ca. 32 times more cytotoxic than Ketoconazole (4.70 µM). This 
anthracene complex was also more active than the three simple silver(I) 
compounds. A similar high level of activity was also reported for the 
structurally related complex, [Ag2(salH)2(NH3)2] (0.50 µM)124. Both complexes 
contain silver(I) ions coordinated to carboxylate and ammonia ligands, although 
the carboxylate binding mode in each is different. The carboxylates in [Ag4(9-
aca)4(NH3)2] have syn-syn and syn-anti bridging conformations, while the 
salicylates of [Ag2(salH)2(NH3)2] are monodenate. In both complexes, the 
ammonia ligands are coordinated to the silver(I) in an approximately linear 
arrangement. It has previously been reported that the presence of this Ag-N  
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Table 11. Minimum inhibitory concentrations (MIC100) of silver(I) complexes 









Ketoconazole# 2.50 4.70 n/a 
AgNO3 0.31 1.83 1.83 
AgClO4 0.31 1.50 1.50 
Ag2O# 0.16 0.67 1.34 
[Ag2(9-aca)2]n 0.63 0.95 1.90 
[Ag2(9-aca)2(DMSO)2]n 0.78 0.96 1.92 
[Ag(imidH)2.3(CH3CN)0.7](9-aca) 0.20 0.38 0.38 
[Ag6(imidH)4(9-aca)6(MeOH)2] 1.25 0.54 3.24 
[Ag(1-Me-imid)2]2[Ag4(9-aca)6] 0.78 0.34 2.04 
[Ag2(1-Me-imid)2(9-aca)2] 1.00 1.22 2.44 
[Ag(2-Me-imidH)2(9-aca)] 0.78 1.58 1.58 
[Ag(1-Bu-imid)2]2[Ag4(9-aca)6] 0.78 0.32 1.92 
[Ag2(1-Bu-imid)2(9-aca)2] 0.78 0.86 1.72 
[Ag(apim)](9-aca)·H2O 0.20 0.43 0.43 
[Ag(2-Ph-imid)]# 1.56 6.21 6.21 
[Ag(4-Ph-imidH)2(9-aca)] 1.56 2.53 2.53 
[Ag(4,5-dicyanoimid)]# 0.39 1.73 1.73 
[Ag(Benz-imid)]# 1.56 6.93 6.93 
[Ag2(2-Mebenz-imidH)4](9-aca)2 1.56 1.31 2.62 
[Ag(2-Mebenz-imid)]# 3.13 13.07 13.07 
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bond allows for good antimicrobial activity and this may be related to the 
relatively weak strength of the Ag-N bond and the release of Ag(I) ions from the 
molecule85. A comparison of the relative activity of these two complexes in 
terms of the concentration of Ag+ ions clearly shows that [Ag4(9-aca)4(NH3)2] is 
almost twice as active as [Ag2(salH)2(NH3)2]. 
 
Although [Ag4(9-aca)4(NH3)2] is the most active of the silver(I) complexes on a 
molecular level, the most active complex per mole of silver(I) present is 
[Ag(imidH)2.3(CH3CN)0.7](9-aca) (MIC100 = 0.38 µM Ag+). This complex is 1.5 
times more active per Ag
+
 than [Ag4(9-aca)4(NH3)2] (MIC100 = 0.56 µM Ag+) and 4-
5 times more active than AgNO3 and AgClO4 (MIC100 = 1.83 and 1.50 µM Ag+, 
respectively). 
 
The anthracene complex, [Ag2(9-aca)2]n (MIC100 = 0.95 µM), was ca. 7 times less 
active than [Ag4(9-aca)4(NH3)2], suggesting again that the presence of NH3 
ligands has a significant influence on bioactivity. However, [Ag2(9-aca)2]n was 
still ca. 5 times more active than its salicylate relative, [Ag2(salH)2] (5.00 µM)124. 
[Ag2(9-aca)2(DMSO)2]n (MIC100 = 0.96 µM) displayed similar activity to [Ag2(9-
aca)2]n.  
 
The most active of the imidazole-containing complexes was the complex salt, 
[Ag(1-Bu-imid)2]2[Ag4(9-aca)6] (MIC100 = 0.32 µM). This salt was 15 times more 
cytotoxic than Ketoconazole and it was also more active than its precursor, 
[Ag2(1-Bu-imid)2(9-aca)2] (0.86 µM). However, a comparison of activities in 
terms of Ag+ content reveals that [Ag2(1-Bu-imid)2(9-aca)2] is slightly more 
active than [Ag(1-Bu-imid)2]2[Ag4(9-aca)6] (1.72 and 1.92 µM Ag+, respectively). 
The activities of the 1-Bu-imid pair of complexes, [Ag2(1-Bu-imid)2(9-aca)2] and 
[Ag(1-Bu-imid)2]2[Ag4(9-aca)6], were superior to that of the related 1-Me-imid 
pair, [Ag2(1-Me-imid)2(9-aca)2] and [Ag(1-Me-imid)2]2[Ag4(9-aca)6] (MIC100 = 
1.22 and 0.34 µM, respectively). This suggests that a longer alkyl substituent 
(butyl vs. methyl) on the imidazole ring enhances activity. The large butyl group 
is expected to confer greater lipid solubility and this may be an important 
attribute in the penetration of the cell membrane. 
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The 2-Me-imidH derivative, [Ag(2-Me-imidH)2(9-aca)] (MIC100 = 1.58 µM), was 
ca. 3 times more active than Ketoconazole (MIC100 = 4.70 µM). This complex 
was less active than its 1-Me-imid counterparts, yet when a comparison is made 
in terms of the quantity of Ag+ present per molecule, the 2-Me-imidH complex 
had the greater cytotoxicity towards C. albicans cells (MIC100 = 1.58, 2.04 and 
2.44 µM Ag+ for [Ag(2-Me-imidH)2(9-aca)], [Ag(1-Me-imid)2]2[Ag4(9-aca)6] and 
[Ag2(1-Me-imid)2(9-aca)2], respectively).  
 
The unsubstituted imidazole complex, [Ag6(imidH)4(9-aca)6(MeOH)2] (MIC100 = 
0.54 µM), had a cytotoxicity 9 times greater than Ketoconazole. Although this 
complex contains silver(I) coordinated approximately linearly by two imidazole 
ligands in a similar manner to that in [Ag(imidH)2.3(CH3CN)0.7](9-aca), it was 
less active per Ag+ ion present (MIC100 = 0.38 and 3.24 µM Ag+, respectively). 
This finding may be related to the quantity of silver(I) which can readily be 
released from the complexes. It is possible that the metal ions are more tightly 
bound in the hexanuclear core of [Ag6(imidH)4(9-aca)6(MeOH)2] than in 
[Ag(imidH)2.3(CH3CN)0.7](9-aca). 
 
Although [Ag(4-Ph-imidH)2(9-aca)] (MIC100 = 2.53 µM) was almost twice as 
active at inhibiting the growth of C. albicans as Ketoconazole, it was not as 
cytotoxic as the three simple silver compounds. Whereas [Ag2(2-Mebenz-
imidH)4](9-aca)2 (MIC100 = 1.31 µM) was less cytotoxic than all of the previously 
discussed silver(I) complexes, it was still 3.5 times more active than 
Ketoconazole. [Ag2(2-Mebenz-imidH)4](9-aca)2 is structurally similar to the 
silver salicylate complex, [Ag2(imidH)4](salH)2126 (MIC100 = 0.10 µM) yet 
[Ag2(imidH)4](salH)2 was ca. 13 times more cytotoxic towards C. albicans cells. 
This suggests that the combination of the 9-aca- counterion with the bulkier and 
more aromatic imidazole ligand is important to how [Ag2(2-Mebenz-
imidH)4](9-aca)2 interacts with the fungal cells. 
 
[Ag(apim)](9-aca)·H2O (MIC100 = 0.43 µM) was ca. 11 times more active than 
Ketoconazole and ca. 4 times more active than AgNO3 at inhibiting the growth of 
C. albicans. This complex is structurally very similar to the known biologically 
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active complex, [Ag(apim)]ClO4126 (MIC100 = 1.80 µM), although the presence of 
the 9-aca- as the counterion (as opposed to the perchlorate counterion) appears 
to have increased the cytoxicity 4-fold. However, this interpretation is 
somewhat contradicted by the fact that the salts, K+9-aca- and Na+ClO4-, are both 
inactive at inhibiting the growth of C. albicans. 
 
Three silver(I) imidazolate complexes that did not contain the anthracene 
carboxylate ligand were also screened for their inhibitory activity. [Ag(4,5-
dicyanoimid)] (MIC100 = 1.734 µM) had a similar activity profile to AgNO3 and 
was ca. 3 times more active than Ketoconazole. [Ag(2-Ph-imid)], [Ag(Benz-
imid)] and [Ag(2-Mebenz-imid)] (MIC100 = 6.214, 6.930 and 13.073 µM, 
respectively) were all less cytotoxic towards C. albicans cells than Ketoconazole. 
Each of these three complexes contain anionic imidazolate ligands 
(deprotonated amine nitrogen) and most likely are polymeric. Bonding of the 
silver(I) to the N- atom of the imidazole is likely to be quite strong and this may 
retard the release of the silver(I) ions from the complex. 
 
 
4.3 In vivo Antifungal Screening 
 
In vivo antifungal screening was carried out using the G. mellonella insect model. 
G. mellonella larvae were administered test solutions by injection directly into 
the haemocoel through the last pro-leg (Figure 106). Survival was monitored 
every 24 h and death was assessed by the lack of movement in response to 
stimulus together with discolouration of the cuticle (Figure 107). 
 
The toxicity of all complexes was assessed at three different concentrations: 
100 µg cm-3, 10 µg cm-3 and twice their MIC100 value. The simple silver(I) salts, 
silver nitrate and silver perchlorate, and the prescription antifungal drug, 
Ketoconazole, were used as reference standards. It was found that the survival 
of the larvae was not affected by Ketoconazole, AgNO3, AgClO4 or any of the 
silver(I) complexes. 
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Figure 106. Injection of test solutions into the haemocoel of G. mellonella 
through the last pro-leg. 
 
    
   (a)                                (b) 
Figure 107. G. mellonella after 72 h incubation at 30 °C: (a) healthy control 
specimens and (b) specimens treated with a lethal dose of C. albicans. 
 
The two types of antifungal screening conducted were prophylactic treatment 
and the treatment of infection (pre-infected larvae). A lethal dose of C. albicans 
was pre-determined to be 2×106 cells administered in 20 µl of PBS solution 
(1×108 cells cm-3). Each of the test compounds was screened at three 
concentrations; 100 µg cm-3, 10 µg cm-3 and twice their MIC100 value. The 
prophylactic dose of complex was administered 1 h prior to infection with C. 
albicans cells, while in treatment form the complex was administered 1 h after 
infection. Survival was analysed at 24, 48 and 72 h intervals and significance 
was determined using the log rank (Mantel-Cox) method. Positive results were 
placed into one of three categories: * = p<0.05, ** = p<0.01 and *** = p<0.001. 
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Results for prophylactic treatment are illustrated in Figures 108-110 and those 
for the treatment of infection are illustrated in Figures 111-113. These data, 
along with significant p categories and values, are listed in Tables 36-39 in the 
Appendix.  
 
Ketoconazole, administered prophylactically at a concentration of 100 µg cm-3, 
significantly increased the survival rate of G. mellonella larvae 48 h (p = 0.0285) 
and 72 h (p = 0.0076) after infection with C. albicans cells. At the lower 
concentrations (10 and 5 µg cm-3) the increased survival was not deemed to be 
statistically significant. A similar pattern was observed for the treatment of C. 
albicans with Ketoconazole in pre-infected larvae (at 100 µg cm-3, p = 0.0076 
after 48 and 72 h). Silver nitrate proved to be more effective than Ketoconazole 
at increasing the survival of G. mellonella larvae, both prophylactically and in 
the treatment of infection. AgNO3 improved survival rates after 48 h and 72 h at 
an administered concentration of 10 µg cm-3 prophylactically (p = 0.0285 and 
0.0076, respectively), and after 72 h at 0.625 µg cm-3 when treating the pre-
infected larvae (p = 0.0223). 
 
The best silver(I) complex for increasing the survival rate of C. albicans infected 
G. mellonella larvae was [Ag4(9-aca)4(NH3)2]. Prophylactically, it significantly 
increased the survival rate after 48 h and 72 h at a concentration of 10 µg cm-3 
(p = 0.0285 and 0.0076, respectively). Furthermore, the complex was also very 
effective after 72 h at a concentration of twice its MIC100 value (0.390 µg cm-3) 
(p = 0.0223). The concentrations of Ketoconazole and AgNO3 required to effect 
the same degree of survival were found to be substantially greater (100 and 10 
µg cm-3, respectively). [Ag4(9-aca)4(NH3)2] was not as effective at treating pre-
infected larvae, requiring a dose of 100 µg cm-3 to significantly increase survival 
(p = 0.0223). 
 
The remaining silver(I) complexes, although not as effective as [Ag4(9-
aca)4(NH3)2], also increased the survival rate of G. mellonella larvae infected 
with C. albicans and their activities are summarised below. 
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When administered prophylactically at a concentration of 100 µg cm-3, [Ag2(9-
aca)2]n, [Ag6(imidH)4(9-aca)6(MeOH)2], [Ag(4,5-dicyanoimid)] and [Ag(Benz-
imid)] all significantly increased the survival rate of larvae subsequently 
infected with C. albicans (p = 0.0223 for each complex). [Ag2(1-Bu-imid)2(9-
aca)2], [Ag(apim)](9-aca)·H2O and [Ag(2-Ph-imid)] improved the survival rate 
after 48 and 72 h at 100 µg cm-3 prophylactically (p = 0.0285 and 0.0076, 
respectively). Although the activity of the latter three complexes was similar to 
that of Ketoconazole, they were not as effective as silver nitrate. [Ag(1-Bu-
imid)2]2[Ag4(9-aca)6] and AgNO3 were found to be substantially more efficient 
than Ketoconazole as prophylactics, requiring only a concentration of 10 µg cm-
3 (as opposed to 100 µg cm-3) to promote the same degree of survival. 
 
In general, the treatment of G. mellonella larvae pre-infected with C. albicans 
was not as good as those treated prophylactically. The most effective silver(I) 
complex at increasing the survival rate of pre-infected larvae was [Ag(2-Me-
imidH)2(9-aca)]. This complex significantly increased the survival rate when 
administered at a concentration of 10 µg cm-3 (p = 0.0223). A Ketoconazole 
concentration of 100 µg cm-3 was required to maintain the same survival rate.  
 
[Ag2(1-Bu-imid)2(9-aca)2] and [Ag(apim)](9-aca)·H2O, at a concentration of 100 
µg cm-3, both significantly increased the larval survival rate 48 h and 72 h after 
pre-infection (p = 0.0285 and 0.0223 for [Ag2(1-Bu-imid)2(9-aca)2] and p = 
0.0076 for [Ag(apim)](9-aca)·H2O). Treatment of pre-infected larvae with 
[Ag(4,5-dicyanoimid)] at 100 µg cm-3 also promoted an increased survival rate. 
Thus, the latter three complexes were equally effective when administered 
either prophylactically or to pre-infected larvae. 
 
When treating pre-infected larvae at 100 µg cm-3, [Ag(2-Ph-imid)] only 
increased the survival rate after a 72 h period (p = 0.0223), whereas with 
prophylactic dosing a beneficial effect was observed after 48 h (p = 0.0285). The 
opposite trend was seen for [Ag(1-Me-imid)2]2[Ag4(9-aca)6]. This complex did 
not significantly increase the survival rate of G. mellonella larvae at any time 
point when administered prophylactically, but when the pre-existing infection 
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was treated with [Ag(1-Me-imid)2]2[Ag4(9-aca)6] (100 µg cm-3) the survival rate 
significantly increased (p = 0.0223). 
 
In summary, the prophylactic method of administering the silver(I) complexes 
proved more effective at increasing the survival rate of G. mellonella infected 
with C. albicans. This may be attributed not only to the efficacy of the complexes 
but also to the anticipated increase in the number of haemocytes, antimicrobial 
peptides and proteins produced by the innate immune system of the larvae in 






Figure 108. Percentage survival of G. mellonella larvae inoculated with complexes (100 µg cm-3) one hour prior to infection with C. 



































Figure 109. Percentage survival of G. mellonella larvae inoculated with complexes (10 µg cm-3) one hour prior to infection with C. 

























Figure 110. Percentage survival of G. mellonella larvae inoculated with complexes (concentration twice the MIC100 value) one hour prior 






















Figure 111. Percentage survival of G. mellonella larvae inoculated with complexes (100 µg cm-3) one hour after infection with C. albicans 
































Figure 112. Percentage survival of G. mellonella larvae inoculated with complexes (10 µg cm-3) one hour after infection with C. albicans 























Figure 113. Percentage survival of G. mellonella larvae inoculated with complexes (concentration twice the MIC100 value) one hour after 
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4.4 In vitro Antibacterial Screening 
 
In a similar manner to that described for fungal growth, bacterial growth can be 
divided into four phases: the lag phase, exponential phase, stationary phase and 
death phase (Figure 104). Bacterial cells replicate faster than fungal cells so the 
exponential and stationary phases are reached more quickly.  
 
Silver(I) complexes, the simple salts silver nitrate and silver perchlorate, and 
the commercial reference standard, silver(I) sulfadiazine, were screened for 
their ability to inhibit the growth of Gram-negative E. coli and Gram-positive 
MRSA. All test solutions were made by dissolving the complex in DMSO (1 cm-3) 
and diluting with water to yield the required concentration. The maximum 
DMSO concentration in any sample was 0.5% v/v, a concentration which does 
not inhibit the growth of the bacterial cells. The metal-free ligands were also 
screened for their antibacterial activity and all proved to be inactive at a 
concentration of 100 µg cm-3. The MIC50 value was calculated for all test 
solutions and results are shown in Tables 12 and 13, and Figure 114. 
 
Of the silver(I) complexes that were screened against E. coli, all but three were 
more active than silver sulfadiazine (MIC50 = 73.05 µM). When tested against 
MRSA, five of the silver(I) complexes proved less cytotoxic than silver 
sulfadiazine. The simple silver salts, AgNO3 and AgClO4, were more cytotoxic 
than silver sulfadiazine against both strains of bacteria (MIC50 = 65.19 and 
51.95 µM for E. coli and MIC50 = 34.32 and 37.09 µM for MRSA, respectively). 
 
The most effective of the silver(I) complexes at inhibiting the growth of E. coli 
was [Ag6(imidH)4(9-aca)6(MeOH)2] (1.87 µM). The complex was ca. 39 times 
more active than silver sulfadiazine and ca. 27 times more active than AgNO3 
and AgClO4. When activity per Ag+ ion was examined, [Ag6(imidH)4(9-
aca)6(MeOH)2] was still the most cytotoxic towards E. coli (MIC50 = 11.22 µM). 
This complex also exhibited good activity against MRSA (MIC50 = 5.85 µM), 
exhibiting cytotoxicity over 8 times greater than that of silver sulfadiazine and 
ca. 6 times more active than AgNO3 (MIC50 = 50.20 and 34.32 µM, respectively). 
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The ammonia-containing complex, [Ag4(9-aca)4(NH3)2], proved to be the most 
effective silver(I) complex at inhibiting the growth of MRSA at both µM 
concentration of complex and µM concentration of Ag+ levels (MIC50 = 5.44 µM, 
21.76 µM Ag+). This complex has an MIC50 value ca. 9 times greater than that of 
silver sulfadiazine (MIC50 = 73.05 µM). A similar high level of activity was 
observed against E. coli (MIC50 = 8.51 µM).  
 
The structurally similar complex salts, [Ag(1-Me-imid)2]2[Ag4(9-aca)6] and 
[Ag(1-Bu-imid)2]2[Ag4(9-aca)6], had similar antibacterial properties. Against 
both E. coli and MRSA, [Ag(1-Bu-imid)2]2[Ag4(9-aca)6] proved more cytotoxic 
than [Ag(1-Me-imid)2]2[Ag4(9-aca)6] (MIC50 = 7.04 and 8.64 µM for E. coli, MIC50 
= 6.16 and 8.10 µM for MRSA, respectively). [Ag(1-Bu-imid)2]2[Ag4(9-aca)6] was 
also ca. 10 times more active against E. coli and ca. 7 times more cytotoxic 
against MRSA than silver sulfadiazine.  
 
The other 1-Me-imid- and 1-Bu-imid-containing compounds, [Ag2(1-Me-
imid)2(9-aca)2] and [Ag2(1-Bu-imid)2(9-aca)2], were also active at inhibiting 
bacterial growth (MIC50 of [Ag2(1-Me-imid)2(9-aca)2] = 16.82 and 35.22 µM, 
MIC50 of [Ag2(1-Bu-imid)2(9-aca)2] = 13.89 and 16.98 µM, against E. coli and 
MRSA, respectively). Both of these complexes were more active than silver 
sulfadiazine, AgNO3 and AgClO4, and, as observed for [Ag(1-Me-imid)2]2[Ag4(9-
aca)6] and [Ag(1-Bu-imid)2]2[Ag4(9-aca)6], the 1-Bu-imid complex showed 
greater antibacterial activity than the 1-Me-imid complex. This would appear to 
confirm earlier suggestions that the length of the alkyl chain may influence the 
mode of interaction of these molecules with the microorganism. 
 
The imidazole-free silver(I) complexes, [Ag2(9-aca)2]n and [Ag2(9-
aca)2(DMSO)2]n, proved to be cytotoxic towards both E. coli and MRSA. Against 
E. coli, [Ag2(9-aca)2(DMSO)2]n was twice as active as [Ag2(9-aca)2]n (MIC50 = 
11.06 and 22.44 µM, respectively) and both were more active towards the two 
bacterial pathogens than silver sulfadiazine, AgNO3 and AgClO4 (MIC50 = 73.05,  
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Table 12. Minimum inhibitory concentrations (MIC50) of silver(I) complexes 









Silver sulfadiazine# 26.09 73.05 73.05 
AgNO3 11.08 65.19 65.19 
AgClO4 10.77 51.95 51.95 
[Ag2(9-aca)2]n 14.77 22.44 44.88 
[Ag2(9-aca)2(DMSO)2]n 9.01 11.06 22.12 
[Ag(imidH)2.3(CH3CN)0.7](9-aca) 10.63 20.66 20.66 
[Ag6(imidH)4(9-aca)6(MeOH)2] 4.32 1.87 11.22 
[Ag(1-Me-imid)2]2[Ag4(9-aca)6] 19.89 8.64 51.84 
[Ag2(1-Me-imid)2(9-aca)2] 13.83 16.82 33.64 
[Ag(2-Me-imidH)2(9-aca)] 11.28 22.87 22.87 
[Ag(1-Bu-imid)2]2[Ag4(9-aca)6] 17.39 7.04 42.24 
[Ag2(1-Bu-imid)2(9-aca)2] 12.59 13.89 27.78 
[Ag(apim)](9-aca)·H2O 14.23 30.13 30.13 
[Ag(2-Ph-imid)]# 37.60 149.77 149.77 
[Ag(4-Ph-imidH)2(9-aca)] 31.00 50.21 50.21 
[Ag(4,5-dicyanoimid)]# 28.75 127.22 127.22 
[Ag(Benz-imid)]# 31.26 138.93 138.93 
[Ag2(2-Mebenz-imidH)4](9-aca)2 15.40 12.98 25.96 
[Ag(2-Mebenz-imid)]# 8.64 36.14 36.14 
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Silver sulfadiazine# 17.93 50.20 50.20 
AgNO3 5.83 34.32 34.32 
AgClO4 7.69 37.09 37.09 
[Ag2(9-aca)2]n 7.48 11.36 22.72 
[Ag2(9-aca)2(DMSO)2]n 18.23 22.38 44.76 
[Ag(imidH)2.3(CH3CN)0.7](9-aca) 34.50 67.07 67.07 
[Ag6(imidH)4(9-aca)6(MeOH)2] 13.53 5.85 35.10 
[Ag(1-Me-imid)2]2[Ag4(9-aca)6] 18.65 8.10 48.60 
[Ag2(1-Me-imid)2(9-aca)2] 28.97 35.22 70.44 
[Ag(2-Me-imidH)2(9-aca)] 17.04 34.54 34.54 
[Ag(1-Bu-imid)2]2[Ag4(9-aca)6] 15.23 6.16 36.96 
[Ag2(1-Bu-imid)2(9-aca)2] 15.39 16.98 33.96 
[Ag(apim)](9-aca)·H2O 12.99 27.50 27.50 
[Ag(2-Ph-imid)]# 19.10 76.08 76.08 
[Ag(4-Ph-imidH)2(9-aca)] 30.40 49.23 49.23 
[Ag(4,5-dicyanoimid)]# 55.25 244.49 244.49 
[Ag(Benz-imid)]# 38.64 171.73 171.73 
[Ag2(2-Mebenz-imidH)4](9-aca)2 17.70 14.91 29.82 
[Ag(2-Mebenz-imid)]# 12.48 52.21 52.21 
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65.19 and 51.95 µM, respectively). The reverse trend was observed for the 
activity of these two complexes against MRSA, with [Ag2(9-aca)2]n being ca. 2 
times more cytotoxic than [Ag2(9-aca)2(DMSO)2]n (MIC50 of 11.36 and 22.38 µM, 
respectively). The reasons for this difference in activity towards these bacterial 
strains have yet to be uncovered, but they may be linked to the difference in the 
structure of their cell walls. E. coli is a Gram-negative bacterium whose cell wall 
consists of a few layers of peptidoglycan and an outer membrane of various 
lipid complexes. MRSA, a Gram-positive bacterium, has a cell wall containing 
many layers of peptidoglycan and no lipid outer membrane. The presence or 
absence of this lipid membrane may significantly influence the absorbance of 
the drug molecules into the cell. 
 
[Ag(imidH)2.3(CH3CN)0.7](9-aca) (MIC50 = 20.66 µM) was ca. 3 times more active 
than silver sulfadiazine against E. coli. However, the complex was substantially 
less cytotoxic towards MRSA (MIC50 = 67.07 µM), with AgNO3 and AgClO4 being 
approximately twice as active. [Ag(apim)](9-aca)·H2O also proved to be twice as 
active as silver sulfadiazine at inhibiting the growth of both E. coli and MRSA 
(MIC50 = 30.13 and 27.50 µM against E. coli and MRSA, respectively). 
 
The 2-Mebenz-imidH complexes, (Ag2(2-Mebenz-imidH)4](9-aca)2 and [Ag(2-
Mebenz-imid)]), both exhibited good antibacterial properties when screened 
against E. coli, with the anthracene complex proving to be more active (MIC50 = 
12.98 and 36.14 µM, respectively). The same trend was observed in tests 
against MRSA (MIC50 = 14.91 and 52.21 µM, respectively). This superior 
antibacterial activity of [Ag2(2-Mebenz-imidH)4](9-aca)2 over [Ag(2-Mebenz-
imid)] may be due to its greater solubility and thus the ease of release of Ag+ 
from the complex. 
 
[Ag(2-Me-imidH)2(9-aca)] contains a three-coordinate silver(I) ion and 
although it is thought that this coordination is also present in [Ag(4-Ph-
imidH)2(9-aca)], the two complexes show varied antibacterial properties. 
Against E. coli, [Ag(2-Me-imidH)2(9-aca)] is ca. 3 times more active than silver 
sulfadiazine and is twice as cytotoxic as [Ag(4-Ph-imidH)2(9-aca)] (MIC50 = 
Chapter 4.                                                                                                     Biological Activity 
171 
22.87 and 50.21 µM, respectively). These two compounds are also effective at 
inhibiting the growth of MRSA (MIC50 of 34.54 and 49.23 µM, respectively) and 
are as active as silver sulfadiazine, AgNO3 and AgClO4 (MIC50 of 50.20, 34.32 and 
37.09 µM, respectively). 
 
The imidazolate complexes, [Ag(2-Ph-imid)], [Ag(4,5-dicyanoimid)] and 
[Ag(Benz-imid)], which all contain deprotonated imidazole rings, exhibit similar 
antibacterial activities. Against E. coli, all three complexes have MIC50 values in 
excess of 125 µM (149.77, 127.22 and 138.93 µM for [Ag(2-Ph-imid)], [Ag(4,5-
dicyanoimid)] and [Ag(Benz-imid)], respectively). This activity is significantly 
less than that of silver sulfadiazine, AgNO3 and AgClO4. A similar trend was 
observed against MRSA (MIC50 of 76.08, 244.49 and 171.73 µM for [Ag(2-Ph-
imid)], [Ag(4,5-dicyanoimid)] and [Ag(Benz-imid)], respectively). It is thought 
that these complexes, with their proposed polymeric structures, may be 
reluctant to release their bioactive Ag+ ions. 
 
 
4.5 In vitro Anticancer Screening 
 
In vitro anticancer screening was carried out using selected silver(I) complexes 
on: 
 
(i) MCF-7, human breast adenocarcinoma cell line.  
(ii) HT-29, human colon adenocarcinoma cell line. 
(iii) Hep-G2, human hepatocellular carcinoma cell line. 
(iv) A-498, human kidney adenocarcinoma cell line. 
 
The results of these studies are presented in Tables 14-16 and Figures 115 and 
116.  
 
All of the silver(I) complexes, the simple silver salt AgNO3, the metal-based 
anticancer drug Cisplatin and the anthracene-containing anticancer drug 
Mitoxantrone were screened against the MCF-7 and HT-29 cancer cell lines. 
Chapter 4.                                                                                                     Biological Activity 
172 
Cisplatin did not stop the proliferation of MCF-7 and HT-29 cells at a 
concentration of 100 µM. Mitoxantrone and the simple silver(I) salt, AgNO3, was 
moderately active against MCF-7 and HT-29 cells (Mitoxantrone IC50 = 44.10 
and 76.90 µM, AgNO3 IC50 = 49.00 and 55.60 µM, for MCF-7 and HT-29, 
respectively). The metal-free ligands were all inactive at a concentration of 100 
µM.  
 
Although all of the new silver(I) complexes decreased the growth of the MCF-7 
cell line, the most active were [Ag6(imidH)4(9-aca)6(MeOH)2], [Ag(1-Bu-
imid)2]2[Ag4(9-aca)6], [Ag(1-Me-imid)2]2[Ag4(9-aca)6] and [Ag4(9-aca)4(NH3)2] 
(IC50 value of 6.30, 6.30, 6.50 and 7.16 µM, respectively). These four complexes 
were ca. 7 times more active than Mitoxantrone and ca. 8 times more active 
than AgNO3. [Ag2(1-Bu-imid)2(9-aca)2] and [Ag(4-Ph-imidH)2(9-aca)] (IC50 = 
19.08 and 17.27 µM, respectively) were also found to be active, but a decrease 
in activity was observed for the methyl-substituted imidazole complexes, 
[Ag2(1-Me-imid)2(9-aca)2] and [Ag(2-Me-imidH)2(9-aca)] (IC50 = 59.70 and 
64.80 µM, respectively) and also the imidazole-free silver(I) carboxylate 
complexes, [Ag2(9-aca)2]n and [Ag2(9-aca)2(DMSO)2]n (IC50 value of 57.33, 54.70 
µM, respectively). [Ag(imidH)2.3(CH3CN)0.7](9-aca), [Ag(apim)](9-aca)·H2O and 
[Ag2(2-Mebenz-imidH)4](9-aca)2 (IC50 = 62.20, 64.00 and 51.30 µM) were also 
less active than  Mitoxantrone and AgNO3 (IC50 = 44.10 and 49.00 µM, 
respectively) against MCF-7 cells. 
 
The polymeric imidazolate complexes [Ag(4,5-dicyanoimid)] and [Ag(Benz-
imid)], were found to have activities similar to the silver(I) complexes 
mentioned above (IC50 = 62.80 and 64.60 µM, respectively), while the other two 
polymeric imidazolate complexes, [Ag(2-Ph-imid)] and [Ag(2-Mebenz-imid)] 
(IC50 = 40.80 and 47.40 µM, respectively), were found to be marginally more 
cytotoxic towards MCF-7 cells with an IC50 comparable to that of Mitoxantrone. 
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Table 14. Minimum inhibitory concentrations (IC50) of silver(I) complexes 









Cisplatin N/A >100 N/A 
Mitoxantrone 19.47 (±1.15) 44.10 (±2.60) N/A 
AgNO3 8.32 (±2.50) 49.00(±14.70) 49.00 
[Ag2(9-aca)2]n 37.73 (±0.72) 57.33 (±1.09) 114.66 
[Ag2(9-aca)2(DMSO)2]n 44.55 (±4.40) 54.70 (±5.40) 109.40 
[Ag(imidH)2.3(CH3CN)0.7](9-
aca) 
32.00 (±2.01) 62.20 (±3.90) 62.20 
[Ag6(imidH)4(9-aca)6(MeOH)2] 14.56 (±1.39) 6.30 (±0.60) 37.80 
[Ag(1-Me-imid)2]2[Ag4(9-aca)6] 14.97 (±0.67) 6.50 (±0.29) 39.00 
[Ag2(1-Me-imid)2(9-aca)2] 49.10 (±2.06) 59.70 (±2.50) 119.40 
[Ag(2-Me-imidH)2(9-aca)] 31.97 (±2.47) 64.80 (±5.00) 64.80 
[Ag(1-Bu-imid)2]2[Ag4(9-aca)6] 15.57 (±0.74) 6.30 (±0.30) 37.80 
[Ag2(1-Bu-imid)2(9-aca)2] 17.30 (±2.47) 19.08 (±1.10) 38.16 
[Ag(apim)](9-aca)·H2O 30.23 (±3.02) 64.00 (±6.40) 64.00 
[Ag(2-Ph-imid)]# 10.24 (±1.86) 40.80 (±7.40) 40.80 
[Ag(4-Ph-imidH)2(9-aca)] 10.66 (±1.25) 17.27 (±2.02) 17.27 
[Ag(4,5-dicyanoimid)]# 14.13 (±1.51) 62.80 (±6.70) 62.80 
[Ag(Benz-imid)]# 14.54 (±0.90) 64.60 (±4.00) 64.60 
[Ag2(2-Mebenz-imidH)4](9-
aca)2 
60.87 (±5.22) 51.30 (±4.40) 102.60 
[Ag(2-Mebenz-imid)]# 11.33 (±0.54) 47.40 (±2.26) 47.40 
[Ag4(9-aca)4(NH3)2] 9.67 (±0.59) 7.16 (±0.44) 28.64 
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Table 15. Minimum inhibitory concentrations (IC50) of silver(I) complexes 









Cisplatin N/A >100 N/A 
Mitoxantrone 33.95 (±2.47) 76.90 (±5.60) N/A 
AgNO3 9.45 (±0.31) 55.60 (±1.80) 55.60 
[Ag2(9-aca)2]n 36.86 (±0.05) 56.00 (±0.76) 112.00 
[Ag2(9-aca)2(DMSO)2]n 43.82 (±1.82) 53.80 (±2.24) 107.60 
[Ag(imidH)2.3(CH3CN)0.7](9-
aca) 
35.29 (±0.93) 68.60 (±1.80) 68.60 
[Ag6(imidH)4(9-aca)6(MeOH)2] 108.62 
(±18.72) 





58.83 (±4.34) 352.98 
[Ag2(1-Me-imid)2(9-aca)2] 48.20 (±0.49) 58.60 (±0.60) 117.20 
[Ag(2-Me-imidH)2(9-aca)] 33.35 (±0.92) 67.60 (±1.86) 67.60 
[Ag(1-Bu-imid)2]2[Ag4(9-aca)6] 150.26 (±7.66) 60.80 (±3.10) 364.80 
[Ag2(1-Bu-imid)2(9-aca)2] 135.92 (±4.20) 149.93(±1.88) 299.86 
[Ag(apim)](9-aca)·H2O 25.27 (±2.49) 53.50 (±5.27) 53.50 
[Ag(2-Ph-imid)]# 14.18 (±1.05) 56.50 (±4.20) 56.50 
[Ag(4-Ph-imidH)2(9-aca)] 9.71 (±0.11) 15.73 (±0.18) 15.73 
[Ag(4,5-dicyanoimid)]# 15.75 (±2.47) 70.00 
(±11.00) 
70.00 
[Ag(Benz-imid)]# 13.21 (±0.14) 58.70 (±0.60) 58.70 
[Ag2(2-Mebenz-imidH)4](9-
aca)2 
74.77 (±1.31) 63.00 (±1.10) 126.00 
[Ag(2-Mebenz-imid)]# 102.70 (±2.55) 429.64 
(±10.67) 
429.64 





Figure 115. IC50 values of silver(I) complexes against MCF-7 and HT-29 cell lines (HT-29 values of [Ag2(1-Bu-imid)2(9-aca)2] and [Ag(2-
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Although most of the silver(I) complexes were more active than Cisplatin 
against HT-29 cells only [Ag(4-Ph-imidH)2(9-aca)] (IC50 = 15.73 µM) was 
significantly more active than AgNO3 (IC50 = 55.60 µM). [Ag(1-Bu-
imid)2]2[Ag4(9-aca)6] and [Ag(2-Mebenz-imid)] had the lowest activity (IC50 = 
149.93 and 429.64 µM, respectively). The remaining silver(I) complexes had 
IC50 values similar to AgNO3 (IC50 ≈ 55 µM). 
 
Overall, [Ag6(imidH)4(9-aca)6(MeOH)2] was the most active of the silver(I) 
complexes against both MCF-7 and HT-29 cell lines (IC50 = 6.30 and 47.00 µM, 
respectively) and it exhibited a higher selectivity towards MCF-7 cells. 
 
Cisplatin, [Ag2(9-aca)2]n and [Ag4(9-aca)4(NH3)2] were also screened against 
Hep-G2 and A-498 cell lines (Table 16 and Figure 116). The metal-free ligand, 9-
acaH, was found to be inactive at the 100 µM concentration level. While both of 
the silver-containing complexes decreased the proliferation of the Hep-G2 and 
A-498 cell lines, [Ag4(9-aca)4(NH3)2] was the most active (IC50 = 3.60 and 5.50 
µM for Hep-G2 and A-498 cell lines, respectively). This ammonia-containing 
complex was 4 times more active than Cisplatin against Hep-G2 cells and over 
twice as active against A-498 cells. [Ag2(9-aca)2]n (IC50 = 27.80 and 30.00 µM for 
the Hep-G2 and A-498 cell lines, respectively) was less active than Cisplatin 
against both cell lines. 
 
Table 16. IC50 values of [Ag2(9-aca)2]n and [Ag4(9-aca)4(NH3)2] against Hep-G2 















Cisplatin 4.50 15.00 4.20 14.00 
[Ag2(9-aca)2]n 18.30 27.80 19.75 30.00 
[Ag4(9-aca)4(NH3)2] 4.86 3.60 7.43 5.50 
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Figure 116. IC50 values of [Ag2(9-aca)2]n and [Ag4(9-aca)4(NH3)2] against Hep-
G2 and A-498 cell lines. 
 
 
4.6 Summary of Biological Activity 
 
The majority of the silver(I) complexes synthesised during this research 
exhibited very good antimicrobial and anticancer activities. In many cases, 
these complexes performed better than the current prescription drugs. While 
many complexes were shown to exhibit both excellent antifungal and 
antibacterial activities (e.g. [Ag4(9-aca)4(NH3)2]), others were more selective 
(e.g. [Ag(apim)](9-aca)·H2O was highly cytotoxic towards fungal cells but not as 
active against bacterial cells).  
 
In tests against cancer cell lines it was found that, in general, the silver(I) 
complexes were more cytotoxic towards breast cancer cells than colon cancer 
cells, thus showing some degree of selectivity. One notable exception to this 
trend was [Ag(4-Ph-imidH)2(9-aca)], which was equally active against both 
MCF-7 and HT-29 cell lines. The varied activity of the silver(I) complexes 
indicates that the presence of the silver(I) ion alone does not necessarily 
guarantee good antimicrobial and anticancer activity, but that the nature of the 
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the bioactivity is attributable to the complex as a whole, rather than to the 
individual constituents acting independently of each other. 
 
To date, the mechanisms of action of the silver(I) complexes prepared in the 
present work have not been examined.  However, it is thought that these 
complexes may have similar modes of action as other silver(I) complexes 
studied by our group. For example, treating C. albicans with 
[Ag2(phen)3(mal)]·2H2O (phen = 1,10-phenanthroline, malH2 = malonic acid) 
resulted in DNA degradation and induced extensive changes to the internal 
structure of the yeast cells, including retraction of the cytoplasm, nuclear 
fragmentation and disruption of the mitochondrion123. This complex was also 
shown to reduce the levels of cytochromes b and c, as well as the concentration 
of ergosterol within the cell166. [Ag(phendio)2]ClO4 (phendio = 1,10-
phenanthroline-5,6-dione) also caused extensive, non-specific DNA cleavage, 
induced gross distortions in fungal cell morphology and disrupted cell 
division127.  
 
Silver(I)-coumarin complexes have also been reported to reduce respiration, 
lower the ergosterol content of C. albicans cells and increase the trans-
membrane leakage of amino acids from the cell130. Silver(I) has been reported 
to accumulate in the cell wall of C. albicans cells, with complexes, such as 
[Ag(apim)]ClO4, depositing ca. 7 times more Ag+ than the simple silver salts 
AgNO3 and AgClO4 167. Recently, silver(0) nano-particles have been reported to 
exert antifungal activity by disrupting the structure of the cell membrane, 
inhibiting the normal budding process of C. albicans and these effects 
contributed to the destruction of the membrane integrity168.  
 
Investigations into the effect of silver(I) on bacterial cells revealed that it 
interacts with the respiratory chain of bacterial cells169. Silver(I) has also been 
reported to react with nucleophilic portions of amino acids and cause 
denaturing of the proteins and, ultimately, leads to cell death139. Electron 
microscopy and X-ray microanalysis have shown that silver builds up as 
granules in the cell wall and in the cytoplasm of E. coli and S. aureus170,171. This 
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causes damage to the RNA and DNA, and proteins are deactivated within the 
cell. The mode of action of silver(I) complexes against human cancer cells has 
also been studied. [Ag2(phen)3(mal)]·2H2O and silver(I)-coumarin complexes 
were shown to inhibit DNA synthesis without intercalating with it and cell 
death occurred primarily in the form of apoptosis72,79,80,172,173. 
 
 




This research project has shown that silver(I) complexes containing 9-
anthracenecarboxylic acid and imidazoles are readily synthesised from widely 
available starting materials. By varying the reaction conditions and functional 
groups on the starting materials it is possible to obtain a range of silver(I) 
complexes with a wide variety of structures, ranging from mononuclear to 
hexanuclear, and from complex salts to polymeric chains.  
 
The silver(I) complexes possess antimicrobial and anticancer properties, and in 
many cases they perform better than the currently prescribed drugs. The 
silver(I) complex, [Ag4(9-aca)4(NH3)2], exhibited the broadest spectrum of in 
vitro biological activity. It was cytotoxic towards fungal cells, bacterial cells and 
human cancer cells. The complex also displayed excellent in vivo activity when 
tested on the insect model, G. mellonella. It is thought that the complexes have a 
mode of action distinct from that of current antimicrobial and anticancer drugs, 
an attribute that could prove extremely useful when combating drug-resistant 
cells.  
 
Although much has been reported in this thesis, there remains much scope for 
further research in this area. Future work would include detailed mode of 
action studies. This would provide valuable information regarding the specific 
cellular targets that the complexes are reaching and could lead to the design 
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X-ray Crystal Data for [Ag2(9-aca)2]n 
 
Identification code  [Ag2(9-aca)2]n 
Empirical formula  C30 H18 Ag2 O4 
Formula weight  658.18 
Temperature  150(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 14.813(3) Å α= 90°. 
 b = 5.6055(12) Å β= 95.250(3)°. 
 c = 27.413(6) Å γ = 90°. 
Volume 2266.6(8) Å3 
Z 4 
Density (calculated) 1.929 Mg/m3 
Absorption coefficient 1.766 mm-1 
F(000) 1296 
Crystal size 0.57 x 0.05 x 0.02 mm3 
Crystal description yellow rod 
Theta range for data collection 1.94 to 25.00°. 
Index ranges -17<=h<=17, -6<=k<=6, -32<=l<=32 
Reflections collected 16694 
Independent reflections 3991 [R(int) = 0.0520] 
Completeness to theta = 25.00° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9655 and 0.4326 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3991 / 0 / 325 
Goodness-of-fit on F2 1.020 
Final R indices [I>2sigma(I)] R1 = 0.0374, wR2 = 0.0854 
R indices (all data) R1 = 0.0610, wR2 = 0.0979 
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Table 17:   Bond lengths [Å] and angles [°] for [Ag2(9-aca)2]n. 
 
Ag(1)-O(1)  2.170(3) 
Ag(1)-O(2)#1  2.190(3) 
Ag(1)-O(2)#2  2.473(4) 
Ag(1)-Ag(1)#1  2.8508(9) 
O(1)-C(1)  1.242(6) 
O(2)-C(1)  1.267(6) 
O(2)-Ag(1)#1  2.190(3) 
O(2)-Ag(1)#3  2.473(4) 
C(1)-C(2)  1.504(7) 
C(2)-C(3)  1.407(7) 
C(2)-C(15)  1.411(6) 
C(3)-C(8)  1.434(7) 
C(3)-C(4)  1.442(6) 
C(4)-C(5)  1.350(7) 
C(5)-C(6)  1.417(7) 
C(6)-C(7)  1.355(7) 
C(7)-C(8)  1.416(7) 
C(8)-C(9)  1.395(7) 
C(9)-C(10)  1.379(7) 
C(10)-C(11)  1.437(6) 
C(10)-C(15)  1.440(7) 
C(11)-C(12)  1.338(8) 
C(12)-C(13)  1.428(8) 
C(13)-C(14)  1.364(7) 
C(14)-C(15)  1.424(7) 
Ag(2)-O(3)  2.190(3) 
Ag(2)-O(4)#4  2.243(3) 
Ag(2)-O(4)#3  2.381(4) 
Ag(2)-Ag(2)#4  2.8643(9) 
O(3)-C(16)  1.239(6) 
O(4)-C(16)  1.257(6) 
O(4)-Ag(2)#4  2.243(3) 
O(4)-Ag(2)#2  2.381(4) 
C(16)-C(17)  1.526(6) 
C(17)-C(18)  1.385(7) 
C(17)-C(30)  1.412(7) 
C(18)-C(19)  1.420(7) 
C(18)-C(23)  1.446(7) 
C(19)-C(20)  1.351(7) 
C(20)-C(21)  1.416(8) 
C(21)-C(22)  1.341(8) 
C(22)-C(23)  1.421(7) 
C(23)-C(24)  1.387(7) 
C(24)-C(25)  1.387(7) 
C(25)-C(26)  1.421(7) 
C(25)-C(30)  1.447(7) 
C(26)-C(27)  1.339(8) 
C(27)-C(28)  1.418(8) 

















































































Symmetry transformations used to generate equivalent atoms:  
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X-ray Crystal Data for [Ag2(9-aca)2(DMSO)2]n 
 
Identification code  [Ag2(9-aca)2(DMSO)2]n 
Empirical formula  C34 H30 Ag2 O6 S2 
Formula weight  814.44 
Temperature  150(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 9.1304(7) Å α= 90°. 
 b = 19.5875(14) Å β= 99.2280(10)°. 
 c = 18.0502(13) Å γ = 90°. 
Volume 3186.3(4) Å3 
Z 4 
Density (calculated) 1.698 Mg/m3 
Absorption coefficient 1.405 mm-1 
F(000) 1632 
Crystal size 0.41 x 0.09 x 0.08 mm3 
Crystal description yellow rod 
Theta range for data collection 1.55 to 27.50°. 
Index ranges -11<=h<=11, -25<=k<=25, -23<=l<=23 
Reflections collected 30770 
Independent reflections 7311 [R(int) = 0.0426] 
Completeness to theta = 27.50° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.8959 and 0.5967 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 7311 / 904 / 527 
Goodness-of-fit on F2 1.026 
Final R indices [I>2sigma(I)] R1 = 0.0317, wR2 = 0.0701 
R indices (all data) R1 = 0.0463, wR2 = 0.0769 
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Ag(1)-O(11)-Ag(1)#1 82.35(6)  
Ag(2)-O(32)-Ag(1) 70.90(5) 
 
Symmetry transformations used to generate equivalent atoms: 
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X-ray Crystal Data for [Ag(imidH)2.3(CH3CN)0.7](9-aca) 
 
Identification code  [Ag(imidH)2.3(CH3CN)0.7](9-aca) 
Empirical formula  C23.30 H20.30 Ag N5.30 O2 
Formula weight  514.42 
Temperature  150(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 9.7905(5) Å α= 90°. 
 b = 14.2012(7) Å β= 101.8640(10)°. 
 c = 16.3251(9) Å γ = 90°. 
Volume 2221.3(2) Å3 
Z 4 
Density (calculated) 1.538 Mg/m3 
Absorption coefficient 0.938 mm-1 
F(000) 1041 
Crystal size 0.33 x 0.22 x 0.21 mm3 
Crystal description colourless block 
Theta range for data collection 1.92 to 26.00°. 
Index ranges -12<=h<=12, -17<=k<=17, -20<=l<=20 
Reflections collected 19005 
Independent reflections 4361 [R(int) = 0.0326] 
Completeness to theta = 25.00° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.8273 and 0.7471 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4361 / 23 / 326 
Goodness-of-fit on F2 1.049 
Final R indices [I>2sigma(I)] R1 = 0.0347, wR2 = 0.0730 
R indices (all data) R1 = 0.0460, wR2 = 0.0782 
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Table 19:  Bond lengths [Å] and angles [°] for [Ag(imidH)2.3(CH3CN)0.7](9-aca). 
 
Ag(1)-N(21)  2.126(2) 
Ag(1)-N(31)  2.126(2) 
Ag(1)-N(41)  2.588(17) 
Ag(1)-N(51)  2.713(8) 
Ag(1)-O(2)#1  3.009(2) 
O(1)-C(1)  1.253(3) 
O(2)-C(1)  1.251(3) 
C(1)-C(2)  1.519(3) 
C(2)-C(3)  1.397(4) 
C(2)-C(15)  1.398(4) 
C(3)-C(4)  1.428(4) 
C(3)-C(8)  1.433(4) 
C(4)-C(5)  1.351(5) 
C(5)-C(6)  1.403(6) 
C(6)-C(7)  1.357(6) 
C(7)-C(8)  1.436(5) 
C(8)-C(9)  1.388(5) 
C(9)-C(10)  1.385(4) 
C(10)-C(11)  1.422(5) 
C(10)-C(15)  1.438(4) 
C(11)-C(12)  1.334(5) 
C(12)-C(13)  1.414(5) 
C(13)-C(14)  1.355(4) 
C(14)-C(15)  1.426(4) 
N(21)-C(21)  1.319(4) 
N(21)-C(22)  1.377(4) 
C(21)-N(22)  1.329(4) 
N(22)-C(23)  1.357(4) 
C(23)-C(22)  1.349(4) 
N(31)-C(31)  1.323(4) 
N(31)-C(33)  1.370(4) 
C(31)-N(32)  1.329(4) 
N(32)-C(32)  1.359(4) 
C(32)-C(33)  1.350(4) 
N(51)-C(52)  1.132(9) 
C(52)-C(53)  1.468(10) 
N(41)-C(41)  1.301(15) 
N(41)-C(43)  1.366(16) 
C(41)-N(42)  1.334(15) 
N(42)-C(42)  1.339(17)  






























































N(42)-C(42)-C(43) 105.7(14)  
N(41)-C(43)-C(42) 109.9(13)
 
Symmetry transformations used to generate equivalent atoms:  
#1 -x+1/2,y-1/2,-z+1/2      
 
 
Table 20: Hydrogen bonds for [Ag(imidH)2.3(CH3CN)0.7](9-aca) [Å and °]. 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
N(22)-H(22)...O(1)#2 0.88 1.87 2.745(3) 178.3 
N(32)-H(32)...O(2) 0.88 1.89 2.752(3) 165.5 
N(42)-H(42)...O(1)#3 0.88 1.86 2.734(10) 174.8 
 
Symmetry transformations used to generate equivalent atoms:  
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X-ray Crystal Data for [Ag6(imidH)4(9-aca)6(MeOH)2] 
 
Identification code  [Ag6(imidH)4(9-aca)6(MeOH)2] 
Empirical formula  C104 H78 Ag6 N8 O14 
Formula weight  2310.96 
Temperature  150(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  Pbcn 
Unit cell dimensions a = 20.6935(8) Å α = 90°. 
 b = 18.2786(7) Å β = 90°. 
 c = 23.6859(10) Å γ = 90°. 
Volume 8959.1(6) Å3 
Z 4 
Density (calculated) 1.713 Mg/m3 
Absorption coefficient 1.358 mm-1 
F(000) 4608 
Crystal size 0.23 x 0.15 x 0.12 mm3 
Crystal description Pale yellow block 
Theta range for data collection 1.72 to 27.00°. 
Index ranges -26<=h<=26, -23<=k<=23, -30<=l<=30 
Reflections collected 80667 
Independent reflections 9793 [R(int) = 0.0580] 
Completeness to theta = 27.00° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.8540 and 0.7453 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 9793 / 0 / 599 
Goodness-of-fit on F2 1.025 
Final R indices [I>2sigma(I)] R1 = 0.0316, wR2 = 0.0695 
R indices (all data) R1 = 0.0475, wR2 = 0.0765 
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Table 21:  Bond lengths [Å] and angles [°] for [Ag6(imidH)4(9-aca)6(MeOH)2]. 
 
Ag(1)-N(21)  2.088(2) 
Ag(1)-N(31)  2.089(2) 
Ag(1)-Ag(2)  3.0651(4) 
N(21)-C(21)  1.325(4) 
N(21)-C(23)  1.363(4) 
C(21)-N(22)  1.336(4) 
N(22)-C(22)  1.360(4) 
C(22)-C(23)  1.363(4) 
N(31)-C(31)  1.330(4) 
N(31)-C(33)  1.379(4) 
C(31)-N(32)  1.334(4) 
N(32)-C(32)  1.363(4) 
C(32)-C(33)  1.353(4) 
Ag(2)-O(1B)  2.218(2) 
Ag(2)-O(1A)  2.416(2) 
Ag(2)-O(2A)  2.424(2) 
O(1A)-C(1A)  1.254(3) 
O(2A)-C(1A)  1.254(3) 
C(1A)-C(2A)  1.510(4) 
C(2A)-C(15A)  1.400(4) 
C(2A)-C(3A)  1.404(4) 
C(3A)-C(4A)  1.427(4) 
C(3A)-C(8A)  1.434(4) 
C(4A)-C(5A)  1.352(4) 
C(5A)-C(6A)  1.415(4) 
C(6A)-C(7A)  1.360(5) 
C(7A)-C(8A)  1.425(4) 
C(8A)-C(9A)  1.387(4) 
C(9A)-C(10A)  1.396(4) 
C(10A)-C(11A)  1.422(4) 
C(10A)-C(15A)  1.438(4) 
C(11A)-C(12A)  1.351(4) 
C(12A)-C(13A)  1.419(5) 
C(13A)-C(14A)  1.349(4) 
C(14A)-C(15A)  1.427(4) 
O(1B)-C(1B)  1.258(3) 
O(2B)-C(1B)  1.253(3) 
O(2B)-Ag(3)  2.789(2) 
C(1B)-C(2B)  1.520(4) 
C(2B)-C(15B)  1.396(4) 
C(2B)-C(3B)  1.403(4) 
C(3B)-C(4B)  1.426(4) 
C(3B)-C(8B)  1.442(4) 
C(4B)-C(5B)  1.357(4) 
C(5B)-C(6B)  1.418(4) 
C(6B)-C(7B)  1.354(5) 
C(7B)-C(8B)  1.432(4) 
C(8B)-C(9B)  1.393(4) 
C(9B)-C(10B)  1.388(4) 
C(10B)-C(11B)  1.424(4) 
C(10B)-C(15B)  1.437(4) 
C(11B)-C(12B)  1.352(4) 
C(12B)-C(13B)  1.420(4) 
C(13B)-C(14B)  1.359(4) 
C(14B)-C(15B)  1.427(4) 
Ag(3)-O(1D)  2.1574(19) 
Ag(3)-O(1C)  2.1681(19) 
Ag(3)-O(41)  2.467(2) 
Ag(3)-Ag(3)#1  2.8818(5) 
O(1C)-C(1C)  1.248(3) 
C(1C)-O(1C)#1  1.248(3) 
C(1C)-C(2C)  1.494(5) 
C(2C)-C(3C)#1  1.398(4) 
C(2C)-C(3C)  1.398(4) 
C(3C)-C(4C)  1.432(5) 
C(3C)-C(8C)  1.443(4) 
C(4C)-C(5C)  1.356(5) 
C(5C)-C(6C)  1.426(5) 
C(6C)-C(7C)  1.349(5) 
C(7C)-C(8C)  1.426(5) 
C(8C)-C(9C)  1.388(4) 
C(9C)-C(8C)#1  1.388(4) 
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O(1D)-C(1D)  1.246(3)  C(1D)-O(1D)#1  1.246(3)
C(1D)-C(2D)  1.512(5) 
C(2D)-C(3D)  1.402(3) 
C(2D)-C(3D)#1  1.402(3) 
C(3D)-C(4D)  1.430(4) 
C(3D)-C(8D)  1.439(4) 
C(4D)-C(5D)  1.351(4) 
C(5D)-C(6D)  1.424(4) 
C(6D)-C(7D)  1.346(4) 
C(7D)-C(8D)  1.418(4) 
C(8D)-C(9D)  1.393(3) 
C(9D)-C(8D)#1  1.393(3) 
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Symmetry transformations used to generate equivalent atoms: 
#1 -x,y,-z+1/2      
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Table 22: Hydrogen bonds for [Ag6(imidH)4(9-aca)6(MeOH)2] [Å and °]. 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
N(22)-
H(22N)...O(2A)#2 
0.88 1.92 2.796(3) 176.3 
N(32)-
H(32N)...O(2B)#3 
0.88 1.94 2.815(3) 170.4 
O(41)-H(41)...O(1A) 0.94 1.92 2.782(3) 150.9 
 
Symmetry transformations used to generate equivalent atoms:  
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X-ray Crystal Data for [Ag(1-Me-imid)2]2[Ag4(9-aca)6] 
 
Identification code  [Ag(1-Me-imid)2]2[Ag4(9-aca)6] 
Empirical formula  C106 H78 Ag6 N8 O12 
Formula weight  2302.98 
Temperature  150(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 11.7251(17) Å α = 111.403(2)°. 
 b = 17.908(3) Å β = 90.095(2)°. 
 c = 23.464(3) Å γ = 101.710(2)°. 
Volume 4476.2(11) Å3 
Z 2 
Density (calculated) 1.709 Mg/m3 
Absorption coefficient 1.357 mm-1 
F(000) 2296 
Crystal size 0.43 x 0.32 x 0.06 mm3 
Crystal description colourless plate 
Theta range for data collection 1.78 to 25.00°. 
Index ranges -13<=h<=13, -21<=k<=21, -27<=l<=27 
Reflections collected 35083 
Independent reflections 15686 [R(int) = 0.0421] 
Completeness to theta = 25.00° 99.5 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9230 and 0.5930 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 15686 / 0 / 1224 
Goodness-of-fit on F2 1.046 
Final R indices [I>2sigma(I)] R1 = 0.0512, wR2 = 0.1262 
R indices (all data) R1 = 0.0706, wR2 = 0.1370 
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Table 23.   Bond lengths [Å] and angles [°] for [Ag(1-Me-imid)2]2[Ag4(9-aca)6]. 
 
Ag(1)-O(12C)#1  2.248(4) 
Ag(1)-O(11C)  2.270(4) 
Ag(1)-O(11A)  2.314(5) 
Ag(1)-O(11B)  2.383(4) 
Ag(1)-Ag(1)#1  2.7860(10) 
Ag(1)-Ag(2)#1  2.9621(7) 
Ag(1)-Ag(2)  3.0085(7) 
Ag(2)-O(12A)  2.188(4) 
Ag(2)-O(12B)#1  2.190(4) 
Ag(2)-Ag(1)#1  2.9621(7) 
O(11A)-C(11A)  1.241(8) 
O(11A)-Ag(5)  2.713(5) 
O(12A)-C(11A)  1.262(8) 
C(11A)-C(12A)  1.523(9) 
C(12A)-C(13A)  1.409(10) 
C(12A)-C(25A)  1.414(9) 
C(13A)-C(14A)  1.414(10) 
C(13A)-C(18A)  1.428(9) 
C(14A)-C(15A)  1.356(11) 
C(15A)-C(16A)  1.411(11) 
C(16A)-C(17A)  1.344(11) 
C(17A)-C(18A)  1.440(10) 
C(18A)-C(19A)  1.386(10) 
C(19A)-C(20A)  1.394(10) 
C(20A)-C(21A)  1.429(10) 
C(20A)-C(25A)  1.440(9) 
C(21A)-C(22A)  1.348(12) 
C(22A)-C(23A)  1.356(11) 
C(23A)-C(24A)  1.396(10) 
C(24A)-C(25A)  1.421(10) 
O(11B)-C(11B)  1.264(8) 
O(11B)-Ag(5)  2.629(4) 
O(12B)-C(11B)  1.259(8) 
O(12B)-Ag(2)#1  2.190(4) 
C(11B)-C(12B)  1.513(9) 
C(12B)-C(25B)  1.407(9) 
C(12B)-C(13B)  1.414(9) 
C(13B)-C(18B)  1.420(9) 
C(13B)-C(14B)  1.435(9) 
C(14B)-C(15B)  1.358(9) 
C(15B)-C(16B)  1.408(10) 
C(16B)-C(17B)  1.366(11) 
C(17B)-C(18B)  1.419(10) 
C(18B)-C(19B)  1.399(10) 
C(19B)-C(20B)  1.389(10) 
C(20B)-C(21B)  1.419(10) 
C(20B)-C(25B)  1.443(9) 
C(21B)-C(22B)  1.346(11) 
C(22B)-C(23B)  1.424(11) 
C(23B)-C(24B)  1.349(10) 
C(24B)-C(25B)  1.416(9) 
O(11C)-C(11C)  1.246(8) 
O(12C)-C(11C)  1.242(8) 
O(12C)-Ag(1)#1  2.248(4) 
C(11C)-C(12C)  1.512(8) 
C(12C)-C(13C)  1.381(9) 
C(12C)-C(25C)  1.409(9) 
C(13C)-C(18C)  1.435(9) 
C(13C)-C(14C)  1.441(9) 
C(14C)-C(15C)  1.349(9) 
C(15C)-C(16C)  1.427(9) 
C(16C)-C(17C)  1.371(10) 
C(17C)-C(18C)  1.435(9) 
C(18C)-C(19C)  1.390(9) 
C(19C)-C(20C)  1.388(9) 
C(20C)-C(21C)  1.430(9) 
C(20C)-C(25C)  1.448(9) 
C(21C)-C(22C)  1.366(10) 
C(22C)-C(23C)  1.419(10) 
C(23C)-C(24C)  1.380(9) 
C(24C)-C(25C)  1.417(9)  
Ag(3)-O(11E)  2.228(5)
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Ag(3)-O(12E)#2  2.248(5) Ag(3)-O(11F)  2.318(5)
Ag(3)-O(11D)  2.392(4) 
Ag(3)-Ag(3)#2  2.7892(10) 
Ag(3)-Ag(4)#2  2.9493(7) 
Ag(3)-Ag(4)  2.9843(8) 
Ag(4)-O(12F)  2.183(4) 
Ag(4)-O(12D)#2  2.183(4) 
Ag(4)-Ag(3)#2  2.9493(7) 
O(11D)-C(11D)  1.241(7) 
O(11D)-Ag(6)  2.607(4) 
O(12D)-C(11D)  1.260(7) 
O(12D)-Ag(4)#2  2.183(4) 
C(11D)-C(12D)  1.514(8) 
C(12D)-C(25D)  1.408(9) 
C(12D)-C(13D)  1.412(9) 
C(13D)-C(18D)  1.431(9) 
C(13D)-C(14D)  1.437(9) 
C(14D)-C(15D)  1.352(10) 
C(15D)-C(16D)  1.429(11) 
C(16D)-C(17D)  1.371(11) 
C(17D)-C(18D)  1.418(10) 
C(18D)-C(19D)  1.386(10) 
C(19D)-C(20D)  1.389(10) 
C(20D)-C(25D)  1.428(9) 
C(20D)-C(21D)  1.430(10) 
C(21D)-C(22D)  1.353(10) 
C(22D)-C(23D)  1.413(10) 
C(23D)-C(24D)  1.366(9) 
C(24D)-C(25D)  1.438(9) 
O(11E)-C(11E)  1.254(8) 
O(12E)-C(11E)  1.229(8) 
O(12E)-Ag(3)#2  2.248(4) 
C(11E)-C(12E)  1.515(8) 
C(12E)-C(25E)  1.392(9) 
C(12E)-C(13E)  1.402(9) 
C(13E)-C(18E)  1.428(9) 
C(13E)-C(14E)  1.440(9) 
C(14E)-C(15E)  1.375(9) 
C(15E)-C(16E)  1.419(10) 
C(16E)-C(17E)  1.382(10) 
C(17E)-C(18E)  1.431(9) 
C(18E)-C(19E)  1.394(10) 
C(19E)-C(20E)  1.395(10) 
C(20E)-C(21E)  1.422(10) 
C(20E)-C(25E)  1.452(9) 
C(21E)-C(22E)  1.354(10) 
C(22E)-C(23E)  1.432(10) 
C(23E)-C(24E)  1.360(10) 
C(24E)-C(25E)  1.427(9) 
O(11F)-C(11F)  1.257(8) 
O(11F)-Ag(6)  2.790(5) 
O(12F)-C(11F)  1.248(8) 
C(11F)-C(12F)  1.518(9) 
C(12F)-C(13F)  1.405(9) 
C(12F)-C(25F)  1.417(9) 
C(13F)-C(18F)  1.424(9) 
C(13F)-C(14F)  1.426(10) 
C(14F)-C(15F)  1.361(10) 
C(15F)-C(16F)  1.422(10) 
C(16F)-C(17F)  1.358(11) 
C(17F)-C(18F)  1.437(10) 
C(18F)-C(19F)  1.393(10) 
C(19F)-C(20F)  1.371(11) 
C(20F)-C(21F)  1.440(10) 
C(20F)-C(25F)  1.445(9) 
C(21F)-C(22F)  1.358(12) 
C(22F)-C(23F)  1.407(12) 
C(23F)-C(24F)  1.359(11) 
C(24F)-C(25F)  1.429(10) 
Ag(5)-N(1B)  2.125(7) 
Ag(5)-N(1A)  2.141(7) 
C(1A)-N(1A)  1.296(10) 
C(1A)-N(2A)  1.354(10) 
N(1A)-C(2A)  1.398(10) 
C(2A)-C(3A)  1.343(12) 
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C(3A)-N(2A)  1.357(10) N(2A)-C(4A)  1.468(10)
C(1B)-N(2B)  1.316(9) 
C(1B)-N(1B)  1.334(10) 
N(1B)-C(2B)  1.391(10) 
C(2B)-C(3B)  1.336(13) 
C(3B)-N(2B)  1.356(11) 
N(2B)-C(4B)  1.464(11) 
Ag(6)-N(1C)  2.127(7) 
Ag(6)-N(1D)  2.143(7) 
C(1C)-N(1C)  1.323(10) 
C(1C)-N(2C)  1.330(10) 
N(1C)-C(2C)  1.381(9) 
C(2C)-C(3C)  1.342(12) 
C(3C)-N(2C)  1.375(10) 
N(2C)-C(4C)  1.430(10) 
C(1D)-N(1D)  1.298(10) 
C(1D)-N(2D)  1.344(9) 
N(1D)-C(2D)  1.366(11) 
C(2D)-C(3D)  1.356(13) 
C(3D)-N(2D)  1.369(10) 
N(2D)-C(4D)  1.455(11) 
Ag(11)-Ag(12)#3  2.360(19) 
Ag(11)-Ag(14)  2.606(19) 
Ag(11)-Ag(13)  2.639(19) 
Ag(11)-Ag(13)#3  2.94(2) 
Ag(11)-Ag(12)  3.019(19) 
Ag(12)-Ag(11)#3  2.361(19) 
Ag(12)-Ag(13)  2.596(19) 
Ag(12)-Ag(13)#3  2.791(19) 
Ag(12)-Ag(14)#3  2.947(19) 
Ag(13)-Ag(12)#3  2.791(19) 
Ag(13)-Ag(11)#3  2.94(2) 
Ag(13)-Ag(14)  3.03(2) 
Ag(14)-Ag(12)#3  2.947(19) 
Ag(15)-Ag(16)#4  2.403(19) 
Ag(15)-Ag(18)#4  2.57(2) 
Ag(15)-Ag(18)  2.79(2) 
Ag(15)-Ag(17)  2.951(19) 
Ag(15)-Ag(16)  3.003(19) 
Ag(16)-Ag(15)#4  2.403(19) 
Ag(16)-Ag(18)#4  2.46(2) 
Ag(16)-Ag(17)#4  2.597(19) 
Ag(16)-Ag(18)  2.96(2) 
Ag(17)-Ag(16)#4  2.597(19) 
Ag(17)-Ag(18)  3.01(2) 
Ag(18)-Ag(16)#4  2.46(2) 


























O(12A)-Ag(2)-Ag(1) 81.70(12)  
O(12B)#1-Ag(2)-Ag(1) 124.95(11) 
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C(15C)-C(14C)-C(13C) 120.8(6)  
C(14C)-C(15C)-C(16C) 122.1(7) 












































































C(11E)-O(11E)-Ag(3) 123.6(4)  
C(11E)-O(12E)-Ag(3)#2 121.3(4) 













































































C(1B)-N(1B)-Ag(5) 125.1(5)  
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Ag(18)#4-Ag(16)-Ag(17)#4 72.9(6)  
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Symmetry transformations used to generate equivalent atoms:  
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X-ray Crystal Data for [Ag(2-Me-imidH)2(9-aca)] 
 
Identification code  [Ag(2-Me-imidH)2(9-aca)] 
Empirical formula  C23 H21 Ag N4 O2 
Formula weight  493.31 
Temperature  150(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  C2/c 
Unit cell dimensions a = 19.8374(17) Å α = 90°. 
 b = 15.2507(13) Å β = 110.140(1)°. 
 c = 14.4941(13) Å γ = 90°. 
Volume 4116.8(6) Å3 
Z 8 
Density (calculated) 1.592 Mg/m3 
Absorption coefficient 1.007 mm-1 
F(000) 2000 
Crystal size 0.28 x 0.14 x 0.13 mm3 
Crystal description colourless pyramid 
Theta range for data collection 1.73 to 28.35°. 
Index ranges -26<=h<=26, -20<=k<=20, -19<=l<=19 
Reflections collected 20857 
Independent reflections 5142 [R(int) = 0.0541] 
Completeness to theta = 28.35° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.8803 and 0.7658 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5142 / 0 / 273 
Goodness-of-fit on F2 1.030 
Final R indices [I>2sigma(I)] R1 = 0.0345, wR2 = 0.0715 
R indices (all data) R1 = 0.0541, wR2 = 0.0787 
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Table 24.  Bond lengths [Å] and angles [°] for [Ag(2-Me-imidH)2(9-aca)]. 
 
Ag(1)-N(31)  2.111(2) 
Ag(1)-N(21)  2.115(2) 
Ag(1)-O(1)  2.4941(19) 
Ag(1) … Ag(1)#1  4.1930(5) 
O(1)-C(1)  1.239(3) 
O(2)-C(1)  1.261(3) 
C(1)-C(2)  1.520(4) 
C(2)-C(15)  1.403(4) 
C(2)-C(3)  1.408(4) 
C(3)-C(4)  1.421(4) 
C(3)-C(8)  1.430(4) 
C(4)-C(5)  1.357(5) 
C(5)-C(6)  1.420(5) 
C(6)-C(7)  1.350(5) 
C(7)-C(8)  1.424(5) 
C(8)-C(9)  1.390(5) 
C(9)-C(10)  1.387(4) 
C(10)-C(11)  1.423(4) 
C(10)-C(15)  1.441(4) 
C(11)-C(12)  1.346(5) 
C(12)-C(13)  1.423(4) 
C(13)-C(14)  1.364(4) 
C(14)-C(15)  1.424(4) 
N(21)-C(21)  1.327(3) 
N(21)-C(24)  1.372(3) 
C(21)-N(22)  1.344(3) 
C(21)-C(22)  1.487(4) 
N(22)-C(23)  1.363(4) 
C(23)-C(24)  1.355(4) 
N(31)-C(31)  1.329(3) 
N(31)-C(34)  1.388(3) 
C(31)-N(32)  1.344(3) 
C(31)-C(32)  1.478(4) 
N(32)-C(33)  1.370(4)  
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C(34)-C(33)-N(32) 106.7(2)  
C(33)-C(34)-N(31) 108.8(2) 
 
Symmetry transformations used to generate equivalent atoms:  
 #1 -x+1,-y,-z+2 
 
 
Table 25. Hydrogen bonds for [Ag(2-Me-imidH)2(9-aca)] [Å and °]. 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
N(22)-H(22)...O(2)#2 0.88 1.97 2.764(3) 149.1 
N(32)-H(32)...O(2)#3 0.88 1.91 2.779(3) 168.8 
 
Symmetry transformations used to generate equivalent atoms:  
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X-ray Crystal Data for [Ag(1-Bu-imid)2]2[Ag4(9-aca)6] 
 
Identification code  [Ag(1-Bu-imid)2]2[Ag4(9-aca)6] 
Empirical formula  C118 H102 Ag6 N8 O12 
Formula weight  2471.30 
Temperature  150(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 17.6333(7) Å α = 96.019(1)°. 
 b = 19.3853(8) Å β = 95.831(1)°. 
 c = 30.4753(13) Å γ = 90.237(1)°. 
Volume 10305.1(7) Å3 
Z 4 
Density (calculated) 1.593 Mg/m3 
Absorption coefficient 1.185 mm-1 
F(000) 4976 
Crystal size 0.32 x 0.19 x 0.12 mm3 
Crystal description Colourless block 
Theta range for data collection 0.68 to 26.00°. 
Index ranges -21<=h<=21, -23<=k<=23, -37<=l<=37 
Reflections collected 89958 
Independent reflections 40407 [R(int) = 0.0422] 
Completeness to theta = 26.00° 99.7 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.4311 and 0.3430 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 40407 / 3021 / 2665 
Goodness-of-fit on F2 1.068 
Final R indices [I>2sigma(I)] R1 = 0.0505, wR2 = 0.1130 
R indices (all data) R1 = 0.0739, wR2 = 0.1229 
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Table 26.  Bond lengths [Å] and angles [°] for [Ag(1-Bu-imid)2]2[Ag4(9-aca)6]. 
 
Ag(1)-O(1A)  2.207(4) 
Ag(1)-O(2D)  2.217(4) 
Ag(1)-Ag(4)  2.8750(6) 
Ag(1)-Ag(2)  2.9028(6) 
Ag(2)-O(1E)  2.222(4) 
Ag(2)-O(1F)  2.226(4) 
Ag(2)-O(2A)  2.335(4) 
Ag(2)-O(1B)  2.357(4) 
Ag(2)-Ag(4)  2.8365(5) 
Ag(2)-Ag(3)  2.8770(6) 
Ag(3)-O(1C)  2.174(4) 
Ag(3)-O(2B)  2.192(4) 
Ag(3)-Ag(4)  2.8949(6) 
Ag(4)-O(1D)  2.275(4) 
Ag(4)-O(2C)  2.304(4) 
Ag(4)-O(2F)  2.354(4) 
Ag(4)-O(2E)  2.355(4) 
O(1A)-C(1A)  1.266(6) 
O(2A)-C(1A)  1.247(6) 
O(2A)-Ag(5)  2.696(4) 
C(1A)-C(2A)  1.516(7) 
C(2A)-C(15A)  1.410(8) 
C(2A)-C(3A)  1.416(8) 
C(3A)-C(4A)  1.416(8) 
C(3A)-C(8A)  1.436(8) 
C(4A)-C(5A)  1.347(9) 
C(5A)-C(6A)  1.420(9) 
C(6A)-C(7A)  1.349(10) 
C(7A)-C(8A)  1.422(9) 
C(8A)-C(9A)  1.394(9) 
C(9A)-C(10A)  1.388(8) 
C(10A)-C(11A)  1.422(8) 
C(10A)-C(15A)  1.431(8) 
C(11A)-C(12A)  1.334(9) 
C(12A)-C(13A)  1.411(9) 
C(13A)-C(14A)  1.373(9) 
C(14A)-C(15A)  1.430(8) 
O(1B)-C(1B)  1.249(6) 
O(1B)-Ag(5)  2.809(4) 
O(2B)-C(1B)  1.248(7) 
C(1B)-C(2B)  1.505(7) 
C(2B)-C(3B)  1.389(8) 
C(2B)-C(15B)  1.413(8) 
C(3B)-C(4B)  1.433(8) 
C(3B)-C(8B)  1.449(8) 
C(4B)-C(5B)  1.359(9) 
C(5B)-C(6B)  1.403(10) 
C(6B)-C(7B)  1.347(10) 
C(7B)-C(8B)  1.435(9) 
C(8B)-C(9B)  1.372(8) 
C(9B)-C(10B)  1.414(8) 
C(10B)-C(11B)  1.397(8) 
C(10B)-C(15B)  1.423(7) 
C(11B)-C(12B)  1.347(9) 
C(12B)-C(13B)  1.423(9) 
C(13B)-C(14B)  1.360(8) 
C(14B)-C(15B)  1.423(8) 
O(1C)-C(1C)  1.269(7) 
O(2C)-C(1C)  1.220(7) 
O(2C)-Ag(6)  2.756(4) 
C(1C)-C(2C)  1.522(7) 
C(2C)-C(3C)  1.392(8) 
C(2C)-C(15C)  1.402(8) 
C(3C)-C(8C)  1.429(8) 
C(3C)-C(4C)  1.430(8) 
C(4C)-C(5C)  1.342(9) 
C(5C)-C(6C)  1.421(9) 
C(6C)-C(7C)  1.352(10) 
C(7C)-C(8C)  1.430(9) 
C(8C)-C(9C)  1.403(9) 
C(9C)-C(10C)  1.377(9) 
C(10C)-C(15C)  1.438(8) 
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C(10C)-C(11C)  1.444(9) 
C(11C)-C(12C)  1.324(10) 
C(12C)-C(13C)  1.397(10) 
C(13C)-C(14C)  1.363(9) 
C(14C)-C(15C)  1.428(9) 
O(1D)-C(1D)  1.230(7) 
O(1D)-Ag(6)  2.603(4) 
O(2D)-C(1D)  1.235(7) 
C(1D)-C(2D)  1.511(7) 
C(2D)-C(15D)  1.398(8) 
C(2D)-C(3D)  1.404(8) 
C(3D)-C(8D)  1.422(8) 
C(3D)-C(4D)  1.421(9) 
C(4D)-C(5D)  1.338(9) 
C(5D)-C(6D)  1.415(11) 
C(6D)-C(7D)  1.359(12) 
C(7D)-C(8D)  1.432(10) 
C(8D)-C(9D)  1.359(10) 
C(9D)-C(10D)  1.401(10) 
C(10D)-C(11D)  1.413(10) 
C(10D)-C(15D)  1.446(9) 
C(11D)-C(12D)  1.323(12) 
C(12D)-C(13D)  1.403(12) 
C(13D)-C(14D)  1.384(10) 
C(14D)-C(15D)  1.434(9) 
O(1E)-C(1E)  1.271(6) 
O(2E)-C(1E)  1.227(7) 
C(1E)-C(2E)  1.516(7) 
C(2E)-C(3E)  1.398(8) 
C(2E)-C(15E)  1.410(8) 
C(3E)-C(4E)  1.417(8) 
C(3E)-C(8E)  1.457(8) 
C(4E)-C(5E)  1.373(9) 
C(5E)-C(6E)  1.429(10) 
C(6E)-C(7E)  1.348(10) 
C(7E)-C(8E)  1.441(9) 
C(8E)-C(9E)  1.376(9) 
C(9E)-C(10E)  1.386(9) 
C(10E)-C(11E)  1.430(9) 
C(10E)-C(15E)  1.431(8) 
C(11E)-C(12E)  1.358(10) 
C(12E)-C(13E)  1.402(10) 
C(13E)-C(14E)  1.373(9) 
C(14E)-C(15E)  1.424(9) 
O(1F)-C(1F)  1.224(7) 
O(2F)-C(1F)  1.265(6) 
O(2F)-Ag(12)  14.267(4) 
C(1F)-C(2F)  1.529(8) 
C(2F)-C(15F)  1.388(9) 
C(2F)-C(3F)  1.410(9) 
C(3F)-C(4F)  1.400(10) 
C(3F)-C(8F)  1.460(9) 
C(4F)-C(5F)  1.360(10) 
C(5F)-C(6F)  1.406(12) 
C(6F)-C(7F)  1.327(13) 
C(7F)-C(8F)  1.455(12) 
C(8F)-C(9F)  1.373(12) 
C(9F)-C(10F)  1.376(12) 
C(10F)-C(11F)  1.427(12) 
C(10F)-C(15F)  1.456(9) 
C(11F)-C(12F)  1.330(14) 
C(12F)-C(13F)  1.397(13) 
C(13F)-C(14F)  1.380(10) 
C(14F)-C(15F)  1.405(10) 
Ag(5)-N(1A)  2.116(5) 
Ag(5)-N(1B)  2.117(5) 
Ag(5)-O(2A)  2.696(4) 
ag(5)-O(1B)  2.809(4) 
C(21A)-N(1A)  1.327(7) 
C(21A)-N(2A)  1.335(7) 
N(1A)-C(22A)  1.372(7) 
C(22A)-C(23A)  1.323(8) 
C(23A)-N(2A)  1.377(7) 
N(2A)-C(24A)  1.474(8) 
C(24A)-C(25A)  1.589(12) 
C(25A)-C(26A)  1.425(11) 
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C(26A)-C(27A)  1.483(13) 
C(21B)-N(1B)  1.314(7) 
C(21B)-N(2B)  1.338(7) 
N(1B)-C(22B)  1.376(7) 
C(22B)-C(23B)  1.346(8) 
C(23B)-N(2B)  1.374(7) 
N(2B)-C(24B)  1.462(8) 
C(24B)-C(25B)  1.514(9) 
C(25B)-C(26B)  1.488(9) 
C(26B)-C(27B)  1.535(10) 
Ag(6)-N(1D)  2.131(5) 
Ag(6)-N(1C)  2.131(5) 
Ag(6)-O(1D)  2.603(4) 
Ag(6)-O(2C)  2.756(4) 
C(21C)-N(1C)  1.326(8) 
C(21C)-N(2C)  1.346(8) 
N(1C)-C(22C)  1.372(8) 
C(22C)-C(23C)  1.340(9) 
C(23C)-N(2C)  1.378(8) 
N(2C)-C(24C)  1.462(8) 
C(24C)-C(25C)  1.484(11) 
C(25C)-C(26C)  1.395(18) 
C(26C)-C(27C)  1.52(4) 
C(26X)-C(27X)  1.57(4) 
C(21D)-N(1D)  1.306(8) 
C(21D)-N(2D)  1.345(8) 
N(1D)-C(22D)  1.374(8) 
C(22D)-C(23D)  1.350(9) 
C(23D)-N(2D)  1.375(8) 
N(2D)-C(24D)  1.442(8) 
C(24D)-C(25D)  1.538(9) 
C(25D)-C(26D)  1.503(9) 
C(26D)-C(27D)  1.533(10) 
Ag(7)-O(1G)  2.196(4) 
Ag(7)-O(2J)  2.202(4) 
Ag(7)-O(1L)  2.564(4) 
Ag(7)-Ag(10)  2.8760(6) 
Ag(7)-Ag(8)  2.9646(6) 
Ag(8)-O(1K)  2.217(4) 
Ag(8)-O(2L)  2.257(4) 
Ag(8)-O(2G)  2.301(4) 
Ag(8)-O(1H)  2.382(4) 
Ag(8)-Ag(10)  2.8165(6) 
Ag(8)-Ag(9)  2.8544(6) 
Ag(9)-O(1I)  2.178(4) 
Ag(9)-O(2H)  2.203(4) 
Ag(9)-Ag(10)  2.9511(6) 
Ag(10)-O(2I)  2.286(4) 
Ag(10)-O(1J)  2.305(4) 
Ag(10)-O(2K)  2.309(4) 
Ag(10)-O(1L)  2.374(4) 
O(1G)-C(1G)  1.245(6) 
O(2G)-C(1G)  1.233(6) 
O(2G)-Ag(11)  2.847(4) 
C(1G)-C(2G)  1.519(7) 
C(2G)-C(15G)  1.400(8) 
C(2G)-C(3G)  1.403(8) 
C(3G)-C(4G)  1.413(8) 
C(3G)-C(8G)  1.447(7) 
C(4G)-C(5G)  1.352(8) 
C(5G)-C(6G)  1.420(8) 
C(6G)-C(7G)  1.353(9) 
C(7G)-C(8G)  1.420(8) 
C(8G)-C(9G)  1.380(8) 
C(9G)-C(10G)  1.379(8) 
C(10G)-C(11G)  1.415(8) 
C(10G)-C(15G)  1.454(8) 
C(11G)-C(12G)  1.362(10) 
C(12G)-C(13G)  1.412(10) 
C(13G)-C(14G)  1.359(9) 
C(14G)-C(15G)  1.409(8) 
O(1H)-C(1H)  1.243(7) 
O(1H)-Ag(11)  2.678(4) 
O(2H)-C(1H)  1.257(7) 
C(1H)-C(2H)  1.519(7) 
C(2H)-C(15H)  1.395(8) 
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C(2H)-C(3H)  1.417(8) 
C(3H)-C(4H)  1.424(8) 
C(3H)-C(8H)  1.427(8) 
C(4H)-C(5H)  1.359(9) 
C(5H)-C(6H)  1.423(9) 
C(6H)-C(7H)  1.343(10) 
C(7H)-C(8H)  1.434(9) 
C(8H)-C(9H)  1.392(9) 
C(9H)-C(10H)  1.389(9) 
C(10H)-C(11H)  1.425(9) 
C(10H)-C(15H)  1.439(8) 
C(11H)-C(12H)  1.345(10) 
C(12H)-C(13H)  1.424(9) 
C(13H)-C(14H)  1.362(9) 
C(14H)-C(15H)  1.433(9) 
O(1I)-C(1I)  1.261(7) 
O(2I)-C(1I)  1.236(7) 
C(1I)-C(2I)  1.512(7) 
C(2I)-C(3I)  1.388(8) 
C(2I)-C(15I)  1.401(8) 
C(3I)-C(4I)  1.424(8) 
C(3I)-C(8I)  1.447(8) 
C(4I)-C(5I)  1.351(9) 
C(5I)-C(6I)  1.427(10) 
C(6I)-C(7I)  1.325(10) 
C(7I)-C(8I)  1.427(9) 
C(8I)-C(9I)  1.391(9) 
C(9I)-C(10I)  1.386(9) 
C(10I)-C(15I)  1.435(8) 
C(10I)-C(11I)  1.445(9) 
C(11I)-C(12I)  1.339(10) 
C(12I)-C(13I)  1.394(10) 
C(13I)-C(14I)  1.375(9) 
C(14I)-C(15I)  1.415(9) 
O(1J)-C(1J)  1.226(7) 
O(1J)-Ag(12)  2.624(4) 
O(2J)-C(1J)  1.244(7) 
C(1J)-C(2J)  1.508(8) 
C(2J)-C(15J)  1.404(9) 
C(2J)-C(3J)  1.420(8) 
C(3J)-C(4J)  1.417(8) 
C(3J)-C(8J)  1.430(8) 
C(4J)-C(5J)  1.356(9) 
C(5J)-C(6J)  1.415(11) 
C(6J)-C(7J)  1.332(11) 
C(7J)-C(8J)  1.454(9) 
C(8J)-C(9J)  1.370(9) 
C(9J)-C(10J)  1.389(10) 
C(10J)-C(11J)  1.419(9) 
C(10J)-C(15J)  1.461(9) 
C(11J)-C(12J)  1.331(12) 
C(12J)-C(13J)  1.403(13) 
C(13J)-C(14J)  1.407(11) 
C(14J)-C(15J)  1.419(10) 
O(1K)-C(1K)  1.250(7) 
O(2K)-C(1K)  1.262(7) 
C(1K)-C(2K)  1.500(8) 
C(2K)-C(15K)  1.388(9) 
C(2K)-C(3K)  1.417(9) 
C(3K)-C(4K)  1.396(10) 
C(3K)-C(8K)  1.445(9) 
C(4K)-C(5K)  1.387(10) 
C(5K)-C(6K)  1.393(12) 
C(6K)-C(7K)  1.348(13) 
C(7K)-C(8K)  1.425(11) 
C(8K)-C(9K)  1.387(11) 
C(9K)-C(10K)  1.365(11) 
C(10K)-C(15K)  1.438(9) 
C(10K)-C(11K)  1.449(11) 
C(11K)-C(12K)  1.321(12) 
C(12K)-C(13K)  1.411(11) 
C(13K)-C(14K)  1.346(10) 
C(14K)-C(15K)  1.430(9) 
O(1L)-C(1L)  1.231(6) 
O(2L)-C(1L)  1.269(6) 
C(1L)-C(2L)  1.525(7) 
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C(2L)-C(3L)  1.389(8) 
C(2L)-C(15L)  1.417(8) 
C(3L)-C(8L)  1.435(8) 
C(3L)-C(4L)  1.438(9) 
C(4L)-C(5L)  1.354(9) 
C(5L)-C(6L)  1.411(11) 
C(6L)-C(7L)  1.362(11) 
C(7L)-C(8L)  1.445(9) 
C(8L)-C(9L)  1.362(9) 
C(9L)-C(10L)  1.416(9) 
C(10L)-C(11L)  1.412(9) 
C(10L)-C(15L)  1.454(8) 
C(11L)-C(12L)  1.341(11) 
C(12L)-C(13L)  1.439(10) 
C(13L)-C(14L)  1.365(9) 
C(14L)-C(15L)  1.395(9) 
Ag(11)-N(1E)  2.112(5) 
Ag(11)-N(1F)  2.113(5) 
Ag(11)-O(1H)  2.678(4) 
Ag(11)-O(2G)  2.847(4) 
C(21E)-N(1E)  1.315(8) 
C(21E)-N(2E)  1.334(8) 
N(1E)-C(22E)  1.371(7) 
C(22E)-C(23E)  1.338(9) 
C(23E)-N(2E)  1.365(8) 
N(2E)-C(24E)  1.456(9) 
C(24E)-C(25E)  1.607(16) 
C(25E)-C(26Y)  1.521(17) 
C(26Y)-C(27E)  1.49(2) 
C(25Y)-C(26E)  1.34(3) 
C(26E)-C(27Y)  1.61(3) 
C(21F)-N(1F)  1.329(7) 
C(21F)-N(2F)  1.338(7) 
N(1F)-C(22F)  1.365(7) 
C(22F)-C(23F)  1.336(9) 
C(23F)-N(2F)  1.376(7) 
N(2F)-C(24F)  1.473(7) 
C(24F)-C(25F)  1.512(9) 
C(25F)-C(26F)  1.500(9) 
C(26F)-C(27F)  1.517(10) 
Ag(12)-N(1H)  2.122(5) 
Ag(12)-N(1G)  2.124(5) 
Ag(12)-O(1J)  2.624(4) 
Ag(12)-O(2F)  2.740(4) 
C(21G)-N(1G)  1.314(8) 
C(21G)-N(2G)  1.328(8) 
N(1G)-C(22G)  1.381(8) 
C(22G)-C(23G)  1.353(9) 
C(23G)-N(2G)  1.371(8) 
N(2G)-C(24G)  1.463(9) 
C(24G)-C(25G)  1.549(10) 
C(25G)-C(26G)  1.501(10) 
C(26G)-C(27G)  1.504(11) 
C(21H)-N(1H)  1.318(8) 
C(21H)-N(2H)  1.361(8) 
N(1H)-C(22H)  1.366(8) 
C(22H)-C(23H)  1.353(9) 
C(23H)-N(2H)  1.372(8) 
N(2H)-C(24H)  1.463(8) 
C(24H)-C(25H)  1.56(2) 
C(25H)-C(26H)  1.48(3) 
C(26H)-C(27H)  1.52(3) 
C(25Z)-C(26Z)  1.52(2) 
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X-ray Crystal Data for [Ag(apim)](9-aca)·H2O 
 
Identification code  [Ag(apim)](9-aca)·H2O 
Empirical formula  C21 H22 Ag N3 O3 
Formula weight  472.29 
Temperature  150(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  Pbca 
Unit cell dimensions a = 9.6450(6) Å α = 90°. 
 b = 19.0589(11) Å β = 90°. 
 c = 21.2920(12) Å γ = 90°. 
Volume 3914.0(4) Å3 
Z 8 
Density (calculated) 1.603 Mg/m3 
Absorption coefficient 1.057 mm-1 
F(000) 1920 
Crystal size 0.20 x 0.17 x 0.07 mm3 
Crystal description colourless plate 
Theta range for data collection 1.91 to 28.35°. 
Index ranges -12<=h<=12, -25<=k<=25, -28<=l<=28 
Reflections collected 37907 
Independent reflections 4890 [R(int) = 0.0398] 
Completeness to theta = 26.00° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9297 and 0.8164 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4890 / 6 / 265 
Goodness-of-fit on F2 1.027 
Final R indices [I>2sigma(I)] R1 = 0.0280, wR2 = 0.0665 
R indices (all data) R1 = 0.0410, wR2 = 0.0723 
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Table 27.  Bond lengths [Å] and angles [°] for [Ag(apim)](9-aca)·H2O. 
 
Ag(1)-N(1)  2.0841(18) 
Ag(1)-N(3)#1  2.1069(18) 
C(21)-N(1)  1.321(3) 
C(21)-N(2)  1.336(3) 
N(1)-C(22)  1.376(3) 
C(22)-C(23)  1.354(3) 
C(23)-N(2)  1.371(3) 
N(2)-C(24)  1.470(3) 
C(24)-C(25)  1.518(3) 
C(25)-C(26)  1.520(3) 
C(26)-N(3)  1.483(3) 
N(3)-Ag(1)#2  2.1069(18) 
O(1)-C(1)  1.246(3) 
O(2)-C(1)  1.253(3) 
C(1)-C(2)  1.513(3) 
C(2)-C(15)  1.404(3) 
C(2)-C(3)  1.409(3) 
C(3)-C(4)  1.431(3) 
C(3)-C(8)  1.434(3) 
C(4)-C(5)  1.368(3) 
C(5)-C(6)  1.415(4) 
C(6)-C(7)  1.348(4) 
C(7)-C(8)  1.436(3) 
C(8)-C(9)  1.391(3) 
C(9)-C(10)  1.395(3) 
C(10)-C(11)  1.429(3) 
C(10)-C(15)  1.432(3) 
C(11)-C(12)  1.358(4) 
C(12)-C(13)  1.425(3) 
C(13)-C(14)  1.362(3)  
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C(2)-C(15)-C(14) 122.39(19) 
C(2)-C(15)-C(10) 119.20(19)  
C(14)-C(15)-C(10) 118.40(19) 
 
Symmetry transformations used to generate equivalent atoms:  
#1 -x+1/2,y+1/2,z    #2 -x+1/2,y-1/2,z      
 
 
Table 28. Hydrogen bonds for [Ag(apim)](9-aca)·H2O [Å and °]. 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
N(3)-H(1N)...O(2) 0.857(16) 2.291(17) 3.128(3) 165(3) 
N(3)-H(2N)...O(2)#3 0.852(16) 2.274(17) 3.080(2) 158(2) 
N(3)-H(2N)...O(2)#3 0.852(16) 2.40(2) 3.131(2) 144(2) 
O(1W)-H(1W)...O(1) 0.810(17) 2.072(18) 2.883(3) 179(4) 
O(1W)-
H(2W)...O(2)#4 
0.832(17) 2.04(2) 2.838(3) 162(3) 
 
Symmetry transformations used to generate equivalent atoms:  
#1 -x+1/2,y+1/2,z    #2 -x+1/2,y-1/2,z    #3 x+1/2,-y-1/2,-z+1     #4 x-1/2,-y-
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X-ray Crystal Data for (2-Mebenz-imidH)(9-aca)·H2O 
 
Identification code  (2-Mebenz-imidH)(9-aca)·H2O 
Empirical formula  C23 H20 N2 O3 
Formula weight  372.41 
Temperature  150(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P2(1)2(1)2(1) 
Unit cell dimensions a = 6.9251(8) Å α = 90°. 
 b = 14.8341(17) Å β = 90°. 
 c = 18.522(2) Å γ = 90°. 
Volume 1902.7(4) Å3 
Z 4 
Density (calculated) 1.300 Mg/m3 
Absorption coefficient 0.087 mm-1 
F(000) 784 
Crystal size 0.41 x 0.08 x 0.08 mm3 
Crystal description colourless rod 
Theta range for data collection 1.76 to 26.35°. 
Index ranges -8<=h<=8, -18<=k<=18, -23<=l<=23 
Reflections collected 16919 
Independent reflections 2241 [R(int) = 0.0507] 
Completeness to theta = 26.35° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9931 and 0.9652 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2241 / 0 / 260 
Goodness-of-fit on F2 1.046 
Final R indices [I>2sigma(I)] R1 = 0.0365, wR2 = 0.0853 
R indices (all data) R1 = 0.0482, wR2 = 0.0917 
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Table 29.   Bond lengths [Å] and angles [°] for (2-Mebenz-imidH)(9-aca)·H2O. 
 
N(1)-C(2)  1.331(3) 
N(1)-C(8)  1.385(3) 
C(1)-C(2)  1.489(4) 
C(2)-N(2)  1.329(3) 
N(2)-C(3)  1.385(3) 
C(3)-C(4)  1.389(3) 
C(3)-C(8)  1.395(3) 
C(4)-C(5)  1.374(4) 
C(5)-C(6)  1.398(4) 
C(6)-C(7)  1.377(4) 
C(7)-C(8)  1.390(4) 
O(1)-C(11)  1.276(3) 
O(2)-C(11)  1.240(3) 
C(11)-C(12)  1.514(3) 
C(12)-C(13)  1.401(3) 
C(12)-C(25)  1.409(3) 
C(13)-C(14)  1.432(4) 
C(13)-C(18)  1.440(3) 
C(14)-C(15)  1.354(4) 
C(15)-C(16)  1.419(4) 
C(16)-C(17)  1.355(4) 
C(17)-C(18)  1.430(4) 
C(18)-C(19)  1.390(3) 
C(19)-C(20)  1.392(3) 
C(20)-C(21)  1.428(3) 
C(20)-C(25)  1.440(3) 
C(21)-C(22)  1.353(4) 
C(22)-C(23)  1.419(4) 
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C(12)-C(25)-C(20) 119.4(2)  C(24)-C(25)-C(20) 117.9(2)
 
Table 30.  Hydrogen bonds for (2-Mebenz-imidH)(9-aca)·H2O [Å and °]. 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
N(1)-H(1N)...O(1W) 0.90(3) 1.75(3) 2.654(3) 172(3) 
N(2)-H(2N)...O(1)#1 0.99(3) 1.67(3) 2.651(3) 178(2) 
O(1W)-
H(1WA)...O(2)#2 
0.86 1.89 2.724(3) 162.8 
O(1W)-H(1WB)...O(1) 0.86 1.91 2.731(3) 158.9 
 
Symmetry transformations used to generate equivalent atoms:  
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X-ray Crystal Data for [Ag4(9-aca)4(NH3)2] 
 
Identification code  [Ag4(9-aca)4(NH3)2] 
Empirical formula  C60 H42 Ag4 N2 O8 
Formula weight  1350.44 
Temperature  150(2) K 
Wavelength  0.84620 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 16.837(3) Å α = 90°. 
 b = 9.8639(16) Å β = 112.383(2)°. 
 c = 16.035(3) Å γ = 90°. 
Volume 2462.4(7) Å3 
Z 2 
Density (calculated) 1.821 Mg/m3 
Absorption coefficient 1.629 mm-1 
F(000) 1336 
Crystal size 0.09 x 0.07 x 0.01 mm3 
Crystal description Colourless plate  
Theta range for data collection 3.82 to 27.50°. 
Index ranges -18<=h<=18, -10<=k<=10, -17<=l<=17 
Reflections collected 12821 
Independent reflections 3344 [R(int) = 0.0853] 
Completeness to theta = 27.50° 99.6 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.0000 and 0.641332 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3344 / 0 / 336 
Goodness-of-fit on F2 1.010 
Final R indices [I>2sigma(I)] R1 = 0.0475, wR2 = 0.0987 
R indices (all data) R1 = 0.0684, wR2 = 0.1079 
Extinction coefficient 0.0021(2) 
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Table 31.   Bond lengths [Å] and angles [°] for [Ag4(9-aca)4(NH3)2]. 
 
Ag(1)-O(3)  2.192(4) 
Ag(1)-O(4)#1  2.261(4) 
Ag(1)-O(1)  2.329(6) 
Ag(1)-Ag(1)#1  2.9390(12) 
Ag(2)-O(2)  2.135(5) 
Ag(2)-N(1)  2.148(5) 
O(1)-C(1)  1.259(9) 
O(2)-C(1)  1.247(9) 
C(1)-C(2)  1.513(10) 
C(2)-C(15)  1.415(10) 
C(2)-C(3)  1.415(10) 
C(3)-C(8)  1.429(11) 
C(3)-C(4)  1.436(11) 
C(4)-C(5)  1.381(12) 
C(5)-C(6)  1.406(16) 
C(6)-C(7)  1.328(15) 
C(7)-C(8)  1.426(12) 
C(8)-C(9)  1.387(12) 
C(9)-C(10)  1.377(11) 
C(10)-C(11)  1.431(12) 
C(10)-C(15)  1.433(10) 
C(11)-C(12)  1.337(13) 
C(12)-C(13)  1.420(13) 
C(13)-C(14)  1.366(10) 
C(14)-C(15)  1.416(10) 
O(3)-C(16)  1.273(8) 
O(4)-C(16)  1.249(8) 
O(4)-Ag(1)#1  2.261(4) 
C(16)-C(17)  1.516(9) 
C(17)-C(30)  1.400(9) 
C(17)-C(18)  1.411(9) 
C(18)-C(19)  1.438(10) 
C(18)-C(23)  1.446(9) 
C(19)-C(20)  1.347(10) 
C(20)-C(21)  1.406(10) 
C(21)-C(22)  1.358(10) 
C(22)-C(23)  1.409(10) 
C(23)-C(24)  1.409(9) 
C(24)-C(25)  1.385(9) 
C(25)-C(30)  1.418(9) 
C(25)-C(26)  1.423(9) 
C(26)-C(27)  1.355(10) 
C(27)-C(28)  1.435(10) 
C(28)-C(29)  1.358(9)  
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Table 32.  Hydrogen bonds for [Ag4(9-aca)4(NH3)2]  [Å and °]. 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
N(1)-H(1A)...O(1)#2 0.91 2.42 3.222(8) 146.5 
N(1)-H(1B)...O(4)#3 0.91 2.32 3.103(7) 143.4 
 
Symmetry transformations used to generate equivalent atoms:  
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UV-Vis and Fluorescence Spectral Data 
 










[Ag2(9-aca)2]n 373 366 (7) N/A 
[Ag(imidH)2.3(CH3CN)0.7](9-
aca) 
373 366 (7) 280 (1) 
[Ag(apim)](9-aca)·H2O 373 366 (7) no maximum 
[Ag(2-Ph-imid)] 273 262(6) N/A 
[Ag(4-Ph-imidH)2(9-aca)] 373 366 (7) 271 (5) 
[Ag(4,5-dicyanoimid)] 264 256 (4) N/A 
[Ag2(2-Mebenz-imidH)4](9-
aca)2 
366 366 (7) 283 (2) 
[Ag4(9-aca)4(NH3)2] 372 366 (7) N/A 
 
 
Table 34. Complex and ligand 1 fluorescence data (a excited at 366 nm, b excited 















[Ag2(9-aca)2]n 448 61 451 (7) 942 (7) 
[Ag(imidH)2.3(CH3CN)0.7](9
-aca) 
448 175 450 (7) 968 (7) 
[Ag(apim)](9-aca)·H2O 440 53 450 (7) 968 (7) 
[Ag(2-Ph-imid)] 342 44 340 (6) 167 (6) 
[Ag(4-Ph-imidH)2(9-aca)] 448 108 450 (7) 968 (7) 







451 (7) 461 (7) 
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Table 35. Complex and ligand 2 fluorescence data (a excited at 366 nm, b excited 















[Ag2(9-aca)2]n 448 61 N/A N/A 
[Ag(imidH)2.3(CH3CN)0.7](9
-aca) 
448 175 561 (1) 15 (1) 
[Ag(apim)](9-aca)·H2O 440 53 0 (4) 0 (4) 
[Ag(2-Ph-imid)] 342 44 N/A N/A 
[Ag(4-Ph-imidH)2(9-aca)] 448 108 290 (5) 2 (5) 







299 (2) 554 (2) 
[Ag4(9-aca)4(NH3)2] 446 15 N/A N/A 
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In vivo Data 
 
Table 36. Survival of G. mellonella larvae after prophylactic treatment with 






after 24 h. 
% 
Survival 
after 48 h 
% 
Survival 
after 72 h 
Control 
(1×108 cells cm-3) 
70 30 10 
Ketoconazole# 
100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 





















after 24 h. 
% 
Survival 
after 48 h 
% 
Survival 
after 72 h 
[Ag(2-Me-imidH)2(9-aca)] 
100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 
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Table 37. Survival of G. mellonella larvae after infection with a lethal dose of C. 






after 24 h. 
% 
Survival 
after 48 h 
% 
Survival 
after 72 h 
Control 
(1×108 cells cm-3) 
70 30 10 
Ketoconazole# 
100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 





















after 24 h. 
% 
Survival 
after 48 h 
% 
Survival 
after 72 h 
[Ag(1-Bu-imid)2]2[Ag4(9-aca)6] 
100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 
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after 24 h.  
(p value) 
Significant 
after 48 h  
(p value) 
Significant 
after 72 h 
(p value) 
Ketoconazole# 
100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 















100 µg cm-3 
10 µg cm-3 


















100 µg cm-3 
10 µg cm-3 















No  (1.000) 
[Ag(1-Me-imid)2]2[Ag4(9-
aca)6] 
100 µg cm-3 
10 µg cm-3 

















100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 




















after 24 h. 
(p value) 
Significant 
after 48 h  
(p value) 
Significant 
after 72 h 
 (p value) 
[Ag(1-bu-imid)2]2[Ag4(9-
aca)6] 
100 µg cm-3 
10 µg cm-3 

















100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 















100 µg cm-3 
10 µg cm-3 

















100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 
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after 24 h.  
(p value) 
Significant 
after 48 h  
(p value) 
Significant 
after 72 h (p 
value) 
Ketoconazole# 
100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 















100 µg cm-3 
10 µg cm-3 


















100 µg cm-3 
10 µg cm-3 
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1 
X-ray Crystal Data for [Ag2(9-aca)2]n 
 
Identification code  [Ag2(9-aca)2]n 
Empirical formula  C30 H18 Ag2 O4 
Formula weight  658.18 
Temperature  150(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 14.813(3) Å α= 90°. 
 b = 5.6055(12) Å β= 95.250(3)°. 
 c = 27.413(6) Å γ = 90°. 
Volume 2266.6(8) Å3 
Z 4 
Density (calculated) 1.929 Mg/m3 
Absorption coefficient 1.766 mm-1 
F(000) 1296 
Crystal size 0.57 x 0.05 x 0.02 mm3 
Crystal description yellow rod 
Theta range for data collection 1.94 to 25.00°. 
Index ranges -17<=h<=17, -6<=k<=6, -32<=l<=32 
Reflections collected 16694 
Independent reflections 3991 [R(int) = 0.0520] 
Completeness to theta = 25.00° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9655 and 0.4326 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3991 / 0 / 325 
Goodness-of-fit on F2 1.020 
Final R indices [I>2sigma(I)] R1 = 0.0374, wR2 = 0.0854 
R indices (all data) R1 = 0.0610, wR2 = 0.0979 
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Table 1.  Atomic coordinates ( x 104) and equivalent isotropic displacement 
parameters (Å2x 103) for [Ag2(9-aca)2]n.  U(eq) is defined as one third of the 
trace of the orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
Ag(1) 4611(1) 7083(1) 193(1) 28(1) 
O(1) 4213(2) 4684(6) 757(1) 26(1) 
O(2) 4681(2) 1377(6) 400(1) 25(1) 
C(1) 4215(3) 2493(9) 691(2) 18(1) 
C(2) 3628(3) 933(9) 978(2) 19(1) 
C(3) 3054(3) -726(9) 720(2) 19(1) 
C(4) 2917(3) -808(9) 192(2) 23(1) 
C(5) 2418(3) -2547(9) -42(2) 28(1) 
C(6) 2005(3) -4364(10) 221(2) 27(1) 
C(7) 2063(3) -4263(10) 716(2) 27(1) 
C(8) 2578(3) -2475(9) 979(2) 21(1) 
C(9) 2666(3) -2418(9) 1490(2) 23(1) 
C(10) 3179(3) -703(9) 1748(2) 22(1) 
C(11) 3229(4) -618(11) 2274(2) 32(1) 
C(12) 3694(4) 1106(11) 2523(2) 34(1) 
C(13) 4184(4) 2861(10) 2276(2) 34(1) 
C(14) 4172(3) 2807(10) 1778(2) 27(1) 
C(15) 3674(3) 1043(9) 1493(2) 19(1) 
Ag(2) 220(1) 7887(1) 4742(1) 27(1) 
O(3) 605(2) 10405(6) 4187(1) 27(1) 
O(4) 334(2) 13714(6) 4597(1) 29(1) 
C(16) 604(3) 12600(9) 4240(2) 20(1) 
C(17) 1001(3) 14151(9) 3855(2) 21(1) 
C(18) 452(3) 15730(9) 3576(2) 20(1) 
C(19) -507(4) 15753(9) 3568(2) 27(1) 
C(20) -1024(4) 17285(10) 3282(2) 31(1) 
C(21) -615(4) 18972(10) 2988(2) 35(1) 
C(22) 289(4) 19049(10) 2982(2) 30(1) 
C(23) 859(4) 17441(9) 3268(2) 23(1) 
C(24) 1795(4) 17450(9) 3266(2) 28(1) 
C(25) 2353(4) 15795(10) 3519(2) 25(1) 
C(26) 3308(4) 15728(11) 3498(2) 31(1) 
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C(27) 3827(4) 14065(11) 3734(2) 34(1) 
C(28) 3431(4) 12270(11) 4010(2) 34(1) 
C(29) 2522(4) 12277(10) 4054(2) 28(1) 
C(30) 1943(3) 14025(9) 3814(2) 19(1) 
 
 
Table 2.   Bond lengths [Å] and angles [°] for [Ag2(9-aca)2]n. 
Ag(1)-O(1)  2.170(3) 
Ag(1)-O(2)#1  2.190(3) 
Ag(1)-O(2)#2  2.473(4) 
Ag(1)-Ag(1)#1  2.8508(9) 
O(1)-C(1)  1.242(6) 
O(2)-C(1)  1.267(6) 
O(2)-Ag(1)#1  2.190(3) 
O(2)-Ag(1)#3  2.473(4) 
C(1)-C(2)  1.504(7) 
C(2)-C(3)  1.407(7) 
C(2)-C(15)  1.411(6) 
C(3)-C(8)  1.434(7) 
C(3)-C(4)  1.442(6) 
C(4)-C(5)  1.350(7) 
C(5)-C(6)  1.417(7) 
C(6)-C(7)  1.355(7) 
C(7)-C(8)  1.416(7) 
C(8)-C(9)  1.395(7) 
C(9)-C(10)  1.379(7) 
C(10)-C(11)  1.437(6) 
C(10)-C(15)  1.440(7) 
C(11)-C(12)  1.338(8) 
C(12)-C(13)  1.428(8) 
C(13)-C(14)  1.364(7) 
C(14)-C(15)  1.424(7) 
Ag(2)-O(3)  2.190(3) 
Ag(2)-O(4)#4  2.243(3) 
Ag(2)-O(4)#3  2.381(4) 
Ag(2)-Ag(2)#4  2.8643(9) 
O(3)-C(16)  1.239(6) 
O(4)-C(16)  1.257(6) 
O(4)-Ag(2)#4  2.243(3) 
O(4)-Ag(2)#2  2.381(4) 
C(16)-C(17)  1.526(6) 
C(17)-C(18)  1.385(7) 
C(17)-C(30)  1.412(7) 
C(18)-C(19)  1.420(7) 
C(18)-C(23)  1.446(7) 
C(19)-C(20)  1.351(7) 
C(20)-C(21)  1.416(8) 
C(21)-C(22)  1.341(8) 
C(22)-C(23)  1.421(7) 
C(23)-C(24)  1.387(7) 
C(24)-C(25)  1.387(7) 
C(25)-C(26)  1.421(7) 
C(25)-C(30)  1.447(7) 
C(26)-C(27)  1.339(8) 
C(27)-C(28)  1.418(8) 















































































Symmetry transformations used to generate equivalent atoms:  
#1 -x+1,-y+1,-z    #2 x,y+1,z    #3 x,y-1,z    #4 -x,-y+2,-z+1      
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Table 3.   Anisotropic displacement parameters (Å2x 103) for [Ag2(9-aca)2]n.  
The anisotropic displacement factor exponent takes the form: -2π2[ h2a*2U11 + ... 
+ 2 h k a* b* U12 ] 
______________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
______________________________________________________________________________ 
Ag(1) 41(1)  18(1) 30(1)  3(1) 24(1)  -1(1) 
O(1) 36(2)  16(2) 28(2)  4(2) 20(2)  0(2) 
O(2) 37(2)  19(2) 23(2)  2(2) 22(2)  3(2) 
C(1) 20(2)  19(3) 16(2)  3(2) 1(2)  2(2) 
C(2) 29(3)  14(3) 16(2)  1(2) 8(2)  7(2) 
C(3) 23(3)  18(3) 19(2)  4(2) 10(2)  5(2) 
C(4) 28(3)  27(3) 16(2)  4(2) 14(2)  3(2) 
C(5) 36(3)  30(3) 18(3)  6(2) 5(2)  0(2) 
C(6) 27(3)  29(3) 27(3)  -4(2) 7(2)  -4(2) 
C(7) 25(3)  32(3) 25(3)  2(2) 10(2)  -3(2) 
C(8) 21(2)  25(3) 18(2)  2(2) 7(2)  2(2) 
C(9) 25(3)  24(3) 24(3)  5(2) 15(2)  -2(2) 
C(10) 28(3)  27(3) 13(2)  6(2) 14(2)  2(2) 
C(11) 41(3)  37(4) 19(3)  6(2) 15(2)  -2(3) 
C(12) 47(4)  40(4) 17(3)  -3(3) 13(2)  -2(3) 
C(13) 42(3)  32(3) 28(3)  -8(3) 5(2)  -1(3) 
C(14) 33(3)  25(3) 24(3)  2(2) 11(2)  -1(2) 
C(15) 19(2)  19(3) 20(3)  1(2) 9(2)  0(2) 
Ag(2) 45(1)  17(1) 23(1)  3(1) 19(1)  -2(1) 
O(3) 48(2)  18(2) 20(2)  -1(2) 17(2)  -1(2) 
O(4) 52(2)  21(2) 17(2)  1(2) 26(2)  -5(2) 
C(16) 26(3)  20(3) 16(2)  1(2) 10(2)  2(2) 
C(17) 32(3)  20(3) 13(2)  -4(2) 14(2)  -6(2) 
C(18) 31(3)  15(3) 15(2)  -6(2) 11(2)  1(2) 
C(19) 39(3)  23(3) 23(3)  -2(2) 19(2)  -2(2) 
C(20) 36(3)  31(3) 26(3)  -5(2) 11(2)  2(3) 
C(21) 54(4)  28(3) 23(3)  6(2) 5(3)  9(3) 
C(22) 51(4)  23(3) 19(3)  4(2) 16(2)  0(3) 
C(23) 42(3)  16(3) 13(2)  -1(2) 13(2)  -4(2) 
C(24) 48(3)  19(3) 20(3)  1(2) 20(2)  -10(2) 
C(25) 37(3)  27(3) 13(2)  -2(2) 12(2)  -6(2) 
C(26) 32(3)  40(4) 22(3)  -5(3) 16(2)  -11(3) 
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C(27) 31(3)  47(4) 25(3)  -5(3) 13(2)  -11(3) 
C(28) 34(3)  45(4) 24(3)  -6(3) 6(2)  3(3) 
C(29) 36(3)  31(3) 17(2)  1(2) 7(2)  -2(2) 
C(30) 27(3)  23(3) 9(2)  -7(2) 9(2)  -4(2) 
 
 
Table 4.   Hydrogen coordinates ( x 104) and isotropic displacement parameters 
(Å2x 103) for [Ag2(9-aca)2]n. 
________________________________________________________________________________ 
 x  y  z  U(eq) 
________________________________________________________________________________ 
H(4) 3184 385 5 27 
H(5) 2341 -2554 -390 33 
H(6) 1691 -5638 51 33 
H(7) 1752 -5418 891 32 
H(9) 2364 -3591 1666 28 
H(11) 2928 -1802 2446 38 
H(12) 3699 1164 2870 41 
H(13) 4516 4064 2459 41 
H(14) 4505 3972 1618 32 
H(19) -795 14659 3768 33 
H(20) -1666 17229 3279 37 
H(21) -984 20060 2793 42 
H(22) 552 20196 2783 36 
H(24) 2067 18646 3082 33 
H(26) 3585 16897 3309 37 
H(27) 4465 14088 3718 40 
H(28) 3801 11055 4166 41 
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X-ray Crystal Data for [Ag2(9-aca)2(DMSO)2]n 
 
Identification code  [Ag2(9-aca)2(DMSO)2]n 
Empirical formula  C34 H30 Ag2 O6 S2 
Formula weight  814.44 
Temperature  150(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 9.1304(7) Å α= 90°. 
 b = 19.5875(14) Å β= 99.2280(10)°. 
 c = 18.0502(13) Å γ = 90°. 
Volume 3186.3(4) Å3 
Z 4 
Density (calculated) 1.698 Mg/m3 
Absorption coefficient 1.405 mm-1 
F(000) 1632 
Crystal size 0.41 x 0.09 x 0.08 mm3 
Crystal description yellow rod 
Theta range for data collection 1.55 to 27.50°. 
Index ranges -11<=h<=11, -25<=k<=25, -23<=l<=23 
Reflections collected 30770 
Independent reflections 7311 [R(int) = 0.0426] 
Completeness to theta = 27.50° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.8959 and 0.5967 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 7311 / 904 / 527 
Goodness-of-fit on F2 1.026 
Final R indices [I>2sigma(I)] R1 = 0.0317, wR2 = 0.0701 
R indices (all data) R1 = 0.0463, wR2 = 0.0769 






                                                                                                        Electronic Appendix 
8 
Table 5. Atomic coordinates ( x 104) and equivalent isotropic displacement 
parameters (Å2x 103) for [Ag2(9-aca)2(DMSO)2]n.  U(eq) is defined as one third 
of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
Ag(1) 4461(1) 5722(1) 4686(1) 34(1) 
Ag(2) 1637(1) 5000(1) 4515(1) 33(1) 
O(1) 7081(2) 5992(1) 4789(1) 44(1) 
S(1) 7744(1) 6306(1) 4151(1) 59(1) 
C(1) 7050(4) 7157(2) 4104(3) 81(1) 
C(2) 6680(4) 5996(2) 3310(2) 64(1) 
O(2) 970(2) 5245(1) 5760(1) 35(1) 
S(2) 1625(1) 5864(1) 6198(1) 39(1) 
C(3) 1220(4) 5729(2) 7120(2) 51(1) 
C(4) 363(4) 6546(2) 5941(2) 45(1) 
O(11) 4822(2) 4701(1) 4048(1) 35(1) 
O(12) 2502(2) 4504(1) 3477(1) 42(1) 
C(10) 3763(14) 4422(9) 3550(9) 34(3) 
C(11) 4511(7) 3894(4) 3104(5) 37(2) 
C(12) 4847(8) 4102(4) 2406(4) 49(2) 
C(13) 4573(7) 4782(5) 2113(4) 60(2) 
C(14) 4950(9) 4971(5) 1442(4) 87(2) 
C(15) 5641(10) 4507(5) 1012(4) 100(3) 
C(16) 5881(9) 3854(5) 1258(4) 94(3) 
C(17) 5521(9) 3621(5) 1962(4) 66(2) 
C(18) 5857(12) 2973(5) 2254(5) 69(3) 
C(19) 5571(18) 2774(6) 2948(5) 60(2) 
C(20) 5956(19) 2111(6) 3254(6) 87(3) 
C(21) 5664(13) 1929(5) 3929(6) 89(3) 
C(22) 4996(12) 2388(5) 4372(6) 68(3) 
C(23) 4584(13) 3024(5) 4101(6) 43(2) 
C(24) 4860(20) 3246(5) 3392(7) 43(2) 
C(10') 3973(19) 4404(13) 3581(13) 26(3) 
C(11') 4479(12) 3959(7) 2978(7) 38(3) 
C(12') 4451(12) 4160(6) 2241(6) 50(3) 
C(13') 3895(14) 4808(6) 1981(6) 63(3) 
C(14') 3804(18) 4979(6) 1249(6) 102(4) 
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C(15') 4340(20) 4537(7) 757(7) 124(5) 
C(16') 5073(19) 3971(8) 997(7) 111(5) 
C(17') 5096(16) 3733(6) 1742(6) 67(3) 
C(18') 5649(17) 3106(7) 1973(7) 56(3) 
C(19') 5570(20) 2868(7) 2678(7) 43(3) 
C(20') 6120(20) 2217(7) 2940(8) 61(3) 
C(21') 6100(20) 2010(8) 3640(8) 71(4) 
C(22') 5443(18) 2418(8) 4150(8) 60(3) 
C(23') 4910(20) 3047(8) 3920(9) 43(3) 
C(24') 4990(30) 3304(8) 3200(9) 36(3) 
O(31) 3461(2) 6591(1) 3826(2) 61(1) 
O(32) 1801(2) 6233(1) 4498(1) 42(1) 
C(30) 2189(3) 6577(2) 3985(2) 37(1) 
C(31) 1026(3) 7009(2) 3506(2) 35(1) 
C(32) 638(3) 7649(2) 3761(2) 40(1) 
C(33) 1207(4) 7899(2) 4488(2) 52(1) 
C(34) 775(5) 8519(2) 4724(2) 70(1) 
C(35) -238(5) 8923(2) 4243(3) 77(1) 
C(36) -797(4) 8713(2) 3550(3) 65(1) 
C(37) -404(3) 8064(2) 3281(2) 47(1) 
C(38) -1036(3) 7819(2) 2587(2) 51(1) 
C(39) -705(3) 7173(2) 2339(2) 48(1) 
C(40) -1391(4) 6899(2) 1636(2) 66(1) 
C(41) -1069(5) 6270(2) 1415(2) 75(1) 
C(42) -15(5) 5859(2) 1879(2) 66(1) 
C(43) 685(4) 6091(2) 2552(2) 48(1) 
C(44) 366(3) 6758(2) 2808(2) 39(1) 
 
 














O(11)-Ag(1)-O(31) 110.86(9) O(11)-Ag(1)-O(11)#1 97.65(6) 























Symmetry transformations used to generate equivalent atoms: 
   #1 -x+1,-y+1,-z+1    #2 -x,-y+1,-z+1 
 
Table 7. Anisotropic displacement parameters (Å2x 103)for [Ag2(9-
aca)2(DMSO)2]n. The anisotropic displacement factor exponent takes the form: -
2π2[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
______________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
______________________________________________________________________________ 
Ag(1) 24(1)  31(1) 44(1)  2(1) 0(1)  1(1) 
Ag(2) 24(1)  36(1) 40(1)  -1(1) 11(1)  -2(1) 
O(1) 25(1)  56(1) 51(1)  15(1) 6(1)  0(1) 
S(1) 24(1)  82(1) 71(1)  33(1) 10(1)  -2(1) 
C(1) 56(2)  71(3) 117(4)  43(3) 14(2)  -15(2) 
C(2) 45(2)  101(3) 49(2)  26(2) 16(2)  11(2) 
O(2) 27(1)  37(1) 41(1)  -5(1) 9(1)  -4(1) 
S(2) 25(1)  46(1) 46(1)  -10(1) 6(1)  -7(1) 
C(3) 48(2)  62(2) 41(2)  -6(2) 3(2)  2(2) 
C(4) 49(2)  38(2) 52(2)  -7(2) 16(2)  -1(1) 
O(11) 32(1)  37(1) 35(1)  -7(1) 5(1)  -2(1) 
O(12) 24(1)  56(1) 47(1)  -11(1) 7(1)  2(1) 
C(10) 40(6)  33(4) 31(4)  -9(4) 9(4)  -3(4) 
C(11) 18(3)  53(4) 42(4)  -26(3) 7(2)  -9(2) 
C(12) 23(3)  77(4) 43(4)  -27(3) -2(3)  2(3) 
C(13) 43(4)  98(5) 36(4)  -17(3) 3(3)  12(4) 
C(14) 81(5)  144(7) 37(4)  3(4) 17(4)  21(5) 
C(15) 73(5)  186(8) 46(4)  -21(5) 24(4)  19(6) 
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C(16) 61(5)  172(7) 48(4)  -44(4) 3(4)  37(5) 
C(17) 31(4)  108(5) 55(4)  -51(4) -5(3)  11(4) 
C(18) 33(4)  108(6) 62(7)  -63(4) -3(5)  15(4) 
C(19) 36(4)  73(5) 66(6)  -51(4) -8(5)  4(4) 
C(20) 83(8)  70(6) 101(10)  -60(5) -12(8)  22(6) 
C(21) 87(8)  44(5) 130(8)  -32(5) -2(6)  16(5) 
C(22) 65(7)  40(4) 96(7)  -14(4) 2(5)  0(4) 
C(23) 30(5)  35(3) 63(5)  -17(3) 3(3)  -3(3) 
C(24) 23(4)  46(4) 57(6)  -30(3) 5(5)  -5(4) 
C(10') 3(4)  38(6) 38(6)  3(5) 3(3)  1(4) 
C(12') 46(7)  69(6) 37(5)  -14(4) 10(5)  -22(5) 
C(13') 80(9)  62(6) 45(5)  -8(4) 0(6)  -26(6) 
C(14') 163(12)  90(8) 55(6)  12(5) 25(8)  -41(8) 
C(15') 189(14)  130(10) 63(7)  7(6) 51(8)  -40(9) 
C(16') 155(14)  145(10) 43(7)  -23(6) 48(8)  -18(9) 
C(17') 81(10)  77(6) 49(6)  -26(4) 23(6)  -29(6) 
C(18') 50(8)  81(7) 40(6)  -46(4) 14(6)  -30(6) 
C(19') 27(5)  54(5) 48(8)  -38(5) 5(8)  -5(4) 
C(20') 42(6)  63(6) 75(8)  -39(5) 1(7)  6(5) 
C(21') 60(9)  54(7) 96(11)  -13(7) 5(9)  20(6) 
C(22') 66(9)  49(6) 65(7)  -1(5) 13(5)  -2(6) 
C(23') 33(8)  43(5) 54(7)  -18(5) 13(6)  2(5) 
C(24') 21(6)  50(5) 39(6)  -20(4) 6(5)  -10(4) 
O(31) 29(1)  67(2) 90(2)  41(1) 14(1)  11(1) 
O(32) 48(1)  38(1) 41(1)  12(1) 10(1)  5(1) 
C(30) 30(2)  34(2) 45(2)  7(1) 4(1)  3(1) 
C(31) 23(1)  40(2) 45(2)  18(1) 9(1)  1(1) 
C(32) 31(2)  38(2) 53(2)  15(1) 14(1)  1(1) 
C(33) 54(2)  47(2) 58(2)  9(2) 16(2)  0(2) 
C(34) 90(3)  53(2) 71(3)  1(2) 29(2)  -1(2) 
C(35) 96(3)  48(2) 97(3)  10(2) 46(3)  19(2) 
C(36) 58(2)  47(2) 96(3)  27(2) 33(2)  19(2) 
C(37) 32(2)  45(2) 66(2)  22(2) 20(2)  8(1) 
C(38) 30(2)  55(2) 70(2)  31(2) 9(2)  7(2) 
C(39) 30(2)  61(2) 51(2)  23(2) 4(1)  -4(2) 
C(40) 51(2)  85(3) 57(2)  21(2) -7(2)  -12(2) 
C(41) 79(3)  93(3) 47(2)  6(2) -2(2)  -24(3) 
C(42) 75(3)  61(2) 63(3)  -2(2) 15(2)  -13(2) 
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C(43) 47(2)  47(2) 52(2)  8(2) 14(2)  -4(2) 
C(44) 27(2)  46(2) 46(2)  14(1) 9(1)  -2(1) 
 
 
Table 8. Hydrogen coordinates ( x 104) and isotropic displacement parameters 
(Å2x 103) for [Ag2(9-aca)2(DMSO)2]n. 
________________________________________________________________________________ 
 x  y  z  U(eq) 
________________________________________________________________________________ 
H(1A) 7536 7415 4540 122 
H(1B) 5976 7149 4103 122 
H(1C) 7255 7375 3643 122 
H(2A) 6931 5516 3239 96 
H(2B) 6900 6266 2884 96 
H(2C) 5622 6034 3342 96 
H(3A) 1835 5355 7359 77 
H(3B) 169 5611 7091 77 
H(3C) 1433 6147 7416 77 
H(4A) 429 6694 5429 68 
H(4B) 614 6929 6288 68 
H(4C) -649 6392 5965 68 
H(13) 4119 5106 2395 71 
H(14) 4744 5422 1262 104 
H(15) 5935 4648 554 120 
H(16) 6304 3539 953 113 
H(18) 6304 2654 1962 83 
H(20) 6429 1794 2972 105 
H(21) 5912 1482 4112 107 
H(22) 4830 2257 4858 82 
H(23) 4102 3324 4398 52 
H(13') 3585 5124 2324 76 
H(14') 3371 5402 1073 122 
H(15') 4186 4641 237 148 
H(16') 5587 3724 666 133 
H(18') 6095 2831 1637 68 
H(20') 6518 1922 2605 73 
H(21') 6520 1582 3801 85 
H(22') 5380 2257 4640 72 
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H(23') 4468 3321 4258 51 
H(33) 1897 7632 4816 63 
H(34) 1159 8677 5214 83 
H(35) -530 9353 4413 92 
H(36) -1464 9000 3233 78 
H(38) -1717 8099 2269 62 
H(40) -2093 7168 1316 79 
H(41) -1549 6098 946 89 
H(42) 203 5415 1715 79 
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X-ray Crystal Data for [Ag(imidH)2.3(CH3CN)0.7](9-aca) 
 
Identification code  [Ag(imidH)2.3(CH3CN)0.7](9-aca) 
Empirical formula  C23.30 H20.30 Ag N5.30 O2 
Formula weight  514.42 
Temperature  150(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 9.7905(5) Å α= 90°. 
 b = 14.2012(7) Å β= 101.8640(10)°. 
 c = 16.3251(9) Å γ = 90°. 
Volume 2221.3(2) Å3 
Z 4 
Density (calculated) 1.538 Mg/m3 
Absorption coefficient 0.938 mm-1 
F(000) 1041 
Crystal size 0.33 x 0.22 x 0.21 mm3 
Crystal description colourless block 
Theta range for data collection 1.92 to 26.00°. 
Index ranges -12<=h<=12, -17<=k<=17, -20<=l<=20 
Reflections collected 19005 
Independent reflections 4361 [R(int) = 0.0326] 
Completeness to theta = 25.00° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.8273 and 0.7471 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4361 / 23 / 326 
Goodness-of-fit on F2 1.049 
Final R indices [I>2sigma(I)] R1 = 0.0347, wR2 = 0.0730 
R indices (all data) R1 = 0.0460, wR2 = 0.0782 
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Table 9.  Atomic coordinates ( x 104) and equivalent isotropic displacement 
parameters (Å2x 103) for [Ag(imidH)2.3(CH3CN)0.7](9-aca).  U(eq) is defined as 
one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
Ag(1) 2421(1) 8163(1) 1512(1) 50(1) 
O(1) 5308(2) 13838(1) 1704(2) 44(1) 
O(2) 3509(2) 12945(1) 1853(1) 36(1) 
C(1) 4781(3) 13083(2) 1887(2) 29(1) 
C(2) 5761(3) 12262(2) 2163(2) 28(1) 
C(3) 6311(3) 12131(2) 3015(2) 33(1) 
C(4) 6059(3) 12786(2) 3632(2) 44(1) 
C(5) 6609(4) 12649(3) 4452(2) 62(1) 
C(6) 7434(4) 11857(4) 4724(3) 74(1) 
C(7) 7710(4) 11215(3) 4165(2) 62(1) 
C(8) 7171(3) 11328(2) 3284(2) 42(1) 
C(9) 7445(3) 10695(2) 2689(2) 47(1) 
C(10) 6927(3) 10826(2) 1842(2) 38(1) 
C(11) 7215(4) 10188(2) 1228(3) 56(1) 
C(12) 6751(4) 10342(2) 412(3) 60(1) 
C(13) 5933(4) 11145(2) 132(2) 49(1) 
C(14) 5598(3) 11767(2) 688(2) 37(1) 
C(15) 6077(3) 11637(2) 1567(2) 29(1) 
N(21) 2503(3) 6688(2) 1303(2) 41(1) 
C(21) 3655(3) 6183(2) 1498(2) 43(1) 
N(22) 3386(3) 5269(2) 1393(2) 40(1) 
C(23) 1986(3) 5171(2) 1122(2) 45(1) 
C(22) 1441(3) 6046(2) 1064(2) 44(1) 
N(31) 2061(2) 9640(2) 1483(2) 36(1) 
C(31) 2977(3) 10309(2) 1769(2) 39(1) 
N(32) 2400(3) 11159(2) 1671(2) 38(1) 
C(32) 1035(3) 11039(2) 1303(2) 45(1) 
C(33) 834(3) 10105(2) 1185(2) 42(1) 
N(51) 5098(8) 8252(8) 2377(5) 73(2) 
C(52) 5748(6) 8377(4) 3026(4) 51(1) 
C(53) 6625(9) 8530(12) 3860(5) 56(2) 
N(41) 4729(15) 8257(19) 2617(12) 62(4) 
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C(41) 6000(13) 8369(10) 2512(10) 62(3) 
N(42) 6917(10) 8515(7) 3226(8) 62(3) 
C(42) 6206(19) 8500(30) 3844(13) 70(5) 
C(43) 4845(12) 8317(9) 3464(10) 75(4) 
 
 
















Symmetry transformations used to generate equivalent atoms: 
#1 -x+1/2,y-1/2,-z+1/2      
 
 
Table 11.  Bond lengths [Å] and angles [°] for [Ag(imidH)2.3(CH3CN)0.7](9-aca). 
Ag(1)-N(21)  2.126(2) 
Ag(1)-N(31)  2.126(2) 
Ag(1)-N(41)  2.588(17) 
Ag(1)-N(51)  2.713(8) 
Ag(1)-O(2)#1  3.009(2) 
O(1)-C(1)  1.253(3) 
O(2)-C(1)  1.251(3) 
C(1)-C(2)  1.519(3) 
C(2)-C(3)  1.397(4) 
C(2)-C(15)  1.398(4) 
C(3)-C(4)  1.428(4) 
C(3)-C(8)  1.433(4) 
C(4)-C(5)  1.351(5) 
C(5)-C(6)  1.403(6) 
C(6)-C(7)  1.357(6) 
C(7)-C(8)  1.436(5) 
C(8)-C(9)  1.388(5) 
C(9)-C(10)  1.385(4) 
C(10)-C(11)  1.422(5) 
C(10)-C(15)  1.438(4) 
C(11)-C(12)  1.334(5) 
C(12)-C(13)  1.414(5) 
C(13)-C(14)  1.355(4) 
C(14)-C(15)  1.426(4) 
N(21)-C(21)  1.319(4) 
N(21)-C(22)  1.377(4) 
C(21)-N(22)  1.329(4) 
N(22)-C(23)  1.357(4) 
C(23)-C(22)  1.349(4) 
N(31)-C(31)  1.323(4) 
N(31)-C(33)  1.370(4) 
C(31)-N(32)  1.329(4) 
N(32)-C(32)  1.359(4) 
C(32)-C(33)  1.350(4) 
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N(51)-C(52)  1.132(9) 
C(52)-C(53)  1.468(10) 
N(41)-C(41)  1.301(15) 
N(41)-C(43)  1.366(16) 
C(41)-N(42)  1.334(15) 































































Symmetry transformations used to generate equivalent atoms:  
#1 -x+1/2,y-1/2,-z+1/2      
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Table 12. Anisotropic displacement parameters (Å2x 103)for 
[Ag(imidH)2.3(CH3CN)0.7](9-aca).  The anisotropic displacement factor exponent 
takes the form: -2π2[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
______________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
______________________________________________________________________________ 
Ag(1) 52(1)  29(1) 74(1)  4(1) 25(1)  8(1) 
O(1) 32(1)  24(1) 75(2)  4(1) 11(1)  3(1) 
O(2) 28(1)  30(1) 50(1)  2(1) 8(1)  4(1) 
C(1) 32(2)  24(1) 31(1)  -4(1) 5(1)  6(1) 
C(2) 26(1)  23(1) 34(2)  0(1) 3(1)  0(1) 
C(3) 28(1)  35(2) 34(2)  2(1) 0(1)  -8(1) 
C(4) 50(2)  46(2) 36(2)  -5(1) 11(1)  -22(2) 
C(5) 78(3)  73(3) 36(2)  -7(2) 10(2)  -49(2) 
C(6) 70(3)  99(3) 44(2)  21(2) -11(2)  -56(3) 
C(7) 41(2)  73(3) 60(2)  38(2) -16(2)  -24(2) 
C(8) 26(2)  47(2) 45(2)  18(2) -7(1)  -11(1) 
C(9) 27(2)  37(2) 75(3)  22(2) 6(2)  8(1) 
C(10) 27(1)  30(2) 60(2)  5(1) 16(1)  5(1) 
C(11) 50(2)  33(2) 94(3)  -2(2) 40(2)  10(2) 
C(12) 67(2)  42(2) 82(3)  -21(2) 46(2)  -5(2) 
C(13) 53(2)  55(2) 45(2)  -14(2) 21(2)  -13(2) 
C(14) 34(2)  39(2) 38(2)  -4(1) 7(1)  -1(1) 
C(15) 25(1)  26(1) 36(2)  -1(1) 5(1)  1(1) 
N(21) 45(2)  34(1) 45(2)  2(1) 13(1)  12(1) 
C(21) 41(2)  33(2) 55(2)  0(1) 12(2)  8(1) 
N(22) 39(1)  32(1) 51(2)  0(1) 10(1)  12(1) 
C(23) 43(2)  36(2) 56(2)  -15(2) 7(2)  3(1) 
C(22) 40(2)  44(2) 45(2)  -8(1) 3(1)  11(1) 
N(31) 39(1)  31(1) 40(1)  6(1) 10(1)  4(1) 
C(31) 34(2)  37(2) 44(2)  6(1) 7(1)  5(1) 
N(32) 44(2)  29(1) 43(2)  4(1) 12(1)  1(1) 
C(32) 37(2)  37(2) 63(2)  13(2) 13(2)  7(1) 
C(33) 37(2)  38(2) 50(2)  11(1) 9(1)  0(1) 
N(51) 42(4)  69(4) 98(5)  -4(4) -7(4)  -2(5) 
C(52) 33(3)  42(3) 81(4)  -3(3) 17(3)  0(2) 
C(53) 52(5)  60(5) 59(4)  0(4) 19(3)  5(5) 
N(41) 28(6)  44(7) 121(10)  5(9) 28(6)  8(6) 
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C(41) 28(7)  55(8) 106(9)  10(9) 17(6)  0(6) 
N(42) 41(6)  35(5) 110(9)  1(6) 16(5)  1(4) 
C(42) 43(9)  52(10) 122(10)  -22(11) 32(7)  -8(10) 
C(43) 52(6)  50(7) 130(10)  -19(8) 37(7)  -6(6) 
 
 
Table 13. Hydrogen coordinates ( x 104) and isotropic displacement 
parameters (Å2x 103) for [Ag(imidH)2.3(CH3CN)0.7](9-aca). 
________________________________________________________________________________ 
 x  y  z  U(eq) 
________________________________________________________________________________ 
H(4) 5497 13325 3462 52 
H(5) 6435 13097 4851 75 
H(6) 7802 11770 5305 89 
H(7) 8270 10682 4360 74 
H(9) 8003 10157 2869 57 
H(11) 7751 9639 1402 67 
H(12) 6972 9909 15 71 
H(13) 5616 11249 -451 59 
H(14) 5036 12298 490 44 
H(21) 4561 6440 1690 51 
H(22) 4003 4810 1482 48 
H(23) 1488 4597 998 54 
H(22A) 480 6196 886 53 
H(31) 3930 10195 2014 46 
H(32) 2823 11698 1816 46 
H(32A) 354 11520 1158 54 
H(33) -25 9814 933 50 
H(53A) 7596 8622 3809 84 
H(53B) 6563 7981 4213 84 
H(53C) 6300 9091 4114 84 
H(41) 6251 8349 1980 75 
H(42) 7821 8607 3281 74 
H(42A) 6567 8586 4425 84 
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Table 14. Hydrogen bonds for [Ag(imidH)2.3(CH3CN)0.7](9-aca) [Å and °]. 
____________________________________________________________________________ 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________ 
 N(22)-H(22)...O(1)#2 0.88 1.87 2.745(3) 178.3 
 N(32)-H(32)...O(2) 0.88 1.89 2.752(3) 165.5 
 N(42)-H(42)...O(1)#3 0.88 1.86 2.734(10) 174.8 
Symmetry transformations used to generate equivalent atoms:  
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X-ray Crystal Data for [Ag6(imidH)4(9-aca)6(MeOH)2] 
 
Identification code  [Ag6(imidH)4(9-aca)6(MeOH)2] 
Empirical formula  C104 H78 Ag6 N8 O14 
Formula weight  2310.96 
Temperature  150(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  Pbcn 
Unit cell dimensions a = 20.6935(8) Å α = 90°. 
 b = 18.2786(7) Å β = 90°. 
 c = 23.6859(10) Å γ = 90°. 
Volume 8959.1(6) Å3 
Z 4 
Density (calculated) 1.713 Mg/m3 
Absorption coefficient 1.358 mm-1 
F(000) 4608 
Crystal size 0.23 x 0.15 x 0.12 mm3 
Crystal description Pale yellow block 
Theta range for data collection 1.72 to 27.00°. 
Index ranges -26<=h<=26, -23<=k<=23, -30<=l<=30 
Reflections collected 80667 
Independent reflections 9793 [R(int) = 0.0580] 
Completeness to theta = 27.00° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.8540 and 0.7453 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 9793 / 0 / 599 
Goodness-of-fit on F2 1.025 
Final R indices [I>2sigma(I)] R1 = 0.0316, wR2 = 0.0695 
R indices (all data) R1 = 0.0475, wR2 = 0.0765 
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Table 15. Atomic coordinates ( x 104) and equivalent isotropic displacement 
parameters (Å2x 103) for [Ag6(imidH)4(9-aca)6(MeOH)2].  U(eq) is defined as 
one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
Ag(1) 3180(1) 3749(1) 2564(1) 33(1) 
N(21) 3367(1) 2768(1) 2143(1) 35(1) 
C(21) 3206(2) 2092(2) 2290(1) 33(1) 
N(22) 3428(1) 1607(1) 1916(1) 35(1) 
C(22) 3748(2) 1981(2) 1506(2) 45(1) 
C(23) 3707(2) 2701(2) 1653(2) 43(1) 
N(31) 3086(1) 4761(1) 2964(1) 29(1) 
C(31) 3244(2) 5417(2) 2764(1) 31(1) 
N(32) 3143(1) 5930(1) 3155(1) 31(1) 
C(32) 2913(2) 5598(2) 3630(1) 34(1) 
C(33) 2878(2) 4876(2) 3510(1) 33(1) 
Ag(2) 1728(1) 4058(1) 2655(1) 37(1) 
O(1A) 1934(1) 4005(1) 1652(1) 34(1) 
O(2A) 1709(1) 5091(1) 2013(1) 33(1) 
C(1A) 1856(1) 4683(2) 1607(1) 27(1) 
C(2A) 1981(1) 5038(2) 1042(1) 24(1) 
C(3A) 2626(1) 5101(2) 865(1) 25(1) 
C(4A) 3156(1) 4820(2) 1183(1) 30(1) 
C(5A) 3772(2) 4897(2) 1001(1) 34(1) 
C(6A) 3907(2) 5260(2) 487(1) 38(1) 
C(7A) 3416(2) 5538(2) 170(1) 38(1) 
C(8A) 2760(2) 5476(2) 346(1) 30(1) 
C(9A) 2258(2) 5776(2) 34(1) 32(1) 
C(10A) 1616(1) 5712(2) 209(1) 28(1) 
C(11A) 1098(2) 6024(2) -104(1) 34(1) 
C(12A) 480(2) 5956(2) 72(2) 39(1) 
C(13A) 336(2) 5563(2) 573(1) 38(1) 
C(14A) 811(1) 5263(2) 887(1) 32(1) 
C(15A) 1472(1) 5329(2) 724(1) 25(1) 
O(1B) 1931(1) 3516(1) 3474(1) 33(1) 
O(2B) 1792(1) 2458(1) 3016(1) 31(1) 
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C(1B) 1860(1) 2833(2) 3455(1) 24(1) 
C(2B) 1831(1) 2442(1) 4021(1) 23(1) 
C(3B) 2394(1) 2324(1) 4338(1) 24(1) 
C(4B) 3017(2) 2579(2) 4172(1) 29(1) 
C(5B) 3548(2) 2437(2) 4489(1) 34(1) 
C(6B) 3501(2) 2032(2) 4998(1) 40(1) 
C(7B) 2920(2) 1778(2) 5174(1) 37(1) 
C(8B) 2343(2) 1920(2) 4859(1) 29(1) 
C(9B) 1739(2) 1682(2) 5042(1) 33(1) 
C(10B) 1179(1) 1835(2) 4742(1) 28(1) 
C(11B) 556(2) 1631(2) 4943(1) 36(1) 
C(12B) 15(2) 1807(2) 4652(1) 37(1) 
C(13B) 54(2) 2186(2) 4130(1) 34(1) 
C(14B) 640(2) 2376(2) 3918(1) 30(1) 
C(15B) 1225(1) 2216(1) 4212(1) 26(1) 
Ag(3) 676(1) 2496(1) 2356(1) 31(1) 
O(1C) 532(1) 3666(1) 2435(1) 37(1) 
C(1C) 0 3978(2) 2500 28(1) 
C(2C) 0 4795(2) 2500 30(1) 
C(3C) -385(2) 5168(2) 2109(1) 33(1) 
C(4C) -770(2) 4807(2) 1691(1) 35(1) 
C(5C) -1173(2) 5183(2) 1346(2) 43(1) 
C(6C) -1204(2) 5961(2) 1378(2) 48(1) 
C(7C) -819(2) 6328(2) 1740(2) 47(1) 
C(8C) -395(2) 5957(2) 2119(2) 38(1) 
C(9C) 0 6321(2) 2500 44(1) 
O(1D) 525(1) 1329(1) 2379(1) 34(1) 
C(1D) 0 1034(2) 2500 24(1) 
C(2D) 0 207(2) 2500 22(1) 
C(3D) -183(1) -166(1) 2008(1) 22(1) 
C(4D) -373(1) 211(2) 1506(1) 26(1) 
C(5D) -547(1) -163(2) 1038(1) 30(1) 
C(6D) -533(2) -942(2) 1039(1) 32(1) 
C(7D) -357(2) -1315(2) 1504(1) 31(1) 
C(8D) -178(1) -953(2) 2011(1) 24(1) 
C(9D) 0 -1325(2) 2500 27(1) 
O(41) 1363(1) 2639(1) 1511(1) 36(1) 
C(41) 1810(2) 2046(2) 1403(2) 55(1) 
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Table 16. Bond lengths [Å] and angles [°] for [Ag6(imidH)4(9-aca)6(MeOH)2]. 
Ag(1)-N(21)  2.088(2) 
Ag(1)-N(31)  2.089(2) 
Ag(1)-Ag(2)  3.0651(4) 
N(21)-C(21)  1.325(4) 
N(21)-C(23)  1.363(4) 
C(21)-N(22)  1.336(4) 
N(22)-C(22)  1.360(4) 
C(22)-C(23)  1.363(4) 
N(31)-C(31)  1.330(4) 
N(31)-C(33)  1.379(4) 
C(31)-N(32)  1.334(4) 
N(32)-C(32)  1.363(4) 
C(32)-C(33)  1.353(4) 
Ag(2)-O(1B)  2.218(2) 
Ag(2)-O(1A)  2.416(2) 
Ag(2)-O(2A)  2.424(2) 
O(1A)-C(1A)  1.254(3) 
O(2A)-C(1A)  1.254(3) 
C(1A)-C(2A)  1.510(4) 
C(2A)-C(15A)  1.400(4) 
C(2A)-C(3A)  1.404(4) 
C(3A)-C(4A)  1.427(4) 
C(3A)-C(8A)  1.434(4) 
C(4A)-C(5A)  1.352(4) 
C(5A)-C(6A)  1.415(4) 
C(6A)-C(7A)  1.360(5) 
C(7A)-C(8A)  1.425(4) 
C(8A)-C(9A)  1.387(4) 
C(9A)-C(10A)  1.396(4) 
C(10A)-C(11A)  1.422(4) 
C(10A)-C(15A)  1.438(4) 
C(11A)-C(12A)  1.351(4) 
C(12A)-C(13A)  1.419(5) 
C(13A)-C(14A)  1.349(4) 
C(14A)-C(15A)  1.427(4) 
O(1B)-C(1B)  1.258(3) 
O(2B)-C(1B)  1.253(3) 
O(2B)-Ag(3)  2.789(2) 
C(1B)-C(2B)  1.520(4) 
C(2B)-C(15B)  1.396(4) 
C(2B)-C(3B)  1.403(4) 
C(3B)-C(4B)  1.426(4) 
C(3B)-C(8B)  1.442(4) 
C(4B)-C(5B)  1.357(4) 
C(5B)-C(6B)  1.418(4) 
C(6B)-C(7B)  1.354(5) 
C(7B)-C(8B)  1.432(4) 
C(8B)-C(9B)  1.393(4) 
C(9B)-C(10B)  1.388(4) 
C(10B)-C(11B)  1.424(4) 
C(10B)-C(15B)  1.437(4) 
C(11B)-C(12B)  1.352(4) 
C(12B)-C(13B)  1.420(4) 
C(13B)-C(14B)  1.359(4) 
C(14B)-C(15B)  1.427(4) 
Ag(3)-O(1D)  2.1574(19) 
Ag(3)-O(1C)  2.1681(19) 
Ag(3)-O(41)  2.467(2) 
Ag(3)-Ag(3)#1  2.8818(5) 
O(1C)-C(1C)  1.248(3) 
C(1C)-O(1C)#1  1.248(3) 
C(1C)-C(2C)  1.494(5) 
C(2C)-C(3C)#1  1.398(4) 
C(2C)-C(3C)  1.398(4) 
C(3C)-C(4C)  1.432(5) 
C(3C)-C(8C)  1.443(4) 
C(4C)-C(5C)  1.356(5) 
C(5C)-C(6C)  1.426(5) 
C(6C)-C(7C)  1.349(5) 
C(7C)-C(8C)  1.426(5) 
C(8C)-C(9C)  1.388(4) 
C(9C)-C(8C)#1  1.388(4) 
O(1D)-C(1D)  1.246(3) 
C(1D)-O(1D)#1  1.246(3) 
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C(1D)-C(2D)  1.512(5) 
C(2D)-C(3D)  1.402(3) 
C(2D)-C(3D)#1  1.402(3) 
C(3D)-C(4D)  1.430(4) 
C(3D)-C(8D)  1.439(4) 
C(4D)-C(5D)  1.351(4) 
C(5D)-C(6D)  1.424(4) 
C(6D)-C(7D)  1.346(4) 
C(7D)-C(8D)  1.418(4) 
C(8D)-C(9D)  1.393(3) 
C(9D)-C(8D)#1  1.393(3) 





































































































































Symmetry transformations used to generate equivalent atoms: 
#1 -x,y,-z+1/2      
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Table 17. Anisotropic displacement parameters (Å2x 103) for [Ag6(imidH)4(9-
aca)6(MeOH)2].  The anisotropic displacement factor exponent takes the form: -
22[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
______________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
______________________________________________________________________________ 
Ag(1) 42(1)  20(1) 36(1)  -6(1) 1(1)  2(1) 
N(21) 44(2)  23(1) 38(2)  -8(1) 2(1)  0(1) 
C(21) 39(2)  24(2) 36(2)  -4(1) -1(1)  1(1) 
N(22) 43(2)  22(1) 39(2)  -4(1) -4(1)  2(1) 
C(22) 56(2)  33(2) 45(2)  -12(2) 10(2)  0(2) 
C(23) 52(2)  31(2) 45(2)  -5(2) 10(2)  -6(2) 
N(31) 33(1)  22(1) 33(1)  -5(1) 0(1)  0(1) 
C(31) 38(2)  23(2) 32(2)  -2(1) 1(1)  -2(1) 
N(32) 37(2)  16(1) 40(2)  -2(1) -4(1)  -2(1) 
C(32) 38(2)  27(2) 39(2)  -6(1) 6(1)  -1(1) 
C(33) 38(2)  27(2) 35(2)  -3(1) 4(1)  -2(1) 
Ag(2) 36(1)  44(1) 31(1)  17(1) -2(1)  -8(1) 
O(1A) 47(1)  22(1) 34(1)  6(1) 6(1)  -3(1) 
O(2A) 46(1)  28(1) 23(1)  1(1) 7(1)  -1(1) 
C(1A) 26(2)  28(2) 26(2)  3(1) 1(1)  -5(1) 
C(2A) 34(2)  18(1) 22(1)  -2(1) 3(1)  -6(1) 
C(3A) 33(2)  21(1) 22(1)  -3(1) 4(1)  -3(1) 
C(4A) 40(2)  24(2) 25(2)  1(1) 2(1)  -3(1) 
C(5A) 33(2)  33(2) 37(2)  -3(1) -3(1)  -2(1) 
C(6A) 30(2)  41(2) 43(2)  1(2) 12(1)  -5(1) 
C(7A) 39(2)  39(2) 36(2)  6(2) 14(2)  -5(2) 
C(8A) 36(2)  24(2) 29(2)  1(1) 6(1)  -3(1) 
C(9A) 42(2)  29(2) 26(2)  6(1) 6(1)  -4(1) 
C(10A) 38(2)  21(1) 25(2)  0(1) 2(1)  -1(1) 
C(11A) 43(2)  27(2) 33(2)  6(1) -1(1)  0(1) 
C(12A) 40(2)  36(2) 43(2)  0(2) -8(2)  6(2) 
C(13A) 28(2)  41(2) 45(2)  0(2) 3(1)  -1(1) 
C(14A) 33(2)  31(2) 31(2)  2(1) 5(1)  -3(1) 
C(15A) 33(2)  20(1) 23(1)  -1(1) 2(1)  -1(1) 
O(1B) 55(1)  20(1) 25(1)  5(1) -4(1)  -6(1) 
O(2B) 48(1)  24(1) 21(1)  -2(1) -1(1)  2(1) 
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C(1B) 29(2)  19(1) 24(1)  3(1) 1(1)  0(1) 
C(2B) 39(2)  12(1) 19(1)  -2(1) 2(1)  0(1) 
C(3B) 36(2)  16(1) 22(1)  -2(1) -1(1)  -1(1) 
C(4B) 40(2)  20(1) 26(2)  -1(1) 4(1)  -2(1) 
C(5B) 36(2)  29(2) 38(2)  -3(1) -1(1)  -5(1) 
C(6B) 41(2)  36(2) 44(2)  0(2) -13(2)  -3(2) 
C(7B) 50(2)  33(2) 29(2)  6(1) -7(2)  -3(2) 
C(8B) 43(2)  22(2) 23(2)  2(1) -4(1)  -3(1) 
C(9B) 46(2)  27(2) 25(2)  7(1) 1(1)  -5(1) 
C(10B) 38(2)  21(1) 25(2)  2(1) 4(1)  -2(1) 
C(11B) 43(2)  33(2) 33(2)  5(1) 7(2)  -5(1) 
C(12B) 37(2)  35(2) 40(2)  -1(1) 9(2)  -4(1) 
C(13B) 36(2)  30(2) 36(2)  -2(1) -3(1)  1(1) 
C(14B) 38(2)  26(2) 25(2)  1(1) -1(1)  1(1) 
C(15B) 38(2)  15(1) 24(1)  -1(1) 2(1)  0(1) 
Ag(3) 41(1)  16(1) 37(1)  -1(1) 6(1)  0(1) 
O(1C) 30(1)  17(1) 65(2)  -5(1) 8(1)  -1(1) 
C(1C) 32(2)  16(2) 36(2)  0 7(2)  0 
C(2C) 37(2)  14(2) 40(2)  0 13(2)  0 
C(3C) 34(2)  20(2) 46(2)  5(1) 18(1)  1(1) 
C(4C) 38(2)  22(2) 46(2)  5(1) 12(2)  2(1) 
C(5C) 37(2)  40(2) 51(2)  7(2) 15(2)  4(2) 
C(6C) 48(2)  37(2) 60(2)  16(2) 12(2)  11(2) 
C(7C) 53(2)  23(2) 64(3)  11(2) 20(2)  7(2) 
C(8C) 44(2)  19(2) 51(2)  7(1) 19(2)  4(1) 
C(9C) 51(3)  16(2) 63(3)  0 19(3)  0 
O(1D) 34(1)  16(1) 51(1)  3(1) 5(1)  -1(1) 
C(1D) 35(2)  19(2) 18(2)  0 -5(2)  0 
C(2D) 22(2)  17(2) 28(2)  0 0(2)  0 
C(3D) 25(1)  18(1) 24(1)  -2(1) 0(1)  0(1) 
C(4D) 28(2)  23(1) 27(2)  2(1) -1(1)  0(1) 
C(5D) 30(2)  32(2) 27(2)  2(1) -4(1)  3(1) 
C(6D) 38(2)  31(2) 28(2)  -9(1) -4(1)  3(1) 
C(7D) 39(2)  21(2) 34(2)  -6(1) -4(1)  4(1) 
C(8D) 25(1)  19(1) 29(2)  -3(1) 1(1)  1(1) 
C(9D) 36(2)  11(2) 34(2)  0 -1(2)  0 
O(41) 38(1)  33(1) 39(1)  -5(1) 6(1)  -8(1) 
C(41) 46(2)  61(3) 59(3)  0(2) 3(2)  15(2) 
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Table 18.  Hydrogen coordinates ( x 104) and isotropic displacement 
parameters (Å2x 103) for [Ag6(imidH)4(9-aca)6(MeOH)2]. 
________________________________________________________________________________ 
 x  y  z  U(eq) 
________________________________________________________________________________ 
H(21) 2965 1970 2618 40 
H(22N) 3377 1129 1931 41 
H(22) 3957 1783 1183 54 
H(23) 3887 3096 1445 51 
H(31) 3407 5508 2396 37 
H(32N) 3212 6402 3114 37 
H(32) 2800 5828 3976 41 
H(33) 2732 4506 3762 40 
H(4A) 3075 4575 1529 36 
H(5A) 4117 4706 1221 41 
H(6A) 4341 5310 362 46 
H(7A) 3513 5778 -175 46 
H(9A) 2353 6030 -306 39 
H(11A) 1188 6283 -442 41 
H(12A) 140 6172 -141 47 
H(13A) -101 5510 689 46 
H(14A) 703 5005 1222 38 
H(4B) 3061 2852 3833 35 
H(5B) 3958 2613 4369 41 
H(6B) 3878 1937 5215 48 
H(7B) 2895 1501 5513 45 
H(9B) 1710 1408 5382 39 
H(11B) 520 1368 5287 44 
H(12B) -396 1675 4800 45 
H(13B) -329 2306 3930 41 
H(14B) 662 2621 3564 36 
H(4C) -741 4290 1655 42 
H(5C) -1435 4927 1082 51 
H(6C) -1497 6222 1144 58 
H(7C) -831 6847 1743 56 
H(9C) 0 6841 2500 52 
H(4D) -377 730 1501 31 
H(5D) -679 93 709 36 
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H(6D) -650 -1202 707 39 
H(7D) -351 -1834 1493 37 
H(9D) 0 -1844 2500 32 
H(41) 1683 3006 1534 44 
H(41A) 2035 1919 1754 83 
H(41B) 2126 2199 1119 83 
H(41C) 1572 1619 1265 83 
 
 
Table 19. Hydrogen bonds for [Ag6(imidH)4(9-aca)6(MeOH)2] [Å and °]. 
____________________________________________________________________________ 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________ 
 N(22)-H(22N)...O(2A)#2 0.88 1.92 2.796(3) 176.3 
 N(32)-H(32N)...O(2B)#3 0.88 1.94 2.815(3) 170.4 
 O(41)-H(41)...O(1A) 0.94 1.92 2.782(3) 150.9 
Symmetry transformations used to generate equivalent atoms:  
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X-ray Crystal Data for [Ag(1-Me-imid)2]2[Ag4(9-aca)6] 
 
Identification code  [Ag(1-Me-imid)2]2[Ag4(9-aca)6] 
Empirical formula  C106 H78 Ag6 N8 O12 
Formula weight  2302.98 
Temperature  150(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 11.7251(17) Å α = 111.403(2)°. 
 b = 17.908(3) Å β = 90.095(2)°. 
 c = 23.464(3) Å γ = 101.710(2)°. 
Volume 4476.2(11) Å3 
Z 2 
Density (calculated) 1.709 Mg/m3 
Absorption coefficient 1.357 mm-1 
F(000) 2296 
Crystal size 0.43 x 0.32 x 0.06 mm3 
Crystal description colourless plate 
Theta range for data collection 1.78 to 25.00°. 
Index ranges -13<=h<=13, -21<=k<=21, -27<=l<=27 
Reflections collected 35083 
Independent reflections 15686 [R(int) = 0.0421] 
Completeness to theta = 25.00° 99.5 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9230 and 0.5930 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 15686 / 0 / 1224 
Goodness-of-fit on F2 1.046 
Final R indices [I>2sigma(I)] R1 = 0.0512, wR2 = 0.1262 
R indices (all data) R1 = 0.0706, wR2 = 0.1370 
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Table 20. Atomic coordinates ( x 104) and equivalent isotropic displacement 
parameters (Å2x 103) for [Ag(1-Me-imid)2]2[Ag4(9-aca)6]. U(eq) is defined as 
one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
Ag(1) 5320(1) 854(1) 268(1) 19(1) 
Ag(2) 3367(1) -33(1) 769(1) 27(1) 
O(11A) 4961(4) 1820(3) 1181(2) 36(1) 
O(12A) 3128(4) 1219(3) 1249(2) 28(1) 
C(11A) 3989(6) 1823(4) 1389(3) 26(2) 
C(12A) 3842(6) 2622(4) 1886(3) 25(2) 
C(13A) 4587(6) 2964(4) 2432(3) 24(1) 
C(14A) 5469(7) 2594(4) 2551(3) 34(2) 
C(15A) 6173(7) 2941(5) 3081(4) 42(2) 
C(16A) 6045(7) 3695(5) 3527(4) 44(2) 
C(17A) 5214(7) 4072(5) 3443(3) 41(2) 
C(18A) 4442(6) 3718(4) 2889(3) 31(2) 
C(19A) 3600(6) 4108(4) 2788(3) 33(2) 
C(20A) 2873(6) 3785(4) 2244(3) 32(2) 
C(21A) 2020(7) 4196(5) 2136(4) 43(2) 
C(22A) 1349(7) 3884(5) 1600(4) 44(2) 
C(23A) 1412(7) 3151(4) 1163(4) 39(2) 
C(24A) 2251(6) 2727(4) 1225(3) 32(2) 
C(25A) 2986(6) 3019(4) 1778(3) 28(2) 
O(11B) 6478(4) 1952(3) 40(2) 25(1) 
O(12B) 6613(4) 1156(3) -938(2) 24(1) 
C(11B) 6508(5) 1820(4) -526(3) 22(1) 
C(12B) 6410(5) 2508(4) -740(3) 21(1) 
C(13B) 5553(5) 2362(4) -1215(3) 21(1) 
C(14B) 4713(6) 1597(4) -1474(3) 24(1) 
C(15B) 3882(6) 1489(5) -1918(3) 32(2) 
C(16B) 3816(6) 2113(5) -2139(3) 35(2) 
C(17B) 4591(6) 2853(5) -1899(3) 35(2) 
C(18B) 5471(6) 2994(4) -1433(3) 26(2) 
C(19B) 6268(6) 3750(4) -1178(3) 30(2) 
C(20B) 7106(6) 3913(4) -704(3) 29(2) 
C(21B) 7878(7) 4694(4) -437(3) 35(2) 
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C(22B) 8641(7) 4870(5) 48(4) 42(2) 
C(23B) 8716(7) 4249(5) 280(4) 41(2) 
C(24B) 8024(6) 3490(4) 25(3) 28(2) 
C(25B) 7172(5) 3283(4) -467(3) 21(1) 
O(11C) 7010(4) 574(3) 522(2) 30(1) 
O(12C) 6234(4) -740(3) 345(2) 31(1) 
C(11C) 6982(5) -91(4) 585(3) 20(1) 
C(12C) 7946(5) -123(4) 998(3) 22(1) 
C(13C) 7885(5) 196(4) 1627(3) 22(1) 
C(14C) 6969(5) 596(4) 1909(3) 25(2) 
C(15C) 6931(6) 885(4) 2525(3) 29(2) 
C(16C) 7766(6) 792(4) 2922(3) 31(2) 
C(17C) 8641(6) 403(4) 2669(3) 29(2) 
C(18C) 8745(5) 106(4) 2019(3) 24(1) 
C(19C) 9655(6) -263(4) 1766(3) 26(2) 
C(20C) 9754(5) -544(4) 1137(3) 25(2) 
C(21C) 10697(6) -911(4) 870(3) 31(2) 
C(22C) 10776(6) -1195(4) 249(3) 31(2) 
C(23C) 9910(6) -1138(4) -147(3) 30(2) 
C(24C) 8977(6) -797(4) 90(3) 26(2) 
C(25C) 8869(5) -489(4) 732(3) 23(1) 
Ag(3) 10314(1) 856(1) 5225(1) 19(1) 
Ag(4) 8434(1) -5(1) 4201(1) 28(1) 
O(11D) 11491(4) 1942(3) 6072(2) 24(1) 
O(12D) 11589(4) 1131(3) 6591(2) 25(1) 
C(11D) 11523(5) 1806(4) 6554(3) 18(1) 
C(12D) 11470(5) 2500(4) 7155(3) 19(1) 
C(13D) 12309(6) 3248(4) 7327(3) 22(1) 
C(14D) 13242(6) 3392(4) 6958(3) 28(2) 
C(15D) 14058(7) 4104(5) 7154(3) 39(2) 
C(16D) 14040(7) 4731(5) 7741(4) 45(2) 
C(17D) 13160(7) 4616(4) 8105(3) 38(2) 
C(18D) 12277(6) 3883(4) 7910(3) 27(2) 
C(19D) 11382(6) 3766(4) 8274(3) 31(2) 
C(20D) 10530(6) 3044(4) 8108(3) 27(2) 
C(21D) 9613(6) 2943(4) 8492(3) 31(2) 
C(22D) 8802(6) 2229(5) 8314(3) 34(2) 
C(23D) 8826(6) 1571(4) 7754(3) 29(2) 
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C(24D) 9687(6) 1652(4) 7376(3) 25(1) 
C(25D) 10581(5) 2392(4) 7539(3) 20(1) 
O(11E) 8759(4) 720(3) 5753(2) 38(1) 
O(12E) 8036(4) -602(3) 5218(2) 35(1) 
C(11E) 8026(5) 56(4) 5635(3) 20(1) 
C(12E) 7053(5) 73(4) 6061(3) 20(1) 
C(13E) 6120(5) 428(4) 6001(3) 23(1) 
C(14E) 6018(6) 753(4) 5530(3) 25(1) 
C(15E) 5077(6) 1086(4) 5487(3) 29(2) 
C(16E) 4196(6) 1112(4) 5903(3) 30(2) 
C(17E) 4270(6) 814(4) 6365(3) 33(2) 
C(18E) 5236(6) 462(4) 6423(3) 25(2) 
C(19E) 5343(6) 168(4) 6890(3) 30(2) 
C(20E) 6273(6) -178(4) 6960(3) 28(2) 
C(21E) 6394(6) -472(5) 7439(3) 35(2) 
C(22E) 7288(6) -833(4) 7474(3) 34(2) 
C(23E) 8147(6) -911(4) 7035(3) 30(2) 
C(24E) 8076(6) -618(4) 6580(3) 26(2) 
C(25E) 7152(5) -235(4) 6520(3) 22(1) 
O(11F) 9953(4) 1868(3) 4899(3) 42(1) 
O(12F) 8162(4) 1238(3) 4428(2) 27(1) 
C(11F) 8988(6) 1848(4) 4654(3) 26(2) 
C(12F) 8833(6) 2669(4) 4653(3) 24(1) 
C(13F) 7977(6) 3053(4) 4984(3) 25(2) 
C(14F) 7210(6) 2688(4) 5327(3) 31(2) 
C(15F) 6416(6) 3082(5) 5665(3) 34(2) 
C(16F) 6316(7) 3860(5) 5665(3) 38(2) 
C(17F) 7028(7) 4232(4) 5346(3) 35(2) 
C(18F) 7876(6) 3833(4) 4986(3) 31(2) 
C(19F) 8633(6) 4214(4) 4667(3) 34(2) 
C(20F) 9453(6) 3840(4) 4329(3) 33(2) 
C(21F) 10220(7) 4219(5) 3986(3) 38(2) 
C(22F) 11059(7) 3852(5) 3675(4) 47(2) 
C(23F) 11174(7) 3079(5) 3661(4) 43(2) 
C(24F) 10468(6) 2689(5) 3972(3) 35(2) 
C(25F) 9581(6) 3048(4) 4316(3) 26(2) 
Ag(5) 6087(1) 3184(1) 996(1) 38(1) 
C(1A) 7975(7) 2597(5) 1516(4) 39(2) 
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N(1A) 7507(6) 3219(4) 1587(3) 40(2) 
C(2A) 8024(8) 3830(6) 2144(4) 51(2) 
C(3A) 8800(7) 3544(5) 2383(4) 48(2) 
N(2A) 8768(6) 2764(4) 1990(3) 39(2) 
C(4A) 9488(8) 2216(5) 2058(4) 52(2) 
C(1B) 3948(7) 2747(5) 72(4) 37(2) 
N(1B) 4765(6) 3350(4) 462(3) 40(2) 
C(2B) 4632(9) 4040(5) 351(5) 56(2) 
C(3B) 3755(8) 3842(5) -78(5) 57(3) 
N(2B) 3329(6) 3022(4) -245(3) 39(2) 
C(4B) 2339(8) 2530(6) -695(4) 55(2) 
Ag(6) 10995(1) 3224(1) 5936(1) 39(1) 
C(1C) 12817(7) 2674(5) 5025(4) 39(2) 
N(1C) 12409(5) 3310(4) 5379(3) 39(2) 
C(2C) 13026(7) 3963(5) 5248(4) 39(2) 
C(3C) 13785(7) 3705(5) 4832(4) 47(2) 
N(2C) 13644(5) 2873(4) 4686(3) 38(2) 
C(4C) 14282(7) 2348(5) 4260(4) 48(2) 
C(1D) 8800(7) 2719(5) 6524(3) 35(2) 
N(1D) 9631(6) 3334(4) 6548(3) 40(2) 
C(2D) 9474(9) 3999(5) 7038(5) 63(3) 
C(3D) 8537(8) 3751(5) 7314(5) 55(2) 
N(2D) 8105(6) 2932(4) 6985(3) 38(2) 
C(4D) 7059(7) 2423(6) 7093(4) 51(2) 
*Ag(11) 11649(12) 53(8) 238(6) 30 
*Ag(12) 9686(12) -836(8) -763(6) 30 
*Ag(13) 9657(12) -875(8) 332(7) 30 
*Ag(14) 11623(12) 16(8) 1337(6) 30 
*Ag(15) 5283(12) 858(8) 4693(6) 30 
*Ag(16) 3412(12) -7(8) 5250(6) 30 
*Ag(17) 6546(12) 17(8) 3647(6) 30 
*Ag(18) 4699(13) -856(9) 4212(7) 30 
*Ag(19) 5969(12) 3237(9) 5277(6) 30 
*Ag(20) 8908(12) -3192(8) -185(6) 30 
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Table 21.  Bond lengths [Å] and angles [°] for [Ag(1-Me-imid)2]2[Ag4(9-aca)6]. 
Ag(1)-O(12C)#1  2.248(4) 
Ag(1)-O(11C)  2.270(4) 
Ag(1)-O(11A)  2.314(5) 
Ag(1)-O(11B)  2.383(4) 
Ag(1)-Ag(1)#1  2.7860(10) 
Ag(1)-Ag(2)#1  2.9621(7) 
Ag(1)-Ag(2)  3.0085(7) 
Ag(2)-O(12A)  2.188(4) 
Ag(2)-O(12B)#1  2.190(4) 
Ag(2)-Ag(1)#1  2.9621(7) 
O(11A)-C(11A)  1.241(8) 
O(11A)-Ag(5)  2.713(5) 
O(12A)-C(11A)  1.262(8) 
C(11A)-C(12A)  1.523(9) 
C(12A)-C(13A)  1.409(10) 
C(12A)-C(25A)  1.414(9) 
C(13A)-C(14A)  1.414(10) 
C(13A)-C(18A)  1.428(9) 
C(14A)-C(15A)  1.356(11) 
C(15A)-C(16A)  1.411(11) 
C(16A)-C(17A)  1.344(11) 
C(17A)-C(18A)  1.440(10) 
C(18A)-C(19A)  1.386(10) 
C(19A)-C(20A)  1.394(10) 
C(20A)-C(21A)  1.429(10) 
C(20A)-C(25A)  1.440(9) 
C(21A)-C(22A)  1.348(12) 
C(22A)-C(23A)  1.356(11) 
C(23A)-C(24A)  1.396(10) 
C(24A)-C(25A)  1.421(10) 
O(11B)-C(11B)  1.264(8) 
O(11B)-Ag(5)  2.629(4) 
O(12B)-C(11B)  1.259(8) 
O(12B)-Ag(2)#1  2.190(4) 
C(11B)-C(12B)  1.513(9) 
C(12B)-C(25B)  1.407(9) 
C(12B)-C(13B)  1.414(9) 
C(13B)-C(18B)  1.420(9) 
C(13B)-C(14B)  1.435(9) 
C(14B)-C(15B)  1.358(9) 
C(15B)-C(16B)  1.408(10) 
C(16B)-C(17B)  1.366(11) 
C(17B)-C(18B)  1.419(10) 
C(18B)-C(19B)  1.399(10) 
C(19B)-C(20B)  1.389(10) 
C(20B)-C(21B)  1.419(10) 
C(20B)-C(25B)  1.443(9) 
C(21B)-C(22B)  1.346(11) 
C(22B)-C(23B)  1.424(11) 
C(23B)-C(24B)  1.349(10) 
C(24B)-C(25B)  1.416(9) 
O(11C)-C(11C)  1.246(8) 
O(12C)-C(11C)  1.242(8) 
O(12C)-Ag(1)#1  2.248(4) 
C(11C)-C(12C)  1.512(8) 
C(12C)-C(13C)  1.381(9) 
C(12C)-C(25C)  1.409(9) 
C(13C)-C(18C)  1.435(9) 
C(13C)-C(14C)  1.441(9) 
C(14C)-C(15C)  1.349(9) 
C(15C)-C(16C)  1.427(9) 
C(16C)-C(17C)  1.371(10) 
C(17C)-C(18C)  1.435(9) 
C(18C)-C(19C)  1.390(9) 
C(19C)-C(20C)  1.388(9) 
C(20C)-C(21C)  1.430(9) 
C(20C)-C(25C)  1.448(9) 
C(21C)-C(22C)  1.366(10) 
C(22C)-C(23C)  1.419(10) 
C(23C)-C(24C)  1.380(9) 
C(24C)-C(25C)  1.417(9) 
Ag(3)-O(11E)  2.228(5) 
Ag(3)-O(12E)#2  2.248(5) Ag(3)-O(11F)  2.318(5) 
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Ag(3)-O(11D)  2.392(4) 
Ag(3)-Ag(3)#2  2.7892(10) 
Ag(3)-Ag(4)#2  2.9493(7) 
Ag(3)-Ag(4)  2.9843(8) 
Ag(4)-O(12F)  2.183(4) 
Ag(4)-O(12D)#2  2.183(4) 
Ag(4)-Ag(3)#2  2.9493(7) 
O(11D)-C(11D)  1.241(7) 
O(11D)-Ag(6)  2.607(4) 
O(12D)-C(11D)  1.260(7) 
O(12D)-Ag(4)#2  2.183(4) 
C(11D)-C(12D)  1.514(8) 
C(12D)-C(25D)  1.408(9) 
C(12D)-C(13D)  1.412(9) 
C(13D)-C(18D)  1.431(9) 
C(13D)-C(14D)  1.437(9) 
C(14D)-C(15D)  1.352(10) 
C(15D)-C(16D)  1.429(11) 
C(16D)-C(17D)  1.371(11) 
C(17D)-C(18D)  1.418(10) 
C(18D)-C(19D)  1.386(10) 
C(19D)-C(20D)  1.389(10) 
C(20D)-C(25D)  1.428(9) 
C(20D)-C(21D)  1.430(10) 
C(21D)-C(22D)  1.353(10) 
C(22D)-C(23D)  1.413(10) 
C(23D)-C(24D)  1.366(9) 
C(24D)-C(25D)  1.438(9) 
O(11E)-C(11E)  1.254(8) 
O(12E)-C(11E)  1.229(8) 
O(12E)-Ag(3)#2  2.248(4) 
C(11E)-C(12E)  1.515(8) 
C(12E)-C(25E)  1.392(9) 
C(12E)-C(13E)  1.402(9) 
C(13E)-C(18E)  1.428(9) 
C(13E)-C(14E)  1.440(9) 
C(14E)-C(15E)  1.375(9) 
C(15E)-C(16E)  1.419(10) 
C(16E)-C(17E)  1.382(10) 
C(17E)-C(18E)  1.431(9) 
C(18E)-C(19E)  1.394(10) 
C(19E)-C(20E)  1.395(10) 
C(20E)-C(21E)  1.422(10) 
C(20E)-C(25E)  1.452(9) 
C(21E)-C(22E)  1.354(10) 
C(22E)-C(23E)  1.432(10) 
C(23E)-C(24E)  1.360(10) 
C(24E)-C(25E)  1.427(9) 
O(11F)-C(11F)  1.257(8) 
O(11F)-Ag(6)  2.790(5) 
O(12F)-C(11F)  1.248(8) 
C(11F)-C(12F)  1.518(9) 
C(12F)-C(13F)  1.405(9) 
C(12F)-C(25F)  1.417(9) 
C(13F)-C(18F)  1.424(9) 
C(13F)-C(14F)  1.426(10) 
C(14F)-C(15F)  1.361(10) 
C(15F)-C(16F)  1.422(10) 
C(16F)-C(17F)  1.358(11) 
C(17F)-C(18F)  1.437(10) 
C(18F)-C(19F)  1.393(10) 
C(19F)-C(20F)  1.371(11) 
C(20F)-C(21F)  1.440(10) 
C(20F)-C(25F)  1.445(9) 
C(21F)-C(22F)  1.358(12) 
C(22F)-C(23F)  1.407(12) 
C(23F)-C(24F)  1.359(11) 
C(24F)-C(25F)  1.429(10) 
Ag(5)-N(1B)  2.125(7) 
Ag(5)-N(1A)  2.141(7) 
C(1A)-N(1A)  1.296(10) 
C(1A)-N(2A)  1.354(10) 
N(1A)-C(2A)  1.398(10) 
C(2A)-C(3A)  1.343(12) 
C(3A)-N(2A)  1.357(10) 
N(2A)-C(4A)  1.468(10) 
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C(1B)-N(2B)  1.316(9) 
C(1B)-N(1B)  1.334(10) 
N(1B)-C(2B)  1.391(10) 
C(2B)-C(3B)  1.336(13) 
C(3B)-N(2B)  1.356(11) 
N(2B)-C(4B)  1.464(11) 
Ag(6)-N(1C)  2.127(7) 
Ag(6)-N(1D)  2.143(7) 
C(1C)-N(1C)  1.323(10) 
C(1C)-N(2C)  1.330(10) 
N(1C)-C(2C)  1.381(9) 
C(2C)-C(3C)  1.342(12) 
C(3C)-N(2C)  1.375(10) 
N(2C)-C(4C)  1.430(10) 
C(1D)-N(1D)  1.298(10) 
C(1D)-N(2D)  1.344(9) 
N(1D)-C(2D)  1.366(11) 
C(2D)-C(3D)  1.356(13) 
C(3D)-N(2D)  1.369(10) 
N(2D)-C(4D)  1.455(11) 
Ag(11)-Ag(12)#3  2.360(19) 
Ag(11)-Ag(14)  2.606(19) 
Ag(11)-Ag(13)  2.639(19) 
Ag(11)-Ag(13)#3  2.94(2) 
Ag(11)-Ag(12)  3.019(19) 
Ag(12)-Ag(11)#3  2.361(19) 
Ag(12)-Ag(13)  2.596(19) 
Ag(12)-Ag(13)#3  2.791(19) 
Ag(12)-Ag(14)#3  2.947(19) 
Ag(13)-Ag(12)#3  2.791(19) 
Ag(13)-Ag(11)#3  2.94(2) 
Ag(13)-Ag(14)  3.03(2) 
Ag(14)-Ag(12)#3  2.947(19) 
Ag(15)-Ag(16)#4  2.403(19) 
Ag(15)-Ag(18)#4  2.57(2) 
Ag(15)-Ag(18)  2.79(2) 
Ag(15)-Ag(17)  2.951(19) 
Ag(15)-Ag(16)  3.003(19) 
Ag(16)-Ag(15)#4  2.403(19) 
Ag(16)-Ag(18)#4  2.46(2) 
Ag(16)-Ag(17)#4  2.597(19) 
Ag(16)-Ag(18)  2.96(2) 
Ag(17)-Ag(16)#4  2.597(19) 
Ag(17)-Ag(18)  3.01(2) 





























Ag(1)#1-Ag(2)-Ag(1) 55.62(2) C(11A)-O(11A)-Ag(1) 124.5(4) 












































































C(17C)-C(16C)-C(15C) 118.7(6) C(16C)-C(17C)-C(18C) 121.5(6) 












































































O(12E)-C(11E)-O(11E) 126.4(6) O(12E)-C(11E)-C(12E) 117.5(5) 












































































C(2B)-N(1B)-Ag(5) 130.7(6) C(3B)-C(2B)-N(1B) 110.5(8) 












































































Ag(15)#4-Ag(16)-Ag(18) 56.1(5) Ag(18)#4-Ag(16)-Ag(18) 88.4(6) 




















Symmetry transformations used to generate equivalent atoms:  
#1 -x+1,-y,-z    #2 -x+2,-y,-z+1    #3 -x+2,-y,-z     #4 -x+1,-y,-z+1      
 
 
Table 22. Anisotropic displacement parameters (Å2x 103)for [Ag(1-Me-
imid)2]2[Ag4(9-aca)6]. The anisotropic displacement factor exponent takes the 
form: -2π2[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
______________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
______________________________________________________________________________ 
Ag(1) 17(1)  20(1) 20(1)  7(1) 1(1)  6(1) 
Ag(2) 31(1)  21(1) 32(1)  9(1) 8(1)  10(1) 
O(11A) 28(3)  30(3) 35(3)  -3(2) 8(2)  6(2) 
O(12A) 29(3)  19(2) 33(3)  7(2) 8(2)  4(2) 
C(11A) 31(4)  20(3) 24(4)  4(3) 3(3)  7(3) 
C(12A) 30(4)  21(3) 23(3)  7(3) 13(3)  4(3) 
C(13A) 23(3)  19(3) 28(4)  6(3) 15(3)  4(3) 
C(14A) 40(4)  27(4) 31(4)  5(3) 6(3)  9(3) 
C(15A) 45(5)  34(4) 42(5)  8(4) -3(4)  9(4) 
C(16A) 47(5)  35(5) 37(5)  2(4) -9(4)  4(4) 
C(17A) 50(5)  30(4) 26(4)  -7(3) 3(4)  3(4) 
C(18A) 30(4)  23(4) 35(4)  7(3) 5(3)  0(3) 
C(19A) 35(4)  18(3) 34(4)  -3(3) 6(3)  7(3) 
C(20A) 28(4)  26(4) 39(4)  8(3) 10(3)  7(3) 
C(21A) 41(5)  30(4) 54(5)  5(4) 11(4)  19(4) 
C(22A) 37(5)  41(5) 62(6)  22(4) 9(4)  19(4) 
C(23A) 50(5)  23(4) 43(5)  13(3) -18(4)  8(3) 
C(24A) 37(4)  28(4) 26(4)  5(3) 7(3)  7(3) 
                                                                                                        Electronic Appendix 
44 
C(25A) 32(4)  22(4) 31(4)  7(3) 12(3)  12(3) 
O(11B) 29(3)  25(2) 24(3)  13(2) 4(2)  7(2) 
O(12B) 24(2)  22(2) 27(2)  8(2) 2(2)  8(2) 
C(11B) 12(3)  24(4) 32(4)  11(3) 1(3)  3(3) 
C(12B) 18(3)  22(3) 24(3)  7(3) 6(3)  7(3) 
C(13B) 20(3)  28(4) 21(3)  11(3) 8(3)  12(3) 
C(14B) 26(4)  24(4) 25(3)  10(3) 2(3)  9(3) 
C(15B) 22(4)  34(4) 36(4)  9(3) -5(3)  4(3) 
C(16B) 31(4)  43(5) 36(4)  16(4) -1(3)  17(4) 
C(17B) 37(4)  40(4) 33(4)  16(4) 0(3)  17(4) 
C(18B) 33(4)  27(4) 23(4)  12(3) 6(3)  11(3) 
C(19B) 42(4)  22(4) 32(4)  15(3) 7(3)  11(3) 
C(20B) 35(4)  19(3) 32(4)  12(3) 4(3)  3(3) 
C(21B) 46(5)  22(4) 39(4)  15(3) 2(4)  5(3) 
C(22B) 42(5)  28(4) 46(5)  10(4) 6(4)  -7(3) 
C(23B) 33(4)  46(5) 37(4)  16(4) -4(3)  -4(4) 
C(24B) 21(3)  34(4) 29(4)  15(3) 2(3)  1(3) 
C(25B) 22(3)  23(3) 19(3)  5(3) 9(3)  8(3) 
O(11C) 25(3)  27(3) 41(3)  17(2) -10(2)  3(2) 
O(12C) 29(3)  28(3) 38(3)  14(2) -12(2)  6(2) 
C(11C) 17(3)  26(4) 18(3)  9(3) -3(3)  6(3) 
C(12C) 16(3)  26(4) 26(4)  15(3) -2(3)  2(3) 
C(13C) 14(3)  24(3) 29(4)  12(3) -1(3)  5(3) 
C(14C) 16(3)  32(4) 34(4)  20(3) -2(3)  4(3) 
C(15C) 23(4)  36(4) 27(4)  12(3) 1(3)  5(3) 
C(16C) 32(4)  38(4) 22(4)  12(3) 2(3)  2(3) 
C(17C) 22(4)  40(4) 28(4)  19(3) -4(3)  -1(3) 
C(18C) 17(3)  27(4) 28(4)  9(3) -4(3)  2(3) 
C(19C) 17(3)  31(4) 29(4)  13(3) -5(3)  1(3) 
C(20C) 14(3)  30(4) 34(4)  16(3) 2(3)  5(3) 
C(21C) 16(3)  39(4) 40(4)  18(4) -1(3)  5(3) 
C(22C) 20(4)  35(4) 44(4)  17(4) 8(3)  11(3) 
C(23C) 26(4)  36(4) 25(4)  5(3) 7(3)  12(3) 
C(24C) 18(3)  32(4) 32(4)  16(3) -2(3)  9(3) 
C(25C) 15(3)  24(3) 28(4)  11(3) 1(3)  1(3) 
Ag(3) 18(1)  21(1) 19(1)  5(1) 3(1)  6(1) 
Ag(4) 32(1)  21(1) 28(1)  2(1) -3(1)  11(1) 
O(11D) 32(3)  20(2) 15(2)  4(2) -1(2)  3(2) 
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O(12D) 28(3)  22(2) 22(2)  4(2) 0(2)  9(2) 
C(11D) 12(3)  20(3) 17(3)  2(3) 0(2)  0(2) 
C(12D) 20(3)  23(3) 17(3)  8(3) 1(3)  10(3) 
C(13D) 26(3)  18(3) 19(3)  3(3) -2(3)  7(3) 
C(14D) 30(4)  29(4) 24(4)  8(3) 6(3)  6(3) 
C(15D) 48(5)  37(4) 26(4)  13(3) 7(3)  -7(4) 
C(16D) 46(5)  31(4) 48(5)  9(4) 8(4)  -5(4) 
C(17D) 43(5)  21(4) 32(4)  -5(3) 6(3)  -5(3) 
C(18D) 32(4)  27(4) 23(4)  10(3) 1(3)  5(3) 
C(19D) 33(4)  27(4) 25(4)  -1(3) 4(3)  10(3) 
C(20D) 29(4)  28(4) 25(4)  9(3) 2(3)  11(3) 
C(21D) 35(4)  29(4) 24(4)  0(3) 10(3)  12(3) 
C(22D) 28(4)  41(4) 34(4)  11(4) 14(3)  10(3) 
C(23D) 28(4)  32(4) 29(4)  13(3) 8(3)  8(3) 
C(24D) 27(4)  27(4) 22(3)  7(3) 4(3)  12(3) 
C(25D) 19(3)  17(3) 21(3)  4(3) -1(3)  8(3) 
O(11E) 32(3)  26(3) 43(3)  2(2) 20(2)  3(2) 
O(12E) 28(3)  27(3) 35(3)  -2(2) 16(2)  2(2) 
C(11E) 17(3)  22(3) 21(3)  9(3) 5(3)  1(3) 
C(12E) 18(3)  18(3) 14(3)  -1(3) 0(2)  0(3) 
C(13E) 15(3)  24(3) 21(3)  0(3) 3(3)  4(3) 
C(14E) 22(3)  25(4) 24(4)  5(3) 9(3)  5(3) 
C(15E) 34(4)  29(4) 30(4)  16(3) -4(3)  11(3) 
C(16E) 19(3)  33(4) 35(4)  8(3) 3(3)  6(3) 
C(17E) 21(4)  31(4) 39(4)  7(3) 6(3)  4(3) 
C(18E) 18(3)  25(4) 29(4)  6(3) 3(3)  4(3) 
C(19E) 25(4)  36(4) 26(4)  8(3) 9(3)  5(3) 
C(20E) 24(4)  35(4) 20(3)  8(3) 7(3)  3(3) 
C(21E) 30(4)  43(5) 31(4)  16(4) 5(3)  3(3) 
C(22E) 33(4)  35(4) 31(4)  15(3) -6(3)  -1(3) 
C(23E) 25(4)  34(4) 30(4)  11(3) -2(3)  6(3) 
C(24E) 21(3)  28(4) 28(4)  9(3) 6(3)  5(3) 
C(25E) 19(3)  20(3) 23(3)  4(3) 3(3)  0(3) 
O(11F) 34(3)  35(3) 64(4)  27(3) -14(3)  5(2) 
O(12F) 30(3)  17(2) 29(3)  3(2) -7(2)  5(2) 
C(11F) 29(4)  34(4) 18(3)  11(3) 2(3)  13(3) 
C(12F) 28(4)  19(3) 24(3)  5(3) -5(3)  7(3) 
C(13F) 30(4)  17(3) 27(4)  6(3) -7(3)  3(3) 
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C(14F) 38(4)  26(4) 30(4)  12(3) 2(3)  9(3) 
C(15F) 32(4)  37(4) 35(4)  13(3) 8(3)  13(3) 
C(16F) 38(4)  40(5) 35(4)  10(4) 9(3)  17(4) 
C(17F) 40(4)  21(4) 41(4)  3(3) -2(4)  14(3) 
C(18F) 29(4)  26(4) 35(4)  8(3) -6(3)  4(3) 
C(19F) 41(4)  24(4) 40(4)  15(3) -11(3)  9(3) 
C(20F) 32(4)  28(4) 37(4)  13(3) -10(3)  0(3) 
C(21F) 46(5)  36(4) 34(4)  21(4) -8(4)  -1(4) 
C(22F) 42(5)  47(5) 45(5)  17(4) 3(4)  -8(4) 
C(23F) 38(5)  57(6) 33(4)  18(4) 0(4)  3(4) 
C(24F) 33(4)  41(4) 36(4)  19(4) 4(3)  9(3) 
C(25F) 23(3)  28(4) 26(4)  11(3) -3(3)  4(3) 
Ag(5) 35(1)  29(1) 41(1)  5(1) 4(1)  6(1) 
C(1A) 43(5)  33(4) 35(4)  10(4) 9(4)  5(4) 
N(1A) 40(4)  33(4) 36(4)  7(3) -1(3)  -1(3) 
C(2A) 53(5)  41(5) 49(5)  8(4) -4(4)  3(4) 
C(3A) 45(5)  44(5) 41(5)  5(4) -10(4)  -2(4) 
N(2A) 36(4)  34(4) 44(4)  16(3) 0(3)  -1(3) 
C(4A) 48(5)  49(5) 61(6)  28(5) 1(4)  3(4) 
C(1B) 38(4)  33(4) 50(5)  23(4) 15(4)  15(4) 
N(1B) 40(4)  33(4) 51(4)  15(3) 20(3)  17(3) 
C(2B) 58(6)  30(5) 85(7)  26(5) 10(5)  14(4) 
C(3B) 60(6)  41(5) 87(7)  35(5) 27(6)  30(5) 
N(2B) 43(4)  48(4) 43(4)  26(3) 19(3)  26(3) 
C(4B) 61(6)  69(7) 46(5)  30(5) 12(5)  24(5) 
Ag(6) 36(1)  34(1) 51(1)  18(1) 1(1)  10(1) 
C(1C) 41(5)  28(4) 51(5)  19(4) 3(4)  2(3) 
N(1C) 36(4)  36(4) 46(4)  18(3) -4(3)  4(3) 
C(2C) 41(5)  27(4) 53(5)  18(4) 1(4)  6(3) 
C(3C) 35(5)  44(5) 68(6)  31(5) -3(4)  4(4) 
N(2C) 32(3)  33(4) 44(4)  14(3) -2(3)  1(3) 
C(4C) 47(5)  42(5) 43(5)  10(4) -1(4)  -8(4) 
C(1D) 37(4)  31(4) 35(4)  6(3) -2(3)  13(4) 
N(1D) 38(4)  31(4) 49(4)  10(3) -1(3)  14(3) 
C(2D) 69(7)  22(4) 81(7)  -3(5) 6(6)  16(4) 
C(3D) 58(6)  32(5) 66(6)  3(4) 19(5)  19(4) 
N(2D) 41(4)  31(4) 41(4)  7(3) 4(3)  16(3) 
C(4D) 34(5)  57(6) 57(6)  15(5) -4(4)  7(4) 
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Table 23. Hydrogen coordinates ( x 104) and isotropic displacement 
parameters (Å2x 103) for [Ag(1-Me-imid)2]2[Ag4(9-aca)6]. 
________________________________________________________________________________ 
 x  y  z  U(eq) 
________________________________________________________________________________ 
 
H(14A) 5572 2091 2252 41 
H(15A) 6752 2676 3153 50 
H(16A) 6556 3941 3892 53 
H(17A) 5135 4575 3752 49 
H(19A) 3515 4609 3097 39 
H(21A) 1923 4694 2445 51 
H(22A) 823 4185 1527 53 
H(23A) 874 2921 808 46 
H(24A) 2330 2241 896 38 
H(14B) 4739 1164 -1334 29 
H(15B) 3332 979 -2083 39 
H(16B) 3234 2019 -2454 42 
H(17B) 4540 3276 -2044 41 
H(19B) 6236 4166 -1335 36 
H(21B) 7857 5101 -604 42 
H(22B) 9126 5405 233 50 
H(23B) 9260 4370 619 49 
H(24B) 8111 3082 181 33 
H(14C) 6384 657 1659 30 
H(15C) 6329 1160 2699 34 
H(16C) 7717 995 3354 38 
H(17C) 9191 327 2930 35 
H(19C) 10218 -325 2028 31 
H(21C) 11279 -959 1128 37 
H(22C) 11414 -1431 82 38 
H(23C) 9973 -1335 -578 36 
H(24C) 8398 -769 -180 31 
H(14D) 13285 2980 6569 34 
H(15D) 14653 4189 6896 47 
H(16D) 14632 5221 7879 54 
H(17D) 13142 5034 8494 45 
H(19D) 11349 4198 8654 37 
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H(21D) 9574 3375 8871 38 
H(23D) 8197 2167 8572 41 
H(23D) 8247 1075 7642 35 
H(24D) 9695 1210 6998 30 
H(14E) 6601 738 5248 30 
H(14E) 5018 1300 5176 35 
H(16E) 3546 1337 5864 36 
H(18E) 3680 842 6644 39 
H(19E) 4759 204 7173 36 
H(22E) 5840 -415 7738 42 
H(21E) 7345 -1036 7792 41 
H(23E) 8768 -1167 7063 36 
H(24E) 8657 -671 6294 32 
H(14F) 7253 2161 5319 37 
H(15F) 5929 2837 5901 40 
H(16F) 5743 4123 5892 45 
H(17F) 6964 4759 5360 42 
H(19F) 8580 4744 4684 41 
H(21F) 10139 4732 3977 46 
H(22F) 11575 4122 3464 57 
H(23F) 11751 2826 3430 52 
H(24F) 10567 2171 3962 42 
H(1A) 7785 2090 1175 46 
H(2A) 7855 4360 2323 62 
H(3A) 9280 3833 2757 58 
H(4A1) 9307 2100 2429 78 
H(4A2) 10317 2480 2092 78 
H(4A3) 9321 1700 1698 78 
H(1B) 3828 2187 27 44 
H(2B) 5099 4578 552 67 
H(3B) 3486 4200 -235 68 
H(4B1) 2365 1948 -833 82 
H(4B2) 2382 2701 -1048 82 
H(4B3) 1606 2612 -506 82 
H(1C) 12548 2131 5014 47 
H(2C) 12927 4513 5426 47 
H(3C) 14320 4034 4669 56 
H(4C1) 14009 2256 3839 73 
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H(4C2) 14157 1820 4313 73 
H(4C3) 15117 2607 4334 73 
H(2D) 8695 2182 6217 42 
H(2D) 9940 4541 7163 76 
H(3D) 8235 4084 7671 66 
H(4D1) 7051 1843 6862 77 
H(4D2) 6365 2561 6958 77 
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X-ray Crystal Data for [Ag(2-Me-imidH)2(9-aca)] 
 
Identification code  [Ag(2-Me-imidH)2(9-aca)] 
Empirical formula  C23 H21 Ag N4 O2 
Formula weight  493.31 
Temperature  150(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  C2/c 
Unit cell dimensions a = 19.8374(17) Å α = 90°. 
 b = 15.2507(13) Å β = 110.140(1)°. 
 c = 14.4941(13) Å γ = 90°. 
Volume 4116.8(6) Å3 
Z 8 
Density (calculated) 1.592 Mg/m3 
Absorption coefficient 1.007 mm-1 
F(000) 2000 
Crystal size 0.28 x 0.14 x 0.13 mm3 
Crystal description colourless pyramid 
Theta range for data collection 1.73 to 28.35°. 
Index ranges -26<=h<=26, -20<=k<=20, -19<=l<=19 
Reflections collected 20857 
Independent reflections 5142 [R(int) = 0.0541] 
Completeness to theta = 28.35° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.8803 and 0.7658 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5142 / 0 / 273 
Goodness-of-fit on F2 1.030 
Final R indices [I>2sigma(I)] R1 = 0.0345, wR2 = 0.0715 
R indices (all data) R1 = 0.0541, wR2 = 0.0787 
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Table 24.  Atomic coordinates ( x 104) and equivalent isotropic displacement 
parameters (Å2x 103) for [Ag(2-Me-imidH)2(9-aca)]. U(eq) is defined as one 
third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
Ag(1) 4366(1) 1099(1) 9399(1) 27(1) 
O(1) 3649(1) 1507(1) 7673(1) 37(1) 
O(2) 2646(1) 1832(1) 6455(1) 36(1) 
C(1) 3066(2) 1893(2) 7332(2) 28(1) 
C(2) 2840(2) 2505(2) 8000(2) 29(1) 
C(3) 3217(2) 3293(2) 8323(2) 33(1) 
C(4) 3833(2) 3527(2) 8089(2) 40(1) 
C(5) 4195(2) 4282(2) 8428(3) 50(1) 
C(6) 3963(2) 4869(2) 9018(3) 54(1) 
C(7) 3378(2) 4672(2) 9250(2) 48(1) 
C(8) 2985(2) 3883(2) 8920(2) 37(1) 
C(9) 2396(2) 3660(2) 9182(2) 39(1) 
C(10) 2020(2) 2884(2) 8878(2) 36(1) 
C(11) 1418(2) 2656(2) 9148(2) 41(1) 
C(12) 1056(2) 1901(2) 8852(2) 47(1) 
C(13) 1268(2) 1310(2) 8244(2) 42(1) 
C(14) 1842(2) 1501(2) 7965(2) 36(1) 
C(15) 2240(2) 2292(2) 8260(2) 30(1) 
N(21) 5238(1) 1981(1) 9699(2) 26(1) 
C(21) 5729(1) 2136(2) 10573(2) 27(1) 
C(22) 5707(2) 1782(2) 11519(2) 36(1) 
N(22) 6242(1) 2665(2) 10476(2) 30(1) 
C(23) 6081(2) 2847(2) 9502(2) 34(1) 
C(24) 5457(2) 2423(2) 9028(2) 35(1) 
N(31) 3679(1) 96(1) 9552(2) 26(1) 
C(31) 3689(1) -284(2) 10383(2) 24(1) 
C(32) 4207(2) -99(2) 11375(2) 32(1) 
N(32) 3147(1) -861(2) 10203(2) 28(1) 
C(33) 2774(2) -857(2) 9212(2) 32(1) 
C(34) 3100(1) -266(2) 8811(2) 29(1) 
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Table 25. Bond lengths [Å] and angles [°] for [Ag(2-Me-imidH)2(9-aca)]. 
Ag(1)-N(31)  2.111(2) 
Ag(1)-N(21)  2.115(2) 
Ag(1)-O(1)  2.4941(19) 
Ag(1) … Ag(1)#1  4.1930(5) 
O(1)-C(1)  1.239(3) 
O(2)-C(1)  1.261(3) 
C(1)-C(2)  1.520(4) 
C(2)-C(15)  1.403(4) 
C(2)-C(3)  1.408(4) 
C(3)-C(4)  1.421(4) 
C(3)-C(8)  1.430(4) 
C(4)-C(5)  1.357(5) 
C(5)-C(6)  1.420(5) 
C(6)-C(7)  1.350(5) 
C(7)-C(8)  1.424(5) 
C(8)-C(9)  1.390(5) 
C(9)-C(10)  1.387(4) 
C(10)-C(11)  1.423(4) 
C(10)-C(15)  1.441(4) 
C(11)-C(12)  1.346(5) 
C(12)-C(13)  1.423(4) 
C(13)-C(14)  1.364(4) 
C(14)-C(15)  1.424(4) 
N(21)-C(21)  1.327(3) 
N(21)-C(24)  1.372(3) 
C(21)-N(22)  1.344(3) 
C(21)-C(22)  1.487(4) 
N(22)-C(23)  1.363(4) 
C(23)-C(24)  1.355(4) 
N(31)-C(31)  1.329(3) 
N(31)-C(34)  1.388(3) 
C(31)-N(32)  1.344(3) 
C(31)-C(32)  1.478(4) 


























































Symmetry transformations used to generate equivalent atoms:  #1 -x+1,-y,-z+2 
 
 
Table 26. Anisotropic displacement parameters (Å2x 103) for [Ag(2-Me-
imidH)2(9-aca)]. The anisotropic displacement factor exponent takes the form: -
2π2[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22 U33 U23 U13 U12 
______________________________________________________________________________ 
Ag(1) 25(1)  32(1) 24(1)  -2(1) 9(1)  -5(1) 
O(1) 36(1)  50(1) 23(1)  1(1) 7(1)  21(1) 
O(2) 32(1)  49(1) 22(1)  -5(1) 4(1)  14(1) 
C(1) 29(2)  35(2) 21(1)  2(1) 11(1)  9(1) 
C(2) 29(2)  37(2) 17(1)  4(1) 4(1)  16(1) 
C(3) 38(2)  37(2) 21(1)  3(1) 6(1)  14(1) 
C(4) 40(2)  43(2) 35(2)  1(2) 12(2)  9(2) 
C(5) 46(2)  46(2) 53(2)  9(2) 13(2)  4(2) 
C(6) 59(2)  40(2) 54(2)  1(2) 7(2)  6(2) 
C(7) 61(2)  40(2) 39(2)  -3(2) 11(2)  10(2) 
C(8) 41(2)  38(2) 26(2)  -1(1) 5(1)  15(2) 
C(9) 48(2)  42(2) 25(2)  1(1) 11(1)  23(2) 
C(10) 39(2)  47(2) 20(1)  5(1) 10(1)  21(2) 
C(11) 48(2)  51(2) 26(2)  5(2) 17(2)  19(2) 
C(12) 41(2)  65(2) 40(2)  16(2) 21(2)  19(2) 
C(13) 41(2)  45(2) 40(2)  5(2) 16(2)  9(2) 
C(14) 37(2)  42(2) 30(2)  4(1) 12(1)  13(2) 
C(15) 34(2)  37(2) 16(1)  2(1) 5(1)  14(1) 
N(21) 23(1)  31(1) 22(1)  0(1) 5(1)  -4(1) 
C(21) 24(2)  29(2) 26(1)  -2(1) 8(1)  -1(1) 
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C(22) 38(2)  44(2) 23(2)  0(1) 7(1)  -7(2) 
N(22) 26(1)  34(1) 27(1)  -2(1) 6(1)  -6(1) 
C(23) 32(2)  38(2) 33(2)  6(1) 13(1)  -4(1) 
C(24) 31(2)  47(2) 25(2)  7(1) 7(1)  -2(1) 
N(31) 25(1)  26(1) 26(1)  2(1) 9(1)  -1(1) 
C(31) 25(1)  24(1) 24(1)  1(1) 8(1)  1(1) 
C(32) 36(2)  35(2) 23(2)  1(1) 9(1)  -7(1) 
N(32) 28(1)  31(1) 26(1)  4(1) 11(1)  -2(1) 
C(33) 26(2)  37(2) 29(2)  -3(1) 6(1)  -7(1) 
C(34) 27(2)  35(2) 25(2)  1(1) 6(1)  -1(1) 
 
 
Table 27. Hydrogen coordinates ( x 104) and isotropic displacement 
parameters (Å2x 103) for [Ag(2-Me-imidH)2(9-aca)]. 
________________________________________________________________________________ 
 x  y  z  U(eq) 
________________________________________________________________________________ 
H(4) 3993 3149 7687 48 
H(5) 4609 4420 8269 59 
H(6) 4219 5397 9249 65 
H(7) 3224 5069 9643 58 
H(9) 2246 4051 9584 46 
H(11) 1267 3048 9548 49 
H(12) 658 1763 9050 56 
H(13) 1009 780 8031 50 
H(14) 1979 1096 7564 44 
H(22A) 5533 2237 11859 54 
H(22B) 6191 1600 11932 54 
H(22C) 5384 1276 11389 54 
H(22) 6618 2860 10958 36 
H(23) 6351 3200 9215 41 
H(24) 5210 2431 8338 42 
H(32A) 4697 -160 11369 48 
H(32B) 4132 -514 11846 48 
H(32C) 4135 501 11566 48 
H(32) 3049 -1184 10643 33 
H(33) 2365 -1203 8873 38 
H(34) 2956 -121 8133 35 
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Table 28. Hydrogen bonds for [Ag(2-Me-imidH)2(9-aca)] [Å and °]. 
____________________________________________________________________________ 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________ 
 N(22)-H(22)...O(2)#2 0.88 1.97 2.764(3) 149.1 
 N(32)-H(32)...O(2)#3 0.88 1.91 2.779(3) 168.8 
Symmetry transformations used to generate equivalent atoms:  
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X-ray Crystal Data for [Ag(1-Bu-imid)2]2[Ag4(9-aca)6] 
 
Identification code  [Ag(1-Bu-imid)2]2[Ag4(9-aca)6] 
Empirical formula  C118 H102 Ag6 N8 O12 
Formula weight  2471.30 
Temperature  150(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 17.6333(7) Å α = 96.019(1)°. 
 b = 19.3853(8) Å β = 95.831(1)°. 
 c = 30.4753(13) Å γ = 90.237(1)°. 
Volume 10305.1(7) Å3 
Z 4 
Density (calculated) 1.593 Mg/m3 
Absorption coefficient 1.185 mm-1 
F(000) 4976 
Crystal size 0.32 x 0.19 x 0.12 mm3 
Crystal description Colourless block 
Theta range for data collection 0.68 to 26.00°. 
Index ranges -21<=h<=21, -23<=k<=23, -37<=l<=37 
Reflections collected 89958 
Independent reflections 40407 [R(int) = 0.0422] 
Completeness to theta = 26.00° 99.7 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.4311 and 0.3430 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 40407 / 3021 / 2665 
Goodness-of-fit on F2 1.068 
Final R indices [I>2sigma(I)] R1 = 0.0505, wR2 = 0.1130 
R indices (all data) R1 = 0.0739, wR2 = 0.1229 
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Table 29.  Atomic coordinates ( x 104) and equivalent isotropic displacement 
parameters (Å2x 103) for [Ag(1-Bu-imid)2]2[Ag4(9-aca)6].  U(eq) is defined as 
one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
Ag(1) 5749(1) -404(1) 7502(1) 41(1) 
Ag(2) 4521(1) 304(1) 7031(1) 22(1) 
Ag(3) 3603(1) 1295(1) 7500(1) 38(1) 
Ag(4) 4754(1) 511(1) 7971(1) 24(1) 
O(1A) 6167(2) -593(2) 6842(1) 39(1) 
O(2A) 4998(2) -483(2) 6497(1) 34(1) 
C(1A) 5691(3) -608(3) 6501(2) 29(1) 
C(2A) 5994(3) -783(3) 6055(2) 27(1) 
C(3A) 6551(3) -344(3) 5920(2) 31(1) 
C(4A) 6865(3) 250(3) 6189(2) 37(1) 
C(5A) 7411(4) 640(4) 6052(2) 48(2) 
C(6A) 7676(4) 479(4) 5629(2) 53(2) 
C(7A) 7373(4) -68(4) 5356(2) 47(2) 
C(8A) 6802(4) -500(3) 5488(2) 37(1) 
C(9A) 6504(3) -1082(3) 5217(2) 36(1) 
C(10A) 5978(3) -1529(3) 5351(2) 33(1) 
C(11A) 5692(4) -2127(3) 5073(2) 39(1) 
C(12A) 5198(4) -2559(3) 5212(2) 47(2) 
C(13A) 4939(4) -2436(3) 5635(2) 49(2) 
C(14A) 5184(4) -1855(3) 5911(2) 38(1) 
C(15A) 5712(3) -1375(3) 5778(2) 32(1) 
O(1B) 3611(2) 750(2) 6518(1) 41(1) 
O(2B) 2713(2) 1137(2) 6941(1) 44(1) 
C(1B) 2958(3) 966(3) 6575(2) 29(1) 
C(2B) 2436(3) 1045(3) 6161(2) 27(1) 
C(3B) 1881(3) 547(3) 5998(2) 32(1) 
C(4B) 1723(3) -38(3) 6227(2) 39(1) 
C(5B) 1174(4) -511(4) 6052(3) 53(2) 
C(6B) 764(4) -450(4) 5639(3) 60(2) 
C(7B) 892(4) 87(4) 5408(2) 50(2) 
C(8B) 1443(3) 621(3) 5577(2) 34(1) 
C(9B) 1556(3) 1187(3) 5355(2) 37(1) 
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C(10B) 2085(3) 1719(3) 5534(2) 32(1) 
C(11B) 2189(4) 2315(3) 5324(2) 39(1) 
C(12B) 2684(4) 2824(3) 5501(2) 43(2) 
C(13B) 3120(4) 2759(3) 5913(2) 43(2) 
C(14B) 3057(3) 2178(3) 6123(2) 38(1) 
C(15B) 2531(3) 1640(3) 5941(2) 28(1) 
O(1C) 3830(2) 2059(2) 8074(1) 38(1) 
O(2C) 4483(2) 1367(2) 8513(1) 41(1) 
C(1C) 4061(3) 1850(3) 8445(2) 32(1) 
C(2C) 3742(3) 2233(3) 8846(2) 32(1) 
C(3C) 3011(3) 2037(3) 8925(2) 31(1) 
C(4C) 2564(3) 1521(3) 8642(2) 38(1) 
C(5C) 1863(4) 1338(4) 8726(2) 47(2) 
C(6C) 1548(4) 1645(4) 9111(2) 50(2) 
C(7C) 1950(4) 2135(4) 9389(2) 48(2) 
C(8C) 2692(3) 2358(3) 9307(2) 34(1) 
C(9C) 3127(4) 2857(3) 9593(2) 39(1) 
C(10C) 3854(4) 3042(3) 9518(2) 38(1) 
C(11C) 4332(5) 3527(3) 9817(2) 51(2) 
C(12C) 5036(5) 3684(4) 9742(2) 58(2) 
C(13C) 5349(4) 3384(3) 9365(2) 53(2) 
C(14C) 4940(4) 2920(3) 9065(2) 46(2) 
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C(15E) 7110(3) 1740(3) 7333(2) 36(1) 
O(1F) 3811(2) -525(2) 7248(1) 39(1) 
O(2F) 3492(2) 78(2) 7867(1) 36(1) 
C(1F) 3434(3) -423(3) 7563(2) 32(1) 
C(2F) 2822(4) -973(3) 7592(2) 38(1) 
C(3F) 3081(4) -1638(3) 7678(2) 42(1) 
C(4F) 3848(4) -1800(4) 7776(2) 54(2) 
C(5F) 4076(6) -2446(4) 7861(3) 70(2) 
C(6F) 3539(7) -2990(5) 7839(3) 85(3) 
C(7F) 2803(7) -2875(4) 7742(3) 82(2) 
C(8F) 2513(5) -2194(4) 7659(2) 61(2) 
C(9F) 1757(5) -2048(5) 7561(3) 70(2) 
C(10F) 1504(4) -1395(5) 7490(2) 60(2) 
C(11F) 719(5) -1241(6) 7388(3) 81(2) 
C(12F) 486(5) -604(7) 7325(3) 93(3) 
C(13F) 1013(5) -61(6) 7337(3) 78(2) 
C(14F) 1784(4) -167(4) 7427(2) 53(2) 
C(15F) 2054(4) -829(4) 7504(2) 48(2) 
Ag(5) 4130(1) -67(1) 5795(1) 37(1) 
C(21A) 5073(3) 1236(3) 6045(2) 38(1) 
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N(1A) 4899(3) 740(3) 5715(2) 35(1) 
C(22A) 5372(3) 855(3) 5398(2) 36(1) 
C(23A) 5806(3) 1411(3) 5533(2) 37(1) 
N(2A) 5622(3) 1655(3) 5949(2) 38(1) 
C(24A) 5916(5) 2282(4) 6231(2) 64(2) 
C(25A) 5384(6) 2922(4) 6140(3) 84(3) 
C(26A) 5545(6) 3539(5) 6433(3) 88(3) 
C(27A) 5040(6) 4117(5) 6317(4) 98(3) 
C(21B) 3230(3) -1143(3) 6207(2) 35(1) 
N(1B) 3335(3) -870(2) 5841(2) 34(1) 
C(22B) 2823(4) -1204(3) 5516(2) 40(2) 
C(23B) 2422(4) -1676(3) 5694(2) 41(2) 
N(2B) 2680(3) -1631(3) 6137(2) 39(1) 
C(24B) 2415(4) -2050(3) 6465(2) 46(2) 
C(25B) 2641(4) -2801(3) 6384(2) 48(2) 
C(26B) 3478(4) -2911(4) 6448(2) 54(2) 
C(27B) 3703(5) -3651(4) 6286(3) 66(2) 
Ag(6) 5148(1) 719(1) 9215(1) 41(1) 
C(21C) 6323(3) 1599(3) 8820(2) 38(1) 
N(1C) 6101(3) 1387(3) 9187(2) 42(1) 
C(22C) 6512(4) 1785(4) 9529(2) 48(2) 
C(23C) 6974(4) 2227(4) 9370(2) 49(2) 
N(2C) 6853(3) 2109(3) 8915(2) 43(1) 
C(24C) 7250(4) 2453(4) 8597(2) 53(2) 
C(25C) 8016(5) 2170(6) 8532(3) 85(3) 
C(26C) 8500(10) 1840(10) 8833(7) 79(5) 
C(27C) 9180(20) 1436(19) 8674(9) 90(10) 
C(25X) 8016(5) 2170(6) 8532(3) 85(3) 
C(26X) 8176(9) 1521(9) 8448(5) 60(3) 
C(27X) 9040(20) 1340(20) 8448(8) 94(9) 
C(21D) 3678(4) -111(3) 8970(2) 40(1) 
N(1D) 4190(3) 92(3) 9300(2) 42(1) 
C(22D) 3971(4) -212(3) 9656(2) 45(2) 
C(23D) 3320(4) -581(4) 9533(2) 45(2) 
N(2D) 3137(3) -525(3) 9089(2) 42(1) 
C(24D) 2467(4) -795(4) 8812(2) 52(2) 
C(25D) 1737(4) -461(4) 8967(2) 50(2) 
C(26D) 1050(4) -636(4) 8640(3) 59(2) 
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C(27D) 342(4) -262(5) 8790(3) 74(2) 
Ag(7) 8305(1) -5328(1) 7538(1) 40(1) 
Ag(8) 9389(1) -4645(1) 7032(1) 23(1) 
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C(15G) 6867(3) -5211(3) 5936(2) 29(1) 
O(1H) 9931(2) -4027(2) 6501(1) 37(1) 
O(2H) 11043(3) -3653(2) 6862(1) 48(1) 
C(1H) 10610(3) -3841(3) 6516(2) 31(1) 
C(2H) 10940(3) -3835(3) 6075(2) 31(1) 
C(3H) 10686(3) -3340(3) 5784(2) 32(1) 
C(4H) 10152(4) -2817(3) 5894(2) 41(2) 
C(5H) 9925(4) -2348(4) 5608(2) 50(2) 
C(6H) 10212(4) -2380(4) 5186(2) 51(2) 
C(7H) 10707(4) -2872(4) 5067(2) 44(2) 
C(8H) 10973(3) -3370(3) 5361(2) 36(1) 
C(9H) 11497(3) -3873(3) 5244(2) 40(1) 
C(10H) 11776(3) -4340(3) 5535(2) 38(1) 
C(11H) 12348(4) -4827(4) 5426(2) 48(2) 
C(12H) 12629(4) -5252(4) 5722(2) 50(2) 
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C(14H) 11782(4) -4815(3) 6251(2) 41(1) 
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C(15H) 11484(3) -4324(3) 5960(2) 34(1) 
O(1I) 10515(2) -2937(2) 8089(1) 40(1) 
O(2I) 10023(3) -3648(2) 8520(1) 45(1) 
C(1I) 10430(3) -3155(3) 8457(2) 31(1) 
C(2I) 10899(3) -2791(3) 8858(2) 29(1) 
C(3I) 11650(3) -2995(3) 8938(2) 33(1) 
C(4I) 11995(4) -3512(3) 8659(2) 39(1) 
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C(2J) 8486(3) -5800(3) 8921(2) 32(1) 
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C(27Z) 5456(17) -3709(17) 8516(8) 107(11) 
 
 






















































Table 31.  Bond lengths [Å] and angles [°] for [Ag(1-Bu-imid)2]2[Ag4(9-aca)6]. 
Ag(1)-O(1A)  2.207(4) 
Ag(1)-O(2D)  2.217(4) 
Ag(1)-Ag(4)  2.8750(6) 
Ag(1)-Ag(2)  2.9028(6) 
Ag(2)-O(1E)  2.222(4) 
Ag(2)-O(1F)  2.226(4) 
Ag(2)-O(2A)  2.335(4) 
Ag(2)-O(1B)  2.357(4) 
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Ag(2)-Ag(4)  2.8365(5) 
Ag(2)-Ag(3)  2.8770(6) 
Ag(3)-O(1C)  2.174(4) 
Ag(3)-O(2B)  2.192(4) 
Ag(3)-Ag(4)  2.8949(6) 
Ag(4)-O(1D)  2.275(4) 
Ag(4)-O(2C)  2.304(4) 
Ag(4)-O(2F)  2.354(4) 
Ag(4)-O(2E)  2.355(4) 
O(1A)-C(1A)  1.266(6) 
O(2A)-C(1A)  1.247(6) 
O(2A)-Ag(5)  2.696(4) 
C(1A)-C(2A)  1.516(7) 
C(2A)-C(15A)  1.410(8) 
C(2A)-C(3A)  1.416(8) 
C(3A)-C(4A)  1.416(8) 
C(3A)-C(8A)  1.436(8) 
C(4A)-C(5A)  1.347(9) 
C(5A)-C(6A)  1.420(9) 
C(6A)-C(7A)  1.349(10) 
C(7A)-C(8A)  1.422(9) 
C(8A)-C(9A)  1.394(9) 
C(9A)-C(10A)  1.388(8) 
C(10A)-C(11A)  1.422(8) 
C(10A)-C(15A)  1.431(8) 
C(11A)-C(12A)  1.334(9) 
C(12A)-C(13A)  1.411(9) 
C(13A)-C(14A)  1.373(9) 
C(14A)-C(15A)  1.430(8) 
O(1B)-C(1B)  1.249(6) 
O(1B)-Ag(5)  2.809(4) 
O(2B)-C(1B)  1.248(7) 
C(1B)-C(2B)  1.505(7) 
C(2B)-C(3B)  1.389(8) 
C(2B)-C(15B)  1.413(8) 
C(3B)-C(4B)  1.433(8) 
C(3B)-C(8B)  1.449(8) 
C(4B)-C(5B)  1.359(9) 
C(5B)-C(6B)  1.403(10) 
C(6B)-C(7B)  1.347(10) 
C(7B)-C(8B)  1.435(9) 
C(8B)-C(9B)  1.372(8) 
C(9B)-C(10B)  1.414(8) 
C(10B)-C(11B)  1.397(8) 
C(10B)-C(15B)  1.423(7) 
C(11B)-C(12B)  1.347(9) 
C(12B)-C(13B)  1.423(9) 
C(13B)-C(14B)  1.360(8) 
C(14B)-C(15B)  1.423(8) 
O(1C)-C(1C)  1.269(7) 
O(2C)-C(1C)  1.220(7) 
O(2C)-Ag(6)  2.756(4) 
C(1C)-C(2C)  1.522(7) 
C(2C)-C(3C)  1.392(8) 
C(2C)-C(15C)  1.402(8) 
C(3C)-C(8C)  1.429(8) 
C(3C)-C(4C)  1.430(8) 
C(4C)-C(5C)  1.342(9) 
C(5C)-C(6C)  1.421(9) 
C(6C)-C(7C)  1.352(10) 
C(7C)-C(8C)  1.430(9) 
C(8C)-C(9C)  1.403(9) 
C(9C)-C(10C)  1.377(9) 
C(10C)-C(15C)  1.438(8) 
C(10C)-C(11C)  1.444(9) 
C(11C)-C(12C)  1.324(10) 
C(12C)-C(13C)  1.397(10) 
C(13C)-C(14C)  1.363(9) 
C(14C)-C(15C)  1.428(9) 
O(1D)-C(1D)  1.230(7) 
O(1D)-Ag(6)  2.603(4) 
O(2D)-C(1D)  1.235(7) 
C(1D)-C(2D)  1.511(7) 
C(2D)-C(15D)  1.398(8) 
C(2D)-C(3D)  1.404(8) 
C(3D)-C(8D)  1.422(8) 
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C(3D)-C(4D)  1.421(9) 
C(4D)-C(5D)  1.338(9) 
C(5D)-C(6D)  1.415(11) 
C(6D)-C(7D)  1.359(12) 
C(7D)-C(8D)  1.432(10) 
C(8D)-C(9D)  1.359(10) 
C(9D)-C(10D)  1.401(10) 
C(10D)-C(11D)  1.413(10) 
C(10D)-C(15D)  1.446(9) 
C(11D)-C(12D)  1.323(12) 
C(12D)-C(13D)  1.403(12) 
C(13D)-C(14D)  1.384(10) 
C(14D)-C(15D)  1.434(9) 
O(1E)-C(1E)  1.271(6) 
O(2E)-C(1E)  1.227(7) 
C(1E)-C(2E)  1.516(7) 
C(2E)-C(3E)  1.398(8) 
C(2E)-C(15E)  1.410(8) 
C(3E)-C(4E)  1.417(8) 
C(3E)-C(8E)  1.457(8) 
C(4E)-C(5E)  1.373(9) 
C(5E)-C(6E)  1.429(10) 
C(6E)-C(7E)  1.348(10) 
C(7E)-C(8E)  1.441(9) 
C(8E)-C(9E)  1.376(9) 
C(9E)-C(10E)  1.386(9) 
C(10E)-C(11E)  1.430(9) 
C(10E)-C(15E)  1.431(8) 
C(11E)-C(12E)  1.358(10) 
C(12E)-C(13E)  1.402(10) 
C(13E)-C(14E)  1.373(9) 
C(14E)-C(15E)  1.424(9) 
O(1F)-C(1F)  1.224(7) 
O(2F)-C(1F)  1.265(6) 
O(2F)-Ag(12)  14.267(4) 
C(1F)-C(2F)  1.529(8) 
C(2F)-C(15F)  1.388(9) 
C(2F)-C(3F)  1.410(9) 
C(3F)-C(4F)  1.400(10) 
C(3F)-C(8F)  1.460(9) 
C(4F)-C(5F)  1.360(10) 
C(5F)-C(6F)  1.406(12) 
C(6F)-C(7F)  1.327(13) 
C(7F)-C(8F)  1.455(12) 
C(8F)-C(9F)  1.373(12) 
C(9F)-C(10F)  1.376(12) 
C(10F)-C(11F)  1.427(12) 
C(10F)-C(15F)  1.456(9) 
C(11F)-C(12F)  1.330(14) 
C(12F)-C(13F)  1.397(13) 
C(13F)-C(14F)  1.380(10) 
C(14F)-C(15F)  1.405(10) 
Ag(5)-N(1A)  2.116(5) 
Ag(5)-N(1B)  2.117(5) 
Ag(5)-O(2A)  2.696(4) 
ag(5)-O(1B)  2.809(4) 
C(21A)-N(1A)  1.327(7) 
C(21A)-N(2A)  1.335(7) 
N(1A)-C(22A)  1.372(7) 
C(22A)-C(23A)  1.323(8) 
C(23A)-N(2A)  1.377(7) 
N(2A)-C(24A)  1.474(8) 
C(24A)-C(25A)  1.589(12) 
C(25A)-C(26A)  1.425(11) 
C(26A)-C(27A)  1.483(13) 
C(21B)-N(1B)  1.314(7) 
C(21B)-N(2B)  1.338(7) 
N(1B)-C(22B)  1.376(7) 
C(22B)-C(23B)  1.346(8) 
C(23B)-N(2B)  1.374(7) 
N(2B)-C(24B)  1.462(8) 
C(24B)-C(25B)  1.514(9) 
C(25B)-C(26B)  1.488(9) 
C(26B)-C(27B)  1.535(10) 
Ag(6)-N(1D)  2.131(5) 
Ag(6)-N(1C)  2.131(5) 
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Ag(6)-O(1D)  2.603(4) 
Ag(6)-O(2C)  2.756(4) 
C(21C)-N(1C)  1.326(8) 
C(21C)-N(2C)  1.346(8) 
N(1C)-C(22C)  1.372(8) 
C(22C)-C(23C)  1.340(9) 
C(23C)-N(2C)  1.378(8) 
N(2C)-C(24C)  1.462(8) 
C(24C)-C(25C)  1.484(11) 
C(25C)-C(26C)  1.395(18) 
C(26C)-C(27C)  1.52(4) 
C(26X)-C(27X)  1.57(4) 
C(21D)-N(1D)  1.306(8) 
C(21D)-N(2D)  1.345(8) 
N(1D)-C(22D)  1.374(8) 
C(22D)-C(23D)  1.350(9) 
C(23D)-N(2D)  1.375(8) 
N(2D)-C(24D)  1.442(8) 
C(24D)-C(25D)  1.538(9) 
C(25D)-C(26D)  1.503(9) 
C(26D)-C(27D)  1.533(10) 
Ag(7)-O(1G)  2.196(4) 
Ag(7)-O(2J)  2.202(4) 
Ag(7)-O(1L)  2.564(4) 
Ag(7)-Ag(10)  2.8760(6) 
Ag(7)-Ag(8)  2.9646(6) 
Ag(8)-O(1K)  2.217(4) 
Ag(8)-O(2L)  2.257(4) 
Ag(8)-O(2G)  2.301(4) 
Ag(8)-O(1H)  2.382(4) 
Ag(8)-Ag(10)  2.8165(6) 
Ag(8)-Ag(9)  2.8544(6) 
Ag(9)-O(1I)  2.178(4) 
Ag(9)-O(2H)  2.203(4) 
Ag(9)-Ag(10)  2.9511(6) 
Ag(10)-O(2I)  2.286(4) 
Ag(10)-O(1J)  2.305(4) 
Ag(10)-O(2K)  2.309(4) 
Ag(10)-O(1L)  2.374(4) 
O(1G)-C(1G)  1.245(6) 
O(2G)-C(1G)  1.233(6) 
O(2G)-Ag(11)  2.847(4) 
C(1G)-C(2G)  1.519(7) 
C(2G)-C(15G)  1.400(8) 
C(2G)-C(3G)  1.403(8) 
C(3G)-C(4G)  1.413(8) 
C(3G)-C(8G)  1.447(7) 
C(4G)-C(5G)  1.352(8) 
C(5G)-C(6G)  1.420(8) 
C(6G)-C(7G)  1.353(9) 
C(7G)-C(8G)  1.420(8) 
C(8G)-C(9G)  1.380(8) 
C(9G)-C(10G)  1.379(8) 
C(10G)-C(11G)  1.415(8) 
C(10G)-C(15G)  1.454(8) 
C(11G)-C(12G)  1.362(10) 
C(12G)-C(13G)  1.412(10) 
C(13G)-C(14G)  1.359(9) 
C(14G)-C(15G)  1.409(8) 
O(1H)-C(1H)  1.243(7) 
O(1H)-Ag(11)  2.678(4) 
O(2H)-C(1H)  1.257(7) 
C(1H)-C(2H)  1.519(7) 
C(2H)-C(15H)  1.395(8) 
C(2H)-C(3H)  1.417(8) 
C(3H)-C(4H)  1.424(8) 
C(3H)-C(8H)  1.427(8) 
C(4H)-C(5H)  1.359(9) 
C(5H)-C(6H)  1.423(9) 
C(6H)-C(7H)  1.343(10) 
C(7H)-C(8H)  1.434(9) 
C(8H)-C(9H)  1.392(9) 
C(9H)-C(10H)  1.389(9) 
C(10H)-C(11H)  1.425(9) 
C(10H)-C(15H)  1.439(8) 
C(11H)-C(12H)  1.345(10) 
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C(12H)-C(13H)  1.424(9) 
C(13H)-C(14H)  1.362(9) 
C(14H)-C(15H)  1.433(9) 
O(1I)-C(1I)  1.261(7) 
O(2I)-C(1I)  1.236(7) 
C(1I)-C(2I)  1.512(7) 
C(2I)-C(3I)  1.388(8) 
C(2I)-C(15I)  1.401(8) 
C(3I)-C(4I)  1.424(8) 
C(3I)-C(8I)  1.447(8) 
C(4I)-C(5I)  1.351(9) 
C(5I)-C(6I)  1.427(10) 
C(6I)-C(7I)  1.325(10) 
C(7I)-C(8I)  1.427(9) 
C(8I)-C(9I)  1.391(9) 
C(9I)-C(10I)  1.386(9) 
C(10I)-C(15I)  1.435(8) 
C(10I)-C(11I)  1.445(9) 
C(11I)-C(12I)  1.339(10) 
C(12I)-C(13I)  1.394(10) 
C(13I)-C(14I)  1.375(9) 
C(14I)-C(15I)  1.415(9) 
O(1J)-C(1J)  1.226(7) 
O(1J)-Ag(12)  2.624(4) 
O(2J)-C(1J)  1.244(7) 
C(1J)-C(2J)  1.508(8) 
C(2J)-C(15J)  1.404(9) 
C(2J)-C(3J)  1.420(8) 
C(3J)-C(4J)  1.417(8) 
C(3J)-C(8J)  1.430(8) 
C(4J)-C(5J)  1.356(9) 
C(5J)-C(6J)  1.415(11) 
C(6J)-C(7J)  1.332(11) 
C(7J)-C(8J)  1.454(9) 
C(8J)-C(9J)  1.370(9) 
C(9J)-C(10J)  1.389(10) 
C(10J)-C(11J)  1.419(9) 
C(10J)-C(15J)  1.461(9) 
C(11J)-C(12J)  1.331(12) 
C(12J)-C(13J)  1.403(13) 
C(13J)-C(14J)  1.407(11) 
C(14J)-C(15J)  1.419(10) 
O(1K)-C(1K)  1.250(7) 
O(2K)-C(1K)  1.262(7) 
C(1K)-C(2K)  1.500(8) 
C(2K)-C(15K)  1.388(9) 
C(2K)-C(3K)  1.417(9) 
C(3K)-C(4K)  1.396(10) 
C(3K)-C(8K)  1.445(9) 
C(4K)-C(5K)  1.387(10) 
C(5K)-C(6K)  1.393(12) 
C(6K)-C(7K)  1.348(13) 
C(7K)-C(8K)  1.425(11) 
C(8K)-C(9K)  1.387(11) 
C(9K)-C(10K)  1.365(11) 
C(10K)-C(15K)  1.438(9) 
C(10K)-C(11K)  1.449(11) 
C(11K)-C(12K)  1.321(12) 
C(12K)-C(13K)  1.411(11) 
C(13K)-C(14K)  1.346(10) 
C(14K)-C(15K)  1.430(9) 
O(1L)-C(1L)  1.231(6) 
O(2L)-C(1L)  1.269(6) 
C(1L)-C(2L)  1.525(7) 
C(2L)-C(3L)  1.389(8) 
C(2L)-C(15L)  1.417(8) 
C(3L)-C(8L)  1.435(8) 
C(3L)-C(4L)  1.438(9) 
C(4L)-C(5L)  1.354(9) 
C(5L)-C(6L)  1.411(11) 
C(6L)-C(7L)  1.362(11) 
C(7L)-C(8L)  1.445(9) 
C(8L)-C(9L)  1.362(9) 
C(9L)-C(10L)  1.416(9) 
C(10L)-C(11L)  1.412(9) 
C(10L)-C(15L)  1.454(8) 
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C(11L)-C(12L)  1.341(11) 
C(12L)-C(13L)  1.439(10) 
C(13L)-C(14L)  1.365(9) 
C(14L)-C(15L)  1.395(9) 
Ag(11)-N(1E)  2.112(5) 
Ag(11)-N(1F)  2.113(5) 
Ag(11)-O(1H)  2.678(4) 
Ag(11)-O(2G)  2.847(4) 
C(21E)-N(1E)  1.315(8) 
C(21E)-N(2E)  1.334(8) 
N(1E)-C(22E)  1.371(7) 
C(22E)-C(23E)  1.338(9) 
C(23E)-N(2E)  1.365(8) 
N(2E)-C(24E)  1.456(9) 
C(24E)-C(25E)  1.607(16) 
C(25E)-C(26Y)  1.521(17) 
C(26Y)-C(27E)  1.49(2) 
C(25Y)-C(26E)  1.34(3) 
C(26E)-C(27Y)  1.61(3) 
C(21F)-N(1F)  1.329(7) 
C(21F)-N(2F)  1.338(7) 
N(1F)-C(22F)  1.365(7) 
C(22F)-C(23F)  1.336(9) 
C(23F)-N(2F)  1.376(7) 
N(2F)-C(24F)  1.473(7) 
C(24F)-C(25F)  1.512(9) 
C(25F)-C(26F)  1.500(9) 
C(26F)-C(27F)  1.517(10) 
Ag(12)-N(1H)  2.122(5) 
Ag(12)-N(1G)  2.124(5) 
Ag(12)-O(1J)  2.624(4) 
Ag(12)-O(2F)  2.740(4) 
C(21G)-N(1G)  1.314(8) 
C(21G)-N(2G)  1.328(8) 
N(1G)-C(22G)  1.381(8) 
C(22G)-C(23G)  1.353(9) 
C(23G)-N(2G)  1.371(8) 
N(2G)-C(24G)  1.463(9) 
C(24G)-C(25G)  1.549(10) 
C(25G)-C(26G)  1.501(10) 
C(26G)-C(27G)  1.504(11) 
C(21H)-N(1H)  1.318(8) 
C(21H)-N(2H)  1.361(8) 
N(1H)-C(22H)  1.366(8) 
C(22H)-C(23H)  1.353(9) 
C(23H)-N(2H)  1.372(8) 
N(2H)-C(24H)  1.463(8) 
C(24H)-C(25H)  1.56(2) 
C(25H)-C(26H)  1.48(3) 
C(26H)-C(27H)  1.52(3) 
C(25Z)-C(26Z)  1.52(2) 












































































































































































































































































































































































































































































































































































































































Table 32: Anisotropic displacement parameters (Å2x 103)for [Ag(1-Bu-
imid)2]2[Ag4(9-aca)6].  The anisotropic displacement factor exponent takes the 
form: -2π2[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
______________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
______________________________________________________________________________ 
Ag(1) 58(1)  45(1) 22(1)  7(1) 9(1)  25(1) 
Ag(2) 23(1)  23(1) 20(1)  1(1) 2(1)  -1(1) 
Ag(3) 47(1)  42(1) 22(1)  -3(1) -3(1)  15(1) 
Ag(4) 27(1)  24(1) 19(1)  1(1) 2(1)  2(1) 
O(1A) 42(2)  53(3) 21(2)  5(2) 4(2)  14(2) 
O(2A) 30(2)  45(2) 25(2)  -5(2) 6(2)  5(2) 
C(1A) 35(3)  29(3) 25(3)  4(2) 3(2)  5(2) 
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C(2A) 30(3)  27(3) 24(3)  2(2) 2(2)  10(2) 
C(3A) 34(3)  35(3) 23(3)  7(2) 4(2)  15(2) 
C(4A) 39(3)  37(3) 37(3)  6(3) 9(3)  6(3) 
C(5A) 50(4)  44(4) 51(4)  11(3) 4(3)  -1(3) 
C(6A) 46(4)  53(4) 65(5)  23(3) 19(3)  6(3) 
C(7A) 50(4)  52(4) 44(4)  16(3) 23(3)  12(3) 
C(8A) 43(3)  39(3) 31(3)  10(2) 9(3)  17(2) 
C(9A) 44(3)  46(3) 21(3)  5(2) 9(2)  17(3) 
C(10A) 37(3)  36(3) 26(3)  3(2) 1(2)  16(2) 
C(11A) 47(4)  42(3) 26(3)  -2(2) -1(3)  17(3) 
C(12A) 58(4)  35(4) 44(4)  -10(3) 2(3)  4(3) 
C(13A) 63(5)  37(4) 48(4)  0(3) 13(3)  -3(3) 
C(14A) 43(4)  39(3) 34(3)  5(3) 8(3)  3(3) 
C(15A) 33(3)  34(3) 28(3)  4(2) 3(2)  15(2) 
O(1B) 33(2)  60(3) 31(2)  8(2) -3(2)  11(2) 
O(2B) 41(2)  65(3) 25(2)  -1(2) -4(2)  16(2) 
C(1B) 29(3)  31(3) 27(3)  7(2) 1(2)  0(2) 
C(2B) 25(3)  35(3) 20(3)  -1(2) 2(2)  9(2) 
C(3B) 25(3)  39(3) 31(3)  -3(2) 2(2)  6(2) 
C(4B) 35(3)  44(4) 39(3)  7(3) 4(3)  1(3) 
C(5B) 43(4)  47(4) 67(5)  8(3) -1(3)  -7(3) 
C(6B) 40(4)  59(5) 75(5)  5(4) -10(3)  -9(3) 
C(7B) 34(4)  57(4) 54(4)  0(3) -14(3)  -2(3) 
C(8B) 26(3)  42(3) 31(3)  -3(2) 1(2)  7(2) 
C(9B) 31(3)  46(3) 30(3)  0(3) -5(2)  9(3) 
C(10B) 28(3)  41(3) 28(3)  5(2) 2(2)  11(2) 
C(11B) 43(4)  46(3) 28(3)  12(3) 1(3)  14(3) 
C(12B) 51(4)  42(4) 38(4)  9(3) 5(3)  9(3) 
C(13B) 40(4)  46(4) 43(4)  6(3) 2(3)  -7(3) 
C(14B) 32(3)  42(3) 38(3)  6(3) -5(3)  4(3) 
C(15B) 23(3)  35(3) 24(3)  0(2) 1(2)  7(2) 
O(1C) 54(3)  36(2) 23(2)  -3(2) 7(2)  4(2) 
O(2C) 53(3)  39(2) 28(2)  -8(2) 2(2)  16(2) 
C(1C) 40(3)  31(3) 24(3)  -5(2) 6(2)  -1(2) 
C(2C) 47(3)  27(3) 20(3)  0(2) 5(2)  7(2) 
C(3C) 39(3)  32(3) 21(3)  4(2) 1(2)  11(2) 
C(4C) 40(3)  46(4) 28(3)  4(3) 5(2)  6(3) 
C(5C) 47(4)  48(4) 45(4)  6(3) -3(3)  -1(3) 
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C(6C) 35(4)  62(5) 56(4)  13(3) 11(3)  7(3) 
C(7C) 44(4)  63(4) 40(4)  9(3) 13(3)  13(3) 
C(8C) 43(3)  37(3) 23(3)  4(2) 4(2)  15(2) 
C(9C) 56(4)  40(3) 22(3)  2(2) 9(3)  16(3) 
C(10C) 56(4)  28(3) 28(3)  -3(2) 3(3)  7(3) 
C(11C) 80(5)  42(4) 29(3)  -6(3) -1(3)  4(3) 
C(12C) 73(5)  48(4) 46(4)  -8(3) -10(4)  -10(4) 
C(13C) 49(4)  41(4) 65(5)  -8(3) -4(3)  -8(3) 
C(14C) 56(4)  38(4) 42(4)  -5(3) 9(3)  1(3) 
C(15C) 44(3)  30(3) 27(3)  1(2) 6(2)  11(2) 
O(1D) 91(4)  57(3) 26(2)  10(2) 6(2)  42(3) 
O(2D) 111(4)  69(3) 23(2)  10(2) 12(3)  54(3) 
C(1D) 40(3)  33(3) 26(3)  9(2) 5(2)  6(2) 
C(2D) 41(3)  26(3) 24(3)  5(2) 1(2)  11(2) 
C(3D) 40(3)  32(3) 31(3)  9(2) 5(2)  7(2) 
C(4D) 43(4)  41(4) 53(4)  11(3) 4(3)  6(3) 
C(5D) 45(4)  48(4) 96(6)  24(4) 11(4)  2(3) 
C(6D) 59(5)  64(5) 110(6)  47(5) 34(4)  15(4) 
C(7D) 79(5)  64(5) 53(4)  39(4) 25(4)  28(4) 
C(8D) 53(4)  49(4) 32(3)  18(3) 6(3)  20(3) 
C(9D) 67(4)  52(4) 27(3)  8(3) -3(3)  23(3) 
C(10D) 47(4)  39(4) 42(3)  -9(3) -11(3)  14(3) 
C(11D) 60(4)  53(5) 70(5)  -13(4) -26(4)  14(3) 
C(12D) 49(5)  48(5) 113(7)  -12(4) -19(4)  2(3) 
C(13D) 53(4)  45(4) 125(7)  18(5) 5(5)  -7(4) 
C(14D) 52(4)  42(4) 75(5)  11(4) 9(3)  0(3) 
C(15D) 36(3)  28(3) 42(3)  3(2) 3(2)  12(2) 
O(1E) 46(2)  42(2) 33(2)  8(2) -11(2)  -23(2) 
O(2E) 35(2)  38(2) 34(2)  8(2) -1(2)  -9(2) 
C(1E) 27(3)  36(3) 22(3)  -6(2) 3(2)  -9(2) 
C(2E) 40(3)  41(3) 15(3)  0(2) 1(2)  -16(2) 
C(3E) 33(3)  39(3) 23(3)  -1(2) -1(2)  -17(2) 
C(4E) 36(3)  42(3) 44(4)  6(3) -4(3)  -7(3) 
C(5E) 47(4)  57(4) 50(4)  -1(3) 1(3)  -1(3) 
C(6E) 62(5)  45(4) 70(5)  -3(4) 1(4)  -3(3) 
C(7E) 53(4)  35(3) 72(5)  9(3) -2(4)  -10(3) 
C(8E) 47(3)  33(3) 39(4)  5(3) -2(3)  -13(3) 
C(9E) 36(3)  46(3) 46(4)  4(3) 4(3)  -20(3) 
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C(10E) 36(3)  53(4) 36(3)  -4(3) 4(3)  -12(3) 
C(11E) 42(4)  70(4) 50(4)  3(4) 6(3)  -13(3) 
C(12E) 39(4)  78(5) 58(5)  -6(4) 11(3)  0(3) 
C(13E) 49(4)  58(4) 56(5)  -9(4) 7(3)  6(3) 
C(14E) 48(4)  53(4) 32(3)  -4(3) 6(3)  -4(3) 
C(15E) 37(3)  44(3) 24(3)  -2(3) 2(2)  -10(2) 
O(1F) 48(2)  40(2) 28(2)  -4(2) 11(2)  -20(2) 
O(2F) 40(2)  38(2) 28(2)  -4(2) 9(2)  -12(2) 
C(1F) 39(3)  31(3) 25(3)  3(2) -1(2)  -10(2) 
C(2F) 42(3)  44(3) 27(3)  -2(3) 9(3)  -23(2) 
C(3F) 61(4)  41(3) 24(3)  0(3) 9(3)  -20(3) 
C(4F) 65(4)  53(4) 46(4)  16(3) 10(3)  -6(3) 
C(5F) 101(6)  62(5) 49(5)  21(4) 9(4)  10(4) 
C(6F) 159(8)  48(5) 52(5)  15(4) 18(6)  -2(5) 
C(7F) 140(6)  48(4) 61(5)  11(4) 21(6)  -42(5) 
C(8F) 85(4)  50(4) 52(4)  6(3) 28(4)  -39(3) 
C(9F) 80(4)  75(5) 57(5)  -7(4) 33(4)  -53(4) 
C(10F) 46(4)  89(5) 45(4)  -8(4) 17(3)  -32(3) 
C(11F) 42(4)  131(7) 66(6)  -22(6) 15(4)  -41(4) 
C(12F) 34(4)  162(9) 81(6)  6(7) 3(4)  -8(5) 
C(13F) 63(5)  117(7) 57(5)  10(5) 16(4)  14(4) 
C(14F) 45(4)  75(4) 38(4)  3(3) 6(3)  -9(3) 
C(15F) 45(3)  62(4) 35(4)  0(3) 8(3)  -20(3) 
Ag(5) 41(1)  39(1) 30(1)  4(1) 2(1)  -9(1) 
C(21A) 39(3)  48(4) 29(3)  8(3) 10(3)  -7(3) 
N(1A) 35(3)  40(3) 33(3)  10(2) 4(2)  -4(2) 
C(22A) 40(3)  39(3) 31(3)  9(2) 9(3)  3(3) 
C(23A) 31(3)  49(4) 32(3)  8(3) 8(2)  3(3) 
N(2A) 38(3)  42(3) 34(3)  12(2) 4(2)  -6(2) 
C(24A) 85(6)  59(4) 46(4)  -4(3) 8(4)  -28(4) 
C(25A) 123(8)  53(4) 74(6)  7(4) -5(5)  -21(5) 
C(26A) 102(7)  77(6) 82(7)  -6(5) 18(6)  -14(5) 
C(27A) 87(7)  99(7) 108(8)  -1(6) 26(6)  14(6) 
C(21B) 41(3)  39(3) 25(3)  0(2) 2(2)  -2(3) 
N(1B) 38(3)  33(3) 30(3)  0(2) -1(2)  -6(2) 
C(22B) 50(4)  47(4) 21(3)  -2(3) -1(3)  -11(3) 
C(23B) 44(4)  45(4) 31(3)  -4(3) -2(3)  -13(3) 
N(2B) 45(3)  42(3) 29(3)  -2(2) 7(2)  -10(2) 
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C(24B) 50(4)  50(4) 39(4)  4(3) 8(3)  -14(3) 
C(25B) 56(4)  47(4) 40(4)  4(3) 8(3)  -16(3) 
C(26B) 60(4)  47(4) 53(4)  8(3) -5(4)  -13(3) 
C(27B) 74(5)  50(4) 73(6)  6(4) -4(4)  -4(4) 
Ag(6) 48(1)  44(1) 30(1)  2(1) 4(1)  -7(1) 
C(21C) 41(3)  44(4) 26(3)  0(3) -9(2)  -4(3) 
N(1C) 48(3)  45(3) 32(3)  7(2) -6(2)  -5(2) 
C(22C) 53(4)  58(4) 29(3)  1(3) -5(3)  -14(3) 
C(23C) 55(4)  54(4) 33(3)  3(3) -16(3)  -16(3) 
N(2C) 45(3)  48(3) 32(3)  2(2) -8(2)  -11(2) 
C(24C) 62(4)  56(4) 41(4)  13(3) -3(3)  -12(3) 
C(25C) 80(5)  105(6) 83(6)  49(5) 26(4)  12(5) 
C(26C) 76(9)  80(11) 93(12)  47(9) 30(8)  17(8) 
C(27C) 91(15)  75(15) 130(30)  57(18) 68(18)  19(11) 
C(25X) 80(5)  105(6) 83(6)  49(5) 26(4)  12(5) 
C(26X) 77(9)  74(8) 32(7)  20(7) 5(7)  -2(7) 
C(27X) 101(13)  113(18) 90(20)  56(19) 44(17)  27(12) 
C(21D) 47(4)  46(4) 30(3)  8(3) 10(3)  2(3) 
N(1D) 49(3)  45(3) 31(3)  4(2) 9(2)  0(2) 
C(22D) 57(4)  50(4) 28(3)  6(3) 9(3)  1(3) 
C(23D) 52(4)  51(4) 38(3)  18(3) 14(3)  0(3) 
N(2D) 44(3)  49(3) 33(3)  6(2) 8(2)  2(2) 
C(24D) 51(4)  68(5) 36(4)  3(3) 5(3)  -5(3) 
C(25D) 54(4)  46(4) 51(4)  13(3) 3(3)  -3(3) 
C(26D) 55(4)  60(5) 61(5)  8(4) 3(3)  -2(4) 
C(27D) 49(4)  79(6) 93(7)  5(5) 6(4)  3(4) 
Ag(7) 53(1)  41(1) 23(1)  7(1) -7(1)  -20(1) 
Ag(8) 23(1)  24(1) 21(1)  1(1) 0(1)  1(1) 
Ag(9) 53(1)  47(1) 22(1)  -6(1) 9(1)  -22(1) 
Ag(10) 27(1)  25(1) 20(1)  2(1) 0(1)  -2(1) 
O(1G) 40(2)  55(3) 21(2)  0(2) 0(2)  -14(2) 
O(2G) 32(2)  60(3) 29(2)  -7(2) -2(2)  -14(2) 
C(1G) 28(3)  23(3) 25(3)  -2(2) -1(2)  -3(2) 
C(2G) 20(3)  33(3) 24(3)  -1(2) 2(2)  -7(2) 
C(3G) 23(3)  33(3) 24(3)  4(2) 4(2)  -8(2) 
C(4G) 35(3)  36(3) 28(3)  4(2) 0(2)  -7(2) 
C(5G) 42(4)  33(3) 43(4)  -4(3) -1(3)  1(3) 
C(6G) 48(4)  37(3) 43(4)  -8(3) 4(3)  -12(3) 
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C(7G) 37(3)  39(3) 33(3)  -5(3) 5(2)  -14(3) 
C(8G) 33(3)  36(3) 23(3)  0(2) 2(2)  -12(2) 
C(9G) 32(3)  45(3) 24(3)  3(2) -4(2)  -13(2) 
C(10G) 28(3)  43(3) 32(3)  4(2) -3(2)  -5(2) 
C(11G) 32(3)  52(4) 46(4)  8(3) -12(3)  0(3) 
C(12G) 43(4)  51(4) 71(5)  15(3) -16(3)  6(3) 
C(13G) 43(4)  36(4) 64(4)  0(3) -1(3)  5(3) 
C(14G) 38(3)  38(3) 40(4)  -1(3) 2(3)  -2(3) 
C(15G) 23(3)  36(3) 28(3)  1(2) 2(2)  -7(2) 
O(1H) 34(2)  52(3) 27(2)  7(2) 8(2)  -6(2) 
O(2H) 52(3)  68(3) 23(2)  -4(2) 10(2)  -21(2) 
C(1H) 37(3)  29(3) 27(3)  4(2) 7(2)  -5(2) 
C(2H) 32(3)  38(3) 20(3)  -5(2) 4(2)  -14(2) 
C(3H) 32(3)  44(3) 20(3)  -1(2) 4(2)  -12(2) 
C(4H) 45(4)  48(4) 35(3)  9(3) 15(3)  1(3) 
C(5H) 61(5)  45(4) 48(4)  12(3) 11(3)  0(3) 
C(6H) 60(4)  54(4) 40(4)  15(3) 3(3)  -9(3) 
C(7H) 51(4)  56(4) 25(3)  5(3) 3(3)  -19(3) 
C(8H) 37(3)  42(3) 27(3)  2(2) 5(2)  -19(2) 
C(9H) 41(3)  51(4) 28(3)  -10(3) 13(3)  -19(3) 
C(10H) 40(3)  38(3) 36(3)  -10(2) 14(3)  -18(2) 
C(11H) 48(4)  49(4) 47(4)  -10(3) 21(3)  -17(3) 
C(12H) 44(4)  46(4) 60(4)  -11(3) 16(3)  -10(3) 
C(13H) 56(4)  39(4) 53(4)  0(3) 8(3)  -5(3) 
C(14H) 47(4)  39(3) 36(3)  -2(3) 7(3)  -9(3) 
C(15H) 36(3)  40(3) 24(3)  -5(2) 2(2)  -12(2) 
O(1I) 57(3)  42(2) 18(2)  -2(2) 1(2)  -14(2) 
O(2I) 57(3)  45(3) 29(2)  -9(2) 6(2)  -26(2) 
C(1I) 36(3)  31(3) 23(3)  -5(2) -2(2)  -6(2) 
C(2I) 40(3)  27(3) 21(3)  2(2) 3(2)  -11(2) 
C(3I) 41(3)  33(3) 25(3)  6(2) -1(2)  -12(2) 
C(4I) 44(3)  41(4) 33(3)  4(3) 8(3)  -2(3) 
C(5I) 46(4)  55(4) 44(4)  13(3) 9(3)  -2(3) 
C(6I) 41(4)  68(5) 60(5)  20(4) -2(3)  -3(3) 
C(7I) 41(3)  57(4) 45(4)  13(3) -11(3)  -10(3) 
C(8I) 42(3)  37(3) 33(3)  9(2) -7(3)  -13(3) 
C(9I) 57(4)  43(4) 29(3)  4(3) -11(3)  -18(3) 
C(10I) 59(4)  34(3) 23(3)  1(2) -4(3)  -12(3) 
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C(11I) 84(5)  40(4) 34(4)  -10(3) 2(3)  -9(3) 
C(12I) 92(5)  41(4) 46(4)  -8(3) 16(4)  6(4) 
C(13I) 61(4)  42(4) 67(5)  -9(3) 8(3)  6(3) 
C(14I) 52(4)  38(4) 40(4)  -7(3) 5(3)  -7(3) 
C(15I) 50(3)  28(3) 28(3)  -1(2) 0(2)  -13(3) 
O(1J) 72(3)  50(3) 28(2)  12(2) -4(2)  -31(2) 
O(2J) 101(4)  66(3) 30(2)  18(2) -14(2)  -47(3) 
C(1J) 41(3)  37(3) 30(3)  9(2) 1(2)  -4(3) 
C(2J) 40(3)  27(3) 30(3)  10(2) -2(2)  -10(2) 
C(3J) 39(3)  29(3) 24(3)  4(2) 2(2)  -5(2) 
C(4J) 42(4)  32(3) 48(4)  12(3) 11(3)  -4(3) 
C(5J) 48(4)  51(4) 79(5)  23(4) 10(4)  0(3) 
C(6J) 51(4)  65(5) 82(5)  30(4) -8(4)  8(4) 
C(7J) 67(5)  65(5) 42(4)  30(4) -10(3)  -4(4) 
C(8J) 52(4)  40(4) 31(3)  9(3) 0(3)  -12(3) 
C(9J) 66(4)  44(4) 27(3)  3(3) 11(3)  -19(3) 
C(10J) 53(4)  37(4) 55(4)  -8(3) 26(3)  -15(3) 
C(11J) 80(5)  40(4) 76(5)  -4(4) 39(4)  -6(3) 
C(12J) 70(5)  52(5) 121(7)  0(5) 44(5)  0(4) 
C(13J) 62(5)  45(5) 139(7)  23(5) 20(5)  13(4) 
C(14J) 51(4)  47(4) 104(6)  26(4) 13(4)  -1(3) 
C(15J) 46(4)  25(3) 56(4)  4(3) 9(3)  -5(3) 
O(1K) 52(3)  40(2) 35(2)  -4(2) -11(2)  21(2) 
O(2K) 37(2)  55(3) 35(2)  -6(2) -5(2)  16(2) 
C(1K) 42(3)  47(4) 30(3)  6(3) 4(3)  18(3) 
C(2K) 35(3)  52(3) 34(3)  2(3) 0(3)  18(3) 
C(3K) 42(3)  66(4) 32(3)  4(3) 0(3)  15(3) 
C(4K) 39(4)  79(5) 44(4)  6(4) -3(3)  8(3) 
C(5K) 47(4)  104(6) 56(5)  8(5) 5(4)  -8(4) 
C(6K) 31(4)  132(7) 91(7)  7(6) 8(4)  4(4) 
C(7K) 44(4)  124(6) 68(6)  -5(6) 6(4)  28(4) 
C(8K) 41(4)  86(5) 49(4)  8(4) 4(3)  30(3) 
C(9K) 70(5)  72(5) 60(5)  9(4) 2(4)  43(4) 
C(10K) 73(4)  59(4) 41(4)  6(3) 6(4)  34(3) 
C(11K) 107(6)  57(4) 66(5)  14(4) 8(5)  40(4) 
C(12K) 111(7)  52(5) 61(5)  13(4) -4(5)  13(4) 
C(13K) 85(5)  61(4) 40(4)  18(4) 1(4)  7(4) 
C(14K) 57(4)  53(4) 33(3)  14(3) 0(3)  8(3) 
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C(15K) 51(4)  49(3) 27(3)  9(3) -1(3)  21(3) 
O(1L) 39(2)  34(2) 27(2)  2(2) 2(2)  7(2) 
O(2L) 48(2)  39(2) 26(2)  10(2) 14(2)  20(2) 
C(1L) 22(3)  35(3) 22(3)  0(2) 1(2)  7(2) 
C(2L) 36(3)  38(3) 21(3)  4(2) 9(2)  13(2) 
C(3L) 35(3)  43(3) 29(3)  4(3) 8(2)  14(2) 
C(4L) 42(3)  55(4) 36(4)  -3(3) 7(3)  1(3) 
C(5L) 47(4)  65(4) 62(5)  -7(4) 0(4)  -6(3) 
C(6L) 41(4)  93(6) 74(6)  -13(5) 5(4)  8(4) 
C(7L) 39(4)  83(5) 55(5)  9(4) 6(3)  21(3) 
C(8L) 43(3)  53(4) 31(3)  1(3) 3(3)  17(3) 
C(9L) 47(4)  49(4) 53(4)  7(3) 5(3)  26(3) 
C(10L) 57(4)  29(3) 32(3)  1(3) 7(3)  13(3) 
C(11L) 72(4)  40(4) 65(5)  6(4) 17(4)  12(3) 
C(12L) 84(5)  30(3) 64(5)  -4(3) 13(4)  -3(3) 
C(13L) 63(4)  45(4) 48(4)  -4(3) 15(3)  -3(3) 
C(14L) 51(4)  39(3) 37(4)  2(3) 11(3)  9(3) 
C(15L) 44(3)  37(3) 20(3)  0(2) 10(2)  15(2) 
Ag(11) 39(1)  41(1) 31(1)  1(1) 3(1)  9(1) 
C(21E) 41(4)  44(4) 42(4)  -4(3) 10(3)  6(3) 
N(1E) 36(3)  38(3) 35(3)  -3(2) 7(2)  1(2) 
C(22E) 33(3)  51(4) 35(3)  -7(3) 7(3)  1(3) 
C(23E) 36(3)  43(4) 40(3)  -13(3) 10(3)  6(3) 
N(2E) 37(3)  43(3) 44(3)  -1(2) 9(2)  8(2) 
C(24E) 85(6)  72(4) 69(5)  24(4) 30(4)  36(4) 
C(25E) 87(10)  72(7) 61(9)  43(6) 34(7)  28(7) 
C(26Y) 82(9)  69(7) 59(8)  27(6) 25(7)  24(6) 
C(27E) 78(11)  68(9) 99(15)  35(9) 30(9)  27(8) 
C(24Y) 85(6)  72(4) 69(5)  24(4) 30(4)  36(4) 
C(25Y) 69(9)  69(7) 79(12)  20(9) -1(10)  36(8) 
C(26E) 69(10)  61(9) 75(13)  15(10) 1(11)  36(7) 
C(27Y) 74(15)  70(11) 74(17)  31(12) 23(13)  25(11) 
C(21F) 36(3)  37(3) 29(3)  9(2) 3(2)  7(2) 
N(1F) 35(3)  40(3) 29(3)  4(2) 2(2)  4(2) 
C(22F) 57(4)  53(4) 21(3)  3(3) -6(3)  13(3) 
C(23F) 51(4)  51(4) 26(3)  7(3) -2(3)  12(3) 
N(2F) 37(3)  41(3) 25(2)  10(2) 6(2)  10(2) 
C(24F) 45(4)  48(4) 31(3)  4(3) 13(3)  14(3) 
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C(25F) 49(4)  44(3) 38(4)  3(3) 7(3)  17(3) 
C(26F) 52(4)  52(4) 52(4)  5(3) 5(3)  14(3) 
C(27F) 75(6)  47(4) 94(7)  3(4) 9(5)  -2(4) 
Ag(12) 49(1)  43(1) 30(1)  3(1) 2(1)  5(1) 
C(21G) 45(4)  43(4) 35(3)  14(3) 1(3)  -1(3) 
N(1G) 51(3)  41(3) 35(3)  6(2) -7(2)  3(2) 
C(22G) 49(4)  53(4) 32(3)  12(3) -5(3)  -2(3) 
C(23G) 49(4)  55(4) 37(3)  12(3) -6(3)  6(3) 
N(2G) 43(3)  46(3) 36(3)  10(2) -7(2)  3(2) 
C(24G) 54(4)  69(5) 41(4)  9(3) 0(3)  10(3) 
C(25G) 59(4)  55(4) 58(5)  15(4) 8(3)  9(4) 
C(26G) 65(5)  69(5) 72(6)  12(4) 16(4)  13(4) 
C(27G) 62(5)  81(6) 95(7)  3(5) 18(5)  4(4) 
C(21H) 46(4)  43(4) 27(3)  -2(3) 10(3)  0(3) 
N(1H) 50(3)  51(3) 27(3)  1(2) 9(2)  3(2) 
C(22H) 66(5)  64(5) 27(3)  2(3) 14(3)  11(3) 
C(23H) 63(5)  59(4) 30(3)  3(3) 16(3)  15(3) 
N(2H) 48(3)  52(3) 30(3)  7(2) 16(2)  10(2) 
C(24H) 69(4)  57(4) 41(4)  17(3) 13(3)  15(3) 
C(25H) 68(8)  58(11) 46(10)  13(9) -3(6)  21(8) 
C(26H) 63(7)  30(7) 64(9)  16(6) 7(6)  14(6) 
C(27H) 60(10)  73(13) 91(18)  24(14) -20(11)  8(8) 
C(24Z) 69(4)  57(4) 41(4)  17(3) 13(3)  15(3) 
C(25Z) 64(6)  57(10) 58(11)  11(8) 9(8)  20(8) 
C(26Z) 89(10)  58(9) 65(10)  21(8) 3(9)  -4(7) 
C(27Z) 84(12)  120(20) 120(20)  80(20) -29(16)  -23(14) 
 
 
Table 33.  Hydrogen coordinates ( x 104) and isotropic displacement 
parameters (Å2x 103) for [Ag(1-Bu-imid)2]2[Ag4(9-aca)6]. 
________________________________________________________________________________ 
 x  y  z  U(eq) 
________________________________________________________________________________ 
 
H(4A) 6688 374 6470 45 
H(5A) 7621 1029 6242 57 
H(6A) 8066 756 5539 63 
H(7A) 7545 -166 5071 56 
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H(9A) 6667 -1175 4929 44 
H(11A) 5853 -2220 4784 47 
H(12A) 5018 -2959 5021 56 
H(13A) 4595 -2755 5730 59 
H(14A) 5001 -1772 6194 46 
H(4B) 2003 -95 6504 47 
H(5B) 1066 -888 6212 63 
H(6B) 391 -792 5520 72 
H(7B) 611 113 5127 60 
H(9B) 1273 1223 5076 44 
H(11B) 1901 2362 5048 46 
H(12B) 2742 3225 5351 52 
H(13B) 3458 3124 6043 52 
H(14B) 3367 2132 6392 46 
H(4C) 2768 1301 8387 45 
H(5C) 1574 1002 8528 56 
H(6C) 1056 1505 9172 60 
H(7C) 1735 2335 9645 58 
H(9C) 2915 3074 9846 47 
H(11C) 4136 3739 10077 61 
H(12C) 5332 4005 9947 69 
H(13C) 5854 3506 9318 64 
H(14C) 5159 2725 8809 55 
H(4D) 4777 -1348 8657 54 
H(5D) 4067 -2078 8992 74 
H(6D) 4479 -2351 9716 88 
H(7D) 5628 -1933 10069 74 
H(9D) 6819 -1293 10044 59 
H(11D) 8024 -631 10041 77 
H(12D) 8803 -8 9685 88 
H(13D) 8436 269 8966 88 
H(14D) 7235 -47 8609 67 
H(4E) 5047 2372 7697 49 
H(5E) 4731 3504 7912 62 
H(6E) 5582 4427 7834 72 
H(7E) 6738 4207 7579 65 
H(9E) 7702 3352 7339 51 
H(11E) 8724 2520 7179 65 
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H(12E) 9134 1396 7096 71 
H(13E) 8310 472 7164 67 
H(14E) 7047 669 7277 54 
H(4F) 4223 -1445 7783 64 
H(5F) 4602 -2530 7936 84 
H(6F) 3704 -3441 7895 102 
H(7F) 2452 -3251 7726 98 
H(9F) 1393 -2415 7541 84 
H(11F) 351 -1606 7363 98 
H(12F) -44 -518 7271 112 
H(13F) 838 388 7282 94 
H(14F) 2134 209 7437 63 
H(21A) 4839 1286 6314 45 
H(22A) 5385 577 5123 43 
H(23A) 6175 1605 5373 44 
H(24A) 6441 2387 6167 76 
H(24B) 5934 2201 6547 76 
H(25A) 5424 3031 5833 101 
H(25B) 4849 2779 6158 101 
H(26A) 6082 3682 6424 105 
H(26B) 5483 3442 6740 105 
H(27A) 5173 4529 6527 147 
H(27B) 4508 3983 6333 147 
H(27C) 5106 4222 6016 147 
H(21B) 3509 -1010 6487 43 
H(22B) 2763 -1116 5213 48 
H(23B) 2035 -1981 5543 49 
H(24C) 1852 -2024 6453 56 
H(24D) 2632 -1857 6765 56 
H(25C) 2391 -3073 6587 57 
H(25D) 2449 -2982 6077 57 
H(26C) 3657 -2814 6768 65 
H(26D) 3739 -2579 6287 65 
H(27D) 4257 -3695 6335 100 
H(27E) 3537 -3748 5968 100 
H(27F) 3457 -3983 6449 100 
H(21C) 6133 1416 8528 46 
H(22C) 6474 1751 9835 57 
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H(23C) 7317 2557 9539 59 
H(24E) 7304 2953 8701 64 
H(24F) 6933 2407 8308 64 
H(25E) 7941 1839 8260 102 
H(25F) 8318 2563 8454 102 
H(26E) 8183 1517 8970 95 
H(26F) 8702 2199 9072 95 
H(27G) 9454 1237 8925 135 
H(27H) 9515 1748 8550 135 
H(27I) 8992 1062 8446 135 
H(25G) 8196 2405 8288 102 
H(25H) 8350 2341 8803 102 
H(26G) 7914 1349 8154 72 
H(26H) 7961 1261 8671 72 
H(27J) 9101 842 8384 141 
H(27K) 9313 1499 8740 141 
H(27L) 9263 1582 8221 141 
H(21D) 3687 21 8679 48 
H(22D) 4238 -168 9945 53 
H(23D) 3043 -831 9717 54 
H(24E) 2433 -1303 8820 62 
H(24F) 2510 -705 8502 62 
H(25E) 1646 -621 9256 60 
H(25F) 1810 49 9013 60 
H(26E) 956 -1144 8607 71 
H(26F) 1151 -500 8346 71 
H(27G) -97 -387 8571 111 
H(27H) 431 240 8816 111 
H(27I) 238 -401 9078 111 
H(4G) 8307 -6676 6368 40 
H(5G) 8422 -7777 6031 48 
H(6G) 7761 -8106 5325 52 
H(7G) 6924 -7367 4997 44 
H(9G) 6307 -6223 5023 41 
H(11G) 5664 -5091 5038 53 
H(12G) 5430 -4035 5414 67 
H(13G) 6061 -3708 6126 58 
H(14G) 6970 -4408 6434 47 
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H(4H) 9950 -2796 6173 50 
H(5H) 9575 -1998 5689 60 
H(6H) 10052 -2050 4988 61 
H(7H) 10884 -2891 4782 53 
H(9H) 11669 -3899 4957 48 
H(11H) 12532 -4851 5142 57 
H(12H) 13031 -5554 5649 60 
H(13H) 12538 -5578 6341 60 
H(14H) 11582 -4829 6528 49 
H(4I) 11700 -3731 8404 47 
H(5I) 12943 -4045 8552 57 
H(6I) 13686 -3512 9193 67 
H(7I) 13181 -2710 9663 58 
H(9I) 12094 -1951 9858 53 
H(11I) 10976 -1261 10083 65 
H(12I) 9716 -1012 9961 72 
H(13I) 8984 -1495 9323 69 
H(14I) 9489 -2295 8818 53 
H(4J) 9726 -6360 8612 48 
H(5J) 10566 -7126 8919 70 
H(6J) 10439 -7424 9638 78 
H(7J) 9503 -6989 10036 69 
H(9J) 8311 -6299 10064 55 
H(11J) 7115 -5660 10099 77 
H(12J) 6229 -4965 9789 95 
H(13J) 6249 -4714 9057 96 
H(14J) 7297 -5020 8658 79 
H(4K) 11948 -4707 7406 65 
H(5K) 13180 -4447 7254 83 
H(6K) 14081 -5330 7216 102 
H(7K) 13738 -6457 7245 95 
H(9K) 12778 -7319 7428 81 
H(11K) 11859 -8171 7639 91 
H(12K) 10692 -8398 7831 90 
H(13K) 9760 -7539 7877 73 
H(14K) 10023 -6442 7718 57 
H(4L) 7023 -4304 7328 53 
H(5L) 5745 -4536 7174 71 
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H(6L) 4871 -3634 7096 85 
H(7L) 5280 -2493 7192 70 
H(9L) 6326 -1647 7374 59 
H(11L) 7364 -758 7614 70 
H(12L) 8596 -504 7880 71 
H(13L) 9506 -1398 7976 62 
H(14L) 9124 -2542 7789 50 
H(21E) 9830 -5816 6344 52 
H(22E) 10369 -5591 5141 48 
H(23E) 11188 -6497 5429 48 
H(24G) 10909 -6614 6610 87 
H(24H) 11482 -6895 6255 87 
H(25I) 9879 -7355 6169 83 
H(25J) 10498 -7674 5860 83 
H(26I) 11126 -8178 6469 80 
H(26J) 10504 -7863 6776 80 
H(27M) 10264 -9035 6564 117 
H(27N) 10184 -8897 6053 117 
H(27O) 9571 -8588 6371 117 
H(24I) 10767 -6619 6586 87 
H(24J) 11497 -6698 6329 87 
H(25K) 11070 -7792 6023 87 
H(25L) 11209 -7705 6558 87 
H(26K) 9851 -7413 6101 82 
H(26L) 10019 -7500 6618 82 
H(27P) 9373 -8544 6225 105 
H(27Q) 10194 -8742 6447 105 
H(27R) 10067 -8664 5927 105 
H(21F) 8508 -3464 6444 40 
H(22F) 7810 -3837 5165 53 
H(23F) 7076 -2855 5460 51 
H(24G) 7567 -2541 6688 49 
H(24H) 6845 -2444 6339 49 
H(25G) 7575 -1634 6010 52 
H(25H) 7420 -1375 6507 52 
H(26G) 8815 -1982 6289 62 
H(26H) 8652 -1633 6769 62 
H(27J) 9376 -869 6423 109 
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H(27K) 8564 -536 6496 109 
H(27L) 8727 -885 6015 109 
H(21G) 10825 -4998 8652 48 
H(22G) 10764 -5216 9921 54 
H(23G) 11843 -5901 9662 57 
H(24I) 11922 -5716 8451 66 
H(24J) 12079 -6344 8750 66 
H(25I) 12847 -5023 8988 68 
H(25J) 13071 -5729 9194 68 
H(26I) 13495 -6193 8525 81 
H(26J) 13223 -5518 8296 81 
H(27M) 14540 -5454 8494 118 
H(27N) 14414 -5521 9000 118 
H(27O) 14139 -4842 8775 118 
H(21H) 8353 -3594 8559 46 
H(22H) 8547 -3252 9865 62 
H(23H) 7585 -2444 9583 60 
H(24K) 7504 -2487 8376 65 
H(24L) 7129 -2090 8787 65 
H(25K) 6167 -2757 8319 69 
H(25L) 6653 -3445 8357 69 
H(26K) 6019 -2721 9083 62 
H(26L) 6444 -3447 9089 62 
H(27P) 5111 -3613 9032 113 
H(27Q) 5447 -3990 8602 113 
H(27R) 5027 -3263 8577 113 
H(24M) 7319 -2044 8722 65 
H(24N) 7413 -2664 8344 65 
H(25M) 6162 -2453 8426 71 
H(25N) 6294 -2600 8935 71 
H(26M) 6422 -3616 8196 84 
H(26N) 6609 -3771 8700 84 
H(27S) 5395 -4209 8431 160 
H(27T) 5128 -3459 8308 160 
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X-ray Crystal Data for [Ag(apim)](9-aca)·H2O 
 
Identification code  [Ag(apim)](9-aca)·H2O 
Empirical formula  C21 H22 Ag N3 O3 
Formula weight  472.29 
Temperature  150(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  Pbca 
Unit cell dimensions a = 9.6450(6) Å α = 90°. 
 b = 19.0589(11) Å β = 90°. 
 c = 21.2920(12) Å γ = 90°. 
Volume 3914.0(4) Å3 
Z 8 
Density (calculated) 1.603 Mg/m3 
Absorption coefficient 1.057 mm-1 
F(000) 1920 
Crystal size 0.20 x 0.17 x 0.07 mm3 
Crystal description colourless plate 
Theta range for data collection 1.91 to 28.35°. 
Index ranges -12<=h<=12, -25<=k<=25, -28<=l<=28 
Reflections collected 37907 
Independent reflections 4890 [R(int) = 0.0398] 
Completeness to theta = 26.00° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9297 and 0.8164 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4890 / 6 / 265 
Goodness-of-fit on F2 1.027 
Final R indices [I>2sigma(I)] R1 = 0.0280, wR2 = 0.0665 
R indices (all data) R1 = 0.0410, wR2 = 0.0723 
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Table 34. Atomic coordinates ( x 104) and equivalent isotropic displacement 
parameters (Å2x 103) for [Ag(apim)](9-aca)·H2O.  U(eq) is defined as one third 
of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
Ag(1) 3338(1) 1127(1) 4314(1) 26(1) 
C(21) 4013(2) -430(1) 4348(1) 28(1) 
N(1) 4502(2) 208(1) 4251(1) 27(1) 
C(22) 5879(2) 123(1) 4101(1) 28(1) 
C(23) 6193(2) -570(1) 4110(1) 26(1) 
N(2) 4998(2) -915(1) 4270(1) 23(1) 
C(24) 4806(2) -1677(1) 4333(1) 25(1) 
C(25) 3976(2) -1963(1) 3784(1) 23(1) 
C(26) 3679(2) -2743(1) 3840(1) 23(1) 
N(3) 2765(2) -2922(1) 4377(1) 23(1) 
O(1) -1841(2) -2015(1) 4164(1) 33(1) 
O(2) 168(2) -1996(1) 4673(1) 33(1) 
C(1) -563(2) -1926(1) 4190(1) 22(1) 
C(2) 185(2) -1729(1) 3591(1) 21(1) 
C(3) 537(2) -1024(1) 3476(1) 24(1) 
C(4) 138(2) -468(1) 3891(1) 30(1) 
C(5) 470(3) 213(1) 3757(1) 38(1) 
C(6) 1247(3) 378(1) 3213(1) 40(1) 
C(7) 1666(3) -129(1) 2815(1) 38(1) 
C(8) 1318(2) -851(1) 2924(1) 27(1) 
C(9) 1721(2) -1383(1) 2515(1) 30(1) 
C(10) 1353(2) -2081(1) 2621(1) 24(1) 
C(11) 1745(2) -2628(1) 2197(1) 30(1) 
C(12) 1377(2) -3305(1) 2304(1) 31(1) 
C(13) 576(2) -3484(1) 2843(1) 28(1) 
C(14) 172(2) -2978(1) 3256(1) 24(1) 
C(15) 552(2) -2260(1) 3164(1) 21(1) 
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Table 35. Bond lengths [Å] and angles [°] for [Ag(apim)](9-aca)·H2O. 
Ag(1)-N(1)  2.0841(18) 
Ag(1)-N(3)#1  2.1069(18) 
C(21)-N(1)  1.321(3) 
C(21)-N(2)  1.336(3) 
N(1)-C(22)  1.376(3) 
C(22)-C(23)  1.354(3) 
C(23)-N(2)  1.371(3) 
N(2)-C(24)  1.470(3) 
C(24)-C(25)  1.518(3) 
C(25)-C(26)  1.520(3) 
C(26)-N(3)  1.483(3) 
N(3)-Ag(1)#2  2.1069(18) 
O(1)-C(1)  1.246(3) 
O(2)-C(1)  1.253(3) 
C(1)-C(2)  1.513(3) 
C(2)-C(15)  1.404(3) 
C(2)-C(3)  1.409(3) 
C(3)-C(4)  1.431(3) 
C(3)-C(8)  1.434(3) 
C(4)-C(5)  1.368(3) 
C(5)-C(6)  1.415(4) 
C(6)-C(7)  1.348(4) 
C(7)-C(8)  1.436(3) 
C(8)-C(9)  1.391(3) 
C(9)-C(10)  1.395(3) 
C(10)-C(11)  1.429(3) 
C(10)-C(15)  1.432(3) 
C(11)-C(12)  1.358(4) 
C(12)-C(13)  1.425(3) 
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C(14)-C(15)-C(10) 118.40(19)
Symmetry transformations used to generate equivalent atoms:  
#1 -x+1/2,y+1/2,z    #2 -x+1/2,y-1/2,z      
 
 
Table 36. Anisotropic displacement parameters (Å2x 103) for [Ag(apim)](9-
aca)·H2O. The anisotropic displacement factor exponent takes the form: -2π2[ 
h2a*2U11 + ... + 2 h k a* b* U12 ] 
______________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
______________________________________________________________________________ 
Ag(1) 27(1)  20(1) 31(1)  -1(1) -1(1)  5(1) 
C(21) 18(1)  24(1) 41(1)  0(1) -1(1)  2(1) 
N(1) 26(1)  21(1) 33(1)  -1(1) -3(1)  1(1) 
C(22) 27(1)  24(1) 34(1)  1(1) 2(1)  -2(1) 
C(23) 19(1)  25(1) 34(1)  -2(1) 2(1)  -1(1) 
N(2) 20(1)  18(1) 32(1)  -1(1) -3(1)  0(1) 
C(24) 20(1)  18(1) 38(1)  3(1) -6(1)  0(1) 
C(25) 20(1)  22(1) 27(1)  0(1) 2(1)  0(1) 
C(26) 21(1)  20(1) 28(1)  -3(1) -1(1)  0(1) 
N(3) 23(1)  21(1) 25(1)  0(1) -3(1)  -2(1) 
O(1) 20(1)  45(1) 34(1)  -3(1) 5(1)  -2(1) 
O(2) 29(1)  44(1) 26(1)  7(1) -2(1)  2(1) 
C(1) 21(1)  18(1) 27(1)  -2(1) 4(1)  1(1) 
C(2) 14(1)  26(1) 23(1)  2(1) -2(1)  0(1) 
C(3) 17(1)  27(1) 29(1)  4(1) -4(1)  2(1) 
C(4) 23(1)  27(1) 40(1)  -1(1) -3(1)  2(1) 
C(5) 35(1)  26(1) 53(2)  -1(1) -11(1)  0(1) 
C(6) 41(1)  24(1) 55(2)  11(1) -12(1)  -5(1) 
C(7) 40(1)  35(1) 40(1)  15(1) -6(1)  -7(1) 
C(8) 24(1)  30(1) 29(1)  10(1) -3(1)  -1(1) 
C(9) 26(1)  39(1) 23(1)  9(1) 0(1)  -3(1) 
C(10) 18(1)  34(1) 22(1)  2(1) -2(1)  2(1) 
C(11) 22(1)  48(1) 21(1)  -1(1) -1(1)  8(1) 
C(12) 28(1)  38(1) 29(1)  -8(1) -4(1)  9(1) 
C(13) 24(1)  28(1) 33(1)  -4(1) -5(1)  2(1) 
C(14) 17(1)  29(1) 25(1)  1(1) -2(1)  1(1) 
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C(15) 13(1)  26(1) 24(1)  3(1) -2(1)  3(1) 
O(1W) 43(1)  35(1) 56(1)  -8(1) 9(1)  7(1) 
 
 
Table 37.  Hydrogen coordinates ( x 104) and isotropic displacement 
parameters (Å2x 103) for [Ag(apim)](9-aca)·H2O. 
________________________________________________________________________________ 
 x  y  z  U(eq) 
________________________________________________________________________________ 
 
H(21) 3080 -531 4458 34 
H(22) 6510 491 4006 34 
H(23) 7069 -775 4022 31 
H(24A) 4315 -1780 4730 30 
H(24B) 5723 -1910 4347 30 
H(25A) 4494 -1876 3390 28 
H(25B) 3085 -1706 3757 28 
H(26A) 3237 -2907 3447 27 
H(26B) 4568 -2998 3887 27 
H(1N) 2140(20) -2605(12) 4430(11) 34 
H(2N) 3250(20) -2970(13) 4710(10) 34 
H(4) -364 -574 4263 36 
H(5) 178 578 4030 45 
H(6) 1477 853 3127 48 
H(7) 2200 -7 2456 46 
H(9) 2260 -1268 2156 35 
H(11) 2273 -2515 1834 36 
H(12) 1656 -3661 2018 38 
H(13) 322 -3959 2914 34 
H(14) -371 -3105 3611 28 
H(1W) -2530(40) -3020(12) 4363(15) 67 
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Table 38. Hydrogen bonds for [Ag(apim)](9-aca)·H2O [Å and °]. 
____________________________________________________________________________ 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________ 
 N(3)-H(1N)...O(2) 0.857(16) 2.291(17) 3.128(3) 165(3) 
 N(3)-H(2N)...O(2)#3 0.852(16) 2.274(17) 3.080(2) 158(2) 
 N(3)-H(2N)...O(1)#3 0.852(16) 2.40(2) 3.131(2) 144(2) 
 O(1W)-H(1W)...O(1) 0.810(17) 2.072(18) 2.883(3) 179(4) 
 O(1W)-H(2W)...O(2)#4 0.832(17) 2.04(2) 2.838(3) 162(3) 
 
Symmetry transformations used to generate equivalent atoms:  
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X-ray Crystal Data for (2-Mebenz-imidH)(9-aca)·H2O 
 
Identification code  (2-Mebenz-imidH)(9-aca)·H2O 
Empirical formula  C23 H20 N2 O3 
Formula weight  372.41 
Temperature  150(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P2(1)2(1)2(1) 
Unit cell dimensions a = 6.9251(8) Å α = 90°. 
 b = 14.8341(17) Å β = 90°. 
 c = 18.522(2) Å γ = 90°. 
Volume 1902.7(4) Å3 
Z 4 
Density (calculated) 1.300 Mg/m3 
Absorption coefficient 0.087 mm-1 
F(000) 784 
Crystal size 0.41 x 0.08 x 0.08 mm3 
Crystal description colourless rod 
Theta range for data collection 1.76 to 26.35°. 
Index ranges -8<=h<=8, -18<=k<=18, -23<=l<=23 
Reflections collected 16919 
Independent reflections 2241 [R(int) = 0.0507] 
Completeness to theta = 26.35° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9931 and 0.9652 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2241 / 0 / 260 
Goodness-of-fit on F2 1.046 
Final R indices [I>2sigma(I)] R1 = 0.0365, wR2 = 0.0853 
R indices (all data) R1 = 0.0482, wR2 = 0.0917 
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Table 39.  Atomic coordinates ( x 104) and equivalent isotropic displacement 
parameters (Å2x 103) for (2-Mebenz-imidH)(9-aca)·H2O.  U(eq) is defined as one 
third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
N(1) -1873(3) 9121(1) 6908(1) 29(1) 
C(1) -1130(4) 7966(2) 7850(1) 42(1) 
C(2) -1688(3) 8265(2) 7112(1) 29(1) 
N(2) -2067(3) 7722(1) 6558(1) 27(1) 
C(3) -2545(3) 8247(2) 5966(1) 25(1) 
C(4) -3088(4) 8018(2) 5268(1) 31(1) 
C(5) -3461(4) 8718(2) 4803(1) 38(1) 
C(6) -3287(4) 9617(2) 5019(2) 37(1) 
C(7) -2763(4) 9848(2) 5712(2) 33(1) 
C(8) -2411(3) 9143(2) 6188(1) 26(1) 
O(1) 1873(2) 10937(1) 8433(1) 33(1) 
O(2) 5080(2) 10932(1) 8514(1) 31(1) 
C(11) 3522(3) 10564(2) 8366(1) 24(1) 
C(12) 3535(3) 9616(2) 8061(1) 23(1) 
C(13) 3967(3) 8877(2) 8504(1) 25(1) 
C(14) 4437(4) 8963(2) 9254(1) 32(1) 
C(15) 4839(4) 8232(2) 9665(2) 39(1) 
C(16) 4794(4) 7352(2) 9366(2) 40(1) 
C(17) 4356(4) 7234(2) 8660(2) 33(1) 
C(18) 3958(3) 7985(2) 8198(1) 26(1) 
C(19) 3596(3) 7872(2) 7466(1) 28(1) 
C(20) 3168(3) 8601(2) 7020(1) 24(1) 
C(21) 2776(4) 8491(2) 6269(1) 29(1) 
C(22) 2352(4) 9205(2) 5843(1) 34(1) 
C(23) 2307(4) 10088(2) 6139(1) 32(1) 
C(24) 2671(4) 10227(2) 6852(1) 28(1) 
C(25) 3115(3) 9495(2) 7323(1) 24(1) 
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Table 40.   Bond lengths [Å] and angles [°] for (2-Mebenz-imidH)(9-aca)·H2O. 
N(1)-C(2)  1.331(3) 
N(1)-C(8)  1.385(3) 
C(1)-C(2)  1.489(4) 
C(2)-N(2)  1.329(3) 
N(2)-C(3)  1.385(3) 
C(3)-C(4)  1.389(3) 
C(3)-C(8)  1.395(3) 
C(4)-C(5)  1.374(4) 
C(5)-C(6)  1.398(4) 
C(6)-C(7)  1.377(4) 
C(7)-C(8)  1.390(4) 
O(1)-C(11)  1.276(3) 
O(2)-C(11)  1.240(3) 
C(11)-C(12)  1.514(3) 
C(12)-C(13)  1.401(3) 
C(12)-C(25)  1.409(3) 
C(13)-C(14)  1.432(4) 
C(13)-C(18)  1.440(3) 
C(14)-C(15)  1.354(4) 
C(15)-C(16)  1.419(4) 
C(16)-C(17)  1.355(4) 
C(17)-C(18)  1.430(4) 
C(18)-C(19)  1.390(3) 
C(19)-C(20)  1.392(3) 
C(20)-C(21)  1.428(3) 
C(20)-C(25)  1.440(3) 
C(21)-C(22)  1.353(4) 
C(22)-C(23)  1.419(4) 
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Table 41. Anisotropic displacement parameters (Å2x 103)for (2-Mebenz-
imidH)(9-aca)·H2O. The anisotropic displacement factor exponent takes the 
form: -2π2[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
______________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
______________________________________________________________________________ 
N(1) 23(1)  31(1) 34(1)  -8(1) 2(1)  -5(1) 
C(1) 27(1)  66(2) 32(1)  8(1) -1(1)  -8(1) 
C(2) 17(1)  40(2) 31(1)  -1(1) 2(1)  -5(1) 
N(2) 24(1)  24(1) 34(1)  5(1) 2(1)  -2(1) 
C(3) 21(1)  26(1) 29(1)  1(1) 6(1)  0(1) 
C(4) 32(2)  32(1) 29(1)  -8(1) 4(1)  1(1) 
C(5) 39(2)  46(2) 28(1)  -1(1) 6(1)  4(1) 
C(6) 34(2)  37(1) 41(2)  10(1) 7(1)  6(1) 
C(7) 29(1)  22(1) 49(2)  1(1) 7(1)  0(1) 
C(8) 20(1)  28(1) 32(1)  -4(1) 4(1)  -1(1) 
O(1) 20(1)  29(1) 50(1)  -16(1) 3(1)  1(1) 
O(2) 23(1)  26(1) 44(1)  -6(1) -4(1)  -1(1) 
C(11) 22(1)  24(1) 25(1)  -1(1) 1(1)  -1(1) 
C(12) 16(1)  22(1) 32(1)  -3(1) 3(1)  -2(1) 
C(13) 18(1)  26(1) 32(1)  -3(1) 3(1)  -1(1) 
C(14) 31(1)  29(1) 36(2)  -4(1) 0(1)  0(1) 
C(15) 42(2)  42(2) 34(2)  1(1) -2(1)  2(1) 
C(16) 38(2)  34(2) 48(2)  11(1) 3(1)  5(1) 
C(17) 28(1)  25(1) 47(2)  1(1) 8(1)  0(1) 
C(18) 18(1)  23(1) 37(1)  -1(1) 6(1)  0(1) 
C(19) 19(1)  23(1) 41(1)  -10(1) 7(1)  -2(1) 
C(20) 17(1)  25(1) 31(1)  -7(1) 5(1)  -2(1) 
C(21) 25(1)  30(1) 32(1)  -12(1) 4(1)  -4(1) 
C(22) 29(1)  45(2) 29(1)  -10(1) 2(1)  -6(1) 
C(23) 29(1)  37(1) 30(1)  0(1) 1(1)  -3(1) 
C(24) 26(1)  24(1) 34(1)  -3(1) 5(1)  -2(1) 
C(25) 15(1)  24(1) 31(1)  -5(1) 5(1)  -2(1) 
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Table 42. Hydrogen coordinates ( x 104) and isotropic displacement 
parameters (Å2x 103) for (2-Mebenz-imidH)(9-aca)·H2O. 
________________________________________________________________________________ 
 x  y  z  U(eq) 
________________________________________________________________________________ 
 
H(1N) -1670(50) 9573(19) 7227(15) 38 
H(1A) -231 8403 8061 63 
H(1B) -506 7374 7823 63 
H(1C) -2287 7924 8153 63 
H(2N) -2000(40) 7059(18) 6547(14) 35 
H(4) -3197 7407 5120 37 
H(5) -3847 8587 4322 45 
H(6) -3538 10081 4678 44 
H(7) -2648 10460 5857 40 
H(14) 4466 9545 9467 38 
H(15) 5156 8310 10160 47 
H(16) 5071 6844 9662 48 
H(17) 4313 6641 8467 40 
H(19) 3641 7283 7264 33 
H(21) 2814 7904 6063 35 
H(22) 2084 9116 5345 41 
H(23) 2020 10586 5836 38 
H(24) 2629 10823 7040 33 
H(1WA) -2519 10594 8116 50 
H(1WB) -632 10586 8109 50 
 
Table 43. Hydrogen bonds for (2-Mebenz-imidH)(9-aca)·H2O [Å and °]. 
____________________________________________________________________________ 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________ 
 N(1)-H(1N)...O(1W) 0.90(3) 1.75(3) 2.654(3) 172(3) 
 N(2)-H(2N)...O(1)#1 0.99(3) 1.67(3) 2.651(3) 178(2) 
 O(1W)-H(1WA)...O(2)#2 0.86 1.89 2.724(3) 162.8 
 O(1W)-H(1WB)...O(1) 0.86 1.91 2.731(3) 158.9 
____________________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  #1 -x,y-1/2,-z+3/2    #2 x-1,y,z      
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X-ray Crystal Data for [Ag4(9-aca)4(NH3)2] 
 
Identification code  [Ag4(9-aca)4(NH3)2] 
Empirical formula  C60 H42 Ag4 N2 O8 
Formula weight  1350.44 
Temperature  150(2) K 
Wavelength  0.84620 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 16.837(3) Å α = 90°. 
 b = 9.8639(16) Å β = 112.383(2)°. 
 c = 16.035(3) Å γ = 90°. 
Volume 2462.4(7) Å3 
Z 2 
Density (calculated) 1.821 Mg/m3 
Absorption coefficient 1.629 mm-1 
F(000) 1336 
Crystal size 0.09 x 0.07 x 0.01 mm3 
Crystal description Colourless plate  
Theta range for data collection 3.82 to 27.50°. 
Index ranges -18<=h<=18, -10<=k<=10, -17<=l<=17 
Reflections collected 12821 
Independent reflections 3344 [R(int) = 0.0853] 
Completeness to theta = 27.50° 99.6 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.0000 and 0.641332 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3344 / 0 / 336 
Goodness-of-fit on F2 1.010 
Final R indices [I>2sigma(I)] R1 = 0.0475, wR2 = 0.0987 
R indices (all data) R1 = 0.0684, wR2 = 0.1079 
Extinction coefficient 0.0021(2) 
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Table 44.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement 
parameters (Å2x 103) for [Ag4(9-aca)4(NH3)2].  U(eq) is defined as one third of  
the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
Ag(1) 4274(1) 951(1) -262(1) 35(1) 
Ag(2) 2883(1) 1955(1) 890(1) 41(1) 
O(1) 3032(4) 2171(6) -1061(4) 51(2) 
O(2) 2012(3) 2141(5) -480(3) 42(1) 
C(1) 2265(5) 2170(7) -1116(5) 34(2) 
C(2) 1603(5) 2184(7) -2071(5) 28(2) 
C(3) 1110(5) 1007(8) -2429(5) 37(2) 
C(4) 1183(6) -184(8) -1890(6) 50(2) 
C(5) 722(7) -1333(10) -2280(9) 75(4) 
C(6) 180(8) -1349(13) -3197(10) 88(4) 
C(7) 97(6) -256(13) -3707(8) 73(3) 
C(8) 554(5) 968(10) -3360(6) 50(2) 
C(9) 524(5) 2092(11) -3891(6) 52(3) 
C(10) 986(5) 3260(9) -3560(5) 38(2) 
C(11) 986(6) 4396(11) -4115(6) 57(3) 
C(12) 1423(6) 5533(11) -3776(7) 62(3) 
C(13) 1929(6) 5618(9) -2839(6) 55(3) 
C(14) 1981(5) 4551(7) -2278(5) 34(2) 
C(15) 1540(5) 3327(7) -2626(5) 31(2) 
O(3) 3822(3) -285(5) 605(3) 31(1) 
O(4) 5094(3) -1335(5) 1257(3) 29(1) 
C(16) 4334(5) -1116(7) 1160(5) 27(2) 
C(17) 3996(5) -1913(7) 1764(4) 24(2) 
C(18) 3313(5) -2827(7) 1356(5) 28(2) 
C(19) 2851(5) -2967(7) 400(5) 30(2) 
C(20) 2257(5) -3948(8) 64(5) 36(2) 
C(21) 2067(5) -4868(8) 632(5) 42(2) 
C(22) 2456(5) -4748(8) 1542(5) 35(2) 
C(23) 3074(5) -3730(7) 1933(5) 27(2) 
C(24) 3456(5) -3530(7) 2873(4) 28(2) 
C(25) 4087(4) -2564(6) 3257(4) 20(2) 
C(26) 4447(5) -2355(7) 4207(5) 30(2) 
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C(27) 5105(5) -1483(7) 4599(5) 32(2) 
C(28) 5442(5) -741(7) 4036(5) 32(2) 
C(29) 5098(5) -878(7) 3125(4) 27(2) 
C(30) 4392(5) -1778(7) 2701(4) 23(2) 
N(1) 3578(4) 1820(6) 2321(4) 32(2) 
 
 
Table 45. Bond lengths [Å] and angles [°] for [Ag4(9-aca)4(NH3)2]. 
Ag(1)-O(3)  2.192(4) 
Ag(1)-O(4)#1  2.261(4) 
Ag(1)-O(1)  2.329(6) 
Ag(1)-Ag(1)#1  2.9390(12) 
Ag(2)-O(2)  2.135(5) 
Ag(2)-N(1)  2.148(5) 
O(1)-C(1)  1.259(9) 
O(2)-C(1)  1.247(9) 
C(1)-C(2)  1.513(10) 
C(2)-C(15)  1.415(10) 
C(2)-C(3)  1.415(10) 
C(3)-C(8)  1.429(11) 
C(3)-C(4)  1.436(11) 
C(4)-C(5)  1.381(12) 
C(5)-C(6)  1.406(16) 
C(6)-C(7)  1.328(15) 
C(7)-C(8)  1.426(12) 
C(8)-C(9)  1.387(12) 
C(9)-C(10)  1.377(11) 
C(10)-C(11)  1.431(12) 
C(10)-C(15)  1.433(10) 
C(11)-C(12)  1.337(13) 
C(12)-C(13)  1.420(13) 
C(13)-C(14)  1.366(10) 
C(14)-C(15)  1.416(10) 
O(3)-C(16)  1.273(8) 
O(4)-C(16)  1.249(8) 
O(4)-Ag(1)#1  2.261(4) 
C(16)-C(17)  1.516(9) 
C(17)-C(30)  1.400(9) 
C(17)-C(18)  1.411(9) 
C(18)-C(19)  1.438(10) 
C(18)-C(23)  1.446(9) 
C(19)-C(20)  1.347(10) 
C(20)-C(21)  1.406(10) 
C(21)-C(22)  1.358(10) 
C(22)-C(23)  1.409(10) 
C(23)-C(24)  1.409(9) 
C(24)-C(25)  1.385(9) 
C(25)-C(30)  1.418(9) 
C(25)-C(26)  1.423(9) 
C(26)-C(27)  1.355(10) 
C(27)-C(28)  1.435(10) 







































































Symmetry transformations used to generate equivalent atoms: 
 #1 -x+1,-y,-z       
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Table 46. Anisotropic displacement parameters  (Å2x 103) for [Ag4(9-
aca)4(NH3)2].  The anisotropic displacement factor exponent takes the form:  -
2π2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
Ag(1) 39(1)  41(1) 31(1)  20(1) 20(1)  4(1) 
Ag(2) 53(1)  50(1) 21(1)  0(1) 16(1)  3(1) 
O(1) 34(4)  73(4) 45(4)  24(3) 15(3)  6(3) 
O(2) 53(4)  52(4) 25(3)  -2(3) 18(3)  -1(3) 
C(1) 42(6)  31(5) 26(5)  8(4) 12(4)  -3(4) 
C(2) 28(4)  36(5) 21(4)  -5(4) 12(3)  4(4) 
C(3) 38(5)  47(5) 38(5)  -14(4) 26(4)  -5(4) 
C(4) 61(6)  43(6) 69(6)  -4(5) 49(5)  -6(5) 
C(5) 96(9)  51(7) 117(10)  -39(7) 83(8)  -36(6) 
C(6) 89(9)  93(10) 121(12)  -71(9) 84(9)  -60(8) 
C(7) 56(7)  95(9) 88(8)  -60(8) 52(7)  -32(7) 
C(8) 32(5)  73(7) 50(6)  -35(6) 24(5)  -4(5) 
C(9) 35(5)  86(8) 30(5)  -18(5) 7(4)  14(5) 
C(10) 36(5)  49(6) 26(5)  4(4) 10(4)  15(4) 
C(11) 51(6)  83(8) 38(6)  11(6) 17(5)  29(6) 
C(12) 62(7)  76(8) 59(7)  40(6) 34(6)  27(6) 
C(13) 62(7)  49(6) 66(7)  17(5) 36(6)  19(5) 
C(14) 43(5)  33(5) 29(4)  8(4) 17(4)  9(4) 
C(15) 39(5)  34(5) 22(4)  -5(4) 13(4)  12(4) 
O(3) 49(3)  23(3) 31(3)  10(2) 27(3)  5(3) 
O(4) 39(3)  35(3) 19(3)  4(2) 18(2)  -3(3) 
C(16) 50(5)  20(4) 21(4)  -2(3) 24(4)  -6(4) 
C(17) 39(5)  19(4) 21(4)  11(3) 21(4)  8(4) 
C(18) 38(5)  24(4) 32(5)  4(3) 23(4)  8(4) 
C(19) 41(5)  36(5) 22(4)  2(4) 22(4)  -2(4) 
C(20) 41(5)  41(5) 24(4)  -8(4) 13(4)  -3(4) 
C(21) 41(5)  41(5) 43(6)  -10(4) 15(4)  -8(4) 
C(22) 39(5)  37(5) 39(5)  4(4) 24(4)  -7(4) 
C(23) 37(5)  25(4) 25(4)  7(3) 20(4)  1(4) 
C(24) 44(5)  27(4) 22(4)  11(3) 22(4)  3(4) 
C(25) 29(4)  19(4) 17(4)  5(3) 16(3)  5(3) 
C(26) 46(5)  26(4) 28(5)  18(4) 26(4)  14(4) 
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C(27) 60(6)  20(4) 19(4)  6(3) 21(4)  12(4) 
C(28) 55(5)  19(4) 25(4)  -6(3) 19(4)  3(4) 
C(29) 48(5)  21(4) 23(4)  0(3) 24(4)  1(4) 
C(30) 37(5)  20(4) 19(4)  -1(3) 20(4)  8(3) 
N(1) 34(4)  32(4) 31(4)  0(3) 15(3)  2(3) 
 
 
Table 47. Hydrogen coordinates ( x 104) and isotropic  displacement 
parameters (Å2x 10 3) for [Ag4(9-aca)4(NH3)2]. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
H(4) 1545 -181 -1268 61 
H(5) 773 -2122 -1923 90 
H(6) -130 -2149 -3455 105 
H(7) -280 -290 -4323 87 
H(9) 167 2055 -4514 62 
H(11) 665 4340 -4746 69 
H(12) 1394 6279 -4161 75 
H(13) 2236 6429 -2599 67 
H(14) 2315 4630 -1651 41 
H(19) 2965 -2360 -1 36 
H(20) 1960 -4019 -570 43 
H(21) 1665 -5577 378 51 
H(22) 2310 -5358 1920 43 
H(24) 3275 -4077 3255 34 
H(26) 4218 -2841 4577 36 
H(27) 5341 -1364 5235 38 
H(28) 5913 -143 4305 39 
H(29) 5328 -372 2765 33 
H(1A) 3211 1955 2608 48 
H(1B) 3997 2463 2499 48 
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Table 48. Hydrogen bonds for [Ag4(9-aca)4(NH3)2]  [Å and °]. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 N(1)-H(1A)...O(1)#2 0.91 2.42 3.222(8) 146.5 
 N(1)-H(1B)...O(4)#3 0.91 2.32 3.103(7) 143.4 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
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UV-Vis and Fluorescence Spectral Data 
 










[Ag2(9-aca)2]n 373 366 (7) N/A 
[Ag(imidH)2.3(CH3CN)0.7](9-
aca) 
373 366 (7) 280 (1) 
[Ag(apim)](9-aca)·H2O 373 366 (7) no maximum 
[Ag(2-Ph-imid)] 273 262(6) N/A 
[Ag(4-Ph-imidH)2(9-aca)] 373 366 (7) 271 (5) 
[Ag(4,5-dicyanoimid)] 264 256 (4) N/A 
[Ag2(2-Mebenz-imidH)4](9-
aca)2 
366 366 (7) 283 (2) 
[Ag4(9-aca)4(NH3)2] 372 366 (7) N/A 
 
 
Table 50. Complex and ligand 1 fluorescence data (a excited at 366 nm, b excited 















[Ag2(9-aca)2]n 448 61 451 (7) 942 (7) 
[Ag(imidH)2.3(CH3CN)0.7](9
-aca) 
448 175 450 (7) 968 (7) 
[Ag(apim)](9-aca)·H2O 440 53 450 (7) 968 (7) 
[Ag(2-Ph-imid)] 342 44 340 (6) 167 (6) 
[Ag(4-Ph-imidH)2(9-aca)] 448 108 450 (7) 968 (7) 







451 (7) 461 (7) 
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Table 51. Complex and ligand 2 fluorescence data (a excited at 366 nm, b excited 















[Ag2(9-aca)2]n 448 61 N/A N/A 
[Ag(imidH)2.3(CH3CN)0.7](9
-aca) 
448 175 561 (1) 15 (1) 
[Ag(apim)](9-aca)·H2O 440 53 0 (4) 0 (4) 
[Ag(2-Ph-imid)] 342 44 N/A N/A 
[Ag(4-Ph-imidH)2(9-aca)] 448 108 290 (5) 2 (5) 







299 (2) 554 (2) 
[Ag4(9-aca)4(NH3)2] 446 15 N/A N/A 
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In vivo Data 
 
Table 52. Survival of G. mellonella larvae after prophylactic treatment with 






after 24 h. 
% 
Survival 
after 48 h 
% 
Survival 
after 72 h 
Control 
(1×108 cells cm-3) 
70 30 10 
Ketoconazole# 
100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 





















after 24 h. 
% 
Survival 
after 48 h 
% 
Survival 
after 72 h 
[Ag(2-Me-imidH)2(9-aca)] 
100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 
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Table 53. Survival of G. mellonella larvae after infection with a lethal dose of C. 






after 24 h. 
% 
Survival 
after 48 h 
% 
Survival 
after 72 h 
Control 
(1×108 cells cm-3) 
70 30 10 
Ketoconazole# 
100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 





















after 24 h. 
% 
Survival 
after 48 h 
% 
Survival 
after 72 h 
[Ag(1-Bu-imid)2]2[Ag4(9-aca)6] 
100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 
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after 24 h.  
(p value) 
Significant 
after 48 h  
(p value) 
Significant 
after 72 h 
(p value) 
Ketoconazole# 
100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 















100 µg cm-3 
10 µg cm-3 


















100 µg cm-3 
10 µg cm-3 















No  (1.000) 
[Ag(1-Me-imid)2]2[Ag4(9-
aca)6] 
100 µg cm-3 
10 µg cm-3 

















100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 




















after 24 h. 
(p value) 
Significant 
after 48 h  
(p value) 
Significant 
after 72 h 
 (p value) 
[Ag(1-bu-imid)2]2[Ag4(9-
aca)6] 
100 µg cm-3 
10 µg cm-3 

















100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 















100 µg cm-3 
10 µg cm-3 

















100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 
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after 24 h.  
(p value) 
Significant 
after 48 h  
(p value) 
Significant 
after 72 h (p 
value) 
Ketoconazole# 
100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 















100 µg cm-3 
10 µg cm-3 


















100 µg cm-3 
10 µg cm-3 


















100 µg cm-3 
10 µg cm-3 

















100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 




















after 24 h. 
(p value) 
Significant 
after 48 h (p 
value) 
Significant 




100 µg cm-3 
10 µg cm-3 

















100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 















100 µg cm-3 
10 µg cm-3 

















100 µg cm-3 
10 µg cm-3 














100 µg cm-3 
10 µg cm-3 
0.390 µg cm-3 
 
No (0.6147) 
No (0.6147) 
No (0.6477) 
 
No (0.1888) 
No (0.3736) 
No (0.6477) 
 
Yes* (0.0223) 
No (0.1311) 
No (0.2758) 
 
 
